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Epoetin and Darbepoetin for Managing Anemia  
in Patients Undergoing Cancer Treatment: 
Comparative Effectiveness Update 
Structured Abstract 
Objectives. To update the 2006 systematic review of the comparative benefits and harms of 
erythropoiesis-stimulating agent (ESA) strategies and non-ESA strategies to manage anemia in 
patients undergoing chemotherapy and/or radiation for malignancy (excluding myelodysplastic 
syndrome and acute leukemia), including the impact of alternative thresholds for initiating 
treatment and optimal duration of therapy. 
 
Data sources. Literature searches were updated in electronic databases (n=3), conference 
proceedings (n=3), and Food and Drug Administration transcripts. Multiple sources (n=13) were 
searched for potential gray literature. A primary source for current survival evidence was a 
recently published individual patient data meta-analysis. In that meta-analysis, patient data were 
obtained from investigators for studies enrolling more than 50 patients per arm. Because those 
data constitute the most currently available data for this update, as well as the source for on-
study (active treatment) mortality data, we limited inclusion in the current report to studies 
enrolling more than 50 patients per arm to avoid potential differential endpoint ascertainment in 
smaller studies. 
 
Review methods. Title and abstract screening was performed by one or two (to resolve 
uncertainty) reviewers; potentially included publications were reviewed in full text. Two or three 
(to resolve disagreements) reviewers assessed trial quality. Results were independently verified 
and pooled for outcomes of interest. The balance of benefits and harms was examined in a 
decision model. 
 
Results. We evaluated evidence from 5 trials directly comparing darbepoetin with epoetin, 41 
trials comparing epoetin with control, and 8 trials comparing darbepoetin with control; 5 trials 
evaluated early versus late (delay until Hb ≤9 to 11 g/dL) treatment. Trials varied according to 
duration, tumor types, cancer therapy, trial quality, iron supplementation, baseline hemoglobin, 
ESA dosing frequency (and therefore amount per dose), and dose escalation. 
 
ESAs decreased the risk of transfusion (pooled relative risk [RR], 0.58; 95% confidence interval 
[CI], 0.53 to 0.64; I2 = 51%; 38 trials) without evidence of meaningful difference between 
epoetin and darbepoetin. Thromboembolic event rates were higher in ESA-treated patients 
(pooled RR, 1.51; 95% CI, 1.30 to 1.74; I2 = 0%; 37 trials) without difference between epoetin 
and darbepoetin. In 14 trials reporting the Functional Assessment of Cancer Therapy (FACT)-
Fatigue subscale, the most common patient-reported outcome, scores decreased by -0.6 in 
control arms (95% CI, -6.4 to 5.2; I2 = 0%) and increased by 2.1 in ESA arms (95% CI, -3.9 to 
8.1; I2 = 0%). There were fewer thromboembolic and on-study mortality adverse events when 
ESA treatment was delayed until baseline Hb was less than 10 g/dL, in keeping with current 
treatment practice, but the difference in effect from early treatment was not significant, and the 
evidence was limited and insufficient for conclusions. No evidence informed optimal duration of 
therapy.  
vii 
 
Mortality was increased during the on-study period (pooled hazard ratio [HR], 1.17; 95% CI, 
1.04 to 1.31; I2 = 0%; 37 trials). There was one additional death for every 59 treated patients 
when the control arm on-study mortality was 10 percent and one additional death for every 588 
treated patients when the control-arm on-study mortality was 1 percent. A cohort decision model 
yielded a consistent result—greater loss of life-years when control arm on-study mortality was 
higher. There was no discernible increase in mortality with ESA use over the longest available 
followup (pooled HR, 1.04; 95% CI, 0.99 to 1.10; I2 = 38%; 44 trials), but many trials did not 
include an overall survival endpoint and potential time-dependent confounding was not 
considered.  
 
Conclusions. Results of this update were consistent with the 2006 review. ESAs reduced the 
need for transfusions and increased the risk of thromboembolism. FACT-Fatigue scores were 
better with ESA use but the magnitude was less than the minimal clinically important difference. 
An increase in mortality accompanied the use of ESAs. An important unanswered question is 
whether dosing practices and overall ESA exposure might influence harms. 
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ES-1 
Executive Summary 
Background 
Anemia, a deficiency in the concentration of hemoglobin-containing red blood cells, is 
prevalent among cancer patients, depending on the type of malignancy and treatment. 
Transfusion is one option for treating anemia related to cancer and cancer treatment. Transfusion 
carries a very low risk of infection and other adverse events, including transfusion reactions, 
alloimmunization, overtransfusion, and immune modulation with theoretically possible adverse 
effects on tumor growth. (For example, adverse events that could be definitively attributed to 
transfusions were not reported in any trial included in this review for adverse event outcomes.) 
Erythropoietin, a hormone produced in the kidney, is the major regulator of red blood cell 
production (erythropoiesis). Commercially produced recombinant human erythropoietins have 
been extensively studied and used clinically for more than a decade to treat anemia in association 
with various diseases, reducing the need for transfusion. These include epoetin alfa (Epogen®, 
Procrit®) and epoetin beta (not available in the United States); they have similar clinical efficacy. 
Darbepoetin alfa (Aranesp®), more recently developed, produces a similar physiologic response 
and is commercially available in the United States. All erythropoietic-stimulating agents (ESAs) 
increase the number of red blood cells within about 2 to 3 weeks when given to individuals with 
functioning erythropoiesis. 
The development of intensified antineoplastic therapies has increased the risk for anemia and 
the likelihood of treatment. Initially, adverse effects that could be conclusively attributed to 
erythropoietin treatment had been reported in very few patients; more recently, randomized 
controlled trials have reported increased incidence of thrombotic events and reduced survival. 
This resulted in multiple pooled analyses of ESA trial data over several years, as well as 
regulatory actions by the U.S. Food and Drug Administration (FDA). The Blue Cross and Blue 
Shield Association Technology Evaluation Center, an Evidence-based Practice Center funded by 
the Agency for Healthcare Research and Quality, conducted a systematic review of epoetin use 
in oncology (2001)1 and a comparative effectiveness review, “Comparative Effectiveness of 
Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment” 
(2006).2 
This update includes new evidence that was not available in 2006. In particular, we 
incorporated results from a recently published meta-analysis3 of individual patient data from 
studies enrolling more than 50 patients per arm; inclusion for this update was limited to studies 
of similar size. In contrast, the previous report2 included studies enrolling 10 or more patients per 
arm. Sensitivity analyses performed for each outcome with data from studies excluded because 
of size showed no differing results. 
This report addresses the following Key Questions: 
Key Question 1. What are the comparative benefits and harms of 
erythropoiesis-stimulating agent strategies and non-ESA strategies to 
manage anemia in patients undergoing chemotherapy or radiation for 
malignancy (excluding myelodysplastic syndrome and acute leukemia)? 
 
ES-2 
Key Question 2. How do alternative thresholds for initiating treatment 
compare regarding their effect on the benefits and harms of erythropoietic 
stimulants? 
Key Question 3. How do different criteria for discontinuing therapy or for 
optimal duration of therapy compare regarding their effect on the benefits 
and harms of erythropoietic stimulants? 
Conclusions 
Evidence from three groups of trials were summarized and analyzed for Key Question 1. 
Five trials directly compared darbepoetin with epoetin (pooled N=1,080 darbepoetin, N=989 
epoetin); 40 trials compared epoetin with control (pooled N=5,959 epoetin, N=5,417 control); 
and 7 trials compared darbepoetin with control (pooled N=1,654 darbepoetin, N=1,520 control). 
There was considerable variability among trials, such as trial duration, tumor types, cancer 
therapy, trial quality, iron supplementation, baseline hemoglobin, ESA dosing frequency (and 
therefore amount per dose), and ESA dose escalation. 
Hematologic Response 
ESAs reduced the proportion of patients receiving transfusions (overall strength of evidence 
moderate) without meaningful difference between epoetin and darbepoetin (overall strength of 
evidence moderate). Table A shows data on transfusion risk. 
Table A. Transfusion risk 
Variable Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Number of trials 5 31 7 38 
Patients analyzed 2,005 8,003 2,806 10,809 
Pooled RR (95% CI) 1.14  0.58 0.58 0.58 
(0.82 to 1.59) (0.52 to 0.65) (0.51 to 0.65) (0.53 to 0.64) 
I2 43% 60% 0% 51% 
CI = confidence interval; RR = relative risk 
There is a consistent body of evidence, although somewhat limited by trial quality, that ESAs 
reduce the probability of transfusion in the setting of cancer treatment. These agents do not 
eliminate the chance of receiving transfusions. 
Survival Outcomes 
ESAs did not affect survival over the longest available followup (overall strength of evidence 
low). Table B shows data on overall survival. 
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Table B. Overall survival 
Variable Epoetin vs. Control 
Darbepoetin vs. 
Control 
Epoetin or 
Darbepoetin vs. 
Control 
Number of trials 37 7 44 
Patients analyzed 11,131 3,147 14,278 
Pooled HR (95% CI) 1.04a 1.04 1.04b 
(0.98 to 1.11) (0.94 to 1.17) (0.99 to 1.10) 
I2 35% 51% 38% 
CI = confidence interval; HR = hazard ratio 
aExcludes the single trial enrolling pediatric patients. 
bExcludes the single trial enrolling pediatric patients. Excluding 5 trials classified here as radiotherapy or predominantly 
radiotherapy yielded an HR of 1.03 (95% CI, 0.97 to 1.09). 
ESAs increased mortality during and shortly following treatment (in this review, referred to 
as “on-study mortality”; overall strength of evidence moderate). Table C shows on-study 
mortality data. 
Table C. On-study mortality 
Variable Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Number of trials 2 31 6 37 
Patients analyzed 1,567 8,618 2,648 11,266 
Pooled HR (95% CI) 0.90 1.19a 1.05  1.17b 
(0.67 to 1.20) (1.05 to 1.36) (0.80 to 1.38) (1.04 to 1.31) 
I2 72% 3% 0% 0% 
CI = confidence interval; HR = hazard ratio 
aExcludes single trial enrolling pediatric patients. 
bExcludes single trial enrolling pediatric patients. Excluding 3 trials classified here as radiotherapy or predominantly 
radiotherapy yielded an HR of 1.16 (95% CI, 1.03 to 1.30). 
ESAs increased mortality during the active treatment or “on-study period” (median study 
duration 3 months) without apparent difference between epoetin and darbepoetin. There was one 
additional death for every 59 treated patients when the control arm on-study mortality was 10 
percent, and there was one additional death for every 588 treated patients when the control arm 
on-study mortality was 1 percent. While there was no discernible increase in mortality with ESA 
use over the longest available followup, many trials did not include an overall survival endpoint 
and potential time-dependent confounding was not considered.  
Thromboembolic Events 
ESA treatment increased the risk of thromboembolic events (overall strength of evidence 
moderate). Epoetin and darbepoetin conferred similar risks. Table D shows data on 
thromboembolic events.  
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Table D. Thromboembolic events 
Variable Darbepoetin vs. Epoetin 
Epoetin 
vs. Controla 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Number of trials 3 31 6 37 
Patients analyzed 1,873 9,585 2,869 12,570 
Pooled RR (95% CI) 0.86 1.50 1.53 1.51 
(0.61 to 1.21) (1.26 to 1.77) (1.18 to 2.00) (1.30 to 1.74) 
I2 0% 0% 0% 0% 
CI = confidence interval; RR = relative risk 
aOne trial reporting no events in either treatment arm not included in totals or pooled results. 
Rates of thromboembolic events were consistently higher in ESA-treated patients. In 
included trials, the number needed to harm was 50 or fewer in 50 percent of trials and 20 or 
fewer in 21 percent of trials. 
Health-Related Quality of Life 
Treating to high target hemoglobin levels (greater than 12 g/dL) was accompanied by 
improved health-related quality of life (HRQoL) scores (e.g., the Functional Assessment of 
Cancer Therapy [FACT] Fatigue score; overall strength of evidence low). Table E shows 
HRQoL data. 
Table E. Health-related quality of life 
Variable Epoetin or Darbepoetin vs. Control 
Number of trials 14 
Patients analyzed 3,643 
Mean difference for change in FACT-Fatigue 
score (95% CI)  
  
2.74 
(1.69 to 3.78) 
I2 45% 
CI = confidence interval; FACT = Functional Assessment of Cancer Therapy 
Any clinical significance of the improvement in HRQoL is likely to be small. On average, 
the difference in change between treatment arms was less than the estimated minimal clinically 
important difference (a value of 3 for the FACT-Fatigue score). 
Early Versus Late ESA Treatment 
Evidence from five trials was summarized and analyzed; 468 and 465 patients randomized to 
early (when chemotherapy or radiotherapy begins) and late (when hemoglobin falls below a 
defined threshold) ESA treatment, respectively. Hemoglobin thresholds for initiating late 
treatment ranged from 9 g/dL to 11 g/dL. 
There were fewer thromboembolic and on-study mortality adverse events when ESA 
treatment was delayed until baseline hemoglobin was less than 10 g/dL, in keeping with current 
treatment practice, but the difference in effect from early treatment was not significant, and the 
evidence was limited and insufficient for conclusions. 
Evidence is lacking to determine whether immediate treatment versus delayed treatment 
produces better outcomes (overall strength of evidence low). 
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Criteria for Discontinuing Therapy or for Optimal Duration  
of Therapy 
No randomized controlled trials were identified that fulfilled the review’s inclusion criteria 
for studies of discontinuing therapy or defining optimal duration of therapy.  
Balance of Potential Benefit and Harm 
ESAs reduce the need for transfusions and increase the risk of thromboembolism. A 
detectable relative increase in mortality risk, which is higher with lower underlying absolute 
mortality risk, accompanies their use. An individual patient receiving ESAs will have, on 
average, better quality-of-life FACT-Fatigue scores, but of a magnitude less than the minimal 
clinically important difference. In a cohort decision model in which increased hemoglobin 
determined the utility-based measure of improvement in quality of life, ESAs were accompanied 
by some additional expected quality-adjusted life-years—consistent with the small difference in 
FACT-Fatigue scores. However, expected life-years were always lost, and the loss was greater 
with higher underlying absolute mortality risk. 
Remaining Issues 
Much of the evidence included here was obtained under treatment protocols that used higher 
baseline and target hemoglobin levels than those used in current practice. While it is possible that 
adverse event rates might be somewhat different with lower baseline and target hemoglobin 
levels, we found little difference in effect when baseline hemoglobin was either less than or more 
than 10 g/dL, the currently recommended threshold for ESA initiation. This result is similar to 
results from a meta-analysis of individual patient data.3 Additionally, three trials included in Key 
Question 1 enrolled patients predominantly undergoing radiotherapy. Although radiotherapy is 
not an FDA-approved indication for ESA use, those results were included because the population 
of interest was patients undergoing treatment for cancer. Moreover, we did not find those trial 
results influential in these analyses.  
Existing evidence establishes with sufficient certainty that use of ESAs to manage anemia in 
patients with cancer is accompanied by increased mortality risk. Whether there are subgroups at 
higher and lower risk of adverse events and mortality is unclear. Recent regulatory and guideline 
changes may have reduced ESA exposure in subsequent clinical trials and routine practice. It is 
unknown whether dosing practices and overall ESA exposure influence harms. However, the 
increased risk of mortality raises questions as to whether equipoise exists to justify enrolling 
patients in clinical trials. Instead, examining observational data collected during the course of 
usual patient care could be adequate to address unanswered questions. Finally, trial registry 
records for all completed studies lacking results or links to them should be appropriately 
updated. Trial registries should also query investigators when studies are completed and post 
responses in a registry record when results are unavailable. 
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Introduction 
This review updates the 2006 Agency for Healthcare Research and Quality (AHRQ) 
comparative effectiveness review of epoetin and darbepoetin for managing anemia in patients 
undergoing cancer treatment.1 Since that review was completed, further evidence concerning a 
number of the Key Questions (KQs) addressed in that review has become available. In addition 
and as a result of new evidence, the U.S. Food and Drug Administration (FDA) made several 
revisions to the approved labeling for erythropoietic-stimulating agents (ESAs). Based on these 
new developments, AHRQ concluded that aspects of the prior review required updating with 
recently published and presented evidence. Importantly, this update accordingly addresses only 
those questions where new evidence has become available. 
The introduction is organized as follows. First, the basic biology of erythropoietin and ESAs 
is reviewed. We then discuss the significance of anemia and its treatment with ESAs in the 
setting of cancer therapy. This is followed by a description of previous AHRQ reports and 
associated collaborations with the Cochrane Hematologic Malignancies Group, who conducted 
additional evaluations, which provides a brief overview of prior evidence and conclusions. 
Subsequent changes in FDA-approved labeling are noted and chronicled. We present the scope 
of this report and KQs followed by an overview of the patient populations included, 
interventions, comparators, and outcomes. The types of studies included in the report are then 
discussed. Finally, we describe some important complexities presented by the evidence for 
synthesis, as these complexities directly or indirectly impact much of the analyses, conclusions, 
and research recommendations. 
Background 
Erythropoietin 
Erythropoietin, a hormone produced in the kidney in response to tissue hypoxia, is the major 
regulator of red blood cell production (erythropoiesis). Erythropoietin binds to specific receptors 
on the surface of immature erythroid cells in the bone marrow that would otherwise undergo 
apoptosis.2 Binding initiates a cascade leading to the survival of these cells. Proliferation of 
erythroid cells may also be a consequence of erythropoietin stimulation. Circulating reticulocytes 
increase, followed by a more delayed increase in hemoglobin and red blood cell count. 
Two commercially produced recombinant human erythropoietins—epoetin alfa (Epogen®; 
Procrit®) and epoetin beta (the latter not available in the United States)—have been extensively 
studied and used clinically for more than a decade to treat anemia in association with various 
diseases; they have similar clinical efficacy.3,4 Darbepoetin alfa (Aranesp®), more recently 
developed, produces a similar physiologic response when compared to recombinant human 
erythropoietin,5 has been tested in prospective clinical trials,6-8 and is commercially available in 
the United States. All ESAs increase the number of red blood cells within about 2 to 3 weeks 
when given to individuals with functioning erythropoiesis. In addition, erythropoietin has effects 
on megakaryocytopoiesis (platelet production and thrombopoiesis) possibly related to structural 
similarities with thrombopoietin.2 
 2 
Anemia 
Anemia, a deficiency in the concentration of hemoglobin-containing red blood cells, is 
prevalent among cancer patients. The National Cancer Institute and others classify anemia based 
on hemoglobin (Hb) values:9  
• Grade 0, within normal limits, Hb values are 12.0-16.0 g/dL for women and 14.0-18.0 
g/dL for men  
• Grade 1, mild (Hb 10 g/dL to normal limits)  
• Grade 2, moderate (Hb 8.0-10.0 g/dL)  
• Grade 3, serious/severe (Hb 6.5-7.9 g/dL)  
• Grade 4, life threatening (Hb less than 6.5 g/dL). 
Anemia and Cancer 
The prevalence of anemia varies according to the type of neoplasia and treatment.10 Patients 
with chronic hematological malignancies or solid tumors frequently experience anemia, which 
may result from the malignancy itself or from treatment or both. For example, the prevalence of 
anemia at diagnosis is approximately 40 percent of patients with non-Hodgkin's or Hodgkin 
lymphoma; following 3 to 4 cycles of chemotherapy up to 70 percent of these patients will be 
anemic.11 The European Cancer Anaemia Survey (ECAS) reported on a subset of cancer patients 
(“incidence population”) who were neither anemic at enrollment in the survey nor treated for 
anemia and who received at least their first two myelosuppressive chemotherapy treatment 
cycles during the survey.12 Among these patients, those with lung or gynecologic cancer were 
three times more likely to become anemic than those with GI/colorectal cancer. In addition, 
anemia was twice as likely with platinum treatment than with non-platinum treatment. 
Additional analysis of a lung cancer population revealed anemia incidences of 80 percent in 
patients treated with chemotherapy, 31 percent for patients treated with chemotherapy plus 
radiotherapy, and 15 percent for patients treated with radiotherapy alone.13 
The pathophysiology of anemia accompanying malignancies is multifactorial. For example, 
in advanced stages of hematologic malignancies, malignant cells replace most of the normal 
hematopoietic cells in the bone marrow, leading to progressive anemia. In general, after 
exclusion of other causes (e.g., iron or vitamin deficiencies, occult bleeding, autoimmune 
hemolysis, or pure red blood cell aplasia), anemia is typically attributed to “anemia of chronic 
disease.” It is characterized by a close interaction between the tumor cell population and the 
immune system, leading to the activation of macrophages and increased expression of various 
cytokines. This results in insufficient endogenous erythropoietin synthesis, suppressed 
differentiation of erythroid precursor cells in the bone marrow, and alterations of iron 
metabolism.14 Anemia of chronic disease is the most common type of anemia in patients with 
malignant disease, but it can be aggravated by chemotherapy or radiotherapy. In particular, 
platinum-based chemotherapy regimens may diminish endogenous erythropoietin production by 
damaging renal tubular cells.15 
Manifestation and severity of anemia vary considerably among individual cancer patients. 
Mild to moderate anemia developing over a short time can cause symptoms including headache, 
palpitations, tachycardia, and shortness of breath. Chronic anemia may result in severe organ 
damage affecting the cardiovascular system, immune system, lungs, kidneys, muscles, and 
central nervous system.16 In addition to the physical symptoms, the subjective impact of cancer-
related anemia on quality of life (QoL), mental health, and social activities may be substantial. 
Studies have reported correlations between hemoglobin levels and quality of life.17-19  
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Anemia may also be associated with outcomes or have direct effects on the tumor itself. In 
malignant diseases like Hodgkin’s lymphoma, chronic lymphocytic leukemia, cervical 
carcinoma, and cancer of the head and neck, anemia is reportedly a prognostic factor.20 There is 
evidence that anemia, causing tumor hypoxia, might result in a poorer response to radio- or 
chemotherapy.21 These factors may lead to a higher tumor burden and decrease overall 
survival.21-24 Although the prognostic significance of anemia may simply reflect progressive or 
advanced disease, the observation generated the hypothesis that strategies to diminish cancer-
related anemia might alleviate not only anemia-related symptoms and improve quality of life, but 
also might improve tumor response and extend overall survival time. 
Correcting Anemia With Blood Transfusion 
Historically, blood transfusion was the treatment of choice for severe cancer-related anemia. 
The literature generally supports treating hemoglobin concentrations below 8 g/dL, while mild-
to-moderate cancer-related anemia (hemoglobin level 8 to 10 g/dL) often goes untreated.25 
Although homologous blood transfusion is the fastest method to alleviate symptoms, short and 
long term risks exist.26 These include transmitting infectious diseases, transfusion reactions, 
alloimmunization, overtransfusion, and immune modulation with theoretically possible adverse 
effects on tumor growth.27 The risk of severe infectious complications of blood transfusions are 
1:30,000 to 1:250,000 units of blood transfused for Hepatitis B, 1:30,000 to 1:150,000 for 
Hepatitis C and 1:250,000 to 1:1,000,000 for HIV.28 Emerging infections, such as the West Nile 
virus epidemic in 2002 in the United States are of concern.29,30 Still, in decision-analytic models 
of ESAs, any risk accompanying blood transfusion appears not to meaningfully impact results 
due to the infrequent occurrence of severe adverse events.31,32 
Prior EPC Pooled Analyses of ESA Treatment Outcomes  
The development of intensified antineoplastic therapies has increased the risk for anemia and 
the need for correction of anemia by blood transfusion or treatment with ESAs. Initially, adverse 
effects such as hypertension, headaches, and thrombotic events that could be attributed to 
erythropoietin treatment had been reported in very few patients;33 however, more recently 
randomized controlled trials have reported increased incidence of thrombotic events34,35 and 
reduced survival.35-37 This resulted in several pooled analyses of ESA trial data over several 
years, as well as regulatory actions by the U.S. Food and Drug Administration (FDA). Following 
is a summary of analyses authored, or contributed to, by the Blue Cross and Blue Shield 
Association Technology Evaluation Center (BCBSA TEC) Evidence-based Practice Center 
(EPC). 
In 2001, the AHRQ-sponsored systematic review “Uses of Epoetin for Anemia in Oncology” 
was completed.38 The American Society of Clinical Oncology (ASCO) and the American 
Society of Hematology (ASH), who intended to use the evidence review as the scientific basis 
for a joint clinical guideline, originally proposed the topic to AHRQ. Members of the 
ASCO/ASH joint guideline committee participated on the Technical Expert Panel for the 
systematic review, and subsequently a member of the BCBSA TEC EPC systematic review team 
participated as an ad hoc nonvoting member of the guideline panel. It was clear that 
administering epoetin given to cancer patients treated with chemotherapy and subsequently 
found moderately anemic (hemoglobin <10 g/dL) resulted in increased hemoglobin levels and 
fewer transfusions. Major questions at the time were whether initiating epoetin treatment before 
patients became moderately anemic (i.e., hemoglobin between 10 and 12 g/dL) would result in 
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fewer patients transfused or would improve quality of life. However, the systematic review 
concluded that the available evidence was inadequate to answer either question. 
The database constructed for the 2001 BCBSA TEC EPC systematic review was shared with 
the Cochrane Hematologic Malignancies Group with permission from AHRQ; the data provided 
a starting point for a Cochrane Review completed in 2004.39 The results of this review were also 
consistent with erythropoietin reducing blood transfusions in anemic patients with cancer. 
Evidence as to whether erythropoietin affected tumor response and overall survival was 
inconclusive. It was also unclear whether erythropoietin increased the risk of hypertension and 
thrombotic complications or improved quality of life and reduced fatigue. 
In 2006, the BCBSA TEC EPC published a comparative effectiveness review (CER) of 
epoetin and darbepoetin treatment for anemia related to cancer treatment under the AHRQ 
contract.1 This review was conducted collaboratively between TEC and the Cochrane 
Hematologic Malignancies Group. 
The 2006 CER found no clinically meaningful difference between epoetin and darbepoetin 
with regard to hemoglobin response, transfusion reduction, or thromboembolic events. Three 
trials40-42 failed to show better transfusion-sparing effects when ESA treatment was initiated 
immediately versus only if hemoglobin fell below a specified threshold (9 or 10 g/dL). When 
comparing epoetin or darbepoetin to control, there was an increase in thromboembolic events 
associated with ESA use, but variability in event rates between control arms of different trials 
was high, and several studies targeted higher hemoglobin levels than recommended by product 
labels at the time. Too few trial results were available to perform a subgroup analysis conforming 
to label recommendations. Quality-of-life measures, viewed at the time as one of the most 
important outcomes of treatment, tended to favor ESA treatment, but variability in the amount of 
change, and potential for bias due to a number of methodologic factors made definitive 
conclusions difficult. Several trials included in the 2006 review showed an ESA-associated 
detriment in survival and others did not. Most of the included trials that raised concerns over 
safety, survival, and tumor response were unpublished. Information about trial design and results 
was available only from briefings presented to the FDA Oncologic Drugs Advisory Committee, 
May 4, 2004.a
These trials, the 2006 CER, as well as several pooled analyses, led to a series of FDA-
directed Physician Alerts and label changes to more stringent dosing recommendations (Table 1). 
By May 2007, there were data from six randomized trials showing decreased survival (five 
trials)34,35,43-45 and/or poorer local regional control and progression-free survival (two 
trials)34,46 in the ESA treatment arm. Three trials were stopped early because of adverse events 
in the treatment arms.45-47 In five of the six trials, the target hemoglobin exceeded 12 g/dL and 
patients’ baseline hemoglobin levels were more than 10 g/dL. Five of the six trials each enrolled 
patients with a specific tumor type; these were advanced breast, head and neck, lymphoid, or 
non-small cell lung cancer. The pooled analyses of the BCBSA TEC-authored AHRQ CER and 
the Cochrane Review were also available, along with other published meta-analyses. The most 
  
                                                             
a See http://www.fda.gov/ohrms/dockets/ac/04/briefing/4037b2.htm for May 2004 briefing information and 
http://www.fda.gov/ohrms/dockets/ac/04/slides/4037s2.htm for slides. 
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significant changes to the ESA labels occurred in 2007, and the issue of ESA effect on survival 
became paramount, with quality of life becoming less important by comparison. 
Due to the limitations of pooled analyses from summary measures in published papers, and 
the inconclusive results regarding the overall effect of ESAs on survival, the Cochrane 
Hematologic Malignancies Group undertook an analysis of individual patient data (IPD) with 
BCBSA TEC Staff participating as members of the IPD Steering Committee. The initial IPD 
publication48 and concurrent Cochrane Review,49 found a significant increase in mortality during 
active treatment and poorer overall survival with ESAs in all cancer patients (regardless of 
cancer treatment status). The effect was not statistically significant for patients undergoing 
chemotherapy, but was consistent with an adverse effect. This and other meta-analyses are 
reviewed in detail later in this report. 
Table 1. FDA alerts and actions related to ESA prescribing 
Date Notification Type Content Change 
June 2004 Addition of clinical trial 
results and warning to 
label 
Added descriptions of clinical trial results showing risks for tumor promotion and 
increased mortality among cancer patients who were receiving ESAs in the 
treatment of chemotherapy-induced anemia; an additional warning advised 
physicians of increased thromboembolic event risks with ESAs in the oncology 
setting. 
November 
2006  
FDA Alert regarding 
clinical trial results 
The “Correction of Hemoglobin and Outcomes in Renal Insufficiency” (CHOIR) 
study50 showed that patients treated with an ESA and dosed to a target Hb of 13.5 
g/dL were at a significantly increased risk for serious and life-threatening 
cardiovascular complications, compared to control Hb target of 11.3 g/dL; the alert 
emphasized then current dosing recommendation that the target Hb not exceed 
12 g/dL. 
March 2007 New black box 
warning; updated 
warnings, and a 
change to the dosage 
and administration 
Highlights the risk of death and serious cardiovascular events when the Hb target 
is greater than 12 g/dL and in specific patient categories; recommends avoiding 
serious cardiovascular and arterial and venous thromboembolic events using the 
lowest possible ESA dose to reach the lowest Hb level possible to avoid RBC 
transfusions. Added warnings about increased mortality, cardiovascular events, 
tumor progression and uncontrolled hypertension. Recommended withholding 
ESA dose if Hb increase exceeds 12 g/dL or rises by 1g/dL in any 2-week period. 
November 
2007 
Expanded black box 
warning and more 
specific dosing 
language 
Revisions warn that data are not sufficient to exclude the possibility of shortened 
survival and tumor progression in patients with cancer when ESAs are dosed to 
reach a Hb level between 10 and 12 g/dL. Added information that ESAs caused 
tumor growth and shortened survival in patients with advanced breast, head and 
neck, lymphoid, and non–small-cell lung cancer when they received a dose that 
attempted to achieve Hb ≥12 g/dL. 
March 2008 Changed black box 
warning, modified 
labeling information 
Described the results of two additional studies37,51 showing increased mortality 
and more rapid tumor progression in patients with nonadvanced breast and 
cervical cancers when dosed to target Hb of ≥12 g/dL. 
July 2008 Expanded black box 
warning; dosing 
language modified 
ESAs should not be used in cancer patients receiving chemotherapy if a cure is 
anticipated. Also included is a statement that ESAs are not to be administered 
when Hb levels are ≥ 10 g/dL. Language was removed that seemed to imply that 
it was safe to continue treating patients until their Hb increased to 12 g/dL. 
February 
2010 
Announcement of risk 
evaluation and 
mitigation strategy 
(REMS) 
The FDA requires all ESAs to be prescribed and used under the ESA APPRISE 
(Assisting Providers and cancer Patients with Risk Information for the Safe use of 
ESAs) Oncology Program, part of a REMS, to ensure safe use of the drugs. ESA 
manufacturers must ensure that only those hospitals and healthcare professionals 
who have enrolled and completed training in the ESA APPRISE program will 
prescribe and dispense ESAs to patients with cancer. The ESA APPRISE 
program began on March 24, 2010. 
June 2011 More conservative 
dosing guidelines for 
ESA use in treating 
anemia in patients 
CKD added to black 
box warning. 
In controlled trials with CKD patients, patients experienced greater risks for death, 
serious adverse cardiovascular reactions, and stroke when administered ESAs to 
target a hemoglobin level of greater than 11 g/dL. Thus, the recommended 
hemoglobin level for starting ESA treatment is less than 10 g/dL. 
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Current Guidelines for ESA Use in Cancer Patients 
Table 2 summarizes important points of the FDA-approved label information, which is 
similar for all approved ESAs,36,52,53 and parallel information from joint guidelines for ESA use 
prepared by the American Society of Clinical Oncology (ASCO) and the American Society of 
Hematology (ASH),54,55 and from the National Comprehensive Cancer Network (NCCN) 
Guidelines for Cancer and Chemotherapy-Induced Anemia.56 
KQs and Rationale for Update 
The Southern California EPC reviewed a sample of literature published through 2008 and 
obtained four expert opinions regarding the need to update conclusions for each KQ57 included in 
the 2006 CER.1 The consistency and strength of the evidence and expert opinion supporting 
recommendations to update specific key questions were evaluated by the EPC together with 
more recent evidence. Based on that appraisal, the three KQs listed below were judged relevant 
and are the questions addressed in this CER and illustrated in the analytic framework (Figure 1). 
KQ1: What are the comparative benefits and harms of erythropoiesis 
stimulating agent (ESA) strategies and non-ESA strategies to manage 
anemia in patients undergoing chemotherapy or radiation for malignancy 
(excluding myelodysplastic syndrome and acute leukemia)? 
Outcomes of interest include overall survival (on-study and longest available follow-up), 
progression-free survival, quality of life, hematologic responses, transfusions, tumor response to 
therapy, thromboembolic complications, and other adverse events. Specific comparisons to be 
included are: 
1. Epoetin alfa or beta versus no ESA; 
2. Darbepoetin versus no ESA; 
3. Epoetin alfa or beta or darbepoetin versus no ESA; and 
4. Epoetin alfa or beta versus darbepoetin. 
KQ2: How do alternative thresholds for initiating treatment compare as 
regards their effect on the benefits and harms of erythropoietic stimulants? 
Evidence is limited to directly comparative data from randomized controlled trials. Outcomes 
of interest to include: hematologic response (change in hemoglobin or hematocrit), proportion of 
patients transfused, quality of life, survival (overall and progression-free), and adverse effects. 
KQ3: How do different criteria for discontinuing therapy or for optimal 
duration of therapy compare as regards their effect on the benefits and 
harms of erythropoietic stimulants? 
Evidence is limited to directly comparative data from randomized controlled trials. Outcomes 
of interest to include: hematologic response (change in hemoglobin or hematocrit), proportion of 
patients transfused, quality of life, survival (overall and progression-free), and adverse effects.   
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Table 2. ESA prescribing information and guidelines relevant to ESA use in cancer patients 
Topic 
FDA-Approved Full Prescribing 
Information (similar for all approved 
ESAs)36,52,53 
American Society of Clinical 
Oncology/American Society of 
Hematology Clinical Practice Guideline 
Update54,55 
NCCN Guidelines, Cancer and 
Chemotherapy-Induced Anemia  
(V 2.2012)56 
ESAs are 
indicated for: 
The treatment of anemia due to the effect of 
concomitantly administered 
myelosuppressive chemotherapy 
ESAs are a recommended treatment option 
for patients with chemotherapy-associated 
anemia; red blood cell transfusion may also 
be an option. 
ESAs are also a treatment option for patients 
with lower risk myelodysplastic syndrome 
(MDS) who are not undergoing concurrent 
chemotherapy. 
“Although the FDA label now limits the 
indication for ESA use to patients receiving 
chemotherapy for palliative intent . . . 
determining the treatment intent requires 
clinical judgment of an individual patient’s 
circumstances.” 
 
Patients undergoing palliative treatment or 
myelosuppressive chemotherapy without 
curative intent may be treated with ESAs 
using FDA-approved 
indications/dosing/dosing adjustments OR 
may be treated with red blood cell 
transfusions per provided guidelines. 
Patients with anemia due to 
myelosuppressive chemotherapy should be 
assessed for risk of adverse events due to 
anemia, and need for initial transfusion. 
ESAs are NOT 
indicated for: 
Use in patients receiving hormonal agents, 
therapeutic biologic products, or 
radiotherapy unless receiving concomitant 
myelosuppressive chemotherapy; 
Use in patients receiving myelosuppressive 
therapy when the anticipated outcome is 
cure due to the absence of studies that 
adequately characterize the impact of ESAs 
on progression-free and overall survival; 
The treatment of anemia in cancer patients 
due to other reasons. 
As a substitute for RBC transfusion for 
immediate correction of anemia. 
Clinicians should consider other correctable 
causes of anemia before considering ESA 
therapy. 
Recommends against using ESAs to treat 
anemia associated with malignancy in 
patients (excepting those with lower risk 
MDS) who are not receiving concurrent 
myelosuppressive chemotherapy. 
ESA treatment is not recommended when 
patients are treated with myelosuppressive 
chemotherapy with curative intent. 
ESA treatment 
symptom 
outcomes 
ESA use has not been demonstrated in 
controlled clinical trials to improve quality of 
life, fatigue, or patient well-being. 
Evidence does not conclusively show that 
ESA use leads to improved quality of life as 
can be perceived and valued by patients; 
recommends that the goal of ESA use 
should be to avoid transfusions. 
 
Not discussed. 
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Table 2. ESA prescribing information and guidelines relevant to ESA use in cancer patients (continued) 
 
FDA-Approved Full Prescribing 
Information (similar for all approved 
ESAs)36,52,53 
American Society of Clinical 
Oncology/American Society of 
Hematology Clinical Practice Guideline 
Update54,55 
NCCN Guidelines, Cancer and 
Chemotherapy-Induced Anemia  
(V 2.2012)56 
Risk evaluation 
and mitigation 
strategy (REMS) 
Prescribers and hospitals must enroll in and 
comply with the ESA APPRISE (Assisting 
Providers and cancer Patients with Risk 
Information for the Safe Use of ESAs) 
Oncology Program, part of a REMS, to 
prescribe and/or dispense ESAs to patients 
with cancer. 
 
Notes requirement Notes requirement 
Hb levels for ESA 
initiation 
ESA therapy should not be initiated at Hb 
levels ≥10 g/dL. 
Recommended when Hb level has 
decreased to <10 g/dL. Whether or not to 
initiate treatment when Hb is between 10 
and 12 g/dL should be determined by clinical 
judgment, consideration of ESA risks and 
benefits (transfusion avoidance) and patient 
preferences. Transfusion is also an option. 
If Hb is ≤11 g/dL or >2 g/dL below baseline, 
an evaluation for possible causes of anemia 
is suggested. If a cause is not identified, 
then anemia due to myelosuppressive 
chemotherapy is considered.  
When anemia symptoms, risk, or co-
morbidities indicate, ESAs are a treatment 
option (along with RBC transfusion), per 
FDA-approved indications, unless treatment 
intent is curative. 
 
Span of ESA 
treatment 
ESA therapy should be discontinued 
following the completion of a chemotherapy 
course. 
Recommends discontinuing ESA treatment 
when chemotherapy concludes, per FDA 
guidelines. 
Physicians are advised not to administer 
ESAs outside the treatment period of 
cancer-related chemotherapy. 
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Table 2. ESA prescribing information and guidelines relevant to ESA use in cancer patients (continued) 
 
FDA-Approved Full Prescribing 
Information (similar for all approved 
ESAs)36,52,53 
American Society of Clinical 
Oncology/American Society of 
Hematology Clinical Practice Guideline 
Update54,55 
NCCN Guidelines, Cancer and 
Chemotherapy-Induced Anemia  
(V 2.2012)56 
ESA dosing 
modifications 
Starting ESA dose should be reduced by 
25% when Hb reaches a level needed to 
avoid transfusion or increases >1 g/dL in any 
2-week period. 
ESA dose should be withheld if Hb exceeds 
a level needed to avoid transfusion. (Restart 
at 25% below the previous dose when the 
Hb approaches a level where transfusions 
may be required.) 
Starting ESA dose may be increased (per 
specific product label) if response after 4 
weeks Hb increases by less than 1 g/dL and 
remains below 10 g/dL. 
ESA should be discontinued if after 8 weeks 
of therapy if there is no response as 
measured by Hb levels or if transfusions are 
still required. 
 
Recommends ESA starting doses and dose 
adjustments follow FDA guidelines, noting 
that alternative doses and schedules have 
not improved medical outcomes.  
Refers to product label directing clinicians to 
use the lowest possible ESA dose (i.e., 
minimize ESA exposure) to reach the lowest 
hemoglobin level sufficient to avoid RBC 
transfusions.  
Dosing and titration directions for epoetin-
alfa and darbepoetin-alfa are reproduced 
from the FDA-approved labels. 
Hb target None given (“level needed to avoid 
transfusion”) 
 
Hb can be raised to the lowest hemoglobin 
level needed to avoid RBC transfusions. An 
optimal target Hb cannot be determined from 
the available evidence. 
No Hb target is mentioned; notes that the 
risks of shortened survival and tumor 
progression have not been excluded when 
ESAs are dosed to a target Hb <12 g/dL. 
Iron Prior to and during ESA therapy, should be 
evaluated. Virtually all patients will 
eventually require supplemental iron. 
Iron studies at baseline and periodically 
during treatment may be valuable to 
minimize the need for ESA treatment, 
maximize improvement of symptoms, or 
determine the reason for failure to respond. 
Iron studies and supplementation of 
functional iron deficiency are recommended 
for patients treated with ESAs. 
Survival The black box warning states that ESAs 
shortened overall survival and/or increased 
the risk of tumor progression or recurrence 
in clinical studies of patients with breast, 
non-small cell lung, head and neck, 
lymphoid, and cervical cancers. 
Evidence on survival outcomes is reviewed 
and discussed. The guideline recommends 
the use of clinical judgment in assessing 
risks vs. benefits of ESA use for individual 
patients. 
 
Decreased survival is listed as a risk of ESA 
use in the cancer setting. Evidence is briefly 
discussed and cited; a link to further 
information on the FDA website is provided. 
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Table 2. ESA prescribing information and guidelines relevant to ESA use in cancer patients (continued) 
 
FDA-Approved Full Prescribing 
Information (similar for all approved 
ESAs)36,52,53 
American Society of Clinical 
Oncology/American Society of 
Hematology Clinical Practice Guideline 
Update54,55 
NCCN Guidelines, Cancer and 
Chemotherapy-Induced Anemia  
(V 2.2012)56 
Thromboembolic 
risk 
Using ESAs to target a hemoglobin level of 
greater than 11 g/dL increases the risk of 
serious adverse cardiovascular reactions 
and has not been shown to provide 
additional benefit. 
 
Caution is urged in the use of these agents 
with patients judged to be at high risk for 
thromboembolic events, and regarding ESA 
use together with therapies that increase risk 
of thromboembolic events. 
Patients with previous risk factors for 
thrombosis may be at higher risk when 
administered ESAs and should undergo risk 
assessment; the risk of ESA-associated 
thrombosis is independent of Hb levels.  
Response to 
treatment 
If the patient fails to respond or to maintain a 
response to doses within the recommended 
dosing range after 8 weeks of therapy, ESA 
treatment should be discontinued and other 
etiologies of anemia should be considered 
and evaluated. 
If a patient does not respond to ESAs after 6 
to 8 weeks, despite a dose increase, ESA 
therapy should be discontinued and the 
clinician should investigate possible 
underlying tumor progression, iron 
deficiency, or other causes of the anemia. 
ESA therapy should be discontinued if a 
patient shows no response despite iron 
supplementation after 8-9 weeks of 
treatment. 
ESA = erythropoietic-stimulating agent; FDA = U.S. Food and Drug Administration; Hb = hemoglobin; MDS = myelodysplastic syndrome; NCCN = National Comprehensive 
Cancer Network; RBC = red blood cell 
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Figure 1. Analytic framework for effectiveness of epoetin and darbepoetin for managing anemia in 
patients undergoing cancer treatment—update 
 
ESAs = erythropoietic-stimulating agents; Hct = hematocrit; KQ = Key Question; QoL = quality of life  
A brief summary of the rationale applied to updating key questions from the 2006 CER 
follows. 
The 2006 CER revealed safety concerns for erythropoietic stimulants. Moreover, these safety 
concerns could not be narrowly attributed to use of ESAs to achieve high hemoglobin (Hb) 
targets, but might also be associated with usual use according to the label at the time. 
In 2007, the FDA issued warnings and labeling changes consistent with the safety concerns 
that we raised in the 2006 CER. As noted in the rationale for an updated review,57 the “CER may 
need updating based on new data presented to the FDA and difference in expert opinion.” 
The 2006 findings on quality of life were not judged to require updating.57 The EPC agreed 
in substance and noted that the FDA has stated that there is insufficient evidence to support 
claims of improved quality of life with use of ESAs. However, it was judged important that 
issues surrounding quality of life be at least qualitatively addressed, and quantitatively examined 
for the most important and commonly ascertained outcome—fatigue. The principles of critical 
appraisal of use and interpretation of disease-specific quality of life instruments that were raised 
in the 2006 CER should continue to be accessible to users of the current Update. Moreover, these 
points should be tied to the Guidance for measurement of patient-reported outcomes that was 
issued by the FDA in 2008. 
Issues raised in the 2006 CER were broader than a comparison of epoetin and darbepoetin, 
and were more fundamentally a question of approaches to managing anemia of cancer treatment. 
Thus for the current Update, the proposed KQs were modified accordingly. Most notably, KQ1 
was been modified from “What are the comparative efficacy and safety of epoetin (alfa or beta) 
and darbepoetin?” to “What are the comparative benefits and harms of erythropoiesis-stimulating 
(ESA) strategies and non-ESA strategies to manage anemia in patients undergoing chemotherapy 
or radiation for malignancy?” 
An update of KQ2 was not recommended57— “How do alternative dosing strategies affect 
the comparative efficacy and safety of epoetin (alfa or beta) and darbepoetin?” and the TEC EPC 
concurred. It is not included in the current Update KQs. 
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KQ 3, “How do alternative thresholds for initiating treatment or alternative criteria for 
discontinuing therapy or the duration of therapy affect the comparative efficacy and safety of 
epoetin (alfa or beta) and darbepoetin?” was judged as needing updating due to FDA changes to 
labeling and expert opinion.57 Accordingly, the question is included in the current Update. 
Finally, an update of KQ4 was not recommended,57 “Are any patient characteristics at 
baseline or early hematologic changes useful to select patients or to predict responses to 
treatment with erythropoietin?” This recommendation was based on expert opinion that referred 
to patient treatment characteristics and FDA labeling. However, the BCBSA TEC EPC judged 
that updating this question would be of little value. The literature reviewed in the 2006 CER was 
related to single or multifactorial algorithmic predictive testing. None was promising, and the 
literature has no bearing on the FDA changes to labeling, which are closely tied to the evidence 
for KQ1. This question was not included in the update. 
Table 3 reviews the current ESA approval status and approved starting dose. 
Table 3. ESAs, approval status, and approved starting dose 
ESA Approval Status U.S. 
Approval Status 
European Union Approved Dose 
Epoetin alfa EPOGEN® (Amgen)  
 
PROCRIT® (Ortho 
Biotech) 
Eprex® (Janssen-Cilag) Epoetin alfa preparations are formulated 
for IV or SC administration. The 
recommended adult starting dose is 150 
Units/kg SC 3 times per week or 40,000 
Units SC weekly. Dose may be modified 
depending on Hb response. 
Darbepoetin alfa Aranesp® (Amgen) Aranesp® (Amgen) Aranesp® is formulated for IV or SC 
administration. The recommended initial 
adult dose is either 2.25 mcg/kg SC 
weekly or 500 mcg SC every 3 weeks. 
Dose may be modified depending on Hb 
response. 
Epoetin beta Not approved for use 
in the U.S.* 
NeoRecormon® 
(Hoffmann-La Roche) 
NeoRecormon® is formulated for IV or SC 
administration. The recommended initial 
dose is 30,000 IU per week given as one 
injection per week or in divided doses 3 to 
7 times per week. Dose may be modified 
depending on Hb response. 
ESA = erythropoietic-stimulating agent; Hb = hemoglobin; IV = intravenous; IU = international unit; kg = kilogram;  
mcg = microgram; SC = subcutaneous 
*See also Background. While not approved in the United States, effects are considered exchangeable with epoetin alfa.   
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Methods 
This report updates the 2006 report, “Comparative Effectiveness of Epoetin and Darbepoetin 
for Managing Anemia in Patients Undergoing Cancer Treatment.” The current chapter describes 
the search strategies used to identify literature; criteria and methods for selecting eligible articles; 
methods for data abstraction, quality assessment, and evidence synthesis; and, finally, the 
process for technical expert advice and peer review. General and specific guidance from the 
AHRQ Methods Guide for Effectiveness and Comparative Effectiveness Reviews was used 
throughout to advise review conduct.58 
A Technical Expert Panel (TEP) provided consultation for the development phase of the 
systematic review. The draft report was reviewed by external peer reviewers. Revisions were 
made to the draft report based on reviewers’ comments. 
Search Strategies 
The search for randomized controlled trials published subsequent to the 2006 Report was 
initially updated through electronic searching of the Cochrane Central Register of Controlled 
Trials Register (CENTRAL, 03/2005 to 11/2009), MEDLINE® (03/2005 to 10/2009), and 
Embase (03/2005 to 10/2009). Electronic searching also included the conference proceedings of 
the American Society of Clinical Oncology (03/2005 to 10/2009), European Society of Medical 
Oncology (03/2005 to 10/2009), and American Society of Hematology (03/2005 to 10/2009). 
A separate search for comparative observational studies, primarily to augment the evidence 
on adverse events, was conducted in MEDLINE® only. A separate search for published meta-
analyses and individual patient data analyses addressing outcomes of ESA treatment was 
conducted in PubMed and Cochrane databases in March 2010. 
Literature searches were updated (through 12/2011) prior to finalizing the report to determine 
if any new studies were published that might potentially impact the review. New studies were 
screened and evaluated against inclusion/exclusion criteria in the same manner as all other 
studies. Those meeting criteria were included as well as any recent publications of results from 
previously included studies. 
TEP members were invited to provide additional studies. Studies suggested by stakeholders 
during the public review period were also evaluated against inclusion/exclusion criteria in the 
same manner as all other studies. In addition, we received the following materials from the 
Scientific Resource Center: 
1. A search of the grey literature included following sources: regulatory information, 
clinical trial registries (completed trials only), abstracts and conference papers, grants and 
federally funded research, and other miscellaneous sources. 
2. Scientific information packets submitted by Amgen and Centocor Ortho Biotech, Inc. 
All search results were compiled into an EndNote® reference manager database with 
exclusion of duplicates. 
Additional details on these materials and results of our review are provided in the Results 
chapter. Search strategies are detailed in Appendix A.  
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Grey Literature 
The Scientific Resource Center for the AHRQ Effective Health Care Program conducted a 
search of the following grey literature sources in support of this review: 
• Regulatory Information 
a. FDA 
b. Health Canada 
c. Authorized Medicines for EU 
• Clinical Trial Registries (completed trials only) 
a. ClinicalTrials.gov 
b. Current Controlled Trials 
c. Clinical Study Results 
d. WHO Clinical Trials 
• Abstracts and Conference Papers 
a. Conference Papers Index 
b. Scopus 
• Grants and Federally Funded Research 
a. NIH RePORTER (a searchable database of federally funded biomedical research 
projects conducted at universities, hospitals, and other research institutions) 
b. HSRPROJ (a database providing access to ongoing grants and contracts in health 
services research) 
• Other Miscellaneous Sources  
a. Hayes, Inc. Health Technology Assessment 
b. NY Academy of Medicine’s Grey Literature Report 
These sources were searched using sensitive searches similar to the searches in bibliographic 
databases. Citations for published articles linked to trials registered at ClinicalTrials.gov were 
included. 
We evaluated the results of the grey literature search with results summarized in Figure 2. 
Twenty-six literature citations were already included in our reference database. Fifty-six 
references were reviewed at the abstract or summary level, in duplicate, and were excluded 
according to our study protocol. Seven references were retrieved in full and all were excluded (or 
had already been included) according to our study protocol. Thus, no new references were added 
to our review as a result of the grey literature search. We were unable to identify results, 
publications, or reports from 49 trial registry entries noted as completed trials (no results, 
citations, or links to results were listed in the trial registry entries). 
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Figure 2. PRISMA diagram for identified grey literature 
 
Citations from grey literature 
Search
(N=240)
References
(N=175)
Clinical Trial Registry
(N=78)
Duplicate references 
(N=65)
NCT (N=69)
ISRCTN (N=4)
Clinicaltrial.jp (N= 3)
Trialregister.nl (N= 2)
No results posted 
on host website 
(N=49)
Identified published 
papers from trials
(N=32)
New references
(N=6)
Duplicate 
References
(N=26)
Unique citations in grey 
literature search
(N=97)
References
(N=103)
Regulatory documents
(N=8)
EU (N=1)
FDA (N=6)
Canada (N=1)
Title and abstract screen
(N=95)
Excluded
(N=90)
Full text review
(N=5)
Excluded
(N=5)
Reasons:
  • Not RCT (N=3)
  • Duplicate (N=1)
  • <50 patients/arm (N=1)
EU = European Union; FDA = U.S. Food and Drug Administration; ISRCTN = International Standard Randomised Controlled 
Trials Number; NCT = Nationales Centrum für Tumorerkrankungen (National Center for Tumor Diseases); RCT = randomized 
controlled trial 
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Scientific Information Packets 
Industry stakeholders were invited to submit the following types of information for possible 
inclusion as evidence: 
 A current product label; 
 Published randomized controlled trials and observational studies relevant to the clinical 
outcomes; and 
 Unpublished randomized controlled trials and observational studies relevant to the 
clinical outcomes. 
In response, scientific information packets (SIPs) were received from Centocor Ortho 
Biotech, Inc. and Amgen. Disposition of the material can be found in Figure 3. In addition to 
product labels, the submissions consisted of either published references or listings of clinical 
trials; no unpublished data were provided by either company. 
Product Labels 
All submitted product labels, which included labels for countries other than the United 
States, were reviewed for clinical studies that were not included in our search. No new studies 
were found. 
References 
Centocor Ortho Biotech, Inc. submitted 56 citations and Amgen submitted 165. These were 
first compared to our database excluding duplicates. Of the 71 remaining references, 18 were 
duplicates. One reviewer reviewed abstracts for the 53 outstanding references; 10 were identified 
for full review; and those remaining were excluded as not relevant or already were addressed in 
our review. A second reviewer evaluated the 10 studies in full; all were excluded. 
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Figure 3. PRISMA diagram for scientific information packets 
Scientific Information Packet 
References
(N=71)
Duplicates
(N=18)
Title and abstract screen
(N=53)
Excluded
(N=48)
Full text review
(N=5)
Excluded
(N=5)
Reasons:
  • Dose finding (N=1)
  • Observational not
    meeting inclusion
    criteria (N=1)
  • <50 patients/arm (N=2)
  • Ongoing trial (N=1)
Amgen (N=165)
Centocor Ortho Biotech (N=56)
In database
(N=150)
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Observational Studies 
We identified 175 observational studies in the MEDLINE® search. Disposition of the studies 
according to selection criteria is shown in Figure 4. 
Figure 4. PRISMA diagram for observational studies 
 
Trials 
Sources and disposition for identified trials are shown in Figure 5 and Figure 6.   
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Figure 5. PRISMA diagram for identified trials—KQs 
 
KQ = Key Question; RCT = randomized controlled trial   
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Figure 6. PRISMA diagram for identified trials—KQ1, tumor progression  
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Meta-Analyses 
Figure 7 outlines the identification of meta-analyses and systematic reviews. 
Figure 7. PRISMA diagram for meta-analyses  
 
FDA = U.S. Food and Drug Administration   
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Study Selection Criteria 
Study selection criteria were drafted and described in detail for randomized controlled trials 
and meta-analyses in Table 4. A primary source for survival evidence was a recently published 
individual patient data meta-analysis.48 In that meta-analysis, patient data were obtained from 
investigators for studies enrolling more than 50 patients per arm. Because those data constitute 
the most currently available, as well as the source for on-study mortality data, we limited 
inclusion in the current report to similar size studies to avoid potential differential endpoint 
ascertainment in smaller studies. This contrasts with the previous report that included studies 
enrolling 10 or more patients per arm. Sensitivity analyses were performed for each outcome 
including any studies excluded for that reason. Inclusion criteria for comparative observational 
studies were as in Table 4 except for “Types of studies.” Exclusion criteria were also the same 
except that studies enrolling fewer than 250 patients were excluded. 
Table 4. Inclusion/exclusion criteria for randomized controlled trials; and study-level and 
individual patient data meta-analyses 
 Inclusion Criteria Exclusion Criteria 
Types of 
studies 
• Randomized controlled clinical trials. 
• For studies where the specific randomization 
method is unclear, but the study is described 
as “randomized,” retain and categorize as 
“randomization unclear.” 
• Study-level and individual patient data meta-
analyses.  
• Studies in European languages such as 
German, French, and Spanish; no effort will 
be made to translate languages such as 
Chinese or Arabic. 
• Trials with inadequate allocation 
concealment, e.g. where patients were 
allocated by alternation, the use of case 
record numbers, dates of birth or day of 
week, and any other procedure that is 
transparent before allocation, such as an 
open list of random numbers. Trials with 
unclear allocation concealment were 
retained. 
• Trials with 50 or fewer randomized 
participants per study arm for studies of 
adults; 10 or fewer participants per study 
arm in pediatric samples. 
• Ongoing studies and interim analyses. 
Sources of 
evidence 
• Full text publications. 
• Meeting abstract publications, PowerPoint 
presentations, or posters. 
• Supplementary data communicated by 
primary authors of included trials or studies. 
• Data presented at the ODAC, FDA hearings 
on May 10, 2007 and March 13, 2008. 
These data will be taken from the official 
FDA report and documents submitted by 
pharmaceutical companies and posted on 
the FDA’s Web site. These documents 
include both reports and power point 
presentations and are publicly available. 
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Table 4. Inclusion/exclusion criteria for randomized controlled trials; and study-level and 
individual patient data meta-analyses (continued) 
 Inclusion Criteria Exclusion Criteria 
Types of 
participants 
• Only participants diagnosed with malignant 
disease, using clinical or 
histological/cytological criteria, regardless of 
type or stage of the disease or previous 
therapy.  
• Only participants who are anemic or at risk 
for anemia from chemotherapy and/or 
radiotherapy or the underlying malignant 
disease.  
Patients of any/all ages. 
• Studies of patients with a malignant disease 
NOT undergoing anticancer therapy. 
• Studies of high-dose myeloablative 
chemotherapy regimens followed by bone 
marrow or peripheral blood stem cell 
transplantation. 
• Studies using erythropoietin for short-term 
preoperative treatment to correct anemia or 
to support collection of autologous blood 
prior to cancer surgery for use during or after 
surgery. 
• Studies in which patients received surgical 
treatment while being administered ESA. 
Studies on patients with myelodysplastic 
syndrome or acute leukemia. 
Types of 
interventions 
• Trials on the use of erythropoietin plus 
chemotherapy and/or radiotherapy and red 
blood cell transfusions if necessary, 
compared with identical anticancer therapy 
and red blood cell transfusions if necessary 
(alone or with placebo) will be included.  
• Dose adaptation of erythropoietin depending 
on hematologic response allowed. 
Concomitant supportive treatments, e.g., 
granulocyte colony-stimulating factors (G-
CSF), must be given equally in all study 
arms or any differential effect of supportive 
treatments on outcomes ascertainable, 
EXCEPT studies where iron was given only 
in the ESA arm. These studies will be 
included and sensitivity analyses conducted 
with vs. without them. 
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Table 4. Inclusion/exclusion criteria for randomized controlled trials; and study-level and 
individual patient data meta-analyses (continued) 
 Inclusion Criteria Exclusion Criteria 
Types of 
outcome 
measures 
• Hematologic response: proportion of 
patients with an increase in hemoglobin level 
of 2 g/dl or more, or increase in hematocrit of 
6 points or more, independent of blood 
transfusions. 
• Proportion of patients receiving red blood 
cell transfusions. 
• Quality of Life data will be only abstracted 
from studies employing a validated 
instrument, such as SF-36; EORTC Quality 
of life Questionnaire (QLQ-C30); Functional 
Assessment of Cancer Therapy (FACT, 
including G-General; F-Fatigue; An-Anemia). 
Sample size and extent of missing data will 
be extracted. 
• Tumor response will only be evaluated in 
studies that were prospectively designed to 
assess tumor response, i.e., studies with a 
homogeneous patient population undergoing 
a predefined anticancer therapy, with 
predefined criteria when and how tumor 
response will be assessed and a clear 
definition of tumor response. 
• Overall survival, disease-free, and 
progression-free survival. 
Adverse effects limited to thromboembolic 
events, hypertension, rash and similar 
symptoms, seizures, rEPO antibodies, and 
transfusion adverse events. 
Linear Analog Scale Assessment (LASA), 
Visual Analog Scale (VAS), and Cancer 
Linear Analog Scale (CLAS) scales will be 
excluded 
Randomized Controlled Trial Selection 
One reviewer screened titles and abstracts of trials identified from the above sources against 
the inclusion/exclusion criteria. If this could not be done satisfactorily from the title and abstract, 
a full-text version was obtained for review. We evaluated studies that appeared to meet the 
inclusion criteria in the initial screening with an eligibility form containing the following 
questions: 
1. Is the study described as randomized? 
2. Did the participants in the study have a previously treated or untreated malignant disease? 
3. Were the participants anemic or at risk for anemia from chemotherapy and/or 
radiotherapy? 
4. Was one group given epoetin (alfa or beta) or darbepoetin subcutaneously or 
intravenously for at least four weeks? 
5. Did the control group receive the same care (e.g., chemotherapy and supportive 
therapies) with or without placebo, or is any differential effect of supportive treatments 
on outcomes ascertainable? (Note exception for iron supplementation; see Criteria for 
Considering Studies, Types of Interventions.) 
6. Did the study document one of the relevant outcome measures? 
Eligible trials met all of the criteria listed above. Disagreements between the reviewers were 
resolved by discussion. Duplicate studies were identified and data extracted from the most recent 
publication. However, if there were additional data in one of the older publications, these were 
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extracted as well. Full-text versions of all eligible studies were obtained for quality assessment 
and data extraction. A list of studies excluded, with reasons for exclusion, can be found in 
Appendix B. Detailed data abstraction/evidence tables can be found in Appendix C. 
Observational Study Selection 
A first reviewer screened titles and abstracts of identified studies from the above sources 
against the eligibility criteria. If the first reviewer was unable to categorize the study, it was 
screened by a second reviewer and inclusion/exclusion status established by consensus. If this 
could not be done satisfactorily from the title and abstract, a full-text version was obtained for 
review. Eligible studies met the following criteria: 
1. Was treatment assignment (use) nonrandom? 
2. Were there more than 250 subjects? 
3. Did the participants in the study have a previously treated or untreated malignant disease? 
4. Were the participants anemic or at risk for anemia from chemotherapy and/or 
radiotherapy? 
5. Was epoetin (alfa or beta) or darbepoetin given subcutaneously or intravenously for at 
least 4 weeks? 
6. Did the study document one of the relevant outcome measures (benefit or harm)? 
7. In the study analyses was one of the following techniques used to examine causal effects: 
(a) appropriate propensity score approaches, (b) instrumental variable methods, (c) 
inverse probability weighting, or (d) G-estimation techniques to take into account 
potential bias. 
Selection criteria were defined to identify both carefully conducted observational studies 
(registry or otherwise) accompanied by analyses that could account to nonrandom treatment 
assignment (criterion 7) to identify causal effects. Of particular interest was identifying studies 
that examine dose effects while accounting for time-varying confounding of hemoglobin levels.  
Study and Independent Patient-Level Meta-Analysis 
Selection 
Both study- and patient-level meta-analyses examining benefits or harms of ESA treatment 
were included. Progression-free or disease-free survival study-level results from industry-funded 
meta-analyses were also included if the original study was designed to evaluate that outcome. 
Assessment of Methodologic Quality 
Quality Assessment of Included Randomized Clinical Trials 
Two reviewers evaluated the full text articles included in the review for study quality. Any 
discordance was discussed with the project group until consensus was obtained. We used a 
modification of the The Cochrane Collaboration’s tool for assessing risk of bias (The Cochrane 
Handbook, Table 8.5.a)59 containing the following questions: 
1. Was allocation truly random? 
2. Was the treatment allocation concealed? 
3. Were study participants blinded (masked) to the treatment they received? 
4. Were study clinicians blinded (masked) to the treatment received by individual study 
participants? 
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5. Were the number of patient withdrawals, dropouts, and those lost to follow-up in each 
group stated in the main publication? 
6. Did the analysis include an intention-to-treat analysis? That is, did the analysis include all 
patients randomized according to their randomized assignment? 
7. Were the participant characteristics similar at baseline in the study groups compared? 
For health-related quality-of-life studies (HRQoL), we also evaluated whether patients were 
blinded to their hemoglobin levels when HRQoL questionnaires were completed. For studies for 
which there were several reports/analyses, we used our best judgment for accurately and 
efficiently assessing quality (study level was the default). 
Trials were excluded from the analysis if they were not truly randomized or had inadequately 
concealed allocation. Studies that met all criteria listed below were included in the group of 
higher quality trials for purposes of sensitivity analysis.  
1. The study was a randomized controlled trial (see details under Criteria for Study 
Selection). 
2. The study was double blind. 
3. At least one of the following conditions was true: Less than 10 percent of subjects within 
each study arm were excluded from the analysis and the percentage of subjects excluded 
from analysis in each arm was less than 2:1; or less than 5 percent of subjects were 
excluded in each study arm. 
Quality Assessment of Published Meta-Analyses 
AMSTAR (Assessment of Multiple Systematic Reviews) is a validated instrument used for 
quality assessment of meta-analyses.60 While the instrument has been validated with study-level 
meta-analyses, nine of the 11 elements apply directly and the remaining two elements indirectly 
to individual patient meta-analyses. Accordingly, the instrument was applied to all meta-
analyses. 
Quality Assessment of Observational Studies 
No quality assessment of observational studies was conducted (no studies met inclusion 
criteria). 
Data Extraction 
One reviewer performed data extraction for the review using a standardized data extraction 
form modified slightly from the previous systematic review (Appendix D), including the types of 
items listed below. An independent reviewer checked abstracted data. 
For randomized controlled clinical trials, the following were abstracted: 
1. General information: title, authors, source, contact address, year of publication, duplicate 
publications, setting, funding. 
2. Trial characteristics: design, method of randomization, concealment of allocation, 
blinding of patients and clinicians. 
3. Patients: sampling, exclusion criteria, sample size, baseline characteristics, similarity of 
groups at baseline, diagnostic criteria, withdrawals, losses to followup. 
4. Interventions: placebo use, dose, dosing regimen, duration, route, red blood cell (RBC) 
transfusion trigger, co-medications with dose, route and timing. Outcomes as specified 
previously. 
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5. Analytical methods. 
Any disagreements at any stage were resolved by discussion and consensus. 
Discrepant Data 
For trials published in multiple articles, reports or presentations, we extracted the most recent 
or most comprehensive data. The data of any trial taken from different sources were compared. If 
data from different sources were discrepant, data were selected for analysis using the following 
rules: 
1. We used the most complete data sets (i.e., those with the largest sample size), or data 
with consistently defined outcomes across trials. 
2. If different results were available from the same trial, i.e. “intention-to-treat” and “as 
treated” analyses, we use the intention-to-treat based data for analysis and explored the 
influence of alternative results in sensitivity analyses if appropriate. 
Other Issues 
If a trial only reported the overall number of randomized patients but failed to report the 
number of patients per study arm, we assigned 50 percent of the study patients to each of the 
study arms. For updating reports that were already included in the previous review, the focus was 
on variables important to the analyses, rather than on a global update. 
Trial-level evidence tables were created in Microsoft Excel® and Word®. For summary 
evidence tables, data were entered into Excel® then summarized using and formatted in R.61 
Templates similar to the 2006 report were used. One reviewer performed primary data entry into 
the Excel® evidence tables, and a second performed accuracy checks. 
PRISMA62 or PRISMA-like diagrams were constructed for each KQ and other applicable 
searches (meta-analyses, observational studies, grey literature, scientific information packets). 
Abstracted data used in meta-analyses are either reported in the text or succinctly in 
Appendix G.  
Rating the Body of Evidence 
We rated the overall body of evidence as outlined in the AHRQ EPC Methods Guide for 
Comparative Effectiveness Reviews.63 The EPC approach is largely based on the system 
developed by the GRADE (Grading of Recommendations Assessment, Development and 
Evaluation) Working Group.64 The EPC method explicitly addresses the following domains: risk 
of bias, consistency, directness, and precision. Additional domains are added where appropriate; 
we also considered strength of association and publication bias. We identified five key outcomes 
as the most clinically important for rating: transfusion risk, overall survival, on-study mortality, 
thromboembolic events, and health-related quality-of-life (FACT-Fatigue). 
Strength of evidence was classified into the following four grades: 
1. High: High confidence that the evidence reflects the true effect. Further research is very 
unlikely to change confidence in the estimate of effect. 
2. Moderate: Moderate confidence that the evidence reflects the true effect. Further research 
may change confidence in the estimate of effect and may change the estimate. 
3. Low: Low confidence that the evidence reflects the true effect. Further research is likely 
to change the confidence in the estimate of effect and is likely to change the estimate. 
4. Insufficient: Evidence either is unavailable or does not permit a conclusion. 
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Grading the Evidence 
Two reviewers with primary roles in the report developed consensus for each outcome and 
comparison as follows. First, domains and associated criteria were reviewed alongside AHRQ 
guidance.63 The two reviewers jointly rated domains and rated quality of evidence for each 
outcome and comparison. Agreement was achieved by discussion and consensus. 
Data Analysis 
When study-level outcome data were available from multiple trials (three or more), results 
were pooled in meta-analyses. For overall survival, owing to censoring in individual studies, 
hazard ratios (HR) over the longest follow-up reported were combined in fixed effects models 
using Peto’s method65 for observed and expected events with accompanying variance 
estimates.66,67 For on study mortality, the approach was also used, but because censoring was of 
lesser concern and few deaths occurred in some studies, event rates were additionally pooled in 
Bayesian hierarchical models. From these models posterior 95% credible intervals were 
estimated to convey uncertainty. A credible interval is a Bayesian analogue to the confidence 
intervals—it differs from a confidence interval by representing the probability a true value is 
contained within it, and not the confidence with repeated sampling of including the true value. 
Noninformative priors were specified in these models. To obtain relative risks, the approach 
outlined by Warn et al.68 was adopted. A Bayesian model was also used to examine the 
association between baseline risk (as reflected by control group mortality rate) and relative risk; 
the model accounts for the inherent correlation between relative effect and baseline risk.69 For all 
other meta-analyses, random effects models were fitted and relative risks reported. While values 
of I2 were reported throughout, in many instances its magnitude does not correctly or 
appropriately reflect statistical heterogeneity due to the low event rates in individual trials and 
accompanying imprecision.70 Accordingly and as noted in the Results section, I2 cannot be used 
under such circumstances as an adequate representation of statistical heterogeneity. Between-
study heterogeneity was explored as appropriate in sensitivity analyses examining subgroups 
through meta-regressions. 
Hazard ratios for time to event data were calculated based on individual patient data (IPD) 
when available from Bohlius et al.48 If IPD data were not available, no efforts were made to 
obtain it and the HR calculated from published reports. Recognizing limitations, indications of 
possible publication bias were explored in funnel plots. Funnel plots were inspected, but noted 
only if suggestive of publication bias. Forest plots were included in the main report when 
considered informative. 
Subgroup analyses were performed including the following factors, if feasible and 
appropriate: 
• Hemoglobin at study entry (e.g., continuous and hemoglobin level <10 g/dL versus 10-12 
g/dL versus >12 g/dL) 
• Achieved hemoglobin (e.g., continuous and hemoglobin level 10-11 g/dL versus 11-12 
g/dL versus >12 g/dL) 
• Difference between target and achieved hemoglobin 
• Solid tumors versus hematologic malignancies versus mixed (studies including both solid 
tumors and hematologic malignancies) 
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• Type of treatment given (platinum-based chemotherapy versus chemotherapy without 
platinum; chemotherapy alone versus chemotherapy plus radiotherapy versus 
radiotherapy alone) 
• Radiotherapy alone versus chemotherapy/radio-chemotherapy 
• Planned iron supplementation (e.g., fixed versus as necessary versus none) 
• Planned duration of epoetin or darbepoetin treatment 
• Epoetin versus darbepoetin 
• Study quality (high- versus low-quality studies); (domains of study quality included 
blinding, allocation concealment, and intention to treat analyses) 
• Source of data (full-text publications versus abstract publications versus unreported data 
versus data presented at FDA hearing versus data from published IPD meta-analyses; 
source for data for a given study could differ between outcomes, e.g., survival data taken 
from FDA hearing, transfusion data taken from publication) 
While the protocol included potential categorizations of covariates, to obtain sufficient 
precision (i.e., avoid strata with few trials) subgroup analyses were performed with covariates 
dichotomized into the most clinically relevant categories in meta-regressions. Additionally, there 
was evidence of substantial clinical heterogeneity between trials—design, tumor type, baseline 
and target hemoglobin (defined as the lowest acceptable hemoglobin value—for example, if ESA 
treatment was stopped because of high hemoglobin, it was restarted if hemoglobin level fell 
below this value), chemotherapy, dosing, escalation and de-escalation rules, iron 
supplementation, and length of follow-up, to name a few. Under these conditions, any subgroup 
findings require cautious interpretation and may be problematic. Accordingly, subgroup results 
were explored but not generally discussed at length. Finally, potential ecological bias further 
limits subgroup interpretation (e.g., for hemoglobin). 
Summary descriptive statistics for characteristics of trials included in each meta-analysis 
were calculated based on those reported for the entire trial. Because not all patients were 
included for some outcomes, certain descriptive statistics may not be perfectly precise—e.g., a 
summary statistic was reported for all patients, but the outcome assessed on 95 percent of those 
randomized. Still, the values represent the group of trials examined, albeit with some small 
random error. 
Results in the current report were compared to the 2006 review38 in sensitivity analyses. 
Differences in study inclusion were due to newly identified studies, updated data from recent 
publications, and because inclusion criteria here required more than 50 patients per arm—a 
criterion not previously applied. Also, prior results were generally obtained from fixed effects 
models, while random effects were used here throughout. Consequently, some differences 
between the current and 2006 reviews results may be due to the model used. 
Software 
Analyses were performed using RevMan,71 R61,72-74, and OpenBUGS.75 
Decision Analysis 
To examine the balance of potential benefit and harms, a decision model was developed and 
used to quantify life-years and quality-adjusted life years for representative ESA and non-ESA 
strategies. Utilities accompanying the two alive health states included in the model (9 g/dL and 
11 g/dL) were estimated using those obtained in four manufacturer studies using time trade-off 
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(2 studies) and EQ-5D (2 studies) as reported in a prior technology assessment.76 Midpoints were 
assigned to reported hemoglobin range for the reported utilities and included in a hierarchical 
model (with study as group) to estimate the two utility values used here. Over a 1-year time 
horizon (for the base case and other likely conditions), life years and quality-adjusted life years 
were calculated for a hypothetical cohort of 1,000 patients undergoing 12 weeks of ESA 
treatment and presumed to be at increased risk of mortality through 16 weeks. A 4-week cycle 
(without mid-cycle correction) was used. Other relevant features of the model are described in 
the section “Decision Analysis.” Calculations were performed using Excel® with the model 
replicated in TreeAge Pro.77 
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Results 
Key Question 1 (KQ1). What are the comparative benefits and harms of 
erythropoiesis-stimulating agent (ESA) strategies and non-ESA strategies 
to manage anemia in patients undergoing chemotherapy or radiation for 
malignancy (excluding myelodysplastic syndrome and acute leukemia)?  
Outcomes of interest include overall survival (on-study and longest available followup), 
progression-free survival, quality of life, hematologic responses, transfusions, tumor response to 
therapy, thromboembolic complications, and other adverse events. Specific comparisons to be 
included are: 
1. Epoetin alfa or beta versus no ESA; 
2. Darbepoetin versus no ESA; 
3. Epoetin alfa or beta or darbepoetin versus no ESA; and 
4. Epoetin alfa or beta versus darbepoetin. 
Organization of Results for KQ1 
First, an overview of results for all outcomes is presented (Table 5 through Table 13). A 
detailed tabular listing of trials reporting one or more outcomes is then provided (Table 14); the 
reader is referred there for specific trials included in each pooled result. Next, for each outcome 
and comparison, characteristics of included trials are summarized and results detailed. Changes 
in trials included compared to the previous review are outlined (Appendix Table F1). When 
relevant, sensitivity analyses were performed to account for any trials excluded here, but 
included in the 2006 review. Quality of life and survival outcomes play central roles in 
understanding relative benefit and harms, and contain some differences from the prior report; 
each section accordingly includes discussion of methodologic underpinnings and considerations. 
In addition to meta-analyses of survival outcomes, relevant published meta-analytical results are 
appraised and reviewed. 
Overview of Evidence and Findings for KQ1 
Evidence from three groups of trials were summarized and analyzed (for complete study 
details, refer to Appendix C). Five trials compared darbepoetin to epoetin (N=1,044 to 
darbepoetin, N=1,214 epoetin); 41 trials compared epoetin to control (N=6,048 epoetin, N=5,509 
control); and 8 trials compared darbepoetin to control (N=1,757 darbepoetin, N=1,624 control). 
Trial characteristics differed with respect to: primary and secondary endpoints, reported 
outcomes, types of malignancies, baseline hemoglobin, duration, treatment protocols (e.g., 
frequency of administration and amount, and iron supplementation), publication type, and quality 
ratings (Table 15). Reported target hemoglobin levels (defined on page 29) ranged from 11 g/dL 
to 14 g/dL (mean 12.6 g/dL), but was in only two trials lower than 12 g/dL and in two trials 
higher than 13 g/dL. Three trials comparing epoetin to control (N=286 total) enrolled pediatric 
patients.78-80 
Major findings are summarized in Table 5 through Table 13.   
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Table 5. Overview: hematologic response 
Variable Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Number of trials 2 17 3 20 
Patients analyzed 464 4,242 800 5,042 
Pooled relative risk 0.73 3.6 3.1 3.4 
(95% confidence interval) (0.61 to 0.87) (2.8 to 4.5) (2.4 to 3.9) (2.8 to 4.2) 
I2 0% 78% 0% 64% 
Table 6. Overview: transfusion risk 
Variable Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Number of trials 5 31 7 38 
Patients analyzed 2,005 8,003 2,806 10,809 
Pooled relative risk 1.14  0.58 0.58 0.58 
(95% confidence interval) (0.82 to 1.59) (0.52 to 0.65) (0.51 to 0.65) (0.53 to 0.64) 
I2 43% 60% 0% 51% 
Table 7. Overview: overall survival 
Variable Epoetin vs. Control 
Darbepoetin 
vs. Control 
Epoetin or Darbepoetin vs. 
Control 
Number of trials 37 7 44 
Patients analyzed 11,131 3,147 14,278 
Pooled hazard ratio 1.04a 1.04 1.04b,c 
(95% confidence interval) (0.98 to 1.11) (0.94 to 1.17) (0.99 to 1.10) 
I2 35% 51% 38% 
aIncluding the single trial enrolling pediatric patients 1.04 (0.96 to 1.09). 
bIncluding the single trial enrolling pediatric patients 1.04 (0.99 to 1.10). 
cExcluding the 5 trials classified here as radiotherapy or predominantly radiotherapy34,46,81,82,83 yielded a hazard ratio of 1.03 
(95% CI: 0.97 to 1.09). 
Table 8. Overview: on-study mortality 
Variable Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Number of trials 2 31 6 37 
Patients analyzed 1,567 8,618 2,648 11,266 
Pooled hazard ratio 0.90 1.19a,b 1.05c 1.17d,e,f 
(95% confidence interval) (0.67 to 1.20) (1.05 to 1.36) (0.80 to 1.38) (1.04 to 1.31) 
I2 72% 3% 0% 0% 
aIncluding the trial enrolling pediatric patients left estimate and confidence interval unchanged. 
bEstimate in Bayesian random effects model 1.16 (95% CrI: 1.00 to 1.32). 
cEstimate in Bayesian random effects model 1.10 (95% CrI: 0.76 to 1.58). 
dEstimate in Bayesian random effects model 1.15 (95% CrI: 1.02 to 1.31). 
eIncluding the trial enrolling pediatric patients left estimate and CI unchanged. 
fExcluding the 2 radiotherapy only trials34,81 1.16 (95% CI: 1.03 to 1.31), or the 3 trials classified here as radiotherapy or 
predominantly radiotherapy34,81,83 1.16 (95% CI: 1.03 to 1.30). 
Table 9. Overview: progression-free survival and related outcomes 
22 trials reported some outcome related to survival with disease progression; 3 reported significant 
differences in disease-free or progression-free survival, one trial in favor of epoetin and two in favor of 
control 
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Table 10. Overview: thromboembolic events 
Variable Darbepoetin vs. Epoetin 
Epoetin 
vs. Controla 
Darbepoetin 
vs. Control 
Epoetina or 
Darbepoetin 
vs. Control 
Number of trials 3 31 6 37 
Patients analyzed 1,873 9,585 2,869 12,570 
Pooled relative risk 0.86 1.50 1.53 1.51 
(95% confidence interval) (0.61 to 1.21) (1.26 to 1.77) (1.18 to 2.00) (1.30 to 1.74) 
I2 0% 0% 0% 0% 
aOne trial reporting no events in either treatment arm not included in totals or pooled. 
Table 11. Overview: health-related quality of life 
Variable  Epoetin or Darbepoetin vs. Control 
Number of trials 14 
Patients analyzed 3,643 
Mean Difference for Change 
Fact Fatigue Score 2.74 
(95% confidence interval) (1.69 to 3.78) 
I2 45% 
Table 12. Overview: tumor response and progression 
Variable Epoetin or Darbepoetin vs. Control 
Number of trials 15 
Patients 5,577 
Tumor Response or 
Progression 
No evidence of an association with ESAs; results not pooled due to 
heterogeneous outcome definitions    
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Table 13. Overview: other adverse events 
Adverse Event Variable Epoetin vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Hypertension Number of trials 13a 3 16 
Patients analyzed 3,021 1,297 4,318 
Pooled relative risk 1.62 1.31 1.48 
(95% confidence interval) (1.05 to 2.50) (0.79 to 2.18) (1.07 to 2.06) 
I2 0% 0% 0% 
Thrombocytopenia/Hemorrhage Number of trials 10 2 12 
Patients analyzed 2,403 1,311 3,714 
Pooled relative risk 1.11 1.46 1.17 
(95% confidence interval) (0.94 to 1.31) (1.03 to 2.06) (1.01 to 1.36) 
I2 0% 0% 0% 
Rash Number of trials 5 – 5 
Patients analyzed 1,467 – 1,467 
Pooled relative risk 2.00 – 2.00 
(95% confidence interval) (0.98 to 4.07) – (0.98 to 4.07) 
I2 0% – 0% 
Seizures Number of trials 3 2 5 
Patients analyzed 604 983 1,587 
Pooled relative risk 1.49 0.88 0.93 
(95% confidence interval) (0.45 to 4.87) (0.14 to 5.41) (0.43 to 2.04) 
I2 0% 54% 0% 
aTwo other trials not included in pooled result—one with no events in either arm and one outlier (15 trials reported hypertension 
outcomes).  
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Table 14. Trials contributing evidence to specific outcomes and comparisons 
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Epoetin beta Aapro 200884 • • • • •  •      ◦   ◦ 
Epoetin Antonadou 200182   •  •         ◦   
Epoetin alfa Bamias 200385 • • • •   •  • •   ◦    
Epoetin alfa Blohmer 201186  • •  • • •      ◦  ◦  
Epoetin beta Boogaerts 2003,87 Coiffier 200188 • • • •    •  •   ◦   ◦ 
Epoetin alfa Case 199389 • • • •   •  •   • ◦  ◦ ◦ 
Epoetin alfa Chang 200590 • • • •   • •     ◦   ◦ Epoetin alfa Christodoulou 2009,91 Janinis92  • •     •     ◦    
Epoetin alfa Dammacco 200193 • • • •   •  • •   ◦  ◦ ◦ 
Epoetin alfa Debus 200694   • •  • •       ◦ ◦ ◦ 
Epoetin alfa Engert 2009,95 Engert 201096   •  • • •      ◦    
Epoetin alfa EPO-INT-197   • • •  •       ◦ ◦ ◦ 
Epoetin alfa EPO-INT-398  • • •   •        ◦ ◦ 
Epoetin beta Fugisaka 201199  • • • •  •  • •   ◦    
Epoetin alfa Goss 2005,100 EPO-CAN-15101  • • • • • •   •    ◦ ◦ ◦ 
Epoetin alfa Grote 2005102 (N93-004)  • • • •  •      ◦  ◦ ◦ 
Epoetin beta Gupta 2009103  • •   • •    •  ◦    
Epoetin beta Henke 200334   • • • • •      ◦  ◦ ◦ 
Epoetin alfa Henry 1995104 • • • •   •  •  • • ◦  ◦ ◦ 
Epoetin alfa Hoskin 2009,81 EPO-GBR-7105   • • • • • • •    ◦  ◦ ◦ 
Epoetin alfa Iconomou 2003106 • •      • •    ◦    
Epoetin alfa Leyland-Jones 2005,35 L-Jones 200347  • • • •  •      ◦  ◦ ◦ 
Epoetin alfa Littlewood 2001107 • • • •   • • • •   ◦  ◦ ◦ 
Epoetin alfa Machtay 2007,83 Machtay 2004108    • • • • •      ◦   ◦ 
Epoetin alfa Milroy 2011109 • • • •   •  • • •  ◦   ◦ 
Epoetin alfa Moebus 2007110  • • • • • •      ◦  ◦ ◦ 
Epoetin beta Shanghai-Roche Pharm 2006,111 ML17620 •  • •          ◦   
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Table 14. Trials contributing evidence to specific outcomes and comparisons (continued) 
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Epoetin beta Oberhoff 1998112 • • • •         ◦   ◦ 
Epoetin beta Osterborg 2002,113 Osterborg 2005114 • • • • •  • • •  •  ◦   ◦ 
Epoetin alfa Porter 199678  •           ◦    
Epoetin alfa Pronzato 2010115  • • •   •      ◦   ◦ 
Epoetin alfa Ray-Coquard 2009116  • • • •  •      ◦   ◦ 
Epoetin alfa (pediatric) Razzouk 2004,117 Razzouk 200679 • • c c   •  •    ◦    
Epoetin alfa Rose 1994118 • • • •   •  •     ◦ ◦ ◦ 
Epoetin alfa Savonije 2005,119 Savonije 2006120 • • • •   • • • •  • ◦   ◦ 
Epoetin alfa Thomas 2002121  • • •          ◦  ◦ 
Epoetin alfa Thomas 2008,51 GOG-0191122   • • • • •      ◦  ◦ ◦ 
Epoetin beta Tsuboi 2009123  • •    • • • • •  ◦    
Epoetin alfa Wagner 200480      •       ◦    
Epoetin alfa Wilkinson 2006124  • • • •  •  •    ◦   ◦ 
Epoetin alfa Witzig 2005125 • • • • •  • •  • •  ◦  ◦ ◦ 
Darbepoetin alfa Hedenus 2003126 • • • •   • •     ◦  ◦ ◦ 
Darbepoetin alfa Hernandez 2009127  • • •   •  •   • ◦   ◦ 
Darbepoetin alfa Katakami 2008128 • •            ◦   
Darbepoetin alfa Kotasek 2003129  • • • •    •     ◦   ◦ 
Darbepoetin alfa Overgaard 200946   •  • • •       ◦   
Darbepoetin alfa Pirker 2008130  • • • •  • • • •  • ◦   ◦ 
Darbepoetin alfa Untch 2011131  • • • • • •   •   ◦   ◦ 
Darbepoetin alfa Vansteenkiste 20028  • • • •  • • •    ◦  ◦ ◦ 
Epoetin/Darbepoetin Glaspy 2002132 • •           ◦    
 37 
Table 14. Trials contributing evidence to specific outcomes and comparisons (continued) 
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Epoetin/Darbepoetin Glaspy 2005,133 Glaspy 2006134 b •  •   •      ◦    
Epoetin/Darbepoetin Kotsori 2006135  •            ◦   
Epoetin/Darbepoetin Schwartzberg 2004136 b •    • •      ◦    
Epoetin/Darbepoetin Waltzman 2005137 • •  •  • •      ◦    
Totals 54 22 43 44 39 22 15 41 14 18 12 6 5 4
 
1
 
1
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FACT = Functional Assessment of Cancer Therapy; FDA = U.S. Food and Drug Administration; HTN = hypertension; QoL = quality of life 
aData for overall and on-study mortality from Bohlius et al.48 
bUsed different response definition, but used to supplement analyses for completeness. 
cEnrolled pediatric patients and reported overall survival, but not pooled in main result with trials of adult patients.  
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Table 15. Summary characteristics of the 54 trials included in KQ1 
Characteristic Group Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Trials N/A 5 41 8 49 
Patients Treatment 1,044 6,048 1,757 7,805 
Comparator 1,214 5,509 1,624 7,133 
Mean Age Rangea Treatment 57.8-63.7 3.2-68.3 49.0-64.8 3.2-68.3 
Comparator 58.7-63.4 3.2-68.1 48.0-64.6 3.2-68.1 
Trial Quality n (%) High 0 (0) 16 (39) 5 (62.5) 21 (42.9) 
Low 5 (100) 25 (61) 3 (37.5) 28 (57.1) 
Treatment Modality n (%) Chemotherapy 5 (100) 31 (75.6) 7 (87.5) 38 (77.6) 
Chemotherapy 
includes Platinum 
3 (60) 25 (61) 5 (62.5) 30 (61.2) 
Radiotherapy 0 (0) 4 (9.8) 1 (12.5) 5 (10.2) 
Chemoradiotherapy 0 (0) 6 (14.6) 0 (0) 6 (12.2) 
Dose Escalation n (%) Allowed 0 (0) 18 (43.9) 3 (37.5) 21 (42.9) 
Not allowed 5 (100) 20 (48.8) 4 (50) 24 (49) 
Unknown 0 (0) 3 (7.3) 1 (12.5) 4 (8.2) 
Iron n (%) As necessary 0 (0) 28 (68.3) 5 (62.5) 33 (67.3) 
Other including fixed 1 (20) 10 (24.4) 2 (25) 12 (24.5) 
Unknown 4 (80) 3 (7.3) 1 (12.5) 4 (8.2) 
Tumor Type n (%) Solid 4 (80) 27 (65.9) 6 (75) 33 (67.3) 
Mixed 1 (20) 8 (19.5) 1 (12.5) 9 (18.4) 
Hematologic 0 (0) 4 (9.8) 1 (12.5) 5 (10.2) 
Baseline Hb g/dL N/A 9.9-10.4 8.8-13.7 9.5-13.6 8.8-13.7 
Therapy Duration (weeks) N/A 8-16 4-52 9-23 4-52 
Hb g/dL = hemoglobin grams per deciliter; N/A = not applicable 
aAverage of reported means or medians. 
Note: Percentages may not sum to 100 due to unclear trial characteristics.    
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KQ1: Hematologic Response 
Hematologic response was defined as the proportion of patients demonstrating a hemoglobin 
increase ≥2 g/dL. In the 20 included trials, baseline hemoglobin levels ranged from 9.0 to 12.8 
g/dL (mean 10.1 g/dL). Data from the seven trials using different definitions of hematologic 
response are reported in Appendix Tables C7–C9, but were not pooled. Table 16 summarizes 
characteristics of included trials. 
Table 16. Summary of characteristics for trials included in analysis of hematologic response 
Characteristic Factor Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Trials N/A 2 17 3 20 
Patients 
Treatment 236 2,281 475 2,756 
Comparator 228 1,961 325 2,286 
Mean Age Rangea 
Treatment 57.8-62.1 12.4-68.3 58.3-64.8 12.4-68.3 
Comparator 61.9-63.4 10.8-68.1 56.2-64.6 10.8-68.1 
Trial Quality n (%) 
High 0 (0) 8 (47.1) 2 (66.7) 10 (50) 
Low 2 (100) 9 (52.9) 1 (33.3) 10 (50) 
Treatment Modality n (%) 
Chemotherapy 2 (100) 17 (100) 3 (100) 20 (100) 
Chemotherapy 
Includes Platinum 1 (50) 10 (58.8) 2 (66.7) 12 (60) 
Radiotherapy 0 (0) 0 (0) 0 (0) 0 (0) 
Chemoradiotherapy 0 (0) 0 (0) 0 (0) 0 (0) 
Dose Escalation 
Allowed 0 (0) 8 (47.1) 2 (66.7) 10 (50) 
Not allowed 2 (100) 8 (47.1) 1 (33.3) 9 (45) 
Unknown 0 (0) 1 (5.9) 0 (0) 1 (5) 
Iron n (%) 
As necessary 0 (0) 13 (76.5) 2 (66.7) 15 (75) 
Other including fixed 1 (50) 3 (17.6) 0 (0) 3 (15) 
Unknown 1 (50) 1 (5.9) 1 (33.3) 2 (10) 
Tumor Type n (%) 
Solid 2 (100) 8 (47.1) 2 (66.7) 10 (50) 
Mixed 0 (0) 5 (29.4) 0 (0) 5 (25) 
Hematologic 0 (0) 3 (17.6) 1 (33.3) 4 (20) 
Baseline Hb g/dL N/A 9.9-10.2 9.0-12.8 9.5-9.9 9.0-12.8 
Therapy Duration (weeks) N/A 12-14 12-28 12-12 12-28 
Hb g/dL = hemoglobin grams per deciliter; N/A = not applicable 
aAverage of reported means or medians. 
Percentages may not sum to 100 due to unclear trial characteristics. 
Darbepoetin Versus Epoetin 
Two trials132,137 compared hematologic response rates as defined in this review between 
patients randomized to darbepoetin or epoetin (Appendix Table C9). Both trials were unblinded 
and judged of poor quality. Two trials applying other response definitions, Glaspy et al.134 and 
Schwartzberg et al.136 employed different dose adjustments in the darbepoetin and epoetin arms. 
No trial included a control arm. Only Waltzman et al.137 described any supplemental iron 
administration. Study results for the two trials forming the main result here, and two others 
employing different response definitions, are summarized in Table 17.  
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Table 17. Study characteristics and results of trials comparing hematologic response rates for 
darbepoetin versus epoetin 
Trial 
Darbepoetin 
(200 mcg 
once per 2 
weeks) 
Epoetin 
(40,000 IU 
once weekly) 
Response 
≥2 g/dL 
Response 
Rate 
Darbepoetin 
N (%) 
Response 
Rate  
Epoetin 
N (%) 
RR (95% CI) 
Waltzman 
2005a,b,137 
177 175 yes 74 (41.8) 101 (57.7) 0.72  
(0.58 to 0.90) 
Glaspy 2006134 606 603 noc 463 (76.4) 487 (80.8) 0.95  
(0.89 to 1.00) 
Schwartzberg 
2004136 
157 155 nod 109 (69.4) 112 (72.3) 0.96  
(0.83 to 1.11) 
Glaspy 2002Aa,e,132 59 (2.25 
mcg/kg QW) 
53 (150 IU/kg 
TIW) 
yes 31 (52.5) 38 (71.7) 0.73  
(0.55 to 0.98) 
CI = confidence interval; g/dL = grams per deciliter; IU = international unit; kg = kilogram; mcg = micrograms; RR = relative 
risk; TIW = three times a week 
aArms differed in dose adjustment for inadequate response. 
bWaltzman 2005137 patients with <1 g/dL Hb rise from baseline had 1.5-fold dose increase at week 6 if randomized to 
darbepoetin (from 200 to 300 mcg q2W), but at week 4 if randomized to epoetin (from 40,000 to 60,000 IU/week). 
cGlaspy 2006134 defined response as reaching Hb >11 g/dL and remaining between 11 and 13 g/dL, results from Glaspy 
2005133 abstract darbepoetin 90.3% (95% CI: 87.5%, 93.1%), epoetin 95.5% (95% CI: 93.6%, 97.4%). 
dSchwartzberg 2004136 defined response as reaching Hb >12 g/dL or increasing by 2 g/dL from baseline to end of study. 
eGlaspy 2002A132 compared arms given 2.25 mcg/kg darbepoetin QW versus epoetin alfa 150 IU/kg TIW (arm d); dose increase 
for inadequate Hb response only permitted for epoetin arm. (Results derived from published figure and calculated from 
percentages reported; randomization of the darbepoetin arms was not clearly stated). 
Results 
Fewer patients randomized to darbepoetin experienced ≥2 g/dL improvement in hemoglobin 
in the two trials137,138 employing that response definition—pooled RR 0.73 (95% CI: 0.61 to 
0.87; I2=0%). For all four trials, using response definitions from each trial, the pooled RR of 
response comparing darbepoetin to epoetin was 0.88 (95% CI: 0.77 to 1.00; I2=65%). 
Hematologic response of ≥2 g/dL increase, or as variously defined in the trials, was less 
frequent in the darbepoetin-treated arms. However, the trials and results are accompanied by 
clinical variability owing to differing doses and dosing adjustment strategies, both between trials 
and arms. Accounting for any influence of dose-adjustment strategy (a time-varying treatment 
induced by hemoglobin as a time-varying confounder) requires analytical methods not applied in 
any trial.139 These results are not consistent with differences between drugs in achieving 
hematologic response. 
Changes From 2006 Review 
Two trials from the previous review were excluded, three trials included unchanged (two 
with a different definition of response and therefore not pooled), and one new trial identified 
(Appendix Table F1). Table 18 compares current results to sensitivity analysis with two excluded 
trials.   
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Table 18. Hematologic response results: darbepoetin versus epoetin—current report, current with 
trials excluded but in 2006 review, and 2006 review 
 Trials Darbepoetin vs. Epoetin N Control N RR (95% CI) I
2 
Current 2 236 228 0.73 (0.61 to 0.87) 0% 
Current & Excluded 4 999 986 0.88 (0.77 to 1.00) 65% 
2006 review NR NR NR NR NR 
NR = not reported; RR = relative risk 
Epoetin Versus Control 
Seventeen trials (Table 14) compared hematologic response rates (≥2 g/dL) between patients 
randomized to epoetin (N=2,281) or control (N=1,961). Trial characteristics varied as 
summarized in Table 16, including antineoplastic therapies and dose escalation. Nine trials were 
judged of low quality due primarily to lack of blinding. Individual trial characteristics are 
detailed in Appendix Table C7. 
Results 
More patients randomized to epoetin experienced ≥2 g/dL hemoglobin improvement 
compared with control—pooled RR 3.6 (95% CI: 2.8 to 4.5; I2=78%). Heterogeneity (Figure 8) 
was consistent with the varied trial characteristics. In meta-regressions trial quality, blinding, 
baseline hemoglobin, or iron use did not meaningfully account for the heterogeneity (e.g., 
decreasing I2 or was a significant covariate). Five additional trials employed different response 
definitions 34,51,121,123,124 
Hematologic response ≥2 g/dL was more frequent in the epoetin treated than control arms of 
included trials. While heterogeneity accompanied the pooled estimates, trials consistently 
demonstrated higher response rates with epoetin. These results are consistent with superiority of 
epoetin to a transfusion strategy for achieving a ≥2 g/dL hematologic response. 
Figure 8. Forest plot—hematologic response: epoetin versus control 
 
CI = confidence interval; ESA = erythropoiesis-stimulating agent; RR = relative risk; W = weight  
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Changes From 2006 Review 
Two trials from the previous review were excluded, 12 trials were included unchanged, data 
were updated for one trial, and three new trials were identified (Appendix Table F1). Table 19 
compares current results with the 2006 review and sensitivity analysis with the excluded trials. 
Table 19. Hematologic response results: epoetin versus control—current report, current with trials 
excluded but in 2006 review, and 2006 review 
Comparison Trials Epoetin N Control N RR (95% CI) I2 
Current 17 2,281 1,961 3.6 (2.8 to 4.5) 78% 
Current & Excluded 19 2,433 2,039 3.6 (2.9 to 4.5) 76% 
2006 review 15 1,844 1,449 3.4 (3.0 to 3.9) 66% 
CI = confidence interval; RR = relative risk 
Darbepoetin Versus Control 
Three trials (Table 14) compared hematologic response rates (≥2 g/dL) between patients 
randomized to darbepoetin (N=475) or control (N=325). Kotasek et al.129 examined six doses. 
Except for dosing, characteristics of the three trials were generally similar (Table 16). 
Results 
More patients randomized to darbepoetin experienced ≥2 g/dL improvement in hemoglobin 
compared to control—pooled RR 3.1 (95% CI: 2.4 to 3.9; I2=0%). Outcomes from two other 
trials127,140 defining response differently (Appendix Table C11) were consistent with a similar 
clinical effect improving hemoglobin for darbepoetin compared to control. 
Changes From 2006 Review 
One trial from the previous review was excluded, two trials were included unchanged, and no 
new trials were identified (Appendix Table F1). Table 20 shows similar current results with the 
2006 review and sensitivity analysis with the excluded trial. 
Table 20. Hematologic response results: darbepoetin versus control—current report, current with 
trials excluded but in 2006 review, and 2006 review 
Comparison Trials Darbepoetin N Control N RR (95% CI) I2 
Current 3 475 325 3.1 (2.4 to 3.9) 0% 
Current & Excluded 4 530 336 3.1 (2.4 to 4.0) 0% 
2006 review 3 427 232 3.4 (2.5 to 4.6) 0% 
CI = confidence interval; RR = relative risk 
KQ1: Risk of Transfusion 
Transfusion risk was defined according to the proportion of patients transfused at least once 
during the trial. 
Darbepoetin Versus Epoetin 
Five trials132,134-137 compared transfusion risk between patients randomized to darbepoetin or 
epoetin. All trials were unblinded and judged of poor quality. Schwartzberg et al.136 randomized 
patients with breast, lung, and gynecologic tumors independently; results were reported 
separately and accordingly pooled. Glaspy et al.132 evaluated multiple darbepoetin doses in a 
dose-finding study, and results for 2.25 mcg/kg every week were included in the main analysis; 
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sensitivity analyses performed including all results were not different. No trial included a control 
arm. Trial characteristics are summarized in Table 21 and detailed in Appendix Tables C1–6. 
Table 21. Summary of characteristics for trials included in analysis of transfusion risk 
Characteristic Group Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Trials N/A 5 31 7 38 
Patients Treatment 1,016 4,222 1,461 5,683 
Comparator 989 3,781 1,345 5,126 
Mean Age Rangea Treatment 57.8-63.7 12.4-68.3 49-64.8 12.4-68.3 
Comparator 58.7-63.4 10.8-68.1 48-64.6 10.8-68.1 
Trial Quality n (%) High 0 (0) 13 (41.9) 5 (71.4) 18 (47.4) 
Low 5 (100) 18 (58.1) 2 (28.6) 20 (52.6) 
Treatment Modality n (%) Chemotherapy 5 (100) 27 (87.1) 7 (100) 34 (89.5) 
Chemotherapy 
Includes Platinum 3 (60) 19 (61.3) 5 (71.4) 24 (63.2) 
Radiotherapy 0 (0) 0 (0) 0 (0) 0 (0) 
Chemoradiotherapy 0 (0) 4 (12.9) 0 (0) 4 (10.5) 
Dose Escalation Allowed 0 (0) 15 (48.4) 3 (42.9) 18 (47.4) 
Not allowed 5 (100) 15 (48.4) 4 (57.1) 19 (50) 
Unknown 0 (0) 1 (3.2) 0 (0) 1 (2.6) 
Iron n (%) As necessary 0 (0) 23 (74.2) 4 (57.1) 27 (71.1) 
Other including 
 
1 (20) 7 (22.6) 2 (28.6) 9 (23.7) 
Unknown 4 (80) 1 (3.2) 0 (0) 1 (2.6) 
Tumor Type n (%) Solid 4 (80) 18 (58.1) 5 (71.4) 23 (60.5) 
Mixed 1 (20) 8 (25.8) 1 (14.3) 9 (23.7) 
Hematologic 0 (0) 5 (16.1) 1 (14.3) 6 (15.8) 
Baseline Hb g/dL N/A 9.9-10.4 9.0-13.5 9.5-13.6 9.0-13.6 
Therapy Duration 
 
N/A 8-16 7-52 12-23 7-52 
Hb g/dL = hemoglobin grams per deciliter; N/A = not applicable 
aAverage of reported means or medians 
Percentages may not add up to 100 due to unclear trial characteristics 
Results 
More patients randomized to darbepoetin received one or more transfusions—pooled RR 
1.14 (95% CI: 0.82 to 1.59; I2=43%); including all comparisons from Glaspy et al.132 yielded a 
similar estimate—RR 1.12 (95% CI: 0.82 to 1.53; I2=35%). Similar to results for hemoglobin 
response, analytical methods applied in these trials did not account for dose-adjustment 
strategies. Results are consistent with no difference between agents in risk for transfusion. 
Changes From 2006 Review 
One trial from the previous review was excluded, three trials were included unchanged, data 
were updated for one trial, and one new trial was identified (Appendix Table F1). Table 22 
compares current results with the 2006 review and sensitivity analysis with the excluded trial.   
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Table 22. Risk of transfusion: darbepoetin versus epoetin—current report, current with trials 
excluded but in 2006 review, and 2006 review 
 Comparison Trials Darbepoetin N Epoetin N RR (95% CI) I2 
Current 5 1,016 989 1.14 (0.82 to 1.59) 43% 
Current & Excluded 6 1,041 1,014 1.16 (0.85 to 1.56) 34% 
2006 review 6 1,169 989 1.10 (0.93 to 1.29) 48% 
CI = confidence interval; RR = relative risk 
Epoetin Versus Control 
Thirty-one trials comparing transfusion between patients randomized to epoetin (N=4,222) or 
control (N=3,781) were included (Table 14). Seventeen trials were unblinded and 18 were 
judged to be low quality. Trial characteristics varied in other respects, including 
chemotherapeutic agents, dose adjustment protocols, and transfusion triggers (mean 8.3 g/dL, as 
high as 10 g/dL, and nine unblinded trials using physician discretion). 
Results 
Fewer patients randomized to epoetin received one or more transfusions—pooled RR 0.58 
(95% CI: 0.52 to 0.65; I2=60%). Heterogeneity displayed in the forest plot (Figure 9) is 
consistent with varied trial characteristics. The results are consistent with superiority of epoetin 
over a transfusion strategy for avoiding transfusion. The data do not allow estimating the number 
of transfusions avoided. 
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Figure 9. Forest plot—relative risk of transfusion: epoetin versus control 
CI = confidence interval; ESA = erythropoiesis-stimulating agent; RR = relative risk; W = weight  
Changes From 2006 Review 
Eighteen trials from the previous review were excluded, 14 trials were included unchanged, 
data were updated for two trials, and 15 new trials were identified (Appendix Table F1). Table 
23 compares current results with the 2006 review and sensitivity analysis with excluded trials—
all are similar. 
Table 23. Risk of transfusion: epoetin versus co
but in 2006 review, and 2006 review 
ntrol—current report, current with trials excluded 
Comparison Trials Epoetin N Control N RR (95% CI) I2 
Current 31 4,222 3,781 0.58 (0.52 to 0.65) 60% 
Current & Excluded 49 5,016 4,375 0.56 (0.51 to 0.62) 64% 
2006 review 34 2,859 2,351 0.63 (0.59 to 0.67) 63% 
CI = confidence interval; RR = relative risk 
Darbepoetin Versus Control 
Seven trials comparing transfusion between patients randomized to darbepoetin (N=1,461) or 
control (N=1,345) were included (Table 14). Kotasek et al.129 examined six doses. Five trials 
were blinded and judged to be high quality, but other characteristics varied. Transfusion triggers 
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were specified as 8 g/dL in four trials (also allowing physician discretion) but not reported in the 
others. 
Results 
Fewer patients randomized to darbepoetin received one or more transfusions—pooled RR 
0.58 (95% CI: 0.51 to 0.65; I2=0%). 
Changes From 2006 Review 
One trial was excluded, three trials were included unchanged, and four new trials were 
identified (Appendix Table F1). Table 24 compares current results with the 2006 review and 
sensitivity analysis with the excluded trial. 
Table 24. Risk of transfusion: darbepoetin versus control—current report, current with trials 
excluded but in 2006 review, and 2006 review 
Comparison Trials Darbepoetin N Control N RR (95% CI) I2 
Current 7 1,461 1,345 0.58 (0.51 to 0.65) 0% 
Current & Excluded 8 1,516 1,356 0.57 (0.51 to 0.65) 0% 
2006 review 4 566 384 0.61 (0.52 to 0.72) 0% 
CI = confidence interval; RR = relative risk 
Hematologic Outcomes—Erythropoietic-Stimulating Agents 
Considering all ESA trials, pooled effects indicate that these agents improve hemoglobin 
(pooled RR 3.4; 95% CI: 2.8 to 4.2; I2=64%; 20 trials) and result in fewer transfusions (pooled 
RR 0.58; 95% CI: 0.53 to 0.64; I2=51%; 38 trials). The consistency of these corresponding 
relationships is illustrated in Figure 10. Still, these agents decrease but do not eliminate the risk 
of receiving transfusions. 
The pooled proportion receiving ≥1 transfusion with ESA treatment was 0.22 (95% CI: 0.17 
to 0.27; I2=95%) compared with control of 0.39 (95% CI; 0.32 to 0.46; I2=96%); respective 
pooled proportions experiencing hemoglobin response were 0.52 (95% CI: 0.45 to 0.59; I2=92%) 
and 0.14 (95% CI: 0.10 to 0.19; I2=86%).    
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Figure 10. Hemoglobin response rates and proportions receiving ≥1 transfusion in treated and 
control arms of included trials* 
 
ESA = erythropoiesis-stimulating agent; Hb = hemoglobin 
*20 trials of Hb response; 38 trials of transfusion risk. 
Finally, while these results are consistent, they are based on a clinically heterogeneous 
collection of trials. To explore that heterogeneity, we examined trial characteristics that might 
modify pooled estimates for transfusion risk (Table 25). Only transfusion risk was examined, 
both for its clinical relevance and because just over half the trials reported hemoglobin response. 
The relative proportion receiving ≥1 transfusion estimates varied by baseline hemoglobin, trial 
quality, blinding, use of platinum-based chemotherapy, and iron administration. These results are 
consistent with a notion that physician judgment influenced transfusion policies in these trials 
and probably more so in unblinded ones.   
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Table 25. Relative risks from single covariate meta-regressions—transfusion risk 
Covariate Factor RR (95% CI) p-Value 
Dose Escalation No 0.56 (0.49 to 0.65)  0.45 
  Yes 0.61 (0.48 to 0.77) 
Iron All other 0.49 (0.41 to 0.58)  0.01 
  As necessary 0.63 (0.49 to 0.81) 
Platinum-Base Chemotherapy No 0.68 (0.60 to 0.77)  0.003  
  Yes 0.53 (0.44 to 0.65) 
Baseline Hb >10 g/dL 0.71 (0.65 to 0.79) <0.001  
  ≤10 g/dL 0.49 (0.41 to 0.59) 
Study Duration ≤12 weeks 0.69 (0.52 to 0.93)  0.22 
  >12 weeks 0.62 (0.44 to 0.88) 
Trial Quality Low 0.51 (0.45 to 0.58)  0.006  
  High 0.65 (0.52 to 0.81) 
Blinding No 0.49 (0.41 to 0.59) <0.001 
Yes 0.67 (0.61 to 0.73)  
CI = confidence interval; RR = relative risk 
Evidence GRADE 
ESAs reduced the proportion of patients receiving transfusions (overall strength of evidence 
moderate, Table 26). 
Table 26. Risk of transfusion: ESA versus control (GRADE evidence table) 
Trials 
(N) 
Subjects 
(N) 
Risk of Bias 
Design/Quality Consistency Directness Precision 
Results 
RR 
(95% CI) 
I2 
Overall 
Strength 
 of 
Evidence 
38 10,809 Medium 
trial quality: 
high-18; low-20 
Consistent Direct Precise 0.58 
(0.53 to 0.64) 
51% 
Moderate 
CI = confidence interval; RR = relative risk 
 
The evidence does not show any meaningful difference between epoetin and darbepoetin in 
the proportion of patients receiving transfusion (overall strength of evidence moderate, Table 
27). 
Table 27. Risk of transfusion: darbepoetin versus epoetin, epoetin versus control, and 
darbepoetin versus control (GRADE evidence table) 
Trials 
(N) 
Subjects 
(N) 
Risk of Bias 
Design/Quality Consistency Directness Precision 
Results 
RR 
(95% CI) 
I2 
Overall 
Strength 
 of 
Evidence 
5 
Darbepoetin 
vs. Epoetin 
2,005 Medium 
trial quality  
high-0; low-5 
Consistent Direct/ 
Indirecta 
Precise 1.14  
(0.82 to 1.59) 
43% 
Moderate 
31 
Epoetin 
vs. Control 
8,003 Medium 
trial quality: 
high-13; low-18 
Consistent Direct Precise 0.58  
(0.52 to 0.65) 
60% 
Moderate 
7 
Darbepoetin 
vs. Control 
2,806 Low 
trial quality: 
high-5; low-2 
Consistent Direct Precise 0.58  
(0.51 to 0.65) 
0% 
High 
CI = confidence interval; RR = relative risk 
a5 trials and 2,005 participants direct evidence; similar effect magnitudes for darbepoetin vs. control and epoetin versus control in 
table constitute indirect evidence. 
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Survival Outcomes 
We evaluated survival from two perspectives—“overall survival” and “on-study mortality.” 
Overall survival was defined as survival over the longest available follow-up; on-study mortality 
as mortality ascertained during, and up to 1 month following, ESA treatment (the period of 
active treatment). Although important, limitations accompany the overall survival outcome: (1) 
fewer than half the trials included an overall survival endpoint and detailed a survival analyses; 
(2) over the longer term during post-treatment follow-up, many nonrandom interventions can 
affect survival (i.e., potentially causing a bias to the null or no difference); (3) adverse 
consequences of ESAs are biologically most plausible during the active treatment period or soon 
thereafter—not well after treatment is stopped;b
Matters to contemplate when examining survival and mortality results include: trials of 
varying lengths of followup; different underlying mortality risks; and some trials lacking deaths 
in one or both treatment arms. To address these issues, this section is organized as follows. First, 
sources and important aspects of the evidence are detailed. Next, the approaches to pooling trial 
results and exploring potential subgroup effects are outlined. Finally, details of included trials 
and results for overall survival and on-study mortality are presented. There are considerably 
fewer darbepoetin than epoetin trials and pooled results restricted to darbepoetin are necessarily 
imprecise. Given consistent magnitude of effects and pharmacologic basis of these agents, 
evidence from different ESAs were combined for synthesis. 
 and (4) different trial durations introduce issues 
for pooling (discussed below). Mortality during the active study period is therefore most 
informative because it represents the most biologically plausible causal effect and is little prone 
to the limitations accompanying overall survival, as outlined. 
Overall survival data were abstracted for the longest available follow-up reported—updated 
or obtained from Bohlius et al.48 for 34 trials (see Table 14). For trials not included in Bohlius et 
al.,48 as outlined in Parmar et al.66 data were abstracted. Deaths in three trials82,91,103 were 
estimated from the published Kaplan-Meier curves. On-study mortality data were taken primarily 
from a published individual patient data meta-analysis48 where on-study mortality was defined 
“as death from any cause between date of randomization and 28 days after the end of the active 
study phase. While these trials were in general not designed to evaluate on-study mortality, 
Bohlius et al.48 applied a standardized approach and any measurement error is most likely non-
differential. Any accompanying bias would therefore be conservative or to the null. On-study 
mortality for four trials79,85,99,111 were not derived from Bohlius et al.48 but adequately reported. 
One trial enrolled pediatric patients and was therefore not included in the main analyses.79 
There are three important methodologic issues to consider when pooling survival and 
mortality results. First, while study duration and active treatment periods varied, combining 
estimates assumes that followup duration did not affect relative effects. This, essentially a 
proportional hazards assumption, is unverifiable. Furthermore, if as indicated in other meta-
analyses, mortality is increased during the on-study period,48,141 but not over the long term, then 
the assumption of constant relative effect (proportional hazards) over longest follow-up may not 
hold. Second, it can be difficult to evaluate the relationship between underlying mortality rate or 
baseline risk (i.e., control arms) and relative risk of mortality with ESA use. Yet the relationship                                                              
b Unless ESAs promote tumor progression. 
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is of interest because current labeling recommends avoiding ESA use in patients undergoing 
chemotherapy with curative intent—that is, patients with low expected mortality rates. 
Examining the relationship between underlying mortality rates and relative effects can be 
problematic due to their inherent correlation (control mortality rate is used to calculate relative 
effect). Third, the absence of events in some trial arms, as occurs in these data, can be 
problematic in standard meta-analyses.142 
Because of these issues and fundamental importance of mortality effects, these data were 
analyzed using two approaches. First, from calculated observed and expected events with 
accompanying variance,66 the pooled hazard ratio was estimated using the Peto method, the same 
method used in the 2006 review. 143 The approach includes trials without events in one arm and 
is a fixed-effects estimate. Overall survival was pooled in this manner. In addition, for on-study 
mortality the main results were also pooled in Bayesian hierarchical (random-effects) models. 
The Bayesian approach models events directly (not relative effects) and so appropriately 
incorporates trials lacking events in one arm. To obtain relative risks (as opposed to odds ratios), 
the approach outlined by Warn et al.68 was used. A Bayesian model was also used to examine the 
relationship between underlying risk (control group mortality rate) and relative risk—a model 
that appropriately accounts for correlation between relative effect and underlying risk.69 
Noninformative priors were specified in these models which were fitted using OpenBUGS.75 
Finally, reported or estimated 12- to 16-week mortality rates in the control arms were used to 
represent underlying mortality risk. Because the most common trial duration was 12 weeks, for 
those trials longer or shorter we estimated 12-week mortality in the control arm using the 
relationship between rate, probability, and time. 
KQ1: Overall Survival 
Trials included in overall survival analyses are listed in Table 14 and summary 
characteristics shown in Table 28. Trials varied in quality, use of iron, tumor types, cancer 
treatment, baseline hemoglobin, and duration. Approximately two-thirds of trials reported 
following patients a median or longest followup exceeding 1 year. One trial enrolled pediatric 
patients.79 
Table 28. Summary of characteristics for trials included in analysis of overall survival  
Characteristics Group Epoetin vs. Controla 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Controla 
Trials N/A 37 7 44 
Patients Treatment 5,831 1,638 7,469 
Comparator 5,300 1,509 6,809 
Mean Age Rangeb Treatment 35.0-68.3 49.0-64.8 35.0–68.3 
Comparator 34.0–68.1 48.0-64.6 34.0–68.1 
Trial Quality n (%) High 15 (40.5) 5 (71.4) 20 (45.5) 
Low 22 (59.5) 2 (28.6) 24 (54.5) 
Treatment Modality n (%) Chemotherapy 28 (75.7) 6 (85.7) 34 (77.3) 
Chemo with platinum 23 (62.2) 4 (57.1) 27 (61.4) 
Radiotherapy 4 (10.8) 1 (14.3) 5 (11.4) 
Chemoradiotherapy 5 (13.5) 0 (0) 5 (11.4) 
Dose Escalation n (%) Allowed 18 (48.6) 2 (28.6) 20 (45.5) 
Not allowed 16 (43.2) 4 (57.1) 20 (45.5) 
Unknown 3 (8.1) 1 (14.3) 4 (9.1) 
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Table 28. Summary of characteristics for trials included in analysis of overall survival 
(continued) 
Characteristics Group Epoetin vs. Controla 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Controlb 
Iron n (%) As necessary 25 (67.6) 5 (71.4) 30 (68.2) 
Other including fixed 9 (24.3) 2 (28.6) 11 (25.0) 
Unknown 3 (8.1) 0 (0) 3 (6.8) 
Tumor Type n (%) Solid 24 (64.9) 5 (71.4) 29 (65.9) 
Mixed 7 (18.9) 1 (14.3) 8 (18.2) 
Hematologic 4 (10.8) 1 (14.3) 5 (11.4) 
Baseline Hb g/dL N/A 9.0–13.7 9.5–13.6 9.0–13.7 
Therapy Duration (weeks) N/A 4–52 9–23 4–52 
Hb g/dL = hemoglobin grams per deciliter; N/A = not applicable 
aExcludes trial of pediatric patients.79  
bOf reported means or medians. 
Darbepoetin Versus Epoetin 
No trials reported long-term survival. 
Epoetin Versus Control 
Thirty-seven trials (Table 14) reported overall survival in adult patients randomized to 
epoetin (N=5,831) or control (N=5,300). Trial characteristics varied considerably as summarized 
in Table 28 and detailed in Appendix Table C1. One trial included pediatric patients;79 10 trials 
included only women with gynecologic and/or breast cancers. 
Results 
In adults there was no apparent increased risk accompanying epoetin use—HR 1.04 (95% CI: 
0.98 to 1.11; I2=35%). Including the single trial in pediatric patients resulted in the same relative 
hazard—HR 1.04 (95% CI: 0.96 to 1.09). 
Changes From 2006 Review 
Thirteen trials were excluded, 1 trial was included unchanged, data were updated for 21 
trials, and 16 new trials were identified (Appendix Table F1). Table 29 compares current results 
with the 2006 review and sensitivity analysis with the excluded trials. 
Table 29. Overall survival: epoetin versus control—current report, current with trials excluded but 
in 2006 review, and 2006 review 
Comparison Trials Epoetin N Control N HR (95% CI) I2 
Current 37 5,831 5,300 1.04 (0.98 to 1.11) 35% 
Current (all)a 38 5,943 5,410 1.04 (0.96 to 1.09) 38% 
Current (all)a & Excluded 50 6,467 5,694 1.03 (0.97 to 1.10) 26% 
2006 review 35 3,825 3,093 1.11 (1.00 to 1.22) 48% 
CI = confidence interval; HR = hazard ratio 
aIncludes trial of pediatric patients79 also included in the 2006 result. 
Darbepoetin Versus Control 
Overall survival was reported in seven trials (Table 14) for patients randomized to 
darbepoetin treatment (N=1,638) or control (N=1,509). Similar to epoetin trials, characteristics 
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varied (Table 28), none included pediatric patients and one only women with breast cancer.37 
Five trials were designed for long-term follow-up of at least 12 months.8,37,46,126,130 
Results 
There was no apparent increased relative risk in darbepoetin treated patients—pooled HR 
1.04 (95% CI: 0.94 to 1.17; I2=51%). 
Changes From 2006 Review 
One trial from the previous review was excluded, three trials were included unchanged, and 
four new trials were identified (Appendix Table F1).  
Table 30 compares current results with the 2006 review and sensitivity analysis with the 
excluded trials. 
Table 30. Overall survival: darbepoetin versus control—current report, current with trials excluded 
but in 2006 review, and 2006 review 
Comparison Trials Darbepoetin N Control N HR (95% CI) I2 
Current 7 1,638 1,509 1.04 (0.94 to 1.17) 51% 
Current & Excluded 8 1,701 1,527 1.04 (0.93 to 1.16) 50% 
2006 review 4 583 390 0.96 (0.78 to 1.17) 72% 
CI = confidence interval; HR = hazard ratio 
Evidence Regarding Erythropoietic-Stimulating Agents 
Combined results from the 44 trials of either ESA versus control were similar—pooled HR 
1.04 (95% CI: 0.99 to 1.10; I2=38%). However, this result was obtained from a clinically 
heterogeneous set of trials, so we explored trial characteristics that might modify pooled 
estimates (Table 31). Because the Peto method of combining hazard ratios is not easily amenable 
to including covariates, meta-regressions were performed in random-effects models and so point 
estimates are not precisely comparable. Nonetheless, there is no indication that any of the 
characteristics modifies the pooled estimate. 
Table 31. Relative risks from single covariate meta-regressions—overall survival: epoetin or 
darbepoetin versus control 
Characteristic Group RR (95% CI) p-value 
Dose Escalation Yes 1.00 (0.95 to 1.05) 0.98 
No 0.99 (0.90 to 1.09) 
Iron All other 0.96 (0.89 to 1.03) 0.07 
As necessary 1.04 (0.93 to 1.17) 
Platinum-Base Chemotherapy Yes 1.05 (0.98 to 1.13) 0.12 
No 0.98 (0.87 to 1.10) 
Chemo or Radiotherapy Chemo ± Radiotherapy 1.00 (0.95 to 1.05) 0.19 
Radiotherapy 1.09 (0.94 to 1.25) 
Baseline Hb b > 10 g/dL 0.97 (0.88 to 1.07) 0.30 
≤ 10 g/dL 1.03 (0.89 to 1.20) 
Study Duration ≤ 12 weeks 0.97 (0.83 to 1.13) 0.67 
> 12 weeks 1.00 (0.83 to 1.20) 
Study Quality Low 1.00 (0.94 to 1.07) 0.71 
High 1.02 (0.90 to 1.14) 
Blinding Yes  1.02 (0.95 to 1.09) 0.71 
No 1.00 (0.89 to 1.13) 
CI = confidence interval; RR = relative risk 
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Changes From 2006 Review 
Fourteen trials from the previous review were excluded, four trials were included unchanged, 
results for 21 trials were updated, and 20 new trials were identified (Appendix Table F1).  
Table 32 compares current results with the 2006 review and sensitivity analysis with 
excluded trials. 
Table 32. Overall survival: epoetin or darbepoetin versus control—current report, current with 
trials excluded but in 2006 review, and 2006 review 
Comparison Trials Epoetin or Darbepoetin N Control N RR (95% CI) I
2 
Current 44 7,469 6,809 1.04 (0.99 to 1.10) 38% 
Current (all)a 45 7,581 6,919 1.04 (0.99 to 1.10) 36% 
Current (all)a & Excluded 59 8,257 7,313 1.04 (0.98 to 1.10) 29% 
2006 review 39 4,408 3,483 1.08 (0.98 to 1.18) 13% 
CI = confidence interval; RR = relative risk 
aIncludes trial of pediatric patients79 also included in the 2006 result. 
In summary, we did not detect an association between ESA use and survival over the longest 
available follow-up. There were no meaningful differences from the 2006 effect estimate. 
Evidence GRADE 
The evidence does not show an effect of ESAs on survival over the longest available follow-
up—including both during and following ESA treatment (overall strength of evidence moderate, 
Table 33). 
Table 33. Overall survival: ESA versus control (GRADE evidence table) 
Trials 
(N) 
Subjects 
(N) 
Risk of Bias 
Design/Quality Consistency Directness Precision 
Results 
RR (95% CI) 
I2 
Overall 
Strength 
 of Evidence 
44 14,278 Higha 
trial quality   
high-21; low-23 
Consistent Direct Precise 1.04 
(0.99 to 1.10) 
38% 
Low 
CI = confidence interval; RR = relative risk 
aFewer than half of trials included survival as a primary or secondary outcome; no trial was powered to detect a survival 
difference; time-dependent confounding not considered in analyses. 
KQ1: On-Study Mortality 
On-study mortality was not reported in the 2006 review. The individual patient data meta-
analysis of Bohlius et al.48 allowed evaluating on-study mortality. Trials included in these 
analyses and data source for each trial are listed in Table 14; summary characteristics are shown 
in Table 34.   
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Table 34. Summary of characteristics for trials included in analysis of on-study mortality 
Characteristics Factors Darbepoetin vs. Control 
Epoetin 
vs. Controla 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Controla 
Trials  2 31 6 37 
Patients Treatment 791 4,580 1,391 5,971 
Comparator 776 4,038 1,257 5,295 
Mean Age Rangeb Treatment 62.1-63.7 46.0-68.3 49.0-64.8 46.0-68.3 
Comparator 63.2-63.4 50.0-68.1 48.0-64.6 48.0-68.1 
Trial Quality n (%) High 0 (0) 13 (41.9) 5 (83.3) 18 (48.6) 
Low 2 (100) 18 (58.1) 1 (16.7) 19 (51.4) 
Treatment Modality 
 n (%) 
Chemotherapy 2 (100) 25 (80.6) 6 (100) 31 (83.8) 
Chemotherapy Includes 
Platinum 
2 (100) 19 (61.3) 4 (66.7) 23 (62.2) 
Radiotherapy 0 (0) 3 (9.7) 0 (0) 3 (8.1) 
Chemoradiotherapy 0 (0) 3 (9.7) 0 (0) 3 (8.1) 
Dose Escalation 
 n (%) 
Allowed 0 (0) 14 (45.2) 2 (33.3) 16 (43.2) 
Not allowed 2 (100) 15 (48.4) 4 (66.7) 19 (51.4) 
Unknown 0 (0) 2 (6.5) 0 (0) 2 (5.4) 
Iron n (%) As necessary 0 (0) 24 (77.4) 4 (66.7) 28 (75.7) 
Other including fixed 1 (50) 5 (16.1) 2 (33.3) 7 (18.9) 
Not reported 1 (50) 2 (6.5) 0 (0) 2 (5.4) 
Tumor Type n (%) Solid 1 (50) 20 (64.5) 4 (66.7) 24 (64.9) 
Mixed 1 (50) 6 (19.4) 1 (16.7) 7 (18.9) 
Hematologic 0 (0) 3 (9.7) 1 (16.7) 4 (10.8) 
Baseline Hb g/dL  10.1-10.2 9.0-13.7 9.5-14.0 9.0-13.7 
Therapy Duration 
(weeks) 
 14-16 4-52 12-23 4-52 
Hb g/dL = hemoglobin grams per deciliter 
aExcludes trial of pediatric patients.79 
bOf reported means or medians. 
Darbepoetin Versus Epoetin 
Two trials reported on-study mortality for participants randomized to darbepoetin or 
epoetin.134,137 The trials differed in tumor type, although they were otherwise generally similar 
and judged of low quality. 
Results 
Neither trial reported a survival advantage for a particular agent; no difference was noted 
when the trial results were combined—HR 0.90 (95% CI: 0.67 to 1.20; I2=72%). 
Changes From 2006 Review 
On-study mortality was not reported, but results from one trial were included as overall 
survival.137 
Epoetin Versus Control 
Thirty-one trials (Table 14) reported on-study mortality in adult patients randomized to 
epoetin (N=4,580) or control (N=4,038). Trial characteristics varied (Table 34) and are detailed 
in Appendix Table C1. One trial enrolled pediatric patients;79 eight trials enrolled only women 
with gynecologic or breast cancers. 
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Results 
The pooled hazard ratio was consistent with an increased risk of mortality during the on-
study period—HR 1.19 (95% CI: 1.05 to 1.36; I2=3%); Bayesian random effects RR of 1.16 
(95% CrI: 1.00 to 1.32). Including six trials where on-study mortality was not reported at the end 
of the active study period, but estimated from Kaplan-Meier curves82,91,95,103 or from overall 
survival123,144 yielded a pooled HR of 1.13 (95% CI: 1.01 to 1.26; I2=0%). Including the single 
trial enrolling pediatric patients79 did not alter the estimated relative effect or confidence interval. 
Changes From 2006 Review 
On-study mortality was not examined in the 2006 review. 
Darbepoetin Versus Control 
Six trials (Table 14) reported on-study mortality in patients randomized to darbepoetin 
(N=1,391) or control (N=1,257). The characteristics of included trials (Table 34) were less 
varied than epoetin trials (detailed in Appendix Table C2). None enrolled pediatric patients; one 
trial enrolled only women with gynecologic or breast cancers;37 no patients in the trial died in the 
active treatment period. 
Results 
The pooled hazard ratio during the on-study period was 1.05 (95% CI: 0.80 to 1.38; I2=0%); 
Bayesian random effects RR of 1.10 (95% CI: 0.76 to 1.58). While the small number of trials 
(six contributing to the effect estimate) limits statistical inferences, the result magnitude is 
consistent with an increased risk of mortality during the active treatment period. 
Changes From 2006 Review 
On-study mortality was not examined. 
Evidence Regarding Erythropoietic-Stimulating Agents 
Given the basis for considering ESAs as agents with similar effects and evidence consistent 
with increased mortality during the active treatment period, all trial results were combined for 
analysis with three aims: 1) estimate overall pooled effect, 2) examine potential subgroup 
differences, and 3) explore any relationship between relative and underlying mortality risk (i.e., 
on-study mortality in the control arms). 
Pooling on-study mortality from the 37 trialsc
                                                             
c Hazard ratio for the longest-available follow-up for these 37 trials was 1.05 (95% CI: 0.99 to 1.11) or consistent with the 
estimate in the previous section for the 44 trials analyzed.   
 yielded an estimated hazard ratio of 1.17 (95% 
CI: 1.04 to 1.31; I2=0%) as shown in Figure 11 (including the trial enrolling pediatric patients 
left estimate unchanged) and a Bayesian random effects RR of 1.15 (95% CI: 1.02 to 1.31). I2, 
while zero percent, should not be interpreted as a lack of heterogeneity70 because it depends on 
within-study precision, which in these trials is exceedingly low. Considered as a whole and 
displayed in Table 35, the estimates are consistent with an association between ESA treatment 
and increased mortality during the active treatment period. A limitation of these data is the 
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uncertainty (wide confidence intervals) accompanying individual trial results, as none were 
designed or powered to detect even a lower limit for increased mortality risk during the active 
treatment period. To illustrate, a trial randomized 1:1 to treatment or control with an anticipated 
10 percent mortality rate in the control arm would require just over 13,000 patients to detect a 15 
percent relative increase in mortality with 80 percent power and α=0.05.d
Table 35. All pooled results for on-study mortality 
 
Variable Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Number of trials 2 31 6 37 
Patients analyzed 1,567 8,618 2,648 11,266 
Pooled hazard ratio 0.90 1.19a,b 1.05c 1.17d,e,f 
(95% confidence interval) (0.67 to 1.20) (1.05 to 1.36) (0.80 to 1.38) (1.04 to 1.31) 
I2 72% 3% 0% 0% 
aIncluding the trial enrolling pediatric patients left estimate and CI unchanged. 
bEstimate in Bayesian random effects model 1.16 (95% CrI: 1.00 to 1.32). 
cEstimate in Bayesian random effects model 1.10 (95% CrI: 0.76 to 1.58). 
dEstimate in Bayesian random effects model 1.15 (95% CrI: 1.02 to 1.31). 
eIncluding the trial enrolling pediatric patients left estimate and CI unchanged. 
fExcluding the 2 radiotherapy only trials34,81 1.16 (95% CI: 1.03 to 1.31), or the 3 trials classified here as radiotherapy or 
predominantly radiotherapy34,81,83 1.16 (95% CI: 1.03 to 1.30). 
                                                             
d Obtained from a sample size estimate for proportions assuming complete follow-up. 
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Figure 11. Forest plot of trials pooled to estimate on-study mortality 
 
CI = confidence interval; ESA = erythropoiesis-stimulating agent; HR = hazard ratio 
 
Subgroup differences were explored in meta-regressions. As with overall survival, the Peto 
method of combining hazard ratios is not readily amenable to including covariates, so meta-
regressions were performed using a random-effects model so that estimates are not precisely 
comparable. The lack of effect modification by any study characteristic (Table 36) is consistent 
with the wide confidence intervals among trials. However, given the magnitude of effects, lack 
of precision, and trial variability, meaningful differences would not be expected.   
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Table 36. Relative risks from single covariate meta-regressions—on-study mortality epoetin or 
darbepoetin versus control 
Covariate Group RR (95% CI) p-Value 
Dose Escalation Yes 1.16 (0.97 to 1.38) 0.96 
No 1.15 (0.86 to 1.54) 
Iron All other 1.16 (0.93 to 1.46) 0.89 
As necessary 1.14 (0.81 to 1.61) 
Platinum-Base Chemotherapy Yes 1.21 (1.03 to 1.42) 0.39 
No 1.09 (0.83 to 1.44) 
Chemo or Radiotherapy Chemo ± Radiotherapy 1.14 (1.02 to 1.28) 0.47 
Radiotherapy 1.49 (0.72 to 3.09) 
Baseline Hb > 10 g/dL 0.98 (0.78 to 1.23) 0.12 
≤ 10 g/dL 1.21 (0.85 to 1.72) 
Study Duration ≤ 12 weeks 0.95 (0.62 to 1.47) 0.39 
> 12 weeks 1.06 (0.64 to 1.76) 
Study Quality Low 1.17 (0.98 to 1.41) 0.75 
High 1.13 (0.84 to 1.52) 
Blinding Yes  1.13 (0.98 to 1.30) 0.75 
No 1.17 (0.89 to 1.54) 
CI = confidence interval; RR = relative risk 
Finally, we explored the relationship of underlying mortality rates to increased risk 
accompanying ESA treatment. The single trial of pediatric patients was excluded from these 
analyses. Figure 12 plots the 16-week mortality rate in the control arms (either reported in 
Bohlius et al.48 for trials with 12-weeks of ESA treatment, or estimated for trials of different 
length) against the logarithme of on-study relative risk of mortality. The depiction is consistent 
with a higher relative risk in trials with lower control arm mortality rates. Moreover, when 
included in a model,69 control arm mortality modified the relative effect (p=0.002). Table 37 
displays the estimated relative risks according to approximate quartilesf
                                                             
e The log(RR) is a linear variable while RR is not. 
 of 16-week mortality 
rate in control patients, as well as for a trial with very low (1%) control arm on-study mortality. 
These results are consistent with higher relative risks in trials enrolling patients at lower risk of 
mortality during the active treatment period. 
f Actual quartiles were 0.022, 0.057, and 0.094. 
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Figure 12. Plot of control arm mortality rate during ESA treatment and the four following weeks 
versus relative risk plotted on a logarithmic scale* 
*Excludes trials with no control arm deaths. For trials administering ESA for fewer or more than 12 weeks, the 16-week 
mortality rate was calculated. Symbols proportional to study size. 
Table 37. Relationship between 16-week mortality rate in control arm and relative risk  
Control Arm 12-Week Mortality Relative Risk 95% CrIa 
1.0% 1.66 (1.25 to 2.16) 
2.5% 1.55 (1.23 to 1.95) 
7.5% 1.25 (1.10 to 1.43) 
10.0% 1.13 (1.00 to 1.27) 
CrI = credible interval 
aThe credible interval overlapping with 1.0 should not be interpreted as lack of increased risk. The analysis in this collection of 
trials lacks sufficient power to support conclusions other than a modification of effect by underlying risk or prognosis. 
On-Study Mortality and Number Needed To Harm 
Applying the pooled relative risk estimates, we estimated the number of patients needing to 
be treated to result in one on-study death. Assuming the relative risk constant with control arm 
mortality rate (underlying risk) and on-study mortality rate of 1 percent, or patients with good 
prognoses, treating 588 patients would result in 1 additional death (Table 38). With an on-study 
mortality rate of 10 percent, or patients with generally poor prognosis, treating 59 patients would 
result in 1 additional death. If the relative risk varies with underlying risk as suggested by these 
analyses, the respective numbers of patients would be 152 and 77.   
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Table 38. Number needed to harm or resulting in one on-study death according to underlying 
mortality rate 
Comparison On-Study Mortality Ratea RR NNH 95% CI 
RR uniform with underlying risk 1.0% 1.17 588 (322 to 2500) 
2.5% 1.17 235 (129 to 1000) 
7.5% 1.17 78 (43 to 333) 
10.0% 1.17 59 (32 to 250) 
RR associated with underlying risk 1.0% 1.66 152 (86 to 400) 
2.5% 1.55 73 (42 to 174) 
7.5% 1.25 53 (31 to 133) 
10.0% 1.13 77 (37 to undefined) 
CI = confidence interval; NNH = number needed to harm; RR = relative risk 
aIn 21 trials (57 percent of those pooled), the estimated control arm on-study mortality rate exceeded 7.5 percent. 
Summary of Overall Survival and On-Study Mortality Results 
The body of evidence is consistent with increased mortality risk during the active treatment 
period that is not observed over the longer term including follow-up after active treatment. This 
increased risk is consistent with a biologically plausible effect. While overall or longer-term 
pooled relative hazards were not increased, the on-study results indicate that relative hazards are 
not constant over time and therefore obscured in the long-term estimates.g
Evidence GRADE 
  As pointed out 
previously, a constant relative hazard (proportional hazards) was assumed, yet appears 
inconsistent with these results. The informative result is therefore that mortality risk is increased 
during the duration of ESA therapy. The estimated NNH, or number of patients treated to result 
in one death, was fewer than 100 for those with the poorest prognosis (highest underlying risk). 
The evidence (Table 39) shows an increase in mortality for ESAs during and shortly 
following ESA treatment (on-study) (overall strength of evidence moderate). 
Table 39. On-study mortality: ESA versus control (GRADE evidence table) 
Trials 
(N) 
Subjects 
(N) 
Risk of Bias 
Design/Quality Consistency Directness Precision 
Results 
HR (95% CI); 
I2 
Overall 
Strength 
 of 
Evidence 
37 11,266 Mediuma 
trial quality  
high-18; low-19 
Inconsistent Direct Precise 1.17  
(1.04 to 1.31) 
0% 
Moderate 
CI = confidence interval; HR = hazard ratio 
aNo trial was powered to detect a survival difference 
 
 
                                                             
g The on-study results are hidden within the long-term estimates. 
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Meta-Analyses of Survival Outcomes 
To further examine the consistency of the survival and on-study mortality results, we 
evaluated meta-analyses comparing ESA with control in patients undergoing cancer treatment 
(also reporting results for thromboembolic complications). Only meta-analyses including trials 
published following and not associated with our previous review were included to be able to 
compare results with this update. Our literature search for meta-analyses resulted in 116 
citations, of which 56 were classified as meta-analyses and of which 15 were selected for full 
review.48,141,145-158 We included meta-analyses that: 
1. Evaluated survival, 
2. Were not limited by cancer type, 
3. Excluded trials of patients with myelodysplastic syndrome, and 
4. Analyzed a subgroup of trials in which patients received concurrent chemo/radiotherapy. 
Table 40 shows the 15 published meta-analyses that were reviewed in full, included, or 
excluded (with reasons for exclusion). Appendix Table G1 lists the trials included in the four 
meta-analyses appraised in our assessment. 
Quality Assessment 
We evaluated the methodologic quality of the meta-analyses using AMSTAR,60 a 
measurement instrument for the “assessment of multiple systematic reviews” (Table 41). For 
each AMSTAR domain (question), the instrument provides detail on desirable information to 
include or methods to be used. Table 41 provides a brief summary of our assessment of each 
study for each question (desired answers are indicated in brackets after the question in the first 
column). AMSTAR does not provide a summary score; however, based on the results, Bohlius et 
al.48 appears to be the highest quality review and additionally is a patient-level meta-analysis. 
Ludwig et al.141 is limited compared to the other reviews being focused solely on darbepoetin 
trials in patients with chemotherapy-induced anemia, but is a patient-level meta-analysis. 
Results 
For overall survival using longest available follow-up, only Bennett et al.145 found 
significantly poorer survival with ESA use—HR 1.10 (95% CI: 1.01,1.20; I2=20%; 45 trials). 
Both Bohlius et al.48 and Ludwig et al.141 pooled trial results for the on-study or active treatment 
period only and found increased risks of mortality. In Bohlius et al.,48 including a much larger 
number of trials, the risk of on-study mortality was increased in the chemotherapy trials—HR 
1.10 (95% CI: 0.98 to 1.24; I2=0%; 38 trials); and for all trials a HR of 1.17 (95% CI: 1.06 to 
1.30; I2=0%; 53 trials) (Table 42). Ludwig et al.,141 including individual patient data from six 
darbepoetin trials, found an increased risk of mortality during the on-study period of similar 
magnitude—HR 1.11 (95% CI: 0.84 to 1.47; I2 NR). Both results are similar in magnitude to 
those obtained in the current analysis. 
(As anticipated from previous reviews, estimates of relative effect of ESAs for 
thromboembolic events ranged from 1.5 to 1.6. No effect was found for disease progression.)   
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Table 40. Included and excluded published meta-analyses 
Meta-Analysis Included/ Excluded 
Perioperative, 
Myeloablative 
Procedures 
Excluded? 
(Required=Yes) 
Limited by Cancer 
Type? 
(Required=No) 
Other 
Bennett 2008145  Included Yes No  
Bohlius 200948 Included Yes No  
Glaspy 2010146 Included Yes No  
Ludwig 2009141  Included Yes No  
Shehata 2007147 Excluded  Yes  
Aapro 2008148 & 2009149 Excluded No   
Lambin 2009150  Excluded  Yes  
Tonelli 2009151 Excluded No   
Kimel 2008152  Excluded   Included only trials 
reporting HRQoL 
Gascon 2008153 Excluded   Review of other meta-
 Cornes 2007154 Excluded   Review of cost-
effectiveness studies 
Minton 2008155 Excluded   Limited to fatigue 
 Ray-Coquard 2008156 Excluded   Guidelines based on 
systematic review and 
expert judgment 
Katsumata 2011 157 Excluded   Abstract only; 
insufficient information 
for AMSTAR review 
Vansteenkiste 2012 158 Excluded  Yes  
AMSTAR = assessment of multiple systematic reviews; HRQoL = health-related quality of life
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Table 41. AMSTAR quality evaluation of meta-analyses 
AMSTAR Component Glaspy 2010146 Bohlius 200948 Bennett 2008145 Ludwig 2009141 
A priori design provided? [Yes] Not reported Yes Not reported Not reported 
Duplicate study selection/data  
abstraction? [Yes] 
Not reported Yes Yes Not reported 
Comprehensive literature  
search? [Yes] 
Yes Yes Yes No 
Publication status used as  
inclusion criterion? [No] 
No No No No 
List of included and excluded  
trials provided? [Yes] 
Yes - included only Yes - included list in 
publication; excluded list in 
Cochrane review authored 
by same group 
Yes - included only Yes - included only 
Characteristics of included  
trials provided? [Yes] 
Yes - minimal Yes Yes Yes 
Quality of included trials  
assessed? [Yes] 
No Yes Only with regard to 
prospective evaluation of 
outcomes of interest 
No 
Quality of included trials  
used in formulating  
conclusions? [Yes] 
No Yes Yes No 
Methods used to combine  
study findings appropriate? [Yes] 
Yes Yes Yes Yes 
Publication bias assessed? [Yes] No Yes Yes No 
Conflict of interest stated? [Yes] No Yes - 7 of 23 authors 
received honoraria, travel 
grants, or research funding 
from ESA suppliers; 1 
author conducts systematic 
reviews of health 
technology for the Blue 
Cross and Blue Shield 
Association 
Yes - 2 of 21 authors were 
consultants and/or received 
research funding from an 
ESA supplier 
Yes - all authors reported 
employment, stock 
ownership, consulting, 
honoraria, and/or research 
funding from an ESA 
supplier 
AMSTAR = assessment of multiple systematic reviews; ESA = erythropoiesis-stimulating agent 
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Table 42. Overall survival, thromboembolic events, and disease progression meta-analysis results by study 
Characteristics Factor Glaspy 2010146 Bohlius 200948 Bennett 2008145 Ludwig 2009141 
Analysis methods  ORs were generated 
using the Comprehensive 
Meta-Analysis (V2) 
software and random-
effects models; intention-
to-treat (ITT) and 
modified-ITT approaches 
(only patients who 
received study drug were 
analyzed) were used; 
sensitivity analyses were 
carried out on 20 
chemotherapy trials with 
long-term follow-up (46 
months) “to address 
concerns regarding use of 
OR as a point estimate.” 
For sensitivity analyses, 
patient-level data from 16 
of the 20 trials were 
obtained. 
Authors calculated log 
hazard ratios with log-
rank test and Cox 
regression for each study 
and combined these in 
fixed-effects and random-
effects meta-analyses (2-
stage method). Also 
calculated Cox 
regression models 
stratified by study (1-
stage fixed-effects 
method). Trials with no 
events in both groups did 
not contribute. All 
analyses were by 
intention-to-treat. 
Pooled RR, HR using 
random-effects models; 
"When mortality events 
were not available, HRs 
were calculated by using 
the inverse variance 
method to pool HRs. 
When VTE events were 
not available, a 
correction factor (0.5) 
was used to compute 
the RRs." 
Kaplan-Meier survival 
curves were created for 
overall survival, 
progression-free survival, 
and disease progression; 
all included long-term 
follow-up data. Effect of 
ESAs was characterized 
using Cox proportional 
hazards models stratified 
by study protocol. 
Overall Trials 60 53 51 6 
Patients 15,323 13933 13,611 2,122 
Chemotherapy 
and/or radiotherapy 
Trials 51 53 45   
Patients 13,422 13933 11,522   
Chemotherapy +/- 
radiotherapy 
Trials 47 (includes chemo-
radiotherapy) 
38 (no chemo-
radiotherapy) 
  6 
Patients 12,108 (includes chemo-
radiotherapy) 
10,441 (no chemo-
radiotherapy) 
  2,122 
Radiotherapy alone Trials 4 3 3   
Patients 1,314 799 1,173   
No Treatment Trials 9 5 6   
Patients 1,901 1690 2,089   
Results Report by 
followup 
On-study or active 
treatment 
No Yes No Yes 
Long- or mixed-term 
followup 
Yes Yes Yes Yes 
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Table 42. Overall survival, thromboembolic events, and disease progression meta-analysis results by study (continued) 
Characteristics Factor Glaspy 2010146 Bohlius 200948 Bennett 2008145 Ludwig 2009141 
Meta-Analysis 
Results – Overall 
Survival (Long- or 
Mixed-Term Pooled 
Effect [HR or OR]) 
Chemotherapy and/or 
radiotherapy 
NR NR 1.09 (0.99 to 1.19); 
I2=21% 
  
Chemotherapy +/- 
Radiotherapy 
1.03 (0.93 to 1.13); I2=1% 1.04 (0.97 to 1.11); 
I2=5% 
NR 0.97 (0.85 to 1.10); 
 I2 NR 
Radiotherapy Only 1.18 (0.95 to 1.47);  
I2 NR 
NR NR   
All Trials 1.06 (0.97 to 1.15); I2=0% 1.06 (1.00 to 1.12); 
I2=7% 
1.10 (1.01 to 1.20); 
I2=20% 
  
Chemotherapy 
and/or Radiotherapy 
(On-Study or Active 
Treatment Pooled 
Effect [HR or OR]) 
Chemotherapy +/- 
Radiotherapy 
  1.10 (0.98 to 1.24); 
I2=0% 
  1.11 (0.84 to 1.47);  
I2 NR 
Radiotherapy only    NR     
All trials   1.17 (1.06 to 1.30); 
I2=0% 
    
Thromboembolic 
events 
N trials included 44   38 6 
Total N patients 13,196   8172 2,122 
(HR or OR) 1.48 (1.28 to 1.72)   1.57 (1.31 to 1.87) 1.57 (1.10 to 2.26) 
all reporting  
1.48 (1.27 to 1.72)  
chemotherapy only  
Disease progression N trials included 26   6 
Total N patients 9646   2,122 
(HR or OR) 1.01 (0.90 to 1.14)    0.92 (0.82 to 1.03) 
all reporting 
0.95 (0.85 to 1.06) 
chemotherapy only 
ESA = erythropoiesis-stimulating agent; HR = hazard ratio; NR = not reported; OR = odds ratio; RR = relative risk; VTE = venous thromboembolism   
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KQ1: Progression-Free Survival and Related Outcomes 
Twenty-two trials reported results related to survival with disease progression;8,34,35,46,51,81-
84,86,96,97,99,100,102,110,114,116,124,125,130,131 few trials included progression free survival as a primary 
outcome. Trials and results are briefly summarized in Appendix Table H1. 
Tumor progression was reported variably as a hazard ratio or a risk ratio for progression-free 
survival, as disease-free survival, as time to progression, or as the proportion of patients with 
tumor progression. Only a minority of trials defined how disease progression was measured in 
the published report. Where definitions were provided, they were not always consistent across 
trials. In light of such varied and insufficient reporting, combining results was not possible. 
Of the 22 trials, only three reported significant differences in disease-free or progression-free 
survival, one trial in favor of epoetin82 and two in favor of control.34,46 Thus, these results do not 
add important information to the discussion of ESA outcomes. 
KQ1: Thromboembolic Events 
Ascertainment of thromboembolic events differed considerably across trials. Definitions 
either varied or in a majority of trials were unstated (Appendix Tables C24 and C25). Given lack 
of uniformity, any of the following reported events were included: thrombosis, transient ischemic 
attack, stroke, pulmonary embolism, or myocardial infarction. There were also discrepancies in 
different data sources for the same trials (Appendix Tables C26 and C27). When there were 
discrepancies, the most complete source of data reporting absolute event rates was used or, 
alternatively, data with the most consistent definitions across trials and absolute event rates were 
included (similar to the 2006 review). Accordingly, much of the thromboembolic event data 
were obtained from the 2004 FDA ODAC hearings. Finally, the variable detail in reported 
diagnoses of thromboembolic events and discrepancies among sources advise that effects are 
accompanied by uncertainties in addition to those included in any pooled estimates. 
Trials included in these analyses and data source are listed in Table 14; summary 
characteristics are shown in Table 43.   
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Table 43. Summary of characteristics for trials included in analysis of thromboembolic events 
Characteristics Factor Darbepoetin vs. Epoetin 
Epoetin 
vs. Control 
Darbepoetin 
vs. Control 
Epoetin or 
Darbepoetin 
vs. Control 
Trials N/A 3 32b 6 38 
Patients Treatment 945 5,107 1,398 6,505 
Comparator 928 4,594 1,471 6,065 
Mean Age Rangea Treatment 61.7-63.7 12.4-68.3 49.0-64.8 12.4-68.3 
Comparator 58.7-63.4 10.8-68.1 48.0-64.6 10.8-68.1 
Trial Quality  
 n (%) 
High 0 (0) 16 (50) 4 (66.7) 20 (52.6) 
Low 3 (100) 16 (50) 2 (33.3) 18 (47.4) 
Treatment Modality 
n (%) 
Chemotherapy 3 (100) 24 (75) 5 (83.3) 29 (76.3) 
Chemotherapy 
includes Platinum 
3 (100) 18 (56.2) 3 (50) 21 (55.3) 
Radiotherapy 0 (0) 3 (9.4) 1 (16.7) 4 (10.5) 
Chemoradiotherapy 0 (0) 5 (15.6) 0 (0) 5 (13.2) 
Dose Escalation 
n (%) 
Allowed 0 (0) 15 (46.9) 1 (16.7) 16 (42.1) 
Not allowed 3 (100) 16 (50) 4 (66.7) 20 (52.6) 
Unknown 0 (0) 1 (3.1) 1 (16.7) 2 (5.3) 
Iron n (%) As necessary 0 (0) 22 (68.8) 4 (66.7) 26 (68.4) 
Other including fixed 1 (33.3) 7 (21.9) 2 (33.3) 9 (23.7) 
Unknown 2 (66.7) 3 (9.4) 0 (0) 3 (7.9) 
Tumor Type n (%) Solid 2 (66.7) 20 (62.5) 4 (66.7) 24 (63.2) 
Mixed 1 (33.3) 7 (21.9) 1 (16.7) 8 (21.1) 
Hematologic 0 (0) 4 (12.5) 1 (16.7) 5 (13.2) 
Baseline Hb g/dL N/A 10.1-10.4 9.1-13.7 9.5-13.6 9.1-13.7 
Therapy Duration 
(weeks) 
N/A 14-16 4-52 9-23 4-52 
Hb g/dL = hemoglobin grams per deciliter; N/A = not applicable 
aOf reported means or medians. 
bOne trial103 reported no events in either treatment arm. 
Darbepoetin Versus Epoetin 
Three trials reported thromboembolic event rates for participants randomized to darbepoetin 
or epoetin.134,136,137 The trials differed in tumor type and iron supplementation (Table 43). 
Results 
The pooled relative risk from the three trials showed no difference between agents—RR 0.86 
(95% CI: 0.61 to 1.21; I2=0%). Event rates in the trials ranged from 1.3 to 11.4 percent. 
Changes From 2006 Review 
There were no changes from the 2006 review. 
Epoetin Versus Control 
Thirty-two (Table 14) reported thromboembolic event rates in patients randomized to epoetin 
(N=5,107) or control (N=4,594), but there were no events in one trial.103 Trial characteristics 
varied, summarized in Table 43. One trial included pediatric patients,79 nine trials included only 
women with gynecologic and/or breast cancers. 
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Results 
The pooled relative risk was consistent with an increased risk of thromboembolic events in 
epoetin treated patients—RR 1.50 (95% CI: 1.26 to 1.77; I2=0%). Absolute event rates in the 
epoetin and control arms ranged from 0 to 30.8 percent, and 0 to 12.3 percent, respectively. 
Changes From 2006 Review 
Ten trials from the previous review were excluded, 13 trials included unchanged, data were 
updated for seven trials, and 12 new trials were identified (Appendix Table F1). Table 44 
compares current results with the 2006 review and sensitivity analysis with excluded trials 
showing similar results. 
Table 44. Thromboembolic events: epoetin versus control—current report, current with trials 
excluded but in 2006 review, and 2006 review 
Comparison Trials Epoetin N Control N RR (95% CI) I2 
Current 31 5,050 4,535 1.50 (1.26 to 1.77) 0% 
Current & Excluded 39 5,518 4,839 1.53 (1.30 to 1.81) 0% 
2006 review 30 3,355 2,737 1.69 (1.36 to 2.10) 0% 
CI = confidence interval; RR = relative risk 
Darbepoetin Versus Control 
Six trials (Table 14) reported thromboembolic event rates in patients randomized to 
darbepoetin (N=1,080) or control (N=1,075). Trial characteristics varied somewhat (Table 43). 
In one trial, radiotherapy was the sole treatment modality.46 
Results 
There was evidence for an increased risk of thromboembolic events with darbepoetin—
pooled RR 1.53 (95% CI: 1.18 to 2.00; I2=0%). Absolute event rates in the darbepoetin and 
control arms ranged from 2.7 to 21.6 percent and 0.6 to 14.5 percent, respectively. 
Changes From 2006 Review 
One trial from the previous review was included unchanged and five new trials were 
identified (Appendix Table F1). Table 45 compares current results and those from the single trial 
included in the 2006 review. 
Table 45. Thromboembolic events: darbepoetin versus control—current report, current with trials 
excluded but in 2006 review, and 2006 review 
Comparison Trials Darbepoetin N Control N RR (95% CI) I2 
Current 6 1,398 1,471 1.53 (1.18 to 2.00) 0% 
2006 review 1 155 159 1.44 (0.47 to 4.43) — 
CI = confidence interval; RR = relative risk 
Evidence Regarding Erythropoietic-Stimulating Agents 
Combining results from the 37 trials of epoetin or darbepoetin versus control yielded an 
association between treatment and thromboembolic events—pooled RR 1.51 (95% CI: 1.30 to 
1.74; I2=0%). Absolute events rates ranged from 0 to 30.8 percent in treatment arms (pooled 
5.8%) and from 0 to 14.5 percent in control arms (pooled 3.2%); risk differences ranged from -
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3.4 to 26.9 percent. Figure 13 displays the distribution of absolute risk differences showing that 
in almost all trials thromboembolic event rates accompanying ESA treatment exceeded, often 
substantially, control arm rates. 
Changes From 2006 Review 
Ten trials from the previous review were excluded, 14 included unchanged, data were 
updated for seven trials, and 17 new trials were identified (Appendix Table F1). Table 46 shows 
similar results for the current and 2006 reviews as well as sensitivity analysis with the excluded 
trials. 
Table 46. Thromboembolic events: epoetin or darbepoetin versus control—current report, current 
with trials excluded but in 2006 review, and 2006 review 
Comparison Trials Epoetin or Darbepoetin N Control N RR (95% CI) I
2 
Current 37 6,448 6,006 1.51 (1.30 to 1.74) 0% 
Current & Excluded 44 6,916 6,310 1.53 (1.33 to 1.77) 0% 
2006 review 31 3,510 2,896 1.68 (1.36 to 2.08) 0% 
CI = confidence interval; RR = relative risk 
Figure 13. Distribution of risk differences in thromboembolic event rates—ESA versus control* 
 
*A single outlier trial with a risk difference of 0.27 is not shown. 
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Evidence GRADE 
The evidence is consistent an increased risk of thromboembolic events accompanying ESA 
treatment (overall strength of evidence moderate), but no clinically meaningful difference 
between epoetin and darbepoetin in thromboembolic events (Table 47). 
Table 47. Thromboembolic events: ESA versus control (GRADE evidence table) 
Trials 
(N) 
Subjects 
(N) 
Risk of Bias 
Design/Quality Consistency Directness Precision 
Results 
RR (95% CI); 
I2 
Overall 
Strength 
 of 
Evidence 
37 12,454 Mediuma 
trial quality  
high-20; low-17 
Consistent Direct Precise 1.51 
(1.30 to 
1.74); 0% 
Moderate 
CI = confidence interval; RR = relative risk 
aDue to lack of consistent endpoint ascertainment across trials. 
KQ1: Health-Related Quality of Life 
Quality of life is a general concept that is often inclusive of all aspects of life that impact on a 
person’s well-being. A more specific term, health-related quality of life (HRQoL), describes 
aspects of quality of life directly related to individual health and distinguishes these from 
experiences less directly related to the individual and more dependent on social and political 
trends.159 The FDA includes quality of life measures that support labeling claims, but avoids the 
use of “quality of life” terminology, preferring “patient reported outcomes” (PRO) for this 
particular purpose. A PRO is “any report of the status of a patient’s health condition that comes 
directly from the patient, without interpretation of the patient’s response by anyone.”160 
Measuring HRQoL in clinical trials can be particularly helpful for eventual patient 
management when the symptoms of a condition are many and varied, and when the treatment of 
interest is expected to have little if any impact on survival but a positive impact on HRQoL. Note 
that only controlled trials can support causal inferences about the effects of a particular treatment 
on quality of life.161 Potentially confounding factors (e.g., changes in disease status) that may 
affect both direct treatment outcome and quality of life are distributed randomly and equally 
among trial arms and do not affect the results. 
Instruments designed to measure change in HRQoL may be general (“global”) or specific to 
the disease under study. Global instruments are intended for use across various disease 
populations, and permit comparison of HRQoL outcomes among interventions and diseases. 
Global instruments, however, may be insensitive and fail to detect small but clinically important 
changes. Disease or condition-specific instruments address this problem, but may be limited by 
their narrow range of applicability. Thus, global and specific instruments are often used together. 
Researchers measuring the impact of anemia symptoms due to cancer therapy, and the treatment 
of anemia have used a variety of HRQoL instruments. In fact, one of the difficulties in 
attempting pooled analysis of results in this area has been lack of consensus on one or a very few 
validated instruments for use in clinical trials. 
The FDA presupposes that use of a PRO as a clinical trial endpoint in order to support 
labeling claims is based on use of an instrument that has been “adequately developed and  
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validated.”160 Validation of a fully developed questionnaire consists of studies that address the 
following elements, where patients meet the criteria for the type of study intervention:162 
Reproducibility: repeated administration to stable patients produces the same result; 
• Responsiveness: in stable patients administered a relevant intervention of known 
efficacy, the questionnaire should show sufficiently large improvement in HRQoL 
relative to the variability shown by stable patients; 
• Construct validity: the questionnaire behaves in relation to other measures as expected if 
it was really measuring the intended domains of HRQoL. 
In addition to using a validated instrument, the logistics of questionnaire administration 
should be handled to minimize the impact on the integrity of the quality of life assessment. 
Feedback from the investigator, treating physician, or staff that affects the patient’s reported 
sense of well-being is a potential source of bias. Ideally, the instrument should be administered 
prior to discussions with health care providers as to treatment response, adverse events, or other 
information (e.g., hemoglobin level) that could affect patients’ responses to the quality of life 
questionnaire. The study protocol should detail the time intervals for administering the 
instrument as well as training for staff or for the patient if the instrument is self-administered. 
As noted, trials of ESAs reporting HRQoL outcomes have used a variety of instruments, 
some of them not validated. However, many of the more recent trials have used a validated, 
multi-dimensional instrument, The Functional Assessment of Cancer-Anemia (FACT-An),163 or 
one of its subscales. The core of the FACT-An is the Functional Assessment of Cancer 
Therapy—General (FACT-G), which contains 27 questions that can generate subscale scores 
regarding physical, functional, emotional, and social well-being.164 Data from 1,172 cancer 
patients who answered the FACT-G questionnaire indicated that fatigue was the symptom most 
often reported (73%). As a result, two additional subscales assess fatigue and anemia. The 
FACT-Fatigue (FACT-F) consists of a fatigue-specific subscale of 13 items; the FACT-Anemia 
(FACT-An) adds to the FACT-F seven nonfatigue items relevant to anemia in cancer patients. 
For details and references regarding instrument validation, the reader is referred to the Functional 
Assessment of Chronic Illness Therapy Web site.h
HRQoL results have been evaluated in different ways and often incompletely reported (e.g., 
baseline scores, absolute values, and measures of result dispersion may be missing), making it 
difficult to pool results across trials. Analysis should compare change from baseline between 
study and control arms from randomized controlled trials to adequately control for placebo 
response. Other factors may need to be considered in the analysis. For example, in the previous 
systematic reviews conducted by TEC, only trials with average baseline hemoglobin less than 10 
mg/dL reported statistically significant HRQoL results using FACT-An or subscales whereas 
trials of patients with higher average baseline hemoglobin were not significant for this outcome. 
 Other well-validated global instruments that 
have been used, sometimes in conjunction with the FACT-An or a subscale, include the Short 
Form (36) Health Survey (SF-36) and the European Organization for Research and Treatment of 
Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30). 
Missing data can substantially impact interpretation of HRQoL results. First, when HRQoL is 
a secondary outcome, not all patients in the trial may be administered questionnaires. Often                                                              
h http://facit.org/validity/validation_articles.aspx 
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missing from the trial report is a description of the HRQoL subset and evaluation of potential for 
selection bias. Second, among those followed for HRQoL, nonrandom missing data can result in 
serious bias. For example, patients with missing questionnaires may be the sickest patients or 
those least responsive to therapy; failure to respond to specific items in a questionnaire also 
raises concerns. Trial protocols should include a detailed plan for preventing missing data, 
investigating the pattern and mechanism of missing data, and addressing missing data in the 
analysis using acceptable methods and sensitivity analyses. 
Statistically significant HRQoL results are often reported without additional discussion. 
However, statistically significant improvements in HRQoL measures in an ESA treated clinical 
trial population compared to control may not be clinically perceived by an individual patient as 
an improvement. For example, Clement et al.165 evaluated randomized controlled trials of ESA 
therapy in patients with anemia associated with chronic kidney disease that reported HRQoL 
results from a validated questionnaire (SF-36). The authors found that treating to attain 
hemoglobin >12 g/dL resulted in small, statistically significant, but not clinically meaningful 
changes in HRQoL. That is, on average, patients would not be able to perceive the improvement. 
In recognition of the importance of clinical significance, the FDA160 encourages sponsors to 
“avoid proposing [PRO] labeling claims based on statistical significance alone.” Rather, results 
should ideally be compared to the minimal clinically important difference (MCID), the smallest 
difference in score in the domain of interest that patients perceive as beneficial and which would 
lead to a change in patient management.166 Modifications to this definition have addressed 
deterioration, such that harmful differences, which may be perceived on a different scale,167 are 
also considered.168 While the concept is appealing, MCID estimation is not simple, and estimates 
may vary depending on patient population, disease severity, and clinical study context.168,169 
MCID estimation relies on anchor-based approaches, reviewed in a number of 
publications.168-171 Briefly, a well-understood external indicator (anchor) such as a laboratory 
measure, clinician rating, or patient-based global rating is used to categorize patients by degree 
of change from baseline in the anchor (e.g., none, small positive, large positive, small negative, 
large negative). The groups characterized as a little better or a little worse are the minimal 
change groups, and the change in the PRO in these groups is a measure of the MCID. Anchors 
should be selected for important qualities: change in the anchor should be clinically 
interpretable; and there should be a strong relationship between the anchor and the PRO 
measure. Use of multiple anchors is recommended for MCID estimation, and an MCID range, 
rather than a point estimate, is recommended to accommodate variability in the estimate as well 
as variability in the patient population and clinical scenario.168,169,172 Similarly, use of the lowest 
possible estimate is not recommended as some scores may be falsely included as meaningful; 
rather, a slightly higher cutoff may be more appropriate.173 
Distribution-based methods, which rely on instrument score statistical distributions, may be 
used to supplement anchor-based MCID estimates but are not recommended as sole MCID 
estimation methods. These include defining MCID as one half of a standard deviation of a given 
HRQoL instrument based on a large review of studies by Norman et al.174 Standard error of 
measurement175,176 has also been proposed as a measure of MCID. Cohen et al.177 suggested 0.2, 
0.5, and 0.8 standardized effects representing small, moderate, and large changes but in the 
context of power calculations. Such estimates are not always generalizable; in a review of studies 
using the FACT-G questionnaire,178 the authors found that use of Cohen’s thresholds resulted in 
at times overestimation and in other cases underestimation of an observed effect, concluding that 
“general rules for effect sizes may be too simplistic.” 
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Comparison of the mean difference in the PRO between study arms to the MCID should 
enable determination of clinical significance. However, and particularly when there are several 
HRQoL domains and results are close to the MCID, overall clinical significance may not be so 
clear. In addition to reporting data related to the mean difference, it is also helpful to report the 
difference between study arms in the proportion of patients achieving an improvement greater 
than the MCID as well as deterioration greater than the MCID. “Adding those differences in 
proportion yields a risk difference that one can convert to a number needed to treat (NNT),”170 a 
result that is intuitively easy to understand. 
Both anchor- and distribution-based methods have been used to estimate MCID for FACT-
An and subscales in cancer patients treated with epoetin. Two follow-up studies179,180 used 
change in hemoglobin as an anchor; only Patrick et al.180 reported correlations of 0.26 (FACT-G) 
and 0.29 (FACT-fatigue subscale) between QoL scale and a hemoglobin increase of 1 g/dL, 
similar to correlations reported in other trials.106,107 Neither study provided information on how 
to interpret change in hemoglobin. Cella et al.179 also used ECOG and Karnofsky performance 
scores as anchors. They did not report on the correlation of either performance scores with FACT 
scales, or on interpreting change in performance score. That these changes are closely linked to 
the physical aspects of QoL in epoetin and darbepoetin-treated patients is supported by data from 
an unrelated study of chemotherapy in patients with lung cancer, where baseline ECOG 
performance score was correlated with the EORTC QLQ C-30 scales at -0.52 (physical 
function), -0.63 (global health status), and 0.52 (fatigue).181 EORTC QLQ C-30 and FACT-G 
physical and functional domain scores have shown good correlation.182,183 
In these studies, patients were separated only into “improved,” “unchanged/stable,” or 
“worsened” categories, with no identification of groups with only small improvement or small 
decline. Using simple differences between stable and improved groups, Patrick et al.180 estimated 
MCIDs at 2.5 for FACT-G and 4.2 for FACT-Fatigue. Cella et al.179 reported between-group 
changes for the FACT-Fatigue subscale as 0.2-8.8 score units and for the FACT-G Total as 1.9-
9.9. Using Cohen’s recommendation of 0.2 as a “small” effect size to set MCID lower limits and 
point estimates, the authors reported MCIDs of 3 and 4 for FACT-Fatigue and FACT-G, 
respectively. While this study appropriately uses different anchors to accumulate between-group 
change data, it uses a distribution-based method to choose the actual MCID estimate, rather than 
identifying groups with perceived small changes in the anchor to determine the corresponding 
range of changes in FACT scores. Nevertheless, these MCID estimates have become widely 
reported in the literature. 
Trials that convert health outcomes into a common result, such as quality-adjusted life years 
(QALYs) or cost (cost-utility and cost-benefit), cannot use the HRQoL results from PRO 
measures such as FACT scales. Rather, preference (utility)-based measures are required;184 their 
main purpose is to measure the “utility” of health states (that is, the preferences people have for 
different health states along a continuum extending from death to full health) in a way suitable 
for use in economic evaluation studies. 
No ESA trials have reported HRQoL outcomes using utility-based measures. The scales used 
by instruments such as FACT scales may have minima and maxima that fall well within the 
conceptual range of utility-based measures, making conversion difficult. Such conversion has 
been attempted in other types of studies, and requires ad hoc assignment of reported health-status 
data categories to corresponding values on a standard health utility measure. However, the 
process has not been found uniform across studies or reliable within a single study.185 As an 
alternative, Ossa et al.186 used FACT-An to develop descriptions of health states related to 
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anemia and the associated hemoglobin levels, and time tradeoff methods to determine utility 
values for the different states. Finally, Wilson et al.76 published utility values by hemoglobin 
level from ESA manufacturer submissions and used them to model cost per QALY. 
Thus, recognized MCID estimates for the FACT-G and FACT-Fatigue scales are available to 
help determine whether HRQoL results for ESA clinical trials are clinically meaningful, and are 
used in the following discussion of HRQoL results. However, utility-based HRQoL measures are 
lacking to support decision analyses and health economic studies, forcing the use of basic 
surrogates such as hemoglobin levels (see section, “Decision Analysis”). 
Quality of Life Outcomes 
Summary of Trials 
For this review, we included trials reporting health-related quality of life (HRQoL) evidence 
as change from baseline to final follow-up in each study arm, and change in treatment arm(s) 
compared to that in the control arm. Ideally, trials would also report the percentage of patients in 
each study arm that achieved a prespecified clinically meaningful improvement but few did. We 
also required trials to use a validated instrument; scales and subscales reported by included trials 
are described in Table 48. Trials reporting only linear analogue self-assessment (LASA) or visual 
analog scales (VAS) were excluded. 
Twenty-nine trials reported HRQoL results meeting the above criteria: 
• 10,231 randomized patients (5,339 ESA; 4,835 control); number evaluated for HRQoL 
likely to be less 
• 24 trials of epoetin (8,318 randomized; 4,304 epoetin, 4,014 control) 
• 5 trials of darbepoetin (1,913 randomized; 1,035 epoetin, 878 control) 
• 1 study of epoetin that reported a statistically significant difference in the total FACT-
Anemia scale favoring ESA, but did not report data for inclusion in the evidence 
analysis.121 Three trials that reported results of FACT-Fatigue subscale results but with 
insufficient data to be included in a pooled analysis 99,109,115 Two of these studies also 
reported FACT-An Total Anemia and FACT non-fatigue subscale scores, but also 
without sufficient data for analysis.109,115 
Objective of the Evidence Evaluation 
The most commonly reported HRQoL instrument was the FACT-Fatigue subscale, with 14 
trials of ESA versus no ESA reporting sufficient data for quantitative analysis (Table 48). The 
next most commonly reported instruments were the FACT nonfatigue anemia subscale and the 
total FACT-An in 8 and 7 trials, respectively. In view of the limited number of trials using the 
same instrument, and recommendations of Shekelle et al.57 that the 2006 evaluation of quality of 
life did not need updating (see Introduction), it was decided to limit the goals of the HRQoL 
evidence analysis and conduct a focused, quantitative evaluation of results from trials reporting 
data for the FACT-Fatigue subscale. The comparison is that for KQ1: epoetin (alfa or beta) or 
darbepoetin versus placebo/no treatment.   
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Table 48. Description of the scales and subscales evaluated in trials included in this review 
FACT 
Instrument or 
Subscale 
#Trials 
Reporting 
Type of 
Instrument Domains Addressed (#Questions) 
Range of Scale 
(Highest=Most 
Favorable) 
FACT-fatigue 
subscale 
20 (14 with 
complete data) 
Symptom-specific Fatigue-specific questions from anemia-
specific questions of FACT-An (13) 
0-52 
FACT non-
fatigue anemia 
subscale 
8 Symptom-specific Questions from the anemia-specific questions 
of FACT-An that are not part of the FACT-
fatigue subscale (7) 
0-28 
FACT-An(emia) 7 Symptom-specific Includes FACT-G, all domains (27)a 
Anemia-specific symptoms (20) 
0-188 
FACT-G(eneral) 6 General Physical well-being (7) 
Social/family well-being (7) 
Emotional well-being (6) 
Functional well-being (7) 
0-108 
SF-36 Physical 
Summary 
Component 
(PCS) score 
2 General Physical Functioning (10) 
Role Physical (4) 
Bodily Pain (2) 
(these scales contribute most to PSC scoring)  
Transformed to 
mean of 50 and SD 
of 10 in the US 
population 
EORTC QLQ-
C30 core 
questionnaire 
2 General 5 functional domains 
3 symptom scales 
single items for symptoms 
2 global items 
(30) 
Transformed to  
0-100 
SF-36 Mental 
Summary 
Component 
(MCS) score 
1 General Vitality (4) 
Social functioning (2) 
Role-emotional (3) 
Mental health (5) 
Transformed to 
mean 50 and SD 10 
in the US population 
Nottingham 
Health Profile 
1 General Part I, 38 questions in 6 subareas: 
• energy level (3) 
• pain (8) 
• emotional reaction (9) 
• sleep (5) 
• social isolation (5) 
• physical abilities (8) 
Part II, 7 life areas affected (7) 
Part I:0-100 
 
Part II: 0-7 
Symptom 
Distress Scale 
1 General Nausea frequency, nausea severity, appetite, 
insomnia, pain frequency, pain severity, 
fatigue, bowel pattern, concentration, 
appearance, breathing, outlook, and cough 
(13) 
Transformed to  
0-100 
PedsQL-GCS 1 General Physical functioning (8)  
Emotional functioning (5) 
Social functioning (5)  
School functioning (5) 
Transformed to  
0-100 
PedsQL 3.0 
Cancer Module 
1 Symptom-specific Pain and hurt (2) 
Nausea (5) 
Procedural anxiety (3) 
Treatment anxiety (3) 
Worry (3) 
Cognitive problems (5) 
Perceived physical appearance (3) 
Communication (3) 
Transformed to  
0-100 
Lung Cancer 
Symptom Scale 
1 Symptom/Disease
-specific 
Patient scale: Symptoms, total symptomatic 
distress, activity status, overall quality of life 
 
Observer scale: Symptoms 
VAS 0 (severe) to 
100 
Patient: 9 scales 
Observer: 6 scales 
EORTC QLQ-C30 = ; FACT = Functional Assessment of Cancer Therapy; PedsQL-GCS = Pediatric Quality of Life Inventory-
Generic Core Scale; SD = standard deviation 
aWhile FACT-Anemia incorporates FACT-G, it was not classified as a general instrument since the results could be dominated 
by either the general FACT-G or the symptom-specific subscales. 
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Data Analysis 
The FACT-Fatigue subscale was evaluated in 20 trials; ESA treatment, compared to placebo 
or none, was found to statistically improve fatigue in eight trials (Table 50). Ten trials reported 
no statistically significant differences between ESA treatment and control arms. Vote-counting 
analysis (Table 50) found that no trial result favored the control arm. One trial reported results 
only in relation to increasing hemoglobin, finding a significant test of trend.129 One trial reported 
results without significance testing.130 Six trials did not report sufficient results for inclusion in a 
meta-analysis.35,99,109,115,124,127 Thus, 14 trials were included in a meta-analysis—3,643 
participants (1,999 ESA; 1,644 control). 
Trial quality varied and only five of 14 identified HRQoL as a primary outcome (Table 48); 
up to 55 percent of enrolled patients were not evaluable for HRQoL in study arms. Blinding to 
treatment and patient blinding to hemoglobin value prior to HRQoL questionnaire administration 
was inconsistent. All trials administered ESA to achieve hemoglobin values greater than 12 g/dL 
in the treatment arms, higher than currently recommended. Few trials adjusted their analyses for 
the baseline value of the FACT-Fatigue; only eight reported baseline FACT-Fatigue results, so 
that it was not possible to adjust for this variable in the meta-regressions. 
The mean difference between treatment arms was zero in one study, but never negative.  
The pooled post-test difference in change was 2.74 (95% CI: 1.69 to 3.78; I2=45%) in favor 
of ESA treatment (Figure 14). The pooled mean change in the ESA arms was +2.1 (95% CI: -3.9 
to 8.1; I2=0%), while in control arms -0.6 (95% CI: -6.4 to 5.2; I2=0%). Because it is important 
to control for the placebo effect in studies of HRQoL, we also evaluated the subset of studies 
reporting FACT-Fatigue outcomes that blinded patients to ESA treatment. In these eight 
studies,8,107,113,123,125,126,129,130 the pooled post-test difference in change was +1.92 (95% CI: 0.97 
to 2.86; I2=0%; data not shown). 
Figure 14. Forest plot—difference in change for FACT-Fatigue 
CI = confidence interval; ESA = erythropoiesis-stimulating agent; SD = standard deviation; W = weight  
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Conclusions 
ESA treatment with epoetin or darbepoetin to high hemoglobin target values (>12 g/dL) was 
accompanied by higher HRQoL scores compared to transfusion as needed, as measured by the 
FACT-Fatigue subscale, in nearly all reporting trials (Appendix I). Vote-counting results suggest 
that ESA treatment may at least attenuate the decline seen in non-ESA treatment arms. The 
pooled end-of-treatment difference between study arms favored ESA treatment. The pooled 
mean change in the treatment arm and the pooled mean difference in change between study arms 
are less than 3, the generally accepted minimal clinically important difference estimated by Cella 
et al..179 However, the pooled mean difference between study arms (2.7) is the same as the lowest 
of the reported estimates of the MCID.179 In summarizing their data from anchor-based 
measures, Cella et al.179 accepted only mean differences that corresponded to a Cohen’s effect 
size of at least 0.2 (see Introduction: Health-related Quality of Life). The effect size for the mean 
difference calculated in the meta-analysis is 0.23 and for the change in the ESA treatment arm 
alone is 0.21. Thus, while statistically significant, the clinical significance of the FACT-Fatigue 
difference between ESA treatment and no ESA treatment is likely to be small referent to the 
MCID. Moreover, an analysis of only those studies reporting FACT-Fatigue that also blinded 
patients to treatment (i.e., ESA vs. placebo) resulted in a lower estimate of the pooled mean 
difference in change between study arms, which could be a result of the limited number of 
studies or an indication of a placebo effect in the unblinded studies. 
This analysis has several limitations. First are those noted in the general QoL discussion with 
using MCID estimates as final arbiters of significant results, particularly here where results are 
nearly equal to the value of the estimated MCID. Other FACT scores were not analyzed due to 
insufficient data. In addition, FACT-Fatigue scores were reported in only a subset of included 
trials in this overall review, were not primary outcomes in most reporting studies, and were not 
reported for the vast majority of patients. Moreover, the conditions in which ESAs were 
administered (i.e. target values >12 g/dL) are not consistent with current practice. Thus, results 
may not be generalizable. However, they represent the current best estimate of HRQoL benefits, 
which would need to be considered along with the potential harms of treatment for each patient. 
Changes From 2006 Review 
Eight trials from the previous review were included unchanged and six new trials were 
included (Appendix Table F1). 
Evidence GRADE 
Treating to high target hemoglobin levels (≥12 g/dL) is accompanied by improved health-
related quality of life (HRQoL) scores (e.g., FACT-Fatigue); any clinical significance of the 
improvement is likely to be small (overall strength of evidence low) (Table 49).   
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Table 49. HRQoL: ESA versus control (GRADE evidence table) 
Trials 
(N) 
Subjects 
(N) 
Risk of Bias 
Design/Quality Consistency Directness Precision 
Results 
Mean 
Difference 
Change in 
FACT-
Fatigue 
Score 
 (95% CI); I2 
Overall 
Strength 
 of 
Evidence 
14 3,643 High 
trial quality  
high-2; low-12 
Consistent Direct Precise 2.74 
(1.69 to 3.78); 
45% 
Low 
GRADE = Grading of Recommendations Assessment, Development and Evaluation 
Table 50. Vote-counting results for trials reporting FACT-Fatigue subscale 
Study ESA 
Evaluable 
for QoL 
N 
Enrolled Not 
Evaluable 
% 
Blinded Significantly Favors ESA 
Not 
Significant 
Significantly 
Favors Control 
Boogaerts 200387 Epo 213 19 No •   
Chang 200590 Epo 338 3 No •   
Christodoulou 200991 Epo 153 55 No  •  
Hedenus 2003126 Epo 303 13 Yes •a   
Fujisaka 201199 Epo 170 6 Yes  •  
Hernandez 2009127 Darb 315 19 Yes  •  
Hoskin 200981 Epo NR NR No  •  
Iconomou 2003106 Epo 112 8 No •   
Kotasek 2003129 Darb 249 2 Yes (NR) (NR) (NR) 
Leyland-Jones 200535 Epo NR NR Yes  •  
Littlewood 2001107 Epo 290 23 Yes •   
Osterborg 2002113 Epo 263 23 Yes  •  
Milroy 2011 109 Epo 380 10 No  •  
Pirker 2008130 Darb 484 19 Yes    
Pronzato 2010 115 Epo 141 35 No •   
Savonije 2005119 Epo 221 30 No •   
Tsuboi 2009123 Epo 117 4 Yes  •  
Vansteenkiste 20028 Darb 255 20 Yes •   
Wilkinson 2006124 Epo NR NR No  •  
Witzig 2005125 Epo 299 13 Yes  •  
Darb = darbepoetin; Epo = epoetin; ESA = erythropoiesis-stimulating agent; NR = not reported; QoL = quality of life 
aSignificant after adjusting for baseline fatigue score. 
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KQ1: Tumor Response and Progression 
Different possible effects of erythropoietic stimulants on tumor response and progression 
have been posited. One is that through better tumor oxygenation, ESAs might improve 
chemotherapeutic agents’ cytocidal effects or enhance the effect of radiation therapy.138 
However, overall and on-study mortality results are inconsistent with any potential beneficial 
effect. Moreover, stimulation of erythropoietin receptors on neoplastic cells187,188 could result in 
more rapid tumor growth. 
To evaluate any effect of erythropoietic stimulants on tumor response and progression 
required trials with specific and homogeneous characteristics. Accordingly, we included only 
those that met the following criteria: 
1. Enrolled a homogeneous population including patients with similar tumor types at the 
same stage when clinically appropriate; or trial results were stratified by tumor type and 
stage, 
2. Participants were given a predefined and uniform anticancer therapy; or trial results were 
stratified by anticancer therapy, and  
3. Trial was designed to prospectively assess tumor response or control, reporting either as a 
primary or secondary outcome. 
Fifteen trials (13 epoetin,34,51,80,81,83,86,94,96,100,103,109,110,115 2 darbepoetin46,131) meeting these 
criteria were included. Because definitions of tumor response or progression varied, results were 
not pooled. Table 51 details characteristics of the 15 trials listing the variety of outcome 
measures assessed related to tumor progression and response. Results from those trials reporting 
tumor response outcomes are shown in Table 52. There was no evidence of an association 
between tumor response for any of the definitions and ESA use (results for other tumor outcomes 
are listed in Appendix J). 
Changes From 2006 Review 
Three trials from the previous review were excluded, one trial included unchanged, four 
results updated, and eight new trials were identified (Appendix Table F1). 
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Table 51. Characteristics of trials reporting tumor response or duration-related outcomes 
Study  
Characteristic 
Blohmer  
201186 
Debus  
200694 
Engert  
201096 
Goss  
2005100 
Gupta  
2009103 
Henke  
200334 
Hoskin  
200981 
Drug Epoetin Epoetin Epoetin Epoetin Epoetin Epoetin Epoetin 
Control N  129 190 648 53 60 171 149 
ESA N  128 195 655 53 60 180 151 
Malignancy cervical  
(high risk) 
NSCLC, stage 
IIIA/B, primarily 
inoperable 
advanced HD limited disease 
SCLC 
cervical cancer 
(stage IIB-IIIB) 
advanced 
(stage III , IV) 
head and neck 
head and neck, 
stage I-IV 
Treatment  Pt chemo + 
radio Tx 
cisplatinum 
w/sequential 
chemo-
radiotherapy 
chemotherapy, 
without 
platinum 
Pt chemo + 
radio Tx 
Pt chemo + 
radio Tx 
radiotherapy radiotherapy 
Duration  27 wks NR NR 16-24 wks NR NR 40 days 
Outcome RFS TR TR, FFTF, PFS tumor control, 
PFS 
DFS PFS, tumor 
progression 
local DFS, 
tumor response 
Assessed 1, 2, and 5 yrs NR (planned 2 
years) 
NR NR 2 years 
(survival) 
≈2 years 12 weeks 
ESA dose  3 x 10,000 
IU/wk 
40,000 IU/wk 40,000 IU/wk 40,000 IU/wk 3 x 10,000 
IU/wk 
3 x 300 
IU/kg/wk 
if Hb <12.5 
then 3 x 10,000 
IU (25% of 
patients) if Hb 
>12.5 then 3 x 
4,000 IU (75% 
of patients) sc 
ESA duration (weeks)  27 12 22-24 12-24 7 7 to 9 12 
Baseline Hb (control/ESA)  11.8/12.0 g/dL NR 12.3/12.2 g/dL 13.5/13.5 g/dL 10.7/10.4 g/dL 11.8/11.7 g/dL 13.7/13.4 g/dL 
Hb target 12.5-13.5 g/dL 13-14 g/dL 14 g/dL 16 g/dL NR 14 g/dL,women 
15 g/dL,men 
15 g/dL 
Re-start if Hb less than  NR 12 g/dL NR <14 g/dL NR 14 g/dL,women 
15 g/dL,men 
14.5 g/dL 
Drug Epoetin Epoetin Epoetin Epoetin Epoetin Epoetin Darbepoetin 
Control N  71 167 325 109 55 20 262 
ESA N  77 160 333 107 58 18 260 
Malignancy head and neck 
nonmetastatic, 
not resected 
non-small cell 
lung cancer 
breast cancer breast cancer cervix 
carcinoma 
neuroblastoma head and neck 
cancer 
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Table 51. Characteristics of trials reporting tumor response or duration-related outcomes (continued) 
Study 
Characteristic 
Blohmer 
201186 
Debus 
200694 
Engert 
201096 
Goss 
2005100 
Gupta 
2009103 
Henke 
200334 
Hoskin 
200981 
Treatment  radiotherapy Chemotherapy 
platinum based 
chemotherapy, 
without 
platinum 
chemotherapy radio-
chemotherapy 
chemotherapy radiotherapy 
Duration  NR 28 wks NR 28 wks 8 111 days NR 
Outcome locoregional 
failure rate, 
locoregional 
PFS, CR 
tumor 
response 
DFS, local 
relapse 
tumor response PFS, local tumor 
control 
PFS, tumor 
response 
locoregional 
control, DFS 
Assessed 2 and 3 years 28 wks 5 years 28 wks 3 years 5 years 5 years 
ESA dose  1x 40,000 
IU/wk 
3 x 10,000 IU/wk 
sc 
3 x 150 
IU/kg/wk 
if body 
weight > 
45 kg 3 x 
10,000 IU/wk sc 
(5000 IU if <45kg) 
1 x 40,000 IU/wk 7 x 200 IU/kg 150 mcg QW 
ESA duration (weeks)  8 to 9 28 ≈18 28 6-9 12-16 8-10 
Baseline Hb 
(control/ESA)  
12.1/12.0 g/dL 12.8/12.6 g/dL 12.8/12.4 g/dL 10.8/10.6 10.9/10.6 g/dL 9.4/8.8 g/dL ≈13/≈13 g/dL 
Hb target 14 g/dLwomen 
16 g/dLmen 
14 g/dL 
women 
15 g/dL men 
14 g/dL 12.5-14 g/dL 14 g/dL 13 g/dL 15.5 g/dL 
Re-start if Hb less than  12.5g/dLwomen 
13.5 g/dLmen 
13 g/dL 
women 
13.5 g/dL men 
NR NR 13 g/dL 13g/dL NR 
DFS = disease-free survival; FFTF = freedom from treatment failure; g/dL = grams per deciliter; Hb = hemoglobin; HD = heart disease; IU = international units;  
NR = not reported; NSCLC = non small-cell lung cancer; PFS = progression-free survival; SCLC = small-cell lung cancer; TR = treatment response  
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Table 52. Tumor response outcomes—epoetin or darbepoetin versus control 
CR = complete response; Cru = unconfirmed complete response; NR = not reported; PR = partial response 
aFrom event rates in tables. 
Study ID Drug Outcome Reported Response Definition Intervention (Events/Total) 
Control 
(Events/Total) 
RR (95% CI) 
Calculateda 
Engert 200995  Epoetin complete response  CR/CRu  619/648 614/655 0.98 (0.96 to 1.01) 
Engert 200995 Epoetin partial response  NR  10/648 11/655 1.09 (0.47 to 2.54) 
Goss 2005100 Epoetin overall response 6 wks post chemo CR+PR  48/52 42/52 0.88 (0.75 to 1.02) 
Gupta 2009103 Epoetin overall response rate at 1 month  NR  56/58 53/57 0.96 (0.88 to 1.05) 
Hoskin 200981 Epoetin tumor response  CR+PR  149/151 148/149 1.01 (0.98 to 1.03) 
Milroy 2011109 Epoetin tumor response NR 45/160 48/167 0.98 (0.69 to 1.38) 
Pronzato 2010115 Epoetin tumor response NR 65/107 56/109 1.18 (0.93 to 1.50) 
Wagner 200480 Epoetin tumor response  CR+PR  12/17 12/18 0.94 (0.60 to 1.48) 
Untch 2011131 201137 Darbepoetin pathological complete response w w/o noninvasive 
residual  
57/356 60/377 1.01 (0.72 to 1.40) 
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KQ1: Other Adverse Events 
Non-thromboembolic adverse events reported included hypertension, thrombocytopenia 
and/or hemorrhage, rash, and seizures. Data from trials on the development of potentially 
neutralizing antibodies to ESAs were also reviewed. Adverse events that could be definitively 
attributed to transfusions were not reported in any trial. 
Darbepoetin Versus Epoetin 
Three trials ascertained antibody levels to both drugs.134,136,137 Glaspy et al.132 assessed 
antibodies for only darbepoetin, but none were detected. There were no data reported on 
hypertension, thrombocytopenia and/or hemorrhage, rash, or seizure. 
Changes From 2006 Report 
One trial was excluded; two were included unchanged; data were updated for one trial; and 
one new trial was identified (Appendix Table F1). 
Epoetin Versus Control 
Hypertension 
Fifteen trials (Table 14) reported hypertension incidence (epoetin N=1,855; control N=1,509) 
(Appendix Table C30) but one trial106 reported no events. Only one trial included a definition for 
hypertension. Incidences ranged from 0 to 56 percent and 0 to 59 percent in epoetin and control 
arms respectively. Because one trial118 reported extremely high incidence rates (56 and 59% vs. 
the next highest of 9%) the trial was excluded from pooling. In the remaining trials, the pooled 
relative risk was consistent with an increased risk of hypertension accompanying ESA treatment. 
Thrombocytopenia and/or Hemorrhage 
Ten trials (Table 14) reported incidence of thrombocytopenia and/or hemorrhage (epoetin 
N=1,321; control N=1,082) (Appendix Table C32). The pooled relative risk did not suggest an 
association (Table 53). 
Rash 
Six trials (Table 14) reported that the incidence of rash (epoetin N=739; control N=728) but 
one reported no events103 (Appendix Table C34). Rash appeared more common in the epoetin 
arms (Table 53). 
Seizures 
Three trials (Table 14) reported that seizure incidence (epoetin N=359; control N=245) 
(Appendix Table C35) was higher in the epoetin arms (Table 53).   
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Table 53. Pooled relative risks and other adverse event rates—epoetin versus control 
Outcome Trials Epoetin N 
Control 
N RR (95% CI) I
2 
Incidence 
Epoetin 
 (95% CI) 
Incidence Control 
 (95% CI) 
Hypertension 13a 1,652 1,369 1.62 (1.05 to 2.50) 0% 3.5% (2.2 to 5.0) 1.8% (0.7 to 3.2) 
Thrombocytopenia 
and/or Hemorrhage 
10 1,321 1,082 1.11 (0.94 to 1.31) 0% 12.9% (4.9 to 23.7) 10.5% (3.1 to 21.3) 
Rash 5b 739 728 2.00 (0.98 to 4.07) 0% 2.3% (1.3 to 5.6) 1.0% (0.0 to 3.3) 
Seizures 3 359 245 1.49 (1.45 to 4.87) 0% 2.3% (0.9 to 4.3) 1.3% (0.2 to 4.7) 
CI = confidence interval; RR = relative risk 
aExcluding one trial with no events106 and one outlier.118 
bPooled result excludes one trial with no events;103 six trials reported rash outcomes. 
Antibodies 
Five trials ascertained antibody levels90,104,112,113,123 (epoetin N=498 [461 tested for 
antibodies]; control N=480 [445 tested for antibodies]). In only Henry et al. (1995 #97) were 
antibodies detected (2 patients of 26 tested in each trial arm) (Appendix Table C37). 
Changes from 2006 review are shown in Table 54 and detailed in (Appendix Table F1). 
Table 54. Changes in trials from 2006 review—adverse events epoetin versus control 
Outcome Trials Excluded 
Trials 
Unchanged 
Trials 
 Updated New Trials 
Hypertension 9 7 0 8 
Thrombocytopenia/Hemorrhage 4 3 0 7 
Rash 5 1 0 5 
Seizures 1 2 0 1 
Antibodies 2 4 0 1 
Darbepoetin Versus Control 
Hypertension 
Three trials (Table 14) reported hypertension incidence (darbepoetin N=650; control N=647) 
(Appendix Table C31) but none included a definition of hypertension. Incidence rates ranged 
from 3.1 percent to 6.0 percent and 2.1 percent to 5.1 percent in darbepoetin and control arms, 
respectively. 
Thrombocytopenia and/or Hemorrhage 
Two trials (Table 14) reported incidence of thrombocytopenia and/or hemorrhage 
(darbepoetin N=697; control N=614) (Appendix Table C33). Incidence was high in both arms 
and relative risk elevated in with darbepoetin (Table 55). 
Rash 
No trials comparing darbepoetin with control reported incidence of rash. 
Seizures 
Two trials (Table 14) reported seizure incidences of 1.3 percent and 1.6 percent in the 
darbepoetin and 0.5 percent and 3.0 percent in the control arms, respectively (Appendix Table 
C36) (Table 55).   
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Table 55. Pooled relative risks and other adverse event rates—darbepoetin versus control 
Outcome Trials Darbepoetin N 
Control 
N RR (95% CI) I
2 
Incidence 
Darbepoetin 
 (95% CI) 
Incidence 
Control 
 (95% CI) 
Hypertension 3 650 647 1.31 (0.79 to 2.18) 0% 5.2% (3.5 to 7.2)  3.9% (2.3 to 5.9) 
Thrombocytopenia 
and/or Hemorrhage 
2 697 614 1.46 (1.03 to 2.06) 0% 9.4% (0.0 to 32.6) 6.8% (0.2 to 20.1) 
Rash – – – – – – – 
Seizures 2 495 488 0.88 (0.14 to 5.41) 54% 1.6% (0.7 to 2.9) 1.8% (0.2 to 5.0) 
CI = confidence interval; RR = relative risk 
Antibodies 
Five trials ascertained antibody levels8,126,127,129,130 (darbepoetin N=1,038 [972 tested for 
antibodies]; control N=881 [812 tested for antibodies]) but none were detected (Appendix Table 
C38). 
Changes from the 2006 review are shown in Table 56 and detailed in Appendix Table F1. 
Table 56. Changes in trials from 2006 review—adverse events darbepoetin versus control 
Outcome Trials Excluded 
Trials 
Unchanged 
Trials 
 Updated New Trials 
Hypertension 0 0 0 0 
Thrombocytopenia/Hemorrhage 0 0 0 1 
Rash 0 0 0 0 
Seizures 0 0 0 0 
Antibodies 0 1 1 1 
Evidence Regarding Erythropoietic-Stimulating Agents 
Pooled results and incidence rates for epoetin and darbepoetin are shown in Table 57. These 
adverse events were generally more frequent with ESA use although the magnitude of difference 
was difficult to ascertain given the lack of standard definitions and limited trial data. There is no 
evidence to indicate antibodies to these agents develop during treatment for anemia related to 
cancer therapy. 
Table 57. Pooled relative risks and other adverse event rates—epoetin or darbepoetin versus 
control 
Outcome Trials ESA  N 
Control 
N RR (95% CI) I
2 
Incidence  
ESA 
 (95% CI) 
Incidence Control 
 (95% CI) 
Hypertension 16a 2,302 2,016 1.48 (1.07 to 2.06) 0% 3.8% (2.7 to 5.0) 2.1% (1.1 to 3.4) 
Thrombocytopenia 
and/or Hemorrhage 
12 2,018 1,696 1.17 (1.01 to 1.36)  0% 12.2% (5.5 to 20.9) 9.9% (3.9 to17.8) 
Rash 5b 739 728 2.00 (0.98 to 4.07) 0% 2.3% (0.2 to 5.6) 1.0% (0.0 to 3.3) 
Seizures 5 854 733 0.93 (0.43 to 2.04) 0% 2.1% (1.2 to 3.1) 1.8% (0.6 to 3.7) 
CI = confidence interval; ESA = erythropoiesis-stimulating agent; RR = relative risk 
aExcluding one trial with no events106 and one outlier.118 
bResult excludes one trial with no events.103 
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KQ2. How do alternative thresholds for initiating treatment compare 
regarding their effect on the benefits and harms of erythropoietic 
stimulants? Evidence is limited to directly comparative data from 
randomized controlled trials. Outcomes of interest include: hematologic 
response (change in hemoglobin or hematocrit), proportion of patients 
transfused, quality of life, survival (overall and progression-free), and 
adverse effects. 
Overview of Evidence and Findings for KQ2 
Five trials were included189-193 —a total of 468 patients were randomized to the early 
intervention and 465 to the late intervention (delay until hemoglobin ≤9 to 11 g/dL). All included 
trials were open-label, and thus quality was rated low. All trials were limited to adult patients. 
The KQ pertains to all erythropoietin-stimulating agents; accordingly, results from all trials 
using epoetin and darbepoetin were combined. Among the five included trials, three used the 
same threshold for initiating treatment in the late arm.190-192 For purposes of meta-analysis by 
outcome, all trials reporting a specific outcome were combined (except for hematologic 
response, see following); and the three trials with the same treatment initiation threshold were 
combined in a separate analysis, where appropriate. Major findings are summarized in Table 58 
to Table 62. 
Table 58. Overview: hematologic response, early versus late ESA  
Variable ESA Early vs. Late Response = Hb Increase ≥2g/dL 
Number of studies 1191 
Patients analyzed 180 
Pooled relative risk 1.09 
(95% CI) (0.60 to 1.97) 
I2 N/A 
CI = confidence interval; ESA = erythropoiesis-stimulating agent; Hb = hemoglobin; N/A = not applicable 
Table 59. Overview: transfusion rates, early versus late ESA 
Variable ESA Early vs. Late All Trials 
ESA Early vs. Late 
Same ESA Initiation Threshold 
Number of studies 5 3a 
Patients analyzed 908 520 
Pooled relative risk 0.73 0.74 
(95% CI) (0.56 to 0.96) (0.52 to 1.04) 
I2 0% 0% 
CI = confidence interval; ESA = erythropoiesis-stimulating agent 
a 190-192.   
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Table 60. Overview: thromboembolic events, early versus late ESA 
Variable ESA Early vs. Late All Trials 
ESA Early vs. Late 
Same ESA Initiation Threshold 
Number of studies 5 3a 
Patients analyzed 908 524 
Pooled relative risk 1.61  1.57 
(95% CI) (0.85 to 3.05) (0.71 to 3.46) 
I2 58% 61% 
CI = confidence interval; ESA = erythropoiesis-stimulating agent 
a 190-192. 
Table 61. Overview: on-study mortality, early versus late ESA 
Variable ESA Early vs. Late All Trials 
ESA Early vs. Late 
Same ESA Initiation Threshold 
Number of studies 3 2a 
Patients analyzed 438 319 
Pooled relative risk 1.28 1.40 
(95% CI) (0.62 to 2.64) (0.64 to 3.04) 
I2 0% 0% 
CI = confidence interval; ESA = erythropoiesis-stimulating agent 
a 190-192. 
Table 62. Overview: overall survival, early versus late ESA 
Variable ESA Early vs. Late All Trials 
ESA Early vs. Late 
Same ESA Initiation Threshold 
Number of studies 4 3a 
Patients analyzed 793 524 
Pooled relative risk 0.95 0.95 
(95% CI) (0.77 to 1.17) (0.77 to 1.18) 
I2 0% 0% 
CI = confidence interval; ESA = erythropoiesis-stimulating agent 
a 190-192. 
Detailed Analysis 
Characteristics of Included Trials 
Each trial compared immediate treatment with ESA to treatment delayed until hemoglobin 
level decreased to, or below, a prespecified threshold. Characteristics of the five included trials 
are summarized in Table 63. All enrolled adult patients being treated with chemotherapy; two 
administered chemotherapy regimens including platinum190,192 while one did not report this 
information clearly.191 Hemoglobin level for patient eligibility was ≤12 g/dL in four trials; 
Crawford et al.190 enrolled patients with baseline hemoglobin less than 15 g/dL. As noted, three 
trials use a threshold of hemoglobin ≤10 g/dL for the delayed treatment arm190-192 while Straus et 
al.189 used a threshold hemoglobin ≤9 g/dL and Glaspy et al.193 hemoglobin ≤11 g/dL to start 
ESA treatment. Glaspy et al.193 also administered epoetin every 3 weeks while the other three 
studies of epoetin used the ESA weekly. Straus et al.189 and Charu et al.191 did not supplement 
with iron, whereas the other three trials did. Only Schouwink et al.192 reported information on a 
transfusion trigger, giving transfusion as necessary with the recommendation not to transfuse if 
hemoglobin greater than 9.7 g/dL.  
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Table 63. Characteristics of the five included studies, early versus late ESA 
Study Malignancy 
Total Patients 
(N); Patients 
Randomized 
(E: early; 
L:late)a 
ESA 
Treat-
ment 
Duration 
(weeks) 
ESA 
Early 
(E) 
ESA Late (L) 
(% Treated) 
Hb Level for 
Eligibility to 
Enter Trial 
Baseline 
Hb 
Early (E), 
Late (L) 
Charu 
2007191 
solid and 
hematologic 
tumors 
N=204; 
E: 102, L: 102 
Darb 22 300 μg 
Q3W 
Observation until 
Hb ≤10 g/dL 
then start 
treatment 300 μg 
Q3W (63%) 
≥ 10.5 g/dL but 
≤ 12.0 g/dL; 
E: 11.1, 
L: 11.2 
Crawford 
2007190 
solid tumors 
(lung) 
N=216; 
E: 109, L: 107 
Epo 16 40,000 
IU QW 
Observation until 
Hb ≤10 g/dL 
then start 
treatment 40,000 
IU QW (46%) 
≥ 11.0 g/dL to  
< 15 g/dL; 
E: 13.1, 
L: 13.0 
Schouwink 
2008192 
solid tumors 
(lung, ovary, 
and breast) 
N=110;  
E: 54, L: 54 
Epo 24 40,000 
IU QW 
Observation until 
Hb ≤10 g/dL 
then start 
treatment 40,000 
IU QW 
(61%) 
> 10.0 g/dL to  
≤ 12.0 g/dL 
E: 11.2, 
L: 11.2 
Straus 
2006189 
hematologic 
tumors 
N=269;  
E: 135, L: 134 
Epo 16 40,000 
IU QW 
Observation until 
Hb ≤9 g/dL after 
2nd 
chemotherapy 
cycle, then start 
treatment: 
40,000 IU QW 
(19.4%) 
≥ 10.0 g/dL to  
≤ 12.0 g/dL 
E: 11.1, 
L: 11.2 
Glaspy 
2009193 
solid or 
hematologic 
tumors 
N=136;  
E: 68, L: 68 
Epo 16 120,000 
Q3W 
Observation until 
Hb <11 g/dL 
then start 
treatment 
120,000 IU Q3W 
(75%) 
≥ 11.0 g/dL to  
≤ 12.0 g/dL 
E: 11.5, 
L: 11.5 
Darb = darbepoetin; Epo = epoetin; ESA = erythropoiesis-stimulating agent; Hb = hemoglobin; IU = international unit 
aNote totals represent patients randomized whereas overview includes those analyzed.    
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Hematologic Response 
Four trials compared hematologic response rates of patients randomized to early or late 
treatment.189-191,193 Of these, only Charu et al.191 reported hemoglobin responses as defined in this 
review (hemoglobin increase ≥2 g/dL); the other trials were not included in the analysis of 
hematologic response. In Charu et al.,191 nearly 20 percent of early and 30 percent of late 
randomized patients were not evaluated. Of those assessed, hemoglobin responses were reported 
for 19 of 94 patients (20.2%) in the early arm treated at a mean hemoglobin of 11.1 g/dL and for 
16 of 86 patients (18.6%) in the arm delayed to a threshold of 10 g/dL (Table 58; RR 1.09; 95% 
CI: 0.60 to 1.97) or no detectable difference. 
Transfusion Rates 
All five trials reported effects on transfusion. Trials differed in treatment duration, iron 
supplementation, chemotherapy, and baseline hemoglobin. Results from the five trials and from 
the three using the same late arm hemoglobin threshold for initiating ESA treatment190-192 were 
pooled with nearly the same results (Table 59; for all trials, RR 0.73; 95% CI: 0.56 to 0.96; 
I2=0%). Accordingly, results favor early ESA treatment. 
Thromboembolic Events 
All five trials reported thromboembolic event rates. Trials differed in treatment duration, iron 
supplementation, chemotherapy, and baseline. For all five trials and the three trials using the 
same late arm hemoglobin threshold for initiating ESA treatment190-192 pooled results favored 
late ESA treatment (Table 60; all trials, RR 1.61; 95% CI: 0.85 to 3.05; I2=58%). 
Individual trial results for this outcome varied considerably. For example, Crawford et al.190 
and Glaspy et al.193 found no difference between early and late ESA initiation. In contrast, Straus 
et al.,189 obtained a RR of 3.72 (95% CI: 1.27 to 10.92), favoring late ESA. The threshold for late 
initiation in this trial was the lowest at less than 9 g/dL and baseline hemoglobin 11.1 g/dL for 
the early treatment arm. Consequently, only 19 percent of late patients were treated with ESA. In 
addition, patients had hematologic malignancies and were being treated with chemotherapy, a 
population in which risk of thromboembolic complications may be elevated. Thus, late ESA 
initiation, a low threshold, and overall much lower population exposure in the late intervention 
arm likely resulted in fewer events. 
Survival 
Three trials reported on-study mortality;190,192,193 two of these used similar ESA initiation 
thresholds.190,192 Results were similar whether two or three trials were pooled (Table 61; for all 
trials, the pooled RR was 1.28 (95% CI: 0.62 to 2.64; I2=0%) favoring late ESA but was not 
significant. 
Four trials reported overall survival;189-192 three trials used the same late ESA initiation 
threshold190-192 but observation duration varied among the trials—from 40 months in Crawford et 
al.190 to the on-study time189 of 20 weeks. There was no evidence of difference in pooled relative 
effects comparing risk of early to late initiation for the three trials: RR 0.95 (95% CI: 0.77 to 
1.17; I2=0%). 
Quality of Life 
Of the five trials, only one192 reported no QoL results. Where possible, we focus on FACT-
Fatigue subscale results, as in KQ1. 
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In Charu et al.191 the change in FACT-Fatigue scores from baseline were reported according 
to the change in hemoglobin from baseline to end of treatment. We calculated the weighted mean 
change in FACT-F for the early intervention group and for the late intervention group separately 
(for calculation see Methods). The mean FACT-Fatigue changes from baseline to end of 
treatment (week 22) were 0.7 ± 12.9 (n=94) and 0.6 ± 14.2 (n=86) in the early and late groups 
respectively; less than the MCID of 3.179 
Crawford et al.190 noted that “[i]n the immediate epoetin alfa group, FACT-An subscale 
scores declined significantly from baseline to study end with a mean change of -7.7 and a p-
value of 0.0187.” No data were reported for the delayed intervention group, thus no comparative 
conclusions can be drawn. 
Glaspy et al.193 reported FACT-Fatigue at baseline in the early and late treatment arms of 
33.5 ± 13.2 and 27.8 ± 12.0, and at last visit of 32.0 ± 13.2 and 30.4 ± 11.7 respectively; a 
decrease in the early group of -1.5 and increase in delayed of +2.6. 
Straus et al.189 found an increase of 1.45 for FACT-Fatigue subscale results in the early 
intervention arm and a decrease of -1.68 in the delayed intervention arm; clinically not 
significant changes. 
Overall there is little evidence to support a clinically meaningful improvement in QoL using 
either early or late ESA treatment initiation. 
Other Outcomes 
There was insufficient evidence to report other adverse events or tumor progression. 
Changes From 2006 Review 
Three trials included in the previous review published as abstracts were included as full 
text,189-191 and two new trials were included.192,193 
KQ2: Discussion and Conclusions 
Five trials compared early to late ESA intervention when hemoglobin level decreased below 
a pre-specified threshold. These trials were unblinded and lacked placebo arms, and thus were 
evaluated as low quality, potentially subject to bias. Absence of information on a transfusion 
trigger further complicates interpretation. The evidence base is small and may not be reliable. 
Hematologic response and transfusion rates favored early ESA treatment, in keeping with the 
established hematologic outcomes of ESA treatment, but the estimate was only just significant 
for transfusion. In contrast, thromboembolic event outcomes favored late treatment, which 
exposed fewer patients to treatment, also in keeping with the known increased risk for 
thromboembolic events with increased ESA exposure, but results were not significant. On-study 
mortality outcomes favored delayed treatment as well, but were not significant. The quality of 
life evidence, evaluating the FACT-Fatigue subscale in four trials and FACT-An in a fifth, was 
inconsistent and did not support a clinically meaningful improvement in either study arm. 
In short, the strength of the evidence base is low to determine whether immediate or 
treatment delayed to when hemoglobin falls below a prespecified threshold results in different 
outcomes. Nor is evidence sufficient to identify a preferred hemoglobin threshold, among three 
tested, for initiating ESA treatment. 
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Evidence GRADE for Central Outcomes 
The evidence is lacking to determine whether immediate treatment versus delayed treatment 
produces better transfusion outcomes or fewer thromboembolic events (overall strength of 
evidence low) (Table 64 and Table 65). 
Table 64. Transfusions: early versus late ESA (GRADE evidence table) 
Trials 
(N) 
Subjects 
(N) 
Risk of Bias 
Design/Quality Consistency Directness Precision 
Results 
RR (95% CI); 
I2 
Overall 
Strength 
 of Evidence 
5 908 High 
trial quality  
high-0; low-5 
Consistent Direct Precise 0.73 
(0.56 to 0.96); 
0% 
Low 
CI = confidence interval 
Table 65. Thromboembolic events: early versus late ESA (GRADE evidence table) 
Trials 
(N) 
Subjects 
(N) 
Risk of Bias 
Design/Quality Consistency Directness Precision 
Results 
RR (95% CI); 
I2 
Overall 
Strength 
 of 
Evidence 
5 908 High 
trial quality   
high-0; low-5 
Consistent Direct Imprecise 1.61 
(0.85 to 3.05); 
58% 
Low 
CI = confidence interval 
KQ3. How do different criteria for discontinuing therapy or for optimal 
duration of therapy compare regarding their effect on the benefits and 
harms of erythropoietic stimulants?  
Evidence is limited to directly comparative data from randomized controlled trials. Outcomes 
of interest include: hematologic response (change in hemoglobin or hematocrit), proportion of 
patients transfused, quality of life, overall and progression-free survival, and other adverse 
effects. 
No randomized controlled trials were identified that fulfill the inclusion criteria of this 
review. Therefore, no results can be provided. 
Decision Analysis 
The main benefits of ESA treatment are increased hemoglobin and lower risk of transfusion. 
The most significant potential harm is mortality. While there is uncertainty in the magnitude and 
clinical importance of measured improvements in quality of life with alleviation of anemia 
(higher hemoglobin), utilities (values between 0 and 1 with extremes representing death and 
perfect health, respectively) corresponding to hemoglobin levels have been quantified in cancer 
patients.76 A central question in the decision to administer ESAs is the tradeoff between higher 
hemoglobin and its potential benefit with the relative increase in mortality. What is the balance 
of benefit and harm? Incorporating results obtained from the systematic review in a decision 
model examining that balance is then relevant to the evidence synthesis. For that purpose, we 
have organized this section as follows. First, the basic model and two base cases are outlined. 
Second, base case results are presented. Next, analyses varying relative risk with baseline risk 
and sensitivity analyses are shown. Finally, potential implications and limitations are noted. 
Results are presented for both quality adjusted life-years and life-years in a hypothetical cohort 
of 1,000 similar patients. While transfusions are not without risk, as noted by others194 the 
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frequency of adverse transfusion events is too low to be included here. This is supported by our 
review for reported adverse events attributed to transfusions in the included trials and by review 
of summary articles on the topic.195-200 The model also does not incorporate any decrement in 
quality of life accompanying thromboembolic events more frequent with ESA administration. 
While most are generally short in duration (venous thrombosis) others less common (stroke) may 
have lasting effects.  
Model 
The decision model is depicted in Figure 15 and includes three health states—patients with a 
baseline hemoglobin of 9 g/dL, an achieved of 11 g/dL through either ESA or transfusion, and 
death. A 12-week course of chemotherapy and ESA treatment is assumed (the most common 
scenario in included trials) and patients are followed one year. If an ESA is used, the model 
considered it administered for 12 weeks and any increase in mortality persisting through week 
16.48 From week 16 through week 52 we assumed similar mortality and hemoglobin levels in 
patients initially treated with an ESA or transfusion strategy—based on the lack of evidence here 
for increased long-term mortality risk. 
Two base case scenarios were developed from results obtained in this review, published 
studies, and current recommendations regarding ESA use (i.e., applying to patients treated with 
curative intent versus others). Survival following chemotherapy can vary substantially by tumor 
and stage. Here, mortality ranged from 3 to 93 percent following the on-study period—estimated 
in 15 studies34,81,83,84,99,107,109,110,114-116,119,125,130,201 included in this review with follow-up of one 
year or more and extractable data. From this range, the two base case scenarios were specified: 
(1) patients treated with curative intent (5% annual mortality following treatment or at the lowest 
portion of the distribution), and (2) those not treated with curative intent having an annual 
mortality rate the approximate median or 50 percent. Corresponding on-study mortality rates 
were applied to the two base cases: low or curative intent (2.5% or lower quartile of studies 
included in the review) and higher or noncurative intent (7.5% or the approximate median). 
Utilities, obtained from four studies as described in the methods, corresponding to hemoglobin 
levels of 9 and 11 g/dL were assigned values of 0.61 and 0.70 respectively. Hemoglobin levels 
for treatment were chosen to fall within current guidance. Other parameter estimates and sources 
are shown in Table 66. Ranges for sensitivity analyses were informed by either confidence 
intervals in parameters, distribution quartiles, or relevant upper and lower bounds from reported 
studies (e.g., for utilities). Parameter values and sources are detailed in Table 66. 
For all patients, the risk of mortality was incorporated as follows: during the first 16 weeks or 
on-study period the underlying mortality rate was that accompanying a transfusion strategy (no 
ESA). In the base cases (Table 66), the approximate median of these studies or 7.5 percent was 
used; results are also estimated over approximate quartiles of on-study mortality and a low-risk 
population with a 2.5 percent rate. Based on the on-study mortality and long-term results 
obtained here, receiving ESAs is accompanied by a 17 percent relative increased risk of 
mortality during the first 16 weeks but not thereafter. We assume that following the on-study 
period annual mortality rates as noted. No discounting was used given the short time horizon. 
To illustrate the assumptions and model, consider a hypothetical patient undergoing a 12-
week course of chemotherapy with initial hemoglobin of 9 g/dL who receives and responds to 
ESA and survives 52 weeks. The patient begins with hemoglobin of 9 g/dL, which by week 4 is 
11 g/dL, and quality of life or utility improved from 0.61 to 0.70. The model assumes a patient 
spends the entire 4 weeks with hemoglobin of 11 g/dL or favorable to an ESA strategy (response 
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typically is seen in 3 to 4 weeks) and with the same hemoglobin through 52 weeks. If a patient 
did not respond, the hemoglobin remains 9 g/dL but following chemotherapy (after week 16) 
improves to 11 g/dL. For the purposes of modeling, a 4-week cycle length was used (without 
mid-cycle correction). As noted in the methods, the model was constructed in Excel® and 
replicated in TreeAge Pro.77 A cohort of 1,000 patients was simulated. 
Figure 15. Decision model structure 
g/dl = grams per deciliter; Hb = hemoglobin
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Table 66. Base case parameters for decision model—1-year time horizon 
Parameter  Value Range 
 
Source 
Hemoglobin Baseline 9 — Guideline56 
Achieved during therapy (4 to 16 weeks) 11 — Guideline56 
Following therapy (to week 52) 11 — Estimate 
Response rates ESA 52% 45% to 59% Current meta-analysis 
Control (transfusion only) 14% 10% to 19% Current meta-analysis 
Utilities Hemoglobin 9 g/dL 0.61 0.56 to 0.64 Four ESA-manufacturer studies76 
Hemoglobin 11 g/dL 0.70 0.67 to 0.78 Four ESA-manufacturer studies76 
Dead 0 —  
On-study control mortality rate Patient treated with curative intent 2.5% — Current review 
Patient not treated with curative intent 7.5% 5.0% to 10% Current review 
Annual mortality rates weeks 20 to 52 Patient treated with curative intent 5% —  
Patient not treated with curative intent 50% 25%, 50%, 75% Approximate quartiles of included 
 Mortality relative risk on-study with ESA 
use 
 1.17 1.04 to 1.31 Current meta-analysis 
Utilities Hemoglobin 9 g/dL 0.61 0.56 to 0.64 Four ESA-manufacturer studies76 
Hemoglobin 11 g/dL 0.70 0.67 to 0.78 Four ESA-manufacturer studies76 
Dead 0 —  
ESA = erythropoiesis-stimulating agent 
 95 
Results 
Results for the two base cases are shown in Table 67. In both, ESA treatment resulted in 
more quality-adjusted life years attributable to more patients achieving the target hemoglobin 
during the on-study period. Expected quality of life gains are obtained during that period. The 
tradeoff is fewer life-years—3.6 per 1,000 patients treated with curative intent and 9.2 per 1,000 
patients not treated with curative intent. Table 68 and 69 display results over the range of likely 
parameter values for the two different cases as one-way sensitivity analyses. In curative intent, 
quality adjusted life years were higher with an ESA strategy but life years fewer. In the 
noncurative intent case, almost all parameter values resulted in more quality adjusted life-years, 
but again life-years were lost. Notably, more life years were lost in the noncurative case 
compared with the curative one. Overall, estimates were most sensitive to ESA relative risk for 
mortality and utilities (for quality of life). 
Table 67. Quality-adjusted life-years and life years gained or lost over a 1-year period in the two 
base cases for 1,000 patients 
Base Case QALYs  ESA 
QALYs 
Transfuse 
Difference 
(+ESA Better 
 -ESA Worse) 
Life 
Years  
ESA 
Life 
Years 
Control 
Difference 
(+ESA Better 
 -ESA Worse) 
Curative intent 660.2 652.2 +7.9 961.6 965.2 -3.6 
Non curative intent 557.9 554.0 +3.9 814.6 823.8 -9.2 
ESA = erythropoiesis-stimulating agent; QALYs = quality-adjusted life years 
Table 68. Curative intent—sensitivity to changes in parameters values of quality-adjusted life-
years and life years gained or lost over a 1-year period for 1,000 patients 
Characteristic  
QALYs 
ESA 
QALYs 
Transfuse 
QALY 
Difference 
(+ESA 
Better -ESA 
Worse 
Life Years 
ESA 
Life Years 
Control 
Life-Year 
Difference 
(+ESA 
Better -ESA 
Worse) 
Relative risk 1.04 662.1 652.2 +9.8 964.4 965.2 -0.9 
1.17 660.2 652.2 +7.9 961.6 965.2 -3.6 
1.31 658.1 652.2 +5.9 958.6 965.2 -6.6 
On-study control 
mortality 
2.5% 660.2 652.2 +7.9 961.6 965.2 -3.6 
5.0% Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
7.5% Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
10.0% Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Annual mortality 
20 to 52 weeks 
5% 660.2 652.2 +7.9 961.6 965.2 -3.6 
25% Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
50% Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
75% Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Not 
applicable 
Response rate 
ESA 
45% 658.2 652.2 +6.0 961.6 965.2 -3.6 
52% 660.2 652.2 +7.9 
59% 662.1 652.2 +9.8 
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Table 68. Curative intent—sensitivity to changes in parameters values of quality-adjusted life-years 
and life years gained or lost over a 1-year period for 1,000 patients (continued) 
Characteristic  QALYs ESA 
QALYs 
Transfuse 
QALY 
Difference 
(+ESA 
Better -ESA 
Worse 
Life Years 
ESA 
Life Years 
Control 
Life-Year 
Difference 
(+ESA 
Better -ESA 
Worse) 
Response rate 
transfusion 
10% 660.7 651.1 +9.6 961.6 965.2 -3.6 
14% 660.2 652.2 +7.9 
19% 660.7 653.6 +7.1 
Utility Hgb 9 g/dL 0.56 653.8 639.2 +14.6 961.6 965.2 -3.6 
0.61 660.2 652.2 +7.9 
0.64 664.8 660.0 +4.8 
Utility Hgb 11 g/dL 0.67 636.0 631.1 +4.9 961.6 965.2 -3.6 
0.70 660.2 652.2 +7.9 
0.78 726.6 708.6 +18.0 
ESA = erythropoiesis-stimulating agent; Hgb = hemoglobin; QALYs = quality-adjusted life years 
Note: Base case in italics.  
Table 69. Non curative intent—sensitivity to changes in parameters values of quality-adjusted life-
years and life years gained or lost over a 1-year period for 1,000 patients 
Characteristic  
QALYs 
ESA 
QALYs 
Transfuse 
Difference 
(+ESA 
Better 
-ESA Worse 
Life Years 
ESA 
Life Years 
Control 
Difference 
(+ESA 
Better 
 -ESA 
Worse) 
Relative risk 1.04 562.7 554.0 +8.7 821.6 823.8 -2.2 
1.17 557.9 554.0 +3.9 814.6 823.8 -9.2 
1.31 552.8 554.0 -1.2 807.0 823.8 -16.7 
On-study control 
mortality 
2.5% Not 
applicable 
Not 
applicable 
Not  
applicable 
Not 
applicable 
Not 
applicable 
Not 
 applicable 
5.0% 572.5 566.4 +6.0 835.8 842.1 -6.3 
7.5% 557.9 554.0 +3.9 814.6 823.8 -9.2 
10.0% 543.7 541.8 +1.9 793.8 805.8 -12.0 
Annual mortality 
20 to 52 weeks 
5% Not 
applicable 
Not 
applicable 
Not  
applicable 
Not 
applicable 
Not 
applicable 
Not  
applicable 
25% 594.5 591.0 +3.4 866.8 876.7 -9.9 
50% 557.9 554.0 +3.9 814.6 823.8 -9.2 
75% 511.7 509.2 +2.5 748.0 759.2 -11.2 
Response rate 
ESA 
45% 556.1 554.0 +2.1 814.6 823.8 -9.2 
52% 557.9 554.0 +3.9 
59% 559.8 554.0 +5.8 
Response rate 
transfusion 
10% 557.9 552.9 +5.0 814.6 823.8 -9.2 
14% 557.9 554.0 +3.9 
19% 557.9 555.3 +2.6 
Utility Hgb 9 g/dL 0.56 551.1 541.4 +9.7 814.6 823.8 -9.2 
0.61 557.9 554.0 +3.9 
0.64 562.0 561.5 +0.5 
Utility Hgb 11 g/dL 0.67 537.6 536.8 +0.7 814.6 823.8 -9.2 
0.70 557.9 554.0 +3.9 
0.78 612.2 599.8 +12.4 
ESA = erythropoiesis-stimulating agent; Hgb = hemoglobin; QALYs = quality-adjusted life years 
Note: Base case in italics. 
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Implications and Limitations 
Using base case scenarios representative of patients enrolled in this review and reflecting 
those covered by current guidance for ESA use, these results may clarify the tradeoffs 
accompanying ESA use. Assuming utilities reasonably accurate, there was an expected gain in 
quality-adjusted years at the expense of life-years lost. However, these results must be 
considered together with those obtained in the main body of this CER. As detailed in the HRQoL 
section, results from the most relevant PRO measures such as FACT scales are not equivalent to 
the utilities required for the type of analyses conducted here. In addition, ESA trials have not 
reported HRQoL outcomes using utility-based measures. Given that any improvements in quality 
of life for individual patients given ESAs are on average less than what is clinically meaningful, 
the life-years lost are the most important result. Moreover, the loss of life-years was greatest in 
the patient cohort with the poorest prognosis. 
An important limitation of the decision model used for this analysis is that it is a simplistic 
representation of circumstances that are otherwise complex. For example, details of ESA dosing, 
escalation strategies, and cancer therapies were not accounted or in the model. However, the 
assumptions made are consistent with the natural history of, and evidence surrounding, anemia 
accompanying cancer treatment. Consequences of thromboembolic events were not included in 
the model; however, doing so would favor a transfusion strategy. Additionally, the estimates of 
utilities used in the model may not be precise but were based on the findings from four studies. 
Finally, we limited ourselves to one-way sensitivity analyses for clarity. While further analyses 
could be performed, the results were highly consistent under the different parameter values and 
sufficiently define the tradeoff involved. 
In summary, these results are consistent with others in this review. There is a potential 
benefit obtained from ESA use with cancer therapy, but one that is on average as assessed by 
patient-reported HRQoL measures, not clinically meaningful. The tradeoff is an increased risk of 
mortality that appears most apparent among patients with the poorest prognosis.   
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Discussion 
Previous systematic reviews have shown erythropoietic-stimulating agents to have 
comparable hematologic effects and comparable harms. Their results, together with the 
biochemical and mechanistic similarities of the different agents, argue that evidence from 
different ESAs is appropriately combined for synthesis. The body of evidence included here is 
substantial and adequate to provide sufficient certainty to address the most important questions 
regarding the effects of these drugs: (1) their effect on hemoglobin levels and transfusions, (2) 
impact on HRQoL, and (3) adverse consequences including thromboembolic events and 
mortality. 
The collection of included trials was clinically heterogeneous. Nevertheless, there is 
convincing evidence that ESAs can improve hemoglobin in the setting of cancer treatment, and 
when successful, result in a commensurate reduction in the risk of transfusion. In slightly more 
than half, but not all patients, ESAs improve hemoglobin and help avoid transfusion. ESAs 
reduce the proportion of patients transfused by approximately 40 percent but do not eliminate 
it—25 percent of patients receiving ESAs in the trials reviewed here required ≥1 transfusion. 
Whether, and by what magnitude, ESA use in anemia related to cancer treatment might 
improve quality of life has been the focus of considerable study. The evidence found through 
systematic search in this update, and documented in the previous report, is consistent. In the most 
relevant domain of fatigue, better scores on a well-validated instrument such as FACT-Fatigue 
accompany the higher hemoglobin levels achieved with ESA use. In contrast, patients 
randomized to a transfusion strategy experience on average a small decline in FACT-Fatigue 
score. The magnitude of mean difference in change between the two groups was less than the 
estimated reported minimal clinically important difference; the difference in fatigue experienced 
by patients, is on average, less than clinically meaningful. 
The increased incidence of thromboembolic events and mortality during ESA treatment that 
has been noted here has also been reported by several others, and is consistent with a plausible 
and causal effect of these agents. The relative and absolute increases in thromboembolic events 
allow a high degree of certainty regarding the magnitude of effect. 
The consistent increase in pooled on-study mortality accompanying ESA treatment found in 
systematic reviews is consistent with a causal effect. The increased relative risk estimate during 
the on-study period reported by Bohlius et al.,48 including all trials regardless of cancer 
treatment, and therefore patients with longer ESA exposure, similarly supports a causal effect. 
Although the magnitude of the on-study mortality risk on average is not large, the increase in 
risk alters the balance of benefit and harm. While there was no discernible increase in mortality 
with ESA use over the longest available follow-up, many trials did not include an overall 
survival endpoint and potential time-dependent confounding was not considered.  
Much of the evidence included here was obtained under treatment protocols that used higher 
baseline and target hemoglobin levels than those used in current practice. While it is possible that 
adverse event rates might be somewhat different with lower baseline and target hemoglobin 
levels, we found little difference in effect when baseline hemoglobin was less than, or exceeded 
10 g/dL, the currently recommended threshold for ESA initiation. This result is similar to an 
individual patient data meta-analysis.48 Additionally, three trials included in KQ1 enrolled 
patients predominantly undergoing radiotherapy. Although not an FDA-approved indication for 
ESA use, those results were included because the population of interest was patients undergoing 
treatment for cancer. Moreover, we did not find those trial results influential in these analyses.  
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Some outcomes and aspects of this evidence are accompanied by important uncertainty. First, 
whether ESAs enhance tumor progression remains unanswered in this review. The evidence 
surrounding tumor progression is heterogeneous and insufficient to support conclusions. 
Evidence examining progression-free survival is similarly varied and limited. Likely the most 
salient uncertainty pertains to possible subgroups at highest risk of mortality and/or 
thromboembolic events. We were not able to effectively address those questions with the data 
included in this review; nor does individual trial data address those questions. There are clues 
that lack of response to ESAs35 and dose escalation might be associated with mortality higher 
than with standard dosing in responders. This notion is also supported by data obtained in other 
settings. Among patients with end-stage renal disease managed with hemodialysis and ESA 
treatment the epoetin dose required to attain defined hematocrit values has been reported to be an 
independent predictor of total mortality.202 Similar results have been reported in diabetics with 
chronic kidney disease not on dialysis.203 However, for cancer patients, detailed patient-level 
data are unavailable even in individual patient data meta-analyses. 
Finally, the most important concern regarding ESAs in the setting of cancer therapy is the 
balance of potential benefits and harms. While ESAs reduce the need for transfusions and 
increase the risk of thromboembolism, a detectable relative increase in mortality risk—higher 
with lower underlying absolute mortality risk—accompanies their use. An individual patient 
receiving ESAs will have, on average, better quality of life FACT-Fatigue scores, but of a 
magnitude less than the minimal clinically important difference. For the population of patients 
undergoing cancer treatment, ESAs are similarly accompanied by greater expected quality 
adjusted, yet fewer total life years. The expected loss of life is greater with higher underlying 
absolute mortality risk. 
Future Research 
Given the current state of evidence, unanswered questions, and balance of benefit and harms, 
how should future research be considered? Given the magnitude of relative mortality increase 
and underlying mortality rates in this patient population, it is clear that attempts to reduce 
uncertainty in relative risk of mortality through clinical trials would require very large samples. 
The confidence and credible intervals for the estimated relative increase in mortality span a range 
of values—the true relative increase in risk for adults could be higher or lower than 1.17 
estimated here. Still these data do establish with sufficient certainty that mortality rates increase. 
Questions are therefore raised regarding equipoise in pursuing some “true” relative risk in further 
clinical trials. 
At the same time these agents will continue to be used for reasons beyond the scope of this 
review—for example, patient preference, availability of blood, possible emergence of infectious 
agents in the blood supply. It is therefore important to address whether there are patient 
subgroups with low risk of harm and how dosing practices influence harms. Unfortunately, these 
questions present complexities not addressed even in the most carefully designed trials. The 
fundamental complexity concerns time-varying treatment and confounding—ESA dose is 
typically varied depending on the hemoglobin level achieved. It is well known that traditional 
analytical approaches fail to correctly estimate treatment effects under these conditions.139,204 
Accordingly, it is unlikely that any future meta-analysis or systematic review will be able to 
inform these questions. 
Still, there is a compelling rationale to examine observational data (e.g., carefully conducted 
registries) using methods appropriate to these questions—whether there is a subgroup and dosing 
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strategy accompanied by some lower risk. A large registry with accurate and precise information 
on ESA dose (amount, frequency, duration, escalation), hemoglobin (baseline, and all recorded 
values preferably at times specified by protocol), stage of malignancy, treatment regimen and 
response, and outcomes (including but not limited to thromboembolism, myocardial infarction, 
death including underlying and contributory causes) would provide the best opportunity to 
examine these questions. The Dosing and Outcomes Study of Erythropoiesis-Stimulating 
Therapies (DOSE) is one example.205 While deriving conclusions from appropriate analytical 
methods—inverse probability weighting, G-methods, and marginal structural models—requires 
some assumptions for inference, they are approaches most able to address unanswered questions. 
Lastly, we found many registered completed trials without clearly or readily identified 
results. The goals of trial registration fall short when results from completed trials are difficult to 
identify. Investigators and trials registries must adopt effective procedures to assure timely 
reporting of results in registries.  
In summary, a large collection of trials examining ESA use in patients undergoing cancer 
treatment provides evidence sufficient to conclude that hemoglobin levels are improved and 
transfusions avoided together with higher rates of thromboembolic events and mortality. 
Whether there are subgroups at higher and lower risk of adverse events and mortality is unclear. 
Future research to address the unanswered questions should be limited to examination of 
observational data collected during the course of usual patient care. 
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Appendix A. Search Strategies 
 
Randomized Controlled Trial Search Strategy: PubMed/MEDLINE® 
#97 Search #90 NOT #96 664 
#96 Search #94 NOT #92 455958 
#94 Search "Animals"[Mesh] Limits: Entrez Date from 2005/03/11 to 2009/10/22 2477346 
#92 Search "Humans"[Mesh] Limits: Entrez Date from 2005/03/11 to 2009/10/22 2021388 
#90 Search #64 AND #84 Limits: Entrez Date from 2005/03/11 to 2009/10/22 717 
#89 Search #64 AND #84 2133 
#84 Search #70 OR #73 OR #74 OR #77 OR #82 OR #83 4817344 
#83 Search control OR controlled OR controls OR prospectiv* OR volunteer* 3143028 
#82 Search (("Research Design"[Mesh] OR "Comparative Study "[Publication Type]) OR 
"Evaluation Studies "[Publication Type]) OR "Follow-Up Studies"[Mesh] 
2021817 
#77 Search "Placebos"[Mesh] OR placebo* OR random* 672908 
#74 Search (singl* OR doubl* OR trebl* OR tripl*) AND (mask* OR blind*) 150424 
#73 Search ("Clinical Trial "[Publication Type] OR "Clinical Trials as Topic"[Mesh]) OR 
"clinical trial" 
735975 
#70 Search (((("Randomized Controlled Trial "[Publication Type] OR "Randomized 
Controlled Trials as Topic"[Mesh])) OR "Controlled Clinical Trial "[Publication 
Type]) OR "Random Allocation"[Mesh]) OR "Double-Blind Method"[Mesh] 
460955 
#64 Search #63 AND #62 5655 
#63 Search #58 OR #59 22990 
#62 Search "Neoplasms"[Mesh] OR "Carcinoma"[Mesh] OR malignan* OR cancer OR 
cancers OR cancerous OR oncolog* OR myelodysplas* OR tumor OR tumors OR 
tumour* OR neoplas* OR carcinom* 
2658404 
#59 Search erythropoietin OR epoetin* OR eprex OR neorecormon OR aranesp OR 
procrit OR darbepoetin OR CERA OR "C.E.R.A." 
22990 
#58 Search ((("Erythropoietin, Recombinant"[Mesh] OR "Erythropoietin"[Mesh] OR 
"continuous erythropoietin receptor activator "[Substance Name])) OR ("Epoetin 
Alfa"[Mesh] OR "epoetin beta "[Substance Name])) OR "darbepoetin alfa 
"[Substance Name] 
17551 
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Randomized Controlled Trial Search Strategy: EMBASE 
#7 850 
#5 AND #6  
#6  
[embase]/lim NOT [medline]/lim AND [2005-2010]/py 1,318,658 
#5  
#3 AND #4 2,107 
#4  
'randomized controlled trial'/exp OR 'randomised controlled trial'/exp OR 'controlled clinical 
trial'/exp OR 'random allocation'/exp OR 'double-blind method'/exp OR 'single-blind 
method'/exp OR 'clinical trial'/exp OR (singl* OR doubl* OR trebl* OR tripl* AND (mask* 
OR blind*)) OR placebo* OR random* OR 'research design'/exp OR 'comparative study'/exp 
OR 'evaluation studies'/exp OR 'follow-up studies'/exp OR 'control'/exp OR controlled OR 
controls OR prospectiv* OR volunteer* AND [2005-2010]/py 
1,959,179 
#3  
#1 AND #2 3,171 
#2  
'neoplasms'/exp OR 'carcinoma'/exp OR malignan* OR 'cancer'/exp OR 'cancers'/exp OR 
cancerous OR oncolog* OR myelodysplas* OR 'tumor'/exp OR tumors OR tumour* OR 
neoplas* AND [2005-2010]/py 
606,635 
#1  
'erythropoietin, recombinant'/exp OR 'erythropoietin'/exp OR 'epoetin alfa'/exp OR 'epoetin 
beta'/exp OR 'epoetin'/exp OR 'eprex'/exp OR 'neorecormon'/exp OR 'aranesp'/exp OR 
'procrit'/exp OR 'continuous erythropoietin receptor activator'/exp OR 'cera'/exp OR 'c.e.r.a.' 
OR 'darbepoetin'/exp OR 'darbepoetin alfa'/exp AND [2005-2010]/py 
9,914 
 
Identified in Updated Search (1/4/2012)                  454
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Observational Study Search Strategy: PubMed/MEDLINE® 
#4 Search #1 AND #2 AND #3 158 
#3 Search ("Neoplasms"[Mesh] OR "Carcinoma"[Mesh] OR malignan* OR cancer OR 
cancers OR cancerous OR oncolog* OR myelodysplas* OR tumor OR tumors OR 
tumour* OR neoplas* OR carcinom*) 
2741885 
#2 Search AND ("Erythropoietin, Recombinant"[Mesh] OR "Erythropoietin"[Mesh] OR 
"continuous erythropoietin receptor activator "[Substance Name] OR ("Epoetin 
Alfa"[Mesh] OR "epoetin beta "[Substance Name] OR "darbepoetin alfa "[Substance 
Name] OR erythropoietin OR epoetin* OR eprex OR neorecormon OR aranesp OR 
procrit OR darbepoetin OR CERA OR "C.E.R.A.") 
    23621 
#1 Search Retrospective Studies[MH] 344634 
 
Note:  search results were the same using ("observational/descriptive studies"[MH] ) OR 
"retrospective studies"[MH] for #1 
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Meta-analysis Search Strategy:  PubMed/MEDLINE® 
 
Hits: 61 
 
#1 AND #2 AND #3 
 
#1 neoplasms (mesh) OR cancer OR cancer* 
#2 darbepoetin OR darbepo* OR epoetin OR epoetin* OR erythropoie* 
#3 meta-analysis OR meta-analys* OR “meta-analysis” (publication type) 
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Meta-analysis Search Strategy:  Cochrane 
 
Hits: 273 
 
#2 (epoetin OR epoetin* OR darbepoetin OR darbepo* OR ESA or erythropoie*) 
 
AND 
 
#1 (cancer OR cancer* OR neoplasms) 
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Appendix B.  Excluded Studies 
 
These studies were excluded at the level of full-text paper or abstract if not published as full text. 
Abbreviations/Key to Reasons for Exclusion 
 nrct No Randomized-Controlled Trial 
 allo Trials with inadequate allocation concealment, e.g. where 
 patients were allocated by alternation, the use of case record 
 numbers, dates of birth or day of week, and any other procedure 
 that is transparent before allocation, such as an open list of 
 random numbers 
 ong Ongoing studies and interim analyses 
 none Studies of patients with a malignant disease NOT undergoing 
 anticancer-therapy 
 mbt Studies of high-dose Myeloablative chemotherapy regimens 
 followed by bone marrow or peripheral Blood stem cell 
 Transplantation 
 ept Studies using Erythropoietin for short-term Preoperative 
 Treatment to correct anemia or to support collection of 
 autologous blood prior to cancer surgery for administration 
 during or after surgery 
 surg Studies in which patients received surgical treatment while 
 being administered ESA 
 nop Number Of Patients: Trials with 50 or fewer randomized (≤) 
 participants per study arm for studies of adults; 10 or fewer (≤) 
 participants per study arm in paediatric samples 
 msl Studies on patients with Myelodysplastic Syndrome or acute 
 Leukaemia 
 ora Other Reasons or Anemia, such as hemolysis, iron deficiency 
 and occult bleeding, should have been excluded 
 eqol Quality of life using LASA, VAS and CLAS scales are excluded 
 dup Duplicate Publication 
 other reasons Study objective than comparison of erythropoiesis-stimulating 
products or comparison to control; different drug used than epoetin alfa, 
beta or darbepoetin; different randomization than defined for this review. 
 add reference Additional reference 
 comment ? 
 dose-finding ? 
 
List of Excluded Studies  
1. Abdelrazik N, Fouda M. Once weekly recombinant human erythropoietin treatment for cancer-
induced anemia in children with acute lymphoblastic leukemia receiving maintenance 
chemotherapy: a randomized case-controlled study. Hematology 2007; 12(6): 533-541. 
 Notes: KQ1 a-c: msl. 
2. Abels RI, Larholt KM, Krantz KD et al. Recombinant Human Erythropoietin (rHuEPO) for the 
Treatment of the Anemia of Cancer. Oncologist 1996; 1(3): 140-150.   
 Notes: KQ1 a-c: none. 
3. Alexopoulos CG, Kotsori, AA. A randomized comparison of rHuEPO with darbepoetin for cancer 
related anemia [abstract]. Ann Oncol 2004;15(Suppl 3);<page no>.   
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 Notes: KQ1 d: nop. 
4. Anonymous. High-dose erythropoietin linked to longer survival in patients with MM and anemia. 
Oncol Rep 2005;(FALL): 91. 
 Notes: KQ1 a-c: nrct. 
5. Anonymous. Epoetin alfa shows greater increase in hemoglobin levels than darbepoetin alfa. 
Oncol Rep 2005;(FALL): 122-123.   
 Notes: KQ1 a-c: other reasons. 
6. Aravantinos G, Linardou H, Makridaki D et al. Recombinant human erythropoietin for platinum-
based chemotherapy-induced anaemia: A single-centre randomised study. Journal of BUON 
2003; 8(2): 127-132.   
 Notes: KQ1 a-c: nop. 
7. Arcasoy, MO. Erythropoiesis-stimulating agents in cancer. J Clin Oncol 2008; 26(18): 3097-3098.   
 Notes: KQ1 a-c: comment. 
8. Auerbach M, Ballard H, Trout JR et al. Intravenous iron optimizes the response to recombinant 
human erythropoietin in cancer patients with chemotherapy-related anemia: a multicenter, open-
label, randomized trial. J Clin Oncol 2004; 22(7): 1301-1307.   
 Notes: KQ1 a-c: other reasons. 
9. Aziz, K, Hashem, T, Mobarek, N et al. Does Recombinant Human Erythropoietin Improve the 
Outcome of Radiation Therapy in Head and Neck Cancer Patients? [Abstract]. Proceedings of 
ASTRO 2001; #2274.    
 Notes: KQ1 a-c: nop. 
10. Ban HJ, Chi SY, Park CK et al. Efficacy of darbepoetin alfa in anemia developed during 
chemotherapy for lung cancer. Tuberc Respir Dis. 2009; 66(2): 104-109.  
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Appendix C.  Evidence Tables 
Appendix Table C1.  KQ1: Epoetin versus control, study characteristics, Part I 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Aapro 2008 
 
463 231 232 epoetin beta 1 x 
30,000 
IU/wk  sc 
fixed 24 decreasing: if Hb 
increased > 2 g/dL 
between two visits, dose 
reduced.  Stopped if Hb 
>15 g/dl, restarted when 
Hb ≤13 g/dl 
as needed at discretion 
of physician 
OS, PFS, 
tumor 
response, 
RBCT, Hb 
safety, QoL 
Antonadou 
2001 
 
401 190 
evaluated 
195 
evaluated 
epoetin  5 x 
10,000 
IU/wk sc 
fixed 5 -6 NR fix NR Hb, local 
control, OS, 
safety, DFS,  
Bamias 2003 
 
144 72 72 epoetin alfa 3 x 
10,000 
IU/wk sc 
fixed 21 to 24 wks 
(duration of 
chemo), 
categorized as 
>20 
decreasing: if Hb 
increased by 2 g/dl dose 
reduced to 75%, 
stopping:  if Hb > 15 
g/dL epo stopped and 
resumed at  75% dose 
when Hb <13g/dl 
NR at discretion 
of physician 
RBCT, Hb, 
predictors of 
response, 
QoL in a 
subset of 
centers 
Blohmer 2011 
 
257 128 129 epoetin alfa 3 x 
10,000 
IU/wk sc 
(doubled 
if Hb < 
10.5 
g/dL) 
fixed 4 cycles of 
chemotherapy 
each 3 wks plus 
radiotherapy plus 
additional 2 wks 
approx. 27 wks, 
categorized >20 
decreasing: if Hb 
reached 13 g/dL dose 
reduced to 66%. 
Increasing: if baseline 
Hb < 10.5 g/dL ESA 
10,000 6 times weekly, 
stopping:  if Hb > 14 
g/dL epo stopped  
fix if Hb < 9 g/dL RFS, OS, 
PS, Hb, 
RBCT, QoL, 
safety, local 
and 
systematic 
recurrence 
Boogaerts 
2003, Coiffier 
2001 
 
262 133 129 epoetin beta 3 x 150 
IU/kg/wk 
sc 
weight 12 increasing: if Hb 
increase <0.5 g/dL 
within 3-4 wks or <1 
g/dL within 6-8 wks dose 
increased to 300 IU/kg. 
Decreasing: if Hb 
increase >2 g/dL within 
4 wks dose reduced by 
50%. If Hb >14 g/dL 
stopped and reinstated 
at 50% if Hb <12 g/dL 
as needed Hb <8.5 g/dL  QoL, Hb, 
RBCT, safety 
Case 1993 
 
157 81 76 epoetin alfa 3 x 150 
IU/kg/wk 
sc 
weight 12 decreasing: if Hct 38% 
reached dose reduced 
to maintain Hct level 
as needed at discretion 
of physician 
Hb, RBCT, 
QoL, AE 
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Appendix Table C1.  KQ1: Epoetin versus Control, Study Characteristics, Part I (continued) 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Chang 2005 
 
354 176 178 epoetin 
alfa 
1 x 
40,000 
IU/wk  
sc  
fixed 16, max 28, 
categorized as 
16 wks 
increasing: if at the 
end of week 4 or 6 
Hb had decreased > 
2 g/dl increased to 
60,000 IU, 
decreasing: If Hb > 
14 g/dl stopped until 
<12g/dl, then restart 
with 75%, iff Hb 
increased > 2 g/dl 
per month dose 
reduced by 25% 
as needed Hb < 8 g/dL 
or discretion 
of physician 
QoL, Hb, 
RBCT, 
safety 
Christodoulou 
2009, Janinis 
2003 
 
399 167 
evaluated 
170 
evaluate
d 
epoetin 
alfa 
3 x 
10,000 
IU/wk 
sc 
fixed with concurrent 
chemotherapy, 
minimum 12 
wks 
decreasing: if Hb > 
14 g/dl stopped until 
<12g/dl, then restart 
with 66%, i.e. 
10.000 IU given 
twice a week. 
fix Hb < 8.5 g/dL 
or discretion 
of physician 
QoL, RBCT, 
Hb 
Dammacco 
2001 
 
145 69 76 epoetin 
alfa 
3 x 150 
IU/kg/w
k sc 
weight 12 increasing: if Hb had 
not increased 
>1g/dL by week 4, 
dose doubled to 
300IU/kg tiw, 
decreasing: if Hb 
increased by 2g/dL 
within a 4 week 
period, EPO 
reduced by 25%, if 
Hb >14g/dL withheld 
until Hb<12g/dL 
then reinitiated at 
25% lower dose 
as needed Hb < 8 g/dL 
or discretion 
of physician 
Hb, RBCT, 
QoL, AE 
Debus 2006 
 
385 195 190 epoetin 
alfa 
1 x 
40,000 
IU/wk 
sc 
fixed during chemo 
and 
radiotherapy, 
approx. 12 wks 
stopped at 14 g/dL 
and reinstated at 12 
g/dL, in 11/2003 
reduced to 13 g/dL. 
handled 
different 
NR OS, TR, 
QoL, Hb, 
RBCT, 
safety, 
tolerance to 
EPO 
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Appendix Table C1.  KQ1: Epoetin versus Control, Study Characteristics, Part I (continued) 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Engert 2009 
 
1379, 
evaluated 
1303 
648 655 epoetin alfa 1 x 
40,000 
IU/wk  
sc 
fixed 22-24 Hb target initially 13 
g/dL, after protocol 
amendment 14 g/dL 
NR NR QoL, Hb, 
OS, FFTF, 
PSF, TVE, 
RBCT, safety 
EPO-INT-1 
 
246 165 81 epoetin alfa a: 3 x 
150 
(n=85); 
b: 3 x  
300 
IU/kg 
(n=80) 
sc 
weight 1 month post 
chemotherapy, 
categorized as 
unclear 
increasing: if 
reticulocyte after 4 
wks < 40,000 double 
dose (for 150 arm), 
stopping: if Hb > 14 
g/dL stop until Hb < 
12.5 g/dL then restart 
at 75% 
as needed NR tumor 
response, 
survival, 
disease 
progression, 
TVEs 
EPO-INT-3 
 
201 136 65 epoetin alfa 3 x 
150-
300 
IU/kg 
sc 
weight 12 increasing: if 
reticulocyte after 4 
wks < 40,000 double 
dose, stopping: if Hb > 
14 g/dL (w) or > 16 
g/dL (m) stop until Hb 
< 12 g/dL (w) or 14 
g/dL (m) then restart 
at 75% 
as needed NR RBCT,Hb, 
QoL 
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Appendix Table C1.  KQ1: Epoetin versus Control, Study Characteristics, Part I (continued) 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Fujisaka 2011 181 89 92 epoetin 
beta 
1x 
36000 
IU/wk 
fixed 12 decreasing: dose 
withheld if Hb>12 g/dl-
1 restarted at 66% 
when Hb≤ 11 g/dl-1 
as needed 
(defined) 
at discretion 
of physician 
RBCT rate, 
Hb level, 
QoL, safety 
Goss 2005, 
EPO-CAN-15 
 
106 53 53 epoetin alfa 1 x 
40,000 
IU/wk  
sc  
fixed approximately 
12-24, 
categorized 
as > 20 
target 14 – 16 g/dL as needed NR local tumor 
control, 
progression 
free survival, 
overall 
survival, Hb, 
RBCT, QoL, 
safety, 
median 
survival 
Grote 2005, 
N03-004 
 
224 109 115 epoetin alfa 3 x 150 
IU/kg/w
k sc 
weight 12 (assumed 
as drug given 
during 3 x 3 
wks chemo 
plus 3 wks) 
decreasing: dose 
withheld if Hb >16 
g/dL and restarted at 
50% if Hb <14 g/dL 
as needed* NR tumor 
response, 
overall 
survival, Hb, 
transfusion 
rate 
Gupta 2009 
 
120 60 60 epoetin 
beta 
3 x 
10,000 
IU/wk  
sc 
fixed 7 (assumed, 
drug started 
10-15 days 
before 5 wks 
of chemo- 
radiotherapy) 
NR fix if Hb < 10 
g/dL 
Hb, QoL, OS 
 
* Information taken from Bohlius 2009 Cochrane Review 
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Appendix Table C1.  KQ1: Epoetin versus Control, Study Characteristics, Part I (continued) 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Henke 2003 
 
351 180 171 epoetin 
beta 
3 x 300 
IU/kg/w
k sc 
weight 7-9, median 
duration of epo 
tx: 42.5 days 
stopping: stop if Hb 
level >14g/dL 
(women) or 15g/dL 
(men), or if Hb 
increase >2g/dL/wk, 
resumed if Hb fell 
below target 
as 
needed 
NR locoregional 
progression 
free survival, 
survival, Hb, 
AE, tumor 
progression 
Henry 1995 
 
132 67 65 epoetin alfa 3 x 150 
IU/kg/w
k sc 
weight 12 decreasing: if Hct 38% 
was reached drug 
stopped until Hct < 
38% 
as 
needed 
at discretion 
of physician 
(result:  epo 
Hct 24.7%, 
control Hct 
25.45) 
Hb, RBCT, 
QoL, AE 
Hoskin 2009, 
EPO-GBR-7 
 
301 one 
patient 
assigned 
but no 
data 
collected 
151 149 epoetin alfa if hb < 
12.5,3 
x 
10,000 
IU 
(25% of 
patient
s) ; if 
hb > 
12.5 
then 3 
x 4,000 
IU 
(75% of 
patient
s) sc 
adjusted 12 titration: to achieve 
and maintain Hb 12.5 
g/dl to 15 g/dl, initiate 
at Hb level 15g/dL.; iff 
Hb > 15 g/dL drug 
withheld and restarted 
at Hb 14.5 at 50% 
dose.; if Hb below 
12.5 g/d at week 4 
dose increased to 
120,000 IU per week.  
 
fix NR local disease 
free survival, 
OS, tumor 
response, 
AE, QoL 
Iconomou 2003 
 
122 61 61 epoetin alfa 3 x 
10,000 
IU/wk 
sc 
fixed 12 increasing: if Hb 
increase < 1 g/dL 
dose increased to 3 x 
20,000 IU; decreasing: 
if Hb increased >2g/dL 
dose reduced by 25% 
fix Hb 7.5 g/dL 
or discretion 
of physician 
QoL, Hb 
change, 
RBCTs in an 
outpatients 
oncology 
setting  
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Appendix Table C1.  KQ1: Epoetin versus Control, Study Characteristics, Part I (continued) 
 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Leyland-Jones 
2005; Leyland-
Jones 2003 
 
 
939 469 470 epoetin alfa 1x 
40,000 
IU/wk 
sc 
fixed median 
duration 52 
wks 
increasing: if Hb 
increase <10.5 g/dL 
after 4 wks drug 
increased to 60,000 
IU/wk, decreasing: if 
Hb level >14 g/dL or 
increase > 2 g/dL drug 
withheld 
as 
needed 
NR survival, 
QoL, 
hematologica
l effects, 
transfusions, 
time to 
progression, 
AE, tumor 
response 
Littlewood 2001 
 
375 251 124 epoetin alfa 3 x 150 
IU/kg/w
k sc 
weight 28 stopping: if Hb level 
increased to >15 g/dL 
drug was stopped and 
restarted if Hb 12 g/dL 
as 
needed 
Hb < 8 g/dL 
or clinical 
symptoms 
Hb, RBCT, 
QoL, AE, 
after protocol 
amendment 
also survival 
Machtay 2007, 
Machtay 2004 
 
148 77 71 epoetin alfa 1x 
40,000 
IU/wk 
sc 
fixed approx. 8-9 decreasing: if Hb > 16 
g/dL (men) or >14 
g/dL (women) drug 
stopped, if Hb <13.5 
g/dL (men) or <12.5 
d/dL (women) dosing 
resumed at a dose 
reduction of 30,000 IU, 
increasing: if Hb did 
not increase >1g/dL 
after 4 wks, dose 
increased to 60,000 
IU/week 
handled 
different 
NR local regional 
failure rate, 
local regional 
progression 
free survival, 
overall 
survival, Hb , 
toxicity, 
patterns of 
failure 
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Appendix Table C1.  KQ1: Epoetin versus Control, Study Characteristics, Part I (continued) 
 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Moebus 2007 
 
658 333 325 epoetin alfa 3 x 150 
IU/kg/w
k sc 
weight approx. 18 NR, target Hb 12.5 to 
13 g/dL, stopping rule 
from IPD review Hb 14 
g/dL 
handled 
different 
NR DFS, OS, 
relapse free 
survival, 
anemia, 
RBCT, 
toxicity, Hb, 
local relapse, 
QoL 
Milroy 2011 
 
424  214  210  epoetin alfa 3 x 
10,000 
IU/wk 
sc 
fixed 28 start if Hb ≤ 13 g/dL 
(men) or Hb ≤ 12 g/dL 
(women), drug 
stopped at Hb 15 g/dL 
(men) and 14 g/dL 
(women), restarted at 
66% ; if Hb inc >2 
g/dL/mo, dose 
reduced by 33% 
as 
needed 
NR QoL, Hb, 
RBCT, OS, 
tumor 
response, 
safety 
ML17620 
 
121 Assume 
61 
Assum
e 60 
epoetin 
beta 
3 x 150 
IU/kg/w
k sc 
weight 12 NR as 
needed 
as needed Hb, RBCT, 
safety, iron 
Oberhoff 1998 
 
218 114 104 epoetin 
beta 
7 x 
5,000I
U/wk 
sc 
fixed 12 target ceiling 14 g/dL as 
needed 
discretion of 
physician 
Hb, RBCT, 
AE 
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Appendix Table C1.  KQ1: Epoetin versus Control, Study Characteristics, Part I (continued) 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Osterborg 2002, 
Osterborg 2005 
 
349 173 176 epoetin 
beta 
3 x 150 
IU/kg/w
k sc 
weight 16 increasing: if no signs 
of response within 4 
wks, dose increased 
to 300; decreasing: if 
Hb increase >2 g/dL 
per 4 wks dose 
reduced by 50%; iIf Hb 
level >14 g/dL study 
drug was stopped, if 
Hb level <13 g/dL 
reinstated at 50% 
as 
needed 
Hb < 8.5 
g/dL or 
medically 
indicated 
Hb, RBCT, 
AE, QoL, 
OS, 
transfusion 
free survival, 
Hb response 
Porter 1996 
 
24 10 
evaluat
ed 
10 
evaluat
ed 
epoetin alfa 3 x 150 
IU/kg/w
k sc 
weight 16 increasing: if Hb < 
11.5 g/dL at week 4 
increase by 50 IU/kg, 
decreasing: if Hb  ≥ 15 
g/dL reduce by 50 
IU/kg, stopping: if Hb 
> 16.5 g/dL stop until 
Hb < 11.5 g/dL.  
as 
needed 
Hb < 8.0 
g/dL or 
medically 
indicated 
RBCT 
Pronzato 2010 
 
223 
modified 
ITT 216 
110 
modifie
d ITT 
107   
113 
modifie
d ITT 
109 
epoetin alfa >45 kg 
3 x 
10,000 
IU/wk 
sc 
(5000 
IU if 
<45kg) 
adjusted approximately 
28 wks 
(duration of 
chemotherapy 
plus 4 wks) 
increasing: dose 
adjusted if response < 
1.0 g/dl at week 4, 
stopping: if Hb > 14 
g/dl 
as 
needed 
NR QoL, RBCT, 
OS, PS, Hb, 
safety, tumor 
response  
Ray-Coquard 
2009 
 
218 110 108 epoetin alfa 3 x 150 
IU/kg/w
k sc 
weight 12 decreasing: if Hb 
increased >2g/dL in a 
month, EPO 
decreased to 75%, 
increasing: if after 4 
wks Hb<10.5 g/dl with 
<1g/dL decrease in 
the previous 4w and 
retic  <40,000 EPO 
60,000/week. Hb 
ceiling from IPD 
review: 14 g/dL 
as 
needed 
NR RBCT, OS, 
safety, Hb, 
DFS, QoL, 
time to 
disease 
progression 
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Appendix Table C1.  KQ1: Epoetin versus Control, Study Characteristics, Part I (continued) 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Razzouk 2006; 
Razzouk 2004  
224 113 111 epoetin alfa 1 x 600 
IU/kg/w
k U IV 
weight 16 increasing: if Hb 
increase <1 g/dL 
within 4 wks drug 
increased to 900 
IU/kg, maximal 60,000 
IU iv qw; decreasing: if 
Hb > 15 g/dL drug 
withheld, restarted if 
Hb < 13 g/dL with 25% 
dose reduction 
as 
needed 
Hb < 7 g/dL Hb, QoL, 
RBCT, 
safety, vital 
signs 
Rose 1994 
 
221 142 79 epoetin alfa 3 x 150 
IU/kg/w
k sc 
weight 12 epoetin alfa dose 
titrated to maintain Hct 
between 38%-40%  
as 
needed 
NR HR, RBCT, 
QoL, safety 
Savonije 2005; 
Savonije 2004  
315 211 104 epoetin alfa 3 x 
10,000 
IU/wk 
sc 
fixed until end of 
chemotherapy, 
mean 
treatment 
duration 14 
wks 
increasing: if Hb 
increase <1 g/dL and 
Hb < 12.1 g/d after 4 
wks drug increased to 
20,000 IU tiw; 
decreasing: if Hb > 14 
g/dL drug withheld 
until Hb < 13 g/dL, 
resumed at 10,000 IU 
twice weekly; if Hb > 2 
g/dL in 4 wks drug 
reduced to 10,000 IU 
twice weekly 
handled 
different 
discretion of 
physician, 
to be 
avoided if 
Hb > 9.7 
g/dl 
Hb, RBCT, 
survival, 
safety, QoL 
Thomas 2002 
 
130 65 65 epoetin alfa >45 kg 
3 x 
10,000 
IU 
qw sc,  
<45 kg 
3 x 
5,000 
IU 
qw sc 
adjusted 28 drug stopped if Hb > 
14 g/dL 
as 
needed 
at discretion 
of physician 
Hb, QoL, 
RBCT, tumor 
response, 
survival, 
safety 
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Appendix Table C1.  KQ1: Epoetin versus Control, Study Characteristics, Part I (continued) 
Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration (wks) Dose adjustment Iron 
Transfusion 
trigger 
Prim/Sec 
Outcomes 
Thomas 2008, 
GOG-0191 
 
113 58 55 epoetin alfa 1 x 
40,000 
IU/wk 
sc 
fixed during 
radiochemoth
erapy, approx. 
6-9 wks 
titration to maintain 
>13 g/dl, initiate at Hb 
level 12 g/dl, stop if Hb 
> 14 g/dL for 2 wks or 
more, reinstate if Hb < 
13 g/dL at same dose  
as 
needed 
in ESA arm 
in Hb < 12 
g/dL, in 
control arm 
recommend 
Hb, OS, 
progression 
free survival, 
local tumor 
control, 
quality of life 
Tsuboi 2009 
 
122 63 59 epoetin 
beta 
1 x 
36,000 
IU/wk  
fixed 8 stopping: if Hb level 
>14 g/dL drug stopped 
as 
needed 
at discretion 
of physician 
Hb, RBCT, 
OS (retro), 
QoL 
Wagner 2004 
 
38 18 20 epoetin alfa 
(plus G-
CSF in both 
study arms) 
7 x 200 
IU/kg 
sc 
weight assumed 
category 12-
16 
Hb <10g/dL EPO 
administered daily, if 
Hb >10 g/dL Epo 
administered 3 
times/week, iIf 
Hb>13g/dL EPO 
withheld until 
Hb<13g/dL 
as 
needed 
Hb < 8 g/dL 
or medically 
indicated 
RBCT, safety 
Wilkinson 2006 
 
182 121 61 epoetin alfa 3 x 
10,000 
IU/wk > 
45 kg, 
otherwi
se 3 x 
5,000 
IU/wk 
sc 
adjusted max 28 wks increasing: if Hb 
increase < 1 g/dL or 
reticulcytes not 
>40,000 at 4 wks 
doubled, stopping: if 
Hb > 14 g/dL ESA 
stopped and restarted 
at Hb 12 g/dL with 25-
50% dose reduction, 
decreasing: if Hb 
increase > 2 
g/dL/4wks dose 
reduced by 25-50% 
as 
needed 
Hb < 9 g/dL Hb, RBCT, 
tumor 
response, 
safety, QoL 
Witzig 2005 
 
344 174 170 epoetin alfa 1 x 
40,000 
IU/wk 
sc 
fixed 16 increasing: if Hb 
increase < 1 g/dL after 
4 wks or patients 
required RBCT, dose 
increased to 60,000 
IU; if Hb level >15g/dL 
for two wks, drug 
stopped and restarted 
with 75% when <13 
fix at discretion 
of physician 
RBCT, Hb, 
response 
predictors, 
survival, 
tumor 
response, 
QoL 
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Study N Cancer Type Therapy Hb eligible  
Hb Base 
Epo (SD) 
Hb Base 
Ctl (SD) 
Hb 
Category Age EPO Age Ctl 
Age 
Category 
Aapro 2008 
 
463 breast cancer 
(stage IV) 
solid chemotherapy 
without platinum 
Hb < 12.9 
g/dL 
 11.5 
(SD 1.1) 
11.2 (SD 
1.2) 
10-12  median 56 
(range 27-78) 
median 57.5 
(range 29-83) 
adults 
Antonadou 
2001 
401 pelvic tumors solid radiotherapy NR  9.8 (+/-
0.1) 
10.1 (+/-
0.6) 
10  58.6 (+/- 5) 56 (+/- 6.1) adults 
Bamias 2003 144 ovarian, 
NSCLC, 
SCLC, other 
solid platinum based 
chemotherapy 
Hb <13 g/dL 11.5 
(95% CI 
11.1, 
11.9) 
11.5 
(95% CI 
11.2, 
11.8) 
10-12 median 60 
(range 18-77) 
62 (19-80) adults 
Blohmer 
2011 
 
257 cervical 
cancer 
solid platinum based 
radiochemotherapy 
NR  12.0 (+/-
1.3) 
11.8 (+/-
1.3) 
10-12  41.3 (+/-9) 
median 41 
(24-73) 
43.4 (+/-9.7) 
median 42 
(25-66) 
adults 
Boogaerts 
2003, Coiffier 
2001 
262 MM, NHL, 
CLL, ovarian, 
bone, GI, 
respiratory, 
other 
mixed chemotherapy, 
platinum & non 
platinum, details 
not reported but 
interpreted as such 
as some solid 
cancers which are 
usually treated with 
platinum are 
included 
Hb ≤11 g/dl median 
9.0 
(range 5-
13) 
median 
9.2 
(range 5-
12) 
10 median 62 
(range 24-68) 
median 62 
(range 24-85) 
adults 
Case 1993 
 
157 solid and 
hematological 
tumors 
mixed chemotherapy 
without platinum 
Hb ≤10.5 g/dl 9.29 (SD 
1.14) 
9.57 (SD 
1.04) 
10 median 64 
(range 27-92) 
median 64 
(range 30-88) 
adults 
Chang 2005 
 
354 breast 
cancer, stage 
I-IV 
solid chemotherapy 
without platinum 
Hb <12g/dL 11.2 (SD 
0.9) 
11.3 (SD 
0.8) 
10-12 50.4 (SD 
11.1)  
50.1 (SD 10) adults 
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Study N Cancer Type Therapy Hb eligible 
Hb Base 
Epo (SD) 
Hb Base 
Ctl (SD) 
Hb 
Category Age EPO Age Ctl 
Age 
Category 
Christoudoulou 
2009, Janinis 
2003 
399 solid tumors solid chemotherapy, 
platinum & non 
platinum (38%  
received platinum) 
Hb ≤12.0 
g/dL 
10.15 (+/- 
SD 0.69) 
10.30 
(+/- SD 
0.58) 
10-12 median 61 
(range 22 – 
82) 
median 63 
(range 30 – 
89) 
adults 
Dammacco 
2001 
 
145 MM hematological chemotherapy, 
platinum & non 
platinum, no 
numbers reported 
Hb ≤11 g/dl 9.3 (SD 
1.27) 
9.6 (SD 
0.95) 
10 median 67.3 
range 43.0-
80.4 
median 65.0 
range 38.2-
88.9 
adults 
Debus 2006 
 
385 NSCLC, 
stage IIIA/B, 
primarily 
inoperable 
solid cisplatinum 
containing 
sequential 
chemoradiotherapy 
NR NR NR NR NR NR adults 
Engert 2009 
 
1379 advanced 
HD 
hematological chemotherapy 
without platinum 
NR median 
12.19 
(SD 
1.97)* 
median 
12.34 
(SD 
1.97)* 
12 median 35 
(range 18-60) 
median 34 
(range 18-60) 
adults 
EPO-INT-1 
 
246 ovarian solid NR, categorized as 
platinum-based 
chemotherapy 
Hb ≤ 11 g/dl NR NR NR (no 
assumption 
possible) 
NR NR adults 
EPO-INT-3 
 
201 breast 
cancer, 
NHL, MM, 
ovarian 
SCLC, other 
mixed chemotherapy, 
platinum (27%)  
and non platinum 
(73%) 
Hb ≤ 12 g/dl NR NR NR (no 
assumption 
possible) 
NR NR adults 
Fujisaka 2011 186 lung, 
ovarian, 
other 
solid platinum based 
chemotherapy 
Hb ≤ 10 g/dl median 
9.4 (8.1-
11.4) 
median 
9.3 (7.2-
11.4)  
< 10 median 67 
(40-79) 
63.5 (44-79) adults 
Goss 2005, 
EPO-CAN-15 
 
106 limited 
disease 
SCLC 
solid platinum based 
chemotherapy plus 
radiotherapy, 
categorized as 
radiochemotherapy  
NR 13.5 g/dL 13.5 
g/dL 
12 NR NR adults 
Grote 2005 
 
224 SCLC, 
limited and 
extended 
disease 
solid platinum based 
chemotherapy 
Hb ≤14 g/dl 12.8 (SD 
1.5) 
13.0 (SD 
1.5) 
12 64.4 (SD 8.7) 63.2 (SD 8.9) adults 
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Study N Cancer Type Therapy Hb eligible 
Hb Base 
Epo (SD) 
Hb Base 
Ctl (SD) 
Hb 
Category Age EPO Age Ctl 
Age 
Category 
Gupta 2009 
 
120 Cervical 
cancer (stage 
IIB-IIIB) 
solid Platinum based 
chemotherapy plus 
radiotherapy, 
categorized as 
radiochemotherapy 
Hb 10-11 
g/dL 
10.45 
(range 
9.5-11.0) 
10.70 
(range 
10.0 – 
12.5) 
10-12 48.27 (range 
18-70) 
48.18 (range 
20-65) 
adults 
Henke 2003 
 
351 advanced 
(stage III , IV) 
head and 
neck 
solid radiotherapy after 
surgical resection, 
22% (78/351) of 
patients 
radiotherapy only 
<13 g/dL 
(men), <12 
g/dL (women) 
median 
11.7 
(range 
8.5 –
14.4)  
median 
11.8 
(range 
6.9 – 
14.6) 
10-12 median 58 
(range 25-81)  
median 57 
(range 36-87) 
adults 
Henry 1995 
 
132 solid and 
hematological 
tumors 
mixed platinum based 
chemotherapy 
Hb ≤10.5 g/dl 9.68 (SD 
1.28) 
9.27 (SD 
1.49) 
10 60 (20-84) 60 (34-83) adults 
Hoskin 2009, 
EPO-GBR-7 
 
301 head and 
neck, stage I-
IV 
solid radiotherapy Hb ≤15 g/dl 13.4 
(range 
9.3 – 
15.5) 
13.7 
(range 
8.9 – 
16.7) 
12 60 (range 37 
– 88) 
58 (range 35 
- 84) 
adults 
Iconomou 
2003 
 
122 lung, breast, 
colorectal, 
ovarian, 
unknown 
primary, 
kidney, 
stomach, 
other 
solid chemotherapy, 
platinum & non 
platinum (51/122 
(42%) received 
platinum) 
Hb ≤11.0g/dL 10.1 (+/- 
SD 0.6) 
10.1 (+/-  
SD 0.4) 
10-12 60.6 (SD 
10.7) 
62.6 (SD 
10.3) 
adults 
Leyland-
Jones 2005 
 
939 metastatic 
breast cancer 
solid chemotherapy, no 
details reported, 
categorized as 
chemotherapy 
without platinum 
Hb of any 
level. No 
upper or 
lower limit for 
inclusion 
12.5 (SD 
1.8) 
12.5 (SD 
1.7) 
12 55.8 (SD 
11.13) 
55.1 (SD 
10.49) 
adults 
Littlewood 
2001 
 
375 NHL, MM, 
breast, HD, 
CLL, GI, 
other 
mixed chemotherapy 
without platinum 
Hb ≤10.5 g/dl 
OR 10.5-12 
AND 
decrease of 
>1.5 g/dL per 
cycle 
9.9 (SD 
1.13) 
9.7 (SD 
1.13) 
10 58.3 (SD 
14.8), range 
18.7-84.9 
59.5 (SD 
13.9), range 
21.1-88.6 
adults 
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Study N Cancer Type Therapy Hb eligible 
Hb Base 
Epo (SD) 
Hb Base 
Ctl (SD) 
Hb 
Category Age EPO Age Ctl 
Age 
Category 
Machtay 
2007, 
Machtay 
2004 
 
148 head and 
neck non-
metastatic, 
not resected 
solid radiotherapy, 
advanced stages 
received in 
addition platinum 
based 
chemotherapy, 
categorized as 
radiotherapy 
Hb 9-13.5 
g/dL (men), 
9-12.5 g/dL 
(women) 
median 
12.0 
(range 
9.2 – 
13.5) 
median 
12.1 
(range 
9.0 – 
13.5) 
12 median 64 
(range 24–
90) 
median 61 
(range 42–
86) 
adults 
Milroy 2011 
 
424 
Modified 
ITT 380 
NSCLC, 
stage IIIB/IV 
solid platinum based 
chemotherapy 
Hb ≤15 g/dL 
(men), Hb 
≤14 g/dL 
(women), 
12.8 
(1.4) 
 12.6 
(1.6) 
12  61.6 (8.7)  60.1 (9.3) adults 
ML17620 
 
121 solid tumors Solid platinum based 
chemotherapy 
anemia NR NR NR (no 
assumption 
possible) 
NR NR adults 
Moebus 
2007 
 
658 breast 
cancer 
solid chemotherapy 
without platinum 
NR median 
12.4 
median 
12.8 
12 median 51 median 51 adults 
Oberhoff 
1998 
 
218 solid 
tumours; 
ovarian, 
breast, lung, 
GU, GI, other 
solid chemotherapy, 
platinum (56%) & 
non platinum 
Hb ≤11 g/dl 
OR ≤13 g/dl 
AND 
decrease of 
>1.5 g/dL per 
CT cycle 
9.65 (SD 
1.10) 
9.75 (SD 
1.09) 
10 median 53, 
range 20-77 
56, range 
19-73 
adults 
Osterborg 
2002, 
Osterborg 
2005 
349 MM, NHL, 
CLL 
hematological chemotherapy 
presumably 
without platinum 
Hb ≤10 g/dl 9.2 (SD 
1.1) 
9.3 (SD 
1.0) 
10 63 (32-86) 64 (28-83) adults 
Porter 1996 
 
24 sarcoma Solid chemotherapy 
without platinum, 
patients received 
also radiotherapy 
during study 
(n=10) 
Hb < 10.5 
g/dL 
median 
9.7 
(range 
7.7-10.8) 
median 
9.4 
(range 
8.2-10.1) 
10 median 14 
(range 5-17) 
median 13 
(range 5-16) 
children 
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Study N Cancer Type Therapy Hb eligible 
Hb Base 
Epo (SD) 
Hb Base 
Ctl (SD) 
Hb 
Category Age EPO Age Ctl 
Age 
Category 
Pronzato 
2010 
 
223 
Modified 
ITT 206 
breast 
cancer, stage 
I-IV 
solid chemotherapy not 
reported, assumed 
without platinum  
≤ 12  10.6 10.8 10-12 53.3 (10.3)  54.3 (11.6) adults 
Ray-Coquard 
2009 
 
218 carcinoma, 
sarcoma, 
lymphoma, 
other 
mixed chemotherapy 
‘unclear’ 
Hb <12 g/dl 10 (1.2) 10 (1.2) 10-12 62.7 (SD 
11.6) 
61.7 (11.6) adults 
Razzouk 
2006 
 
224 solid 
tumours, 
Hodgkin’s 
disease, non-
Hodgkin’s 
disease, ALL 
mixed chemotherapy 
‘unclear’ 
Hb ≤10.5 g/dl 
if aged 5-12, 
Hb ≤11 g/dl 
for girls aged  
> 12, Hb ≤12 
for boys 
aged > 12 
9.8 (SD 
1.3) 
9.5 (SD 
1.0) 
10 12.4 (SD 3.6) 10.8 (SD 4.0) children 
Rose 1994 
 
221 CLL, stage 
III, IV 
hematological in the IPD review 
< 70% received 
chemotherapy, 
categorized as 
“other” 
Hct ≤32% 9.1 (1.3) 9.3 (1.2) 10 68.3 (SD 10) 68.1 (9.3) adults 
Savonije 
2005; 
Savonije 
2004 
315 solid tumors solid platinum based 
chemotherapy 
Hb <12.1 
g/dL 
10.7 (SD 
1.0) 
10.8 (SD 
1.0) 
10-12 57.0 (SD 
11.0) 
58.0 (SD 
10.0) 
adults 
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Study N Cancer Type Therapy Hb eligible 
Hb Base 
Epo (SD) 
Hb Base 
Ctl (SD) 
Hb 
Category Age EPO Age Ctl 
Age 
Category 
Thomas 2002 
 
130 “cancer 
patients” 
unclear chemotherapy, 
platinum and non 
platinum based, 
proportion of 
patients unclear 
Hb < 12g/dL 10.59 
(SD 
1.05) 
10.59 
(SD 
1.05) 
10-12 NR NR adults 
Thomas 
2008, GOG-
0191 
 
113 cervix 
carcinoma 
solid platinum based 
chemotherapy plus 
radiotherapy, 
categorized as 
radiochemotherapy 
Hb ≤14 g/dl 10.55 
(SD 
1.98)** 
10.91 
(SD 
1.35)* 
10-12 median 46 
(range 25-
77) 
median 50 
(range 32-
78) 
adults 
Tsuboi 2009 
 
122 lung cancer, 
lymphoma 
mixed chemotherapy, for 
some patients 
platinum based, no 
numbers given 
Hb < 8 g/dL 10.0 (SD 
1.0) 
10.4 (SD 
1.0) 
10-12 61.8 (11.9) 62.1 (9.6) adults 
Wagner 2004 38 neuroblastoma solid chemotherapy NR median 
8.85 
(range 
6.1-11.2) 
median 
9.35 
(range 
7.0-15.3) 
10 median 3.2 
(range 1.2-
19.4) 
median 3.2 
(range 1.1-
7.3) 
children 
Wilkinson 
2006 
 
182 ovarian cancer 
(stage I-IV) 
solid platinum based 
chemotherapy  
Hb ≤12 g/dl 10.75 
(SD 
0.94) 
10.66 
(SD 
0.83) 
10-12 59.1 (SD 
10.6) 
60.3 (SD 
11.2) 
adults 
Witzig 2005 
 
344 lung cancer, 
breast cancer, 
other cancers, 
active 
incurable 
advanced 
stage 
unclear chemotherapy, 
platinum & non 
platinum, 56/330 
(17%) received 
platinum 
Hb ≤11.5 g/dl 
(men), Hb 
≤10.5 g/dl 
(women) 
9.5 , 
range 
6.0-11.4 
9.4 , 
range 
6.9-11.4 
10 63.6 (SD 
11.89) 
63.7 (SD 
13.00) 
adults 
 
* Median and SD estimated from graph, see Hb table.  
** SD estimated from graph, see Hb table. 
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Study N Treated Control Drug Dose 
Weight 
based/fixed 
Treatment 
duration 
(wks) Dose adjustment Iron 
Transfusion 
trigger Prim/Sec Outcomes 
Hedenus 
2003 
 
349 176 173 darbep
oetin 
alfa 
 2.25 µg/kg/ qw 
sc 
weight 12 increasing: if Hb 
increase <1.0 g/dL 
within 4 wks of 
treatment dose was 
doubled; decreasing: if 
Hb increase >15 g/dL 
(men) or >14g/dL 
(women) drug stopped 
until Hb <13 g/dL and 
reinstated at 50% 
as 
needed 
Hb < 8g/dL 
or discretion 
of physician 
Hb response, 
transfusion, Hb 
change, QoL 
Hernandez 
2009 
 
391 196 195 darbep
oetin 
alfa 
300 µg Q3W sc fixed 16 increasing: if Hb < 9 
g/dL at week 4 or < 10 
g/dL at week 7 and  Hb 
increase < 1 g/dL 
compared to baseline 
increase to 500 µg 
Q3W; decreasing: if 
Hb increased >1g/dL 
per 2 wks dose 
reduced.;stopping: if 
Hb > 13 g/dL drug 
stopped until Hb ≤ 12 
g/dL 
as 
needed 
Hb ≤ 8 g/dL 
or discretion 
of physician 
RBCT, QoL, Hb 
Kotasek 2003 
a,b,c,d,e,f 
 
259 208 51 darbep
oetin 
alfa 
a: 4.5 μg/kg 
Q3W, b:6.75 
μg/kg Q3W,  
c: 9 μg/kg Q3W, 
d:12 μg/kg 
Q3W, e:13.5 
μg/kg Q3W,  
f:15 μg/kg Q3W 
sc 
weight 12 increasing not allowed, 
decreasing: if Hb 
increased >15 g/dL 
(men) or >14 g/dl 
(women) drug stopped 
and reinstated at a 
lower dose level if Hb 
<13 g/dL  
as 
needed 
NR safety, antibodies, 
Hb, RBCT, QoL, 
darbepoetin 
concentration in 
blood 
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Appendix Table C2.  KQ1: Darbepoetin versus Control, Study Characteristics, Part I (continued) 
Study author n 
randomized 
n random-
ized in 
experi-
mental 
arm 
n 
random
-ized in 
control 
arm 
Drug Dose Weigh
t 
based 
or fix 
Duration 
of study 
drug 
medicati
on (wks) 
Dose adjustment Iron Transfusio
n trigger  
Primary and 
secondary 
outcomes of the 
study 
Overgaard 2009 
 
522 260 262 darbepo
etin alfa 
150 µg QW sc fixed 8-10 Hb target: 15.5 g/dL as 
needed 
NR loco regional control, 
OS, Hb, safety, DFS 
Pirker 2008 
 
600 299 301 darbepo
etin alfa 
 300 µg Q4W, 
after 4 wks 
changed to Q3W 
sc 
weight until end 
of 
chemoth
erapy, 
categoriz
ed as > 
20 wks 
increasing: if Hb < 
11 g/dL drug given 
QW, stopping: if Hb  
≥ 14 g/dL study 
drug was stopped 
and restarted if Hb 
<13 g/dL 
as 
needed 
NR Hb, OS, RBCT, 
safety, disease 
progression, QoL 
Untch2011 
 
733 356 377 darbepo
etin alfa 
4.5 μg/kg Q2W sc weight during 
chemoth
erapy, 
approxim
ately 21-
25 
Hb target 13 g/dL; 
increasing: dose 
doubled if increase 
<1 g/dl by wk 4; 
discontinued if Hb> 
14 g/dl and 
restarted at 50% 
dose if Hb ≤ 13 g/dl 
handled 
different 
Not reported DFS, OS, success of 
surgery, tumor 
response, safety, 
effect of DA on DFS 
Vansteenkiste 2002 
 
320 159 161 darbepo
etin alfa 
2.25 mcg/kg qw sc weight 12 increasing: if Hb 
increase < 1 g/dL 
within 6 wks dose 
doubled to 4.5 
µg/kg/wk, 
decreasing: If Hb 
>15 g/dl (men) or 
>14 g/dl (women) 
drug stopped, 
reinstated at 50% if 
Hb <13 g/dl 
as 
needed 
Hb < 8g/dL 
or at 
discretion of 
physician 
transfusion, number 
of RBCTs, Hb 
response, AE, overall 
survival, progression 
free survival, QoL, 
hospitalization, 
antibody formation 
 
 C-19 
Appendix Table C2.  KQ1: Darbepoetin versus control, study characteristics, Part II  
 
Study author n 
random-
ized 
Cancer details Cancer 
category 
Therapy Hb 
eligibility 
criteria 
Hb 
baseline 
EPO arm 
[mean g/dl 
(SD)] 
control arm 
mean 
baseline HB 
(SD) 
Hb 
category 
Age; darbepo 
arm, as 
reported 
(mean, SD) 
range if not 
reported 
otherwise 
Age; control 
arm, as 
reported 
(mean or 
median, SD), 
range 
Age 
category 
(children, 
adults, 
elderly 
(>65) 
Hedenus 2003 
 
349 lymphoma: HD, 
NHL, MM 
hematological NR, assumed 
to be 
chemotherapy 
without 
platinum 
Hb ≤11.0 
g/dL 
9.59 (SD 
1.22) 
9.50 (SD 
1.21) 
10 64.8 (SD 13.8) 64.6 (SD 
12.2) 
adults 
Hernandez 2009 
 
391 lung, 
gynecological, 
other solid and 
hematological 
malignancies 
mixed chemotherapy, 
platinum & non 
platinum 
(140/386 
(36%) received 
platinum) 
Hb < 11 
g/dl 
10.1 (0.9) 10.0 (0.9) 10-12 64.5 (12.1) 63.6 (12.3) adults 
Kotasek 2003 a,b,c,d,e,f 
 
259 breast, gyne, 
gastrointestinal, 
lung, other 
solid chemotherapy, 
not reported if 
with or without 
platinum, 
interpreted as 
some patients 
receiving 
platinum as 
some of solid 
cancers 
included are 
usually treated 
with platinum 
Hb ≤11.0 
g/dL 
9.93 (SD 
1.0) 
9.87 (SD 
1.12) 
10 58.3 (SD 11.9) 56.2 (SD 
12.4) 
adults 
Overgaard 2009  522 head and neck 
cancer 
solid radiotherapy Hb < 14.5 
g/dL 
approx. 13 
g/dL 
approx. 13 
g/dL 
12 NR NR adults 
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Study author n 
random-
ized 
Cancer details Cancer 
category 
Therapy Hb 
eligibility 
criteria 
Hb 
baseline 
EPO arm 
[mean g/dl 
(SD)] 
Control arm 
mean 
baseline HB 
(SD) 
Hb 
category 
Age; darbepo 
arm, as 
reported 
(mean, SD) 
range if not 
reported 
otherwise 
Age; control 
arm, as 
reported 
(mean or 
median, SD), 
range 
Age 
category 
(children, 
adults, 
elderly 
(>65) 
Pirker 2008 
 
600 extensive stage 
SCLC 
solid platinum based 
chemotherapy 
Hb >9 
and ≤ 13 
g/dL 
12.03 (1.07) 11.86 (1.03) 10-12 60.6 (9.2) 61.3 (8.3) adults 
Untch 2011 
 
733 breast cancer solid chemotherapy 
without 
platinum 
NR median 
14.0 (range 
9-17) 
13.64 (1.17) 
(from online 
suppl table) 
median 14.0 
(range 9-17) 
13.61 (1.16) 
(from online 
suppl table) 
12 median 49 
(range 23-65) 
median 48 
(range 23-65) 
adults 
Vansteenkiste 2002 
 
320 SCLC, and 
non-SCLC 
solid platinum based 
chemotherapy 
Hb ≤11.0 
g/dL 
10.28 (SD 
1.08) 
9.93 (SD 
1.01) 
10-12 61.6 (SD 9.2) 61.3 (SD 8.8) adults 
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study 
author 
# 
random
ized 
design drug Darbepoeti
n dose per 
week 
Epoetin 
dose 
per 
week 
weight 
based or 
fix 
duratio
n of  
medica
tion 
(wks) 
Dose 
adjustment 
Darbepoetin 
Dose adjustment 
Epoetin 
iron transfu-
sion 
trigger 
primary 
and 
secondary 
outcomes 
of the 
study 
Glaspy 
2002, Part 
A 
269 sequential 
dose 
finding 
study 
Darbepo
etin 
versus 
epoetin 
alfa 
a: 0.5; b: 
1.0; c: 1.5; 
d: 2.25; e: 
4.5; f: 6.0 
and g: 8.0 
µg/kg qw 
150 
IU/kg tiw 
darb 
weight 
based, 
epo 
weight 
based 
12 no dose 
adjustment 
Increasing: if Hb 
increase < 1.0 
g/dL at wk 8 EPO 
increased to 300 
IU/kg tiw 
NR NR safety, Hb 
response, 
Hb levels, 
RBCT, QoL 
Glaspy 
2006  
1,220 phase 3, 
non-
inferiority 
trial 
Darbepo
etin 
versus 
epoetin 
alfa 
1 x 200 µg 
q2w 
40,000 
IU qw 
darb fixed, 
epo fixed 
16 dose escalation 
permitted at wk 
5 if the Hb 
increase < 1 
g/dL.; withheld if 
Hb > 13 g/dL at 
any time, and 
reinstated at 
75% of the 
previously 
administered 
dose after Hb to 
≤ 12 g/dL 
dose escalation 
permitted at wk 5 
if the Hb increase 
< 1 g/dL.; 
withheld if Hb > 
13 g/dL at any 
time, and 
reinstated at 75% 
of the previously 
administered 
dose after Hb to ≤ 
12 g/dL 
Rules changed 
from a mandatory 
requirement to 
physician decision 
NR Hb ≤ 8 
g/dL 
RBCT, 
safety, Hb 
response, 
QoL 
Schwartz
berg 
2004, a-c 
318 to validate 
patient 
questionnai
re 
Darbepo
etin 
versus 
epoetin 
alfa 
200 µg q2w 40,000 
IU qw 
darb fixed, 
epo fixed 
16 Increasing: if Hb 
increase < 1.0 
g/dL at wk 4 
Darb increased 
to 300 µg q2w; 
Stopping: drug 
was withheld if 
Hb level > 13.0 
g/dL and 
reinstated at the 
previous dose if 
Hb < 13 g/dL. 
Increasing: if Hb 
increase < 1.0 
g/dL at  wk 4 EPO 
increased to 
60,000 IU qw; 
Stopping: drug 
was withheld if Hb 
level > 13.0 g/dL 
and reinstated at 
the previous dose 
if  Hb < 13 g/dL. 
NR NR validate 
patient 
satisfaction 
questionnair
e, efficacy 
(Hb, Hct, 
RBCT), 
safety 
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study 
author 
# 
rando
mized 
design drug Darbepoeti
n dose per 
week 
Epoetin 
dose 
per 
week 
weight 
based or 
fix 
duration of  
medication 
(wks) 
Dose 
adjustment 
Darbepoeti
n 
Dose adjustment 
Epoetin 
iron transfu-
sion 
trigger 
primary 
and 
secondary 
outcomes 
of the 
study 
Waltzman 
2005 
358 effectivenes
s study to 
compare Hb 
response 
rates 
Darbepo
etin 
versus 
epoetin 
alfa 
200 µg q2w 40,000 
IU qw 
darb fixed, 
epo fixed 
12 to 16 Increasing: 
if Hb 
increase < 
1.0 g/dL at  
wk 6 Darb 
increased to 
300 µg 
q2w; 
Decreasing: 
if Hb rise > 
1.0 g/dL in 
2 wks dose 
decreased 
by 25%; 
Stopping: 
drug was 
withheld if 
Hb level > 
13.0 g/dL 
resumed at 
25% dose 
reduction 
when Hb < 
12 g/dL. 
Increasing: if Hb 
increase < 1.0 
g/dL at  wk 4 EPO 
increased to 
60,000 IU qw; 
Decreasing: if Hb 
rise > 1.0 g/dL in 
2 wks dose 
decreased by 
25%; Stopping: 
drug was withheld 
if Hb level > 13.0 
g/dL, resumed at 
25% dose 
reduction when 
Hb < 12 g/dL. 
325 
mg/d 
oral in 
each 
arm, 
i.v if 
not 
tolerat
ed 
NR Hb 
response, 
RBCTs, 
QoL, 
safety 
Kotsori 
2006 
110 NR Darbepo
etin 
versus 
epoetin 
150 µg qw 10,000 
IU tiw 
darb fixed, 
epo fixed 
8  If no 
response 
after 4 wks 
dose was 
doubled 
If no response 
after 4 wks dose 
was doubled 
NR NR Hb 
increase, 
QoL 
assessment 
using 
FACT-An 
scale, 
transfusion 
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study 
author 
n 
rando
mize
d 
cancer 
details 
cancer 
categor
y 
therapy Hb eligibility 
criteria 
Hb baseline 
Darb arm 
[mean g/dl 
(SD)] 
Hb 
baseline 
EPO arm 
[mean 
g/dl (SD)] 
Hb 
catego
ry 
 
Target 
Age Darb 
arm [mean 
(SD)] if not 
stated 
otherwise 
Age EPO 
arm 
[mean 
(SD)] if 
not stated 
otherwise 
age category 
(children , 
adults, elderly 
(>65) 
Glaspy 
2002, Part 
A 
269 Breast, 
GI, lung, 
other 
solid chemotherap
y 
Hb ≤ 11 g/dL  9.91 (SD 
0.94) 
10.02 (SD 
0.88) 
> 12 
 
14 for 
women 
15 for 
men 
61.9 (SD 
11.9) 
57.8 (SD 
14.5) 
adults 
Glaspy 
2006  
1220 lung, 
breast, 
GI, gyne, 
lymphopr
oliferativ
e (7.5%), 
other 
cancers 
solid or 
hematolo
gical 
chemotherap
y, some 
(42%) 
platinum-
based 
Hb ≤11 g/dL  10.18 (SD 
0.90) 
10.21 (SD 
0.89) 
> 12 
 
13 
63.2 (SD 
12.4) 
63.7 (SD 
11.6) 
adults 
Schwartzbe
rg 2004, a-c 
318 a: breast 
cancer, 
b: lung 
cancer 
(stage 
IIIb, IV), 
c: 
gynecolo
gical 
cancers 
solid chemotherap
y, some 
platinum-
based (41%) 
Hb ≤ 11 g/dL  10.4 (SD 0.8) 10.4 (SD 
0.8) 
> 12 
 
13 
58.7 (SD 
11.5) 
61.7 (SD 
12.1) 
adults 
Waltzman 
2005 
358 lung, 
breast 
solid chemotherap
y, some 
platinum-
based 
(40.5%) 
Hb ≤ 11 g/dL  10.07 (SD 
0.79) 
10.16 (SD 
0.75) 
> 12 
 
13 
63.4 (SD 
11.8) 
62.1 (SD 
11.8) 
adults 
Kotsori 
2006 
110 Non 
hematolo
gical 
tumors 
solid unclear Hb ≤ 11 g/dL 10.26 (SD 
0.81) 
10.11(SD 
0.94) 
NR NR NR NR 
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Appendix Table C4.  KQ1: Epoetin versus control, study quality  
 
Study author Random 
publication 
Random 
MDQ 
Random 
IPD 
Allocation 
publication 
Allocation 
MDQ 
Allocation 
IPD 
Blinding Placebo ITT or 
10% 
Similar High or 
low 
quality 
Publication 
Aapro 2008 
 
unclear NA unclear adequate NA adequate no no 
placebo 
yes, 
unclear 
for QoL 
yes low full text, IPD 
Antonadou 2001 
 
unclear NA NA unclear NA NA no no 
placebo 
unclear yes low abstract, poster 
Bamias 2003 
 
unclear NA NA unclear NA NA no no 
placebo 
yes, 
exception 
QoL 
Ctl group had statistically 
significant lower EPO 
levels at baseline (EPO: 
24.8 (16.6-37), control: 
12.5 (8.7-18), mU/ml, 
geometric mean, 
p=0.012) 
low full text publication 
Blohmer 2011 
 
Unclear yes yes NA unclear adequate  NA no no 
placebo 
Yes for 
efficacy; ? 
for safety, 
except 
RBCT, 
OS,; 
unclear 
for TVE 
Yes low abstract, slides, 
ODAC, MDQ full 
text publication 
Boogaerts 2003, 
Coiffier 2001 
 
unclear yes unclear unclear adequate adequate no no 
placebo 
yes, 
except 
QoL 
more patients in control 
(80%) had CT before 
study compared to EPO 
(68%), p=0.025 
low full text 
publication, 
abstract 
publication, ODAC 
documents, MDQ, 
IPD 
Case 1993 
 
yes yes yes unclear adequate unclear double placebo yes yes, no details for cancer 
stage available 
high full text 
publication,  
ODAC 
documents, MDQ, 
IPD 
Chang 2005 
 
unclear NA unclear unclear NA adequate no no 
placebo 
yes patients with metastatic 
disease appear to have 
lower baseline and 
significantly higher level 
of serum ferritin, more 
cycles of chemotherapy 
were given in the epo 
arm (mean 5.0 vs 4.6, 
p=0.058) 
low full text 
publication, IPD 
 
NA: not available, MDQ: missing data questionnaire for Cochrane Review 2004, IPD: individual patient data analysis from Bohlius et al 2009, ITT: intention to treat; 
ODAC: Oncologic Drug Advisory Committee
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Appendix Table C4.  KQ1: Epoetin versus Control, Study Quality, (continued) 
 
Study author Random 
publication 
Random 
MDQ 
Random 
IPD 
Allocation 
publication 
Allocation 
MDQ 
Allocation 
IPD 
Blinding Placebo ITT or 10% Similar High or 
low 
quality 
Publication 
Christodoulou 
2009, Janinis 
2003 
yes NA NA adequate NA NA no no 
placebo 
more than 
10% 
excluded 
yes low full text, abstract 
Dammacco 
2001 
 
unclear yes unclear unclear unclear unclear double placebo yes, 
exception: 
Hb 
response 
yes high, low 
for Hb 
response 
full text 
publication,  
ODAC 
documents, MDQ, 
IPD 
Debus 2006; 
EPO-GER-22 
 
unclear NA unclear unclear NA unclear no no 
placebo 
yes, except  
QoL;unclear 
for TVE 
unclear low abstract, IPD 
Engert 2009 
 
unclear NA NA unclear NA NA double placebo yes, except 
QoL 
unclear high, low 
for QoL 
abstract, slides, 
ODAC documents 
EPO-INT-1 
 
unclear NA unclear unclear NA unclear double placebo yes unclear high ODAC 
documents, IPD 
EPO-INT-3  unclear NA unclear unclear NA adequate double placebo yes unclear high ODAC 
documents, IPD, 
online publication 
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Appendix Table C4.  KQ1: Epoetin versus Control, Study Quality, (continued)  
Study author Random 
publication 
Random 
MDQ 
Random 
IPD 
Allocation 
publication 
Allocation 
MDQ 
Allocation 
IPD 
Blinding Placebo ITT or 10% Similar High or 
low 
quality 
Publication 
Fujisaka 2011 yes   yes   double placebo yes, unclear 
for QoL 
yes  full text 
publication 
Goss 2005, 
EPO-CAN-15 
unclear NA yes unclear NA adequate double Placebo yes unclear high abstract, 
ODAC 
documents, 
IPD 
Grote 2005 
 
unclear NA yes unclear NA unclear double placebo yes slightly higher proportion 
of patients in the EPO 
arm had extensive SCLC 
than in the placebo arm 
(66% vs 59%) 
high full text 
publication, 
ODAC 
documents, 
IPD 
Gupta 2009 
 
unclear NA NA Unclear 
(“drawing 
sealed 
envelopes”) 
NA NA no no placebo yes yes low full text 
Henke 2003 
 
unclear NA unclear unclear NA adequate double Placebo yes more smokers (66% vs 
53%) in the EPO group; 
more stage IV patients in 
the EPO hypopharynx 
subgroup (85% vs 70%) 
high full text 
publication, 
ODAC 
documents, 
IPD 
Henry 1995 
 
yes yes yes unclear adequate unclear double Placebo yes yes, no details for cancer 
stage available 
high full text 
publication, 
MDQ, ODAC 
documents, 
IPD 
Hoskin 2009, 
EPO-GBR-7 
 
unclear NA unclear unclear NA unclear no no placebo yes, not 
TVE, 
unclear for 
QoL 
Well balanced, more 
subjects in the EPO arm 
had tumor stage IV (39% 
vs 36%) 
low full text,  
ODAC 
documents, 
IPD 
Iconomou 2003 
 
unclear NA NA yes (was 
performed by a 
telephone call 
to the registry 
of the 
department of 
medicine) 
NA NA no no placebo yes, unclear 
for QoL 
yes (“Univariate analyses 
revealed no 26significant 
differences at baseline 
between groups for any 
of the demographic and 
clinical characteristics 
[…].”) 
low full text 
publication 
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Appendix Table C4.  KQ1: Epoetin versus Control Study Quality (continued) 
Study author Random 
publication 
Random 
MDQ 
Random 
IPD 
Allocation 
publication 
Allocation 
MDQ 
Allocation 
IPD 
Blinding Placebo ITT or 10% Similar High or low 
quality 
Publication 
Leyland-Jones 2005 
 
unclear NA adequate unclear NA adequate double placebo yes, unclear 
for QoL 
EPO patients 
were more likely 
to have adverse 
factors such as 
advanced age, 
lower 
performance 
status, greater 
extent of 
disease at 
baseline, and 
more risk factors 
for TVEs (based 
on retrospective 
chart review) 
high, 
unclear for 
QoL 
full text 
publication, 
ODAC 
documents, 
IPD 
Littlewood 2001 
 
unclear yes yes unclear unclear adequate double placebo yes, except 
for QoL 
Fewer 
previously 
transfused 
patients at 
baseline in the 
ESA arm 
compared to 
controls (28% vs 
36%) 
high, except 
for QoL 
full text 
publication, 
MDQ, ODAC 
documents, 
IPD 
Machtay 2007, Machtay 
2004 
 
unclear NA unclear adequate NA adequate no no 
placebo 
yes More current 
smoker in ESA 
arm (57% vs 
48%), more 
Zubrod 
performance 
score 0 in ESA 
arm (51.5% vs 
46.5%) 
low abstract, 
ODAC 
documents, full 
text, IPD 
Milroy 2011 
 
unclear NA unclear Adequate 
unclear 
NA adequate no no 
placebo 
yes, unclear 
for QoL 
more stage IV 
metastatic 
disease (61.9% 
vs 53.4%) and 
PS of 2 (20.1% 
vs 15.7%) in 
ESA arm 
low full text 
publication 
abstracts, 
ODAC 
documents, 
IPD 
ML17620 
 
unclear NA unclear unclear NA unclear no no 
placebo 
OS and Hb 
unclear 
unclear low online 
document 
Moebus 2007 
 
unclear NA yes unclear NA adequate no no 
placebo 
yes, not for 
TVE 
unclear low abstracts, 
ODAC 
documents, 
IPD 
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Appendix Table C4.  KQ1: Epoetin versus Control Study Quality (continued) 
Study author Random 
publication 
Random 
MDQ 
Random 
IPD 
Allocation 
publication 
Allocation 
MDQ 
Allocation 
IPD 
Blinding Placebo ITT or 10% Similar High or low 
quality 
Publication 
Oberhoff 1998 
 
unclear yes unclear unclear adequate adequate no no 
placebo 
yes yes low full text 
publication, 
MDQ, ODAC 
documents, 
IPD 
Osterborg 2002, 
Osterborg 2005 
 
unclear yes unclear unclear adequate adequate double placebo yes, except 
for QoL 
yes high, low for 
QoL 
full text 
publication,  
MDQ, ODAC 
documents, 
IPD 
Porter 1996 
 
yes NA NA unclear NA NA double placebo no, more 
than 10% 
excluded 
yes low full text 
Pronzato 2010 
 
unclear  NA unclear unclear NA adequate No no 
placebo 
yes , except 
for QoL 
yes low abstract, IPD, 
full text 
publication 
Ray-Coquard 2009 
 
unclear NA yes adequate NA adequate No no 
placebo 
yes, except 
for QoL 
unclear low full text, IPD 
Razzouk 2006, 
Razzouk 2004 
 
unclear NA yes unclear NA adequate double placebo yes unclear high full text, IPD 
Rose 1994 
 
yes yes yes unclear unclear unclear double placebo yes yes high abstract, MDQ, 
ODAC 
documents, 
IPD 
Savonije 2005 
 
yes NA unclear adequate NA adequate no no 
placebo 
yes, except 
for QoL 
significantly 
more patients 
with metastatic 
disease and 
higher ECOG 
score in EPO 
group 
low abstract, full 
text, IPD 
Thomas 2002 
 
unclear NA unclear unclear NA adequate no no 
placebo 
yes yes (“At 
baseline, groups 
balanced for Hb, 
demographics, 
CT and disease 
related 
variables.”) 
low abstract, IPD 
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Appendix Table C4.  KQ1: Epoetin versus Control Study Quality (continued) 
 
Study author Random 
publication 
Random 
MDQ 
Random 
IPD 
Allocation 
publication 
Allocation 
MDQ 
Allocation 
IPD 
Blinding Placebo ITT or 10% Similar High 
or low 
quality 
Publication 
Thomas 2008, GOG-
0191 
yes NA unclear adequate NA adequate no no 
placebo 
yes in ESA arm 
more patients 
aged < 45 
(ESA 49% vs 
control 27%), 
in control more 
patients with 
PS 0 (ESA 
65% vs control 
77%), more 
control 
patients have 
FIGO IIB (ESA 
65% vs control 
75%) 
Low ODAC 
documents, 
full text, 
abstract,  
IPD 
Tsuboi 2009 
 
unclear NA NA adequate NA NA double placebo yes yes high full text 
Wagner 2004 unclear NA NA unclear NA NA no no yes unclear low full text 
Wilkinson 2006 
 
unclear NA unclear unclear NA unclear no no 
placebo 
yes, 
unclear for 
QoL 
yes low full text, 
ODAC 
documents, 
IPD 
Witzig 2005 
 
unclear NA adequate unclear NA adequate double placebo yes, except 
for QoL 
yes high, 
low for 
QoL 
full text 
publication, 
ODAC 
documents, 
IPD 
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Appendix Table C5.  KQ1: Darbepoetin versus control, study quality  
Study author Random 
publication 
Random 
MDQ 
Random 
IPD 
Allocation 
publication 
Allocation 
MDQ 
Allocation 
IPD 
Blinding Placebo ITT or 10% Similar High or low 
quality 
Publication 
Hedenus 2003 
 
unclear NA unclear yes (central 
randomization 
service) 
NA adequate double placebo yes, except 
for QoL,  
unclear for 
TVE 
more patients with 
indolent lymphoma were 
randomized to placebo 
and more patients with 
higher stage of disease 
were randomized to 
Aranesp 
high, low for 
QoL, 
unclear for 
TVE 
full text 
publication, 
ODAC 
documents, 
IPD 
Hernandez 
2009 
 
unclear NA unclear unclear NA adequate double placebo yes, except 
for QoL 
Epo baseline levels 
were higher in placebo 
group, disease stage 
more advanced in 
placebo group (stage IV 
ESA 30%, placebo 
43%) 
high, low for 
QoL 
full text, 
ODAC 
documents, 
IPD 
Kotasek 2003 
a,b,c,d,e,f 
 
unclear NA unclear unclear NA adequate double placebo yes, not  for 
transfusion 
slightly higher proportion 
of patients in the 12 µg 
group had breast cancer 
(61%) compared with 
the other groups, which 
ranged from 15 to 38%. 
The 12 µg group had 
also a slightly higher 
mean Hb at baseline 
(10.4 g/d, compared 
with the other groups 
(9.7 to 10.2). 
high, low for 
transfusion 
full text 
publication, 
IPD, ODAC 
documents 
Overgaard 
2009  
yes Na NA unclear NA NA No no 
placebo 
yes yes low abstract, 
ODAC 
documents, 
protocol 
Pirker 2008 
 
unclear NA unclear adequate NA adequate double placebo yes, except 
for QoL 
yes high, low for 
QoL 
full text 
publication, 
ODAC 
documents, 
IPD 
Untch 2011 
 
unclear NA unclear unclear NA unclear no no 
placebo 
yes yes low abstract, 
ODAC 
documents, 
IPD,full text 
publications 
Vansteenkiste 
2002 
 
unclear NA unclear adequate NA adequate double placebo yes, except 
for QoL 
yes high, low for 
QoL 
full text 
publication, 
ODAC docs, 
IPD 
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Appendix Table C6. KQ1: Darbepoetin versus epoetin, study quality 
 
 
 
study author random allocation blinding placebo ITT or 10% similar 
baseline 
characteristics 
high or low 
quality 
publication 
Glaspy 2002, Part A unclear unclear no no placebo ITT or 10% yes low full text 
Glaspy 2006  unclear yes no no placebo ITT or 10%, not for QoL yes low full text 
Schwartzberg 2004 unclear unclear no no placebo ITT or 10% yes low full text 
Waltzman 2005 unclear unclear no no placebo ITT or 10%, more pts 
excluded for QoL 
yes low full text 
Kotsori 2006 unclear NR NR no placebo NR NR low abstract 
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Appendix Table C7.  KQ1 Outcome I.  Hematologic response:  Epoetin versus control  
 
Study author Hb response definition Epo n Epo N Proportion 
(%) 
Control 
n 
Control 
N 
Proportion 
(%) 
Comments 
Hb at baseline < 10 g/dL         
Boogaerts 2003 Hb increase of 2 g/dL during the 
treatment phase without transfusion 
requirements after the initial 4 
treatment wks 
63 133 47.37% 17 129 13.18% data were included 
in Cochrane Review 
2004 as Coiffier 
2001 
Case 1993 Hct increase of 6% from baseline  
independent of transfusion 
46 79 58.23% 10 74 13.51% Hct definition 
Dammacco 2001 Hb increase of  2 g/dL independent 
of transfusion 
38 66 57.58% 6 66 9.09%  
Henry 1995 Hct increase of 6% from baseline 
independent of transfusion 
31 64 48.44% 4 61 6.56% Hct definition 
Littlewood 2001 Hb increase of 2 g/dL independent of 
transfusion in the previous 28 days 
172 244 70.49% 22 115 19.13% efficacy population: 
patients on study at 
least 28 days 
Oberhoff 1998 Hb increase of 2 g/dL independent of 
transfusion 
38 114 33.33% 7 104 6.73% at week 12, data 
submitted for 
Cochrane Review 
Osterborg 2002 Hb increase of 2 g/dL independent of 
transfusion within 6 wks 
114 170 67.06% 46 173 26.59% at end of week 16 
Razzouk 2006 Hb increase at any time after 4 wks 
independent of red blood cell 
transfusions 
63 111 56.76% 39 111 35.14%  
Rose 1994 Hb Hct increase of > 6% of Hct 
unrelated to transfusion 
67 142 47.18% 13 79 16.46% Hct definitions, data 
submitted for 
Cochrane Review 
Witzig 2004 Hb increase of 2 g/dL from baseline 120 165 72.73% 52 164 31.71% unclear if 
independent of 
transfusion 
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Appendix Table C7.  KQ1 Outcome I. Hematologic response:  Evidence table Epoetin versus Control (continued) 
 
Study author Hb response definition Epo n Epo N Proportion 
(%) 
Control 
n 
Control 
N 
Proportion 
(%) 
Comments 
Hb at baseline 10 to 12 g/dL         
Aapro 2008 Hb increase of 2 g/dL from baseline 
without transfusions in the previous 6 
wks 
157 231 67.97% 32 232 13.79%  
Bamias 2003 Hb increase of 2 g/dl 15 72 20.83% 2 72 2.78% unclear if 
independent of 
transfusion 
Chang 2005 Hb increase of 2 g/dl independent of 
transfusion in the previous 28 days 
115 175 65.71% 11 175 6.29% Hb response was 
evaluated 
retrospectively 
Iconomou 2003 Hb increase of 2 g/dl 25 57 43.86% 7 55 12.73% after 12 wks of 
treatment, unclear if 
independent of 
transfusion 
Milroy 2011 Hb increase of ≥ 2/dL from baseline 
or partial response with inc of 1-1.99 
g/dL 
71 189 37.6% 17 191 8.9%  
Savonije 2005 Hb increase of 2 g/dl independent of 
transfusion in the previous 28 days 
143 208 68.75% 31 100 31.00%  
Hb at baseline not reported 
ML17620 Hb increase of 2 g/dL without 
transfusions in the previous 6 wks 
29 61 47.54% 14 60 23.33%  
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Appendix Table C8.  KQ1 Outcome I. Hematologic response:  Darbepoetin versus control 
Study Author Darbepo n Darbepo N Proportion 
(%) 
Control n Control N Proportion 
(%) 
Hb definition Comment 
Hedenus 2003 104 174 59.77% 31 170 18.24% Hb increase of 2 
g/dL independent 
of transfusion in 
the previous 28 
days 
Derived using Kaplan-
Meier method (darb arm 
response 60%, N=174, 
control response 18%. 
N=170) 
Kotasek 2003a 8 32 25.00% 7 51 13.73%  Derived using Kaplan-
Meier method; arm a: 
24%, N=32, control 14%, 
N=51 
Kotasek 2003b 8 17 47.06%    increase Hb 2 
g/dL from baseline 
during 12 week 
study in the 
absence of RBCT 
in the previous 28 
days  
c: 50%, N=17 
Kotasek 2003c 23 46 50.00%     b: 48%, N=46 
Kotasek 2003d 17 28 60.71%     d: 62%, N=28 
Kotasek 2003e 20 35 57.14%     e: 58%, N=35 
Kotasek 2003f 20 40 50.00%     f: 50%, N=40 
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Appendix Table C9.  KQ1d Outcome I.  Hematologic response:  Darbepoetin versus epoetin 
 
study author Hb response 
definition 
Hb response 
assessed at 
week 
Darb 
(n) 
Darb 
(N) 
Percentage 
(%) 
EPO (n) EPO 
(N) 
Percentage 
(%) 
Comments 
Hb at baseline 10-
12 g/dL 
         
Waltzman 2005 Hb increase of > 2 g/dL 
at week 17 
17 74 177 41.81% 101 175 57.71% based on patients who 
received at least 1 dose 
of study drug and had 
at least 1 postbaseline 
hb or transfusion, 
p=0.004 (logistic 
regression model 
adjusted for CT) 
Hb at baseline 
<10 g/dL 
         
Glaspy 2002 Part A Hb increase of 2 g/dL 
independent of 
transfusion in the 
previous 28 days 
12 31 59 52.5% 38 53 71.7% dosage: 2.25 µg/kg  
arm d 
 
 C-36 
Appendix Table C10.  KQ1 Outcome I.  Hematologic response studies omitted from meta-analysis:  Epoetin versus control  
 
Study author Hb response definition Hb response, 
comments 
Hb response n EPO Hb response n control 
Henke 2003 Hb target level reached 
(women: Hb ≥14 g/dL, men 
Hb ≥15 g/dL) 
 148/180 (82%) 26/171 (15%) 
Thomas 2002 Hb increase 2 g/dL or 
reaching Hb > 14 g/dL 
 42/62 (67%) 17/65 (26%) 
Thomas 2008 Hb ≥ 12g/dL  41/57 (71.9%) 6/52 (11.5%) 
Tsuboi 2009 Hb ≥ 12g/dL and Hb < 12 
g/dL at baseline 
 29/59 (9.649.2%) 5/52 (9.6%) 
Wilkinson 2006 Hb increase ≥ 1 g/dL 
independent of transfusion 
within the preceeding 4 wks 
 87/112 (77.7%) 19/59 (32.32%) 
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Appendix Table C11.  KQ1 Outcome I.  Hematologic response study omitted from meta-analysis:  Darbepoetin versus control  
Study author Hb response definition Hb response, 
comments 
Hb response n EPO Hb response n control 
Hernandez 2009 Hb  ≥ 11 g/dL not in MA, absolute 
numbers were derived 
using Kaplan-Meier 
method, darb 88%, 
N=193, control 49%, 
N=193 
170/193 (88%) 95/193 (49%) 
Vansteenkiste 
2002 
Hematological response as 
defined by Hb increase 2 
g/dL OR target Hb 12g/dL 
not in MA, absolute 
numbers were derived 
using Kaplan-Meier 
method, darb 66%, 
N=156, control 24%, 
N=158 
103/156 (66.3%) 38/158 (24.05%) 
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Appendix Table C12.  KQ1 Outcome I.  Hematologic response studies omitted from meta-analysis:  Darbepoetin versus epoetin 
 
study author Hb response 
definition 
response 
assessed at 
week 
Darb (n) Darb (N) Proportion 
(%) 
EPO (n) EPO (N) Proportion 
(%) 
Comments 
Schwartzberg 2004 Hb increase of > 2 g/dL 
OR Hb level >12 g/dL 
 108 157 68.79% 112 155 72.26% definition did not 
meet our criteria, 
percentages 
reported 
Glaspy 2006  achieving Hb target > 
11 g/dL 
 463 606 80% 487 603 86%  
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Appendix Table C13.  KQ1 Outcome I.  Hematologic response subgroup analysis:  Epoetin versus control; no additional information  
 
Study Subgroups 
prospectively  
Epo n/N (%) Control n/N (%) p-value 
 
stratified for  
Littlewood 2001 
  
  
  
  
Overall efficacy 
population  
172/244 (70.5%) 22/115 (19.1%) <0.001 
solid tumors 87/131 (66.4%) 13/61 (21%) NR 
hematological tumors 85/113 (75.22%) 9/543 (16.6%) NR 
Hb < 10.5 139/293 (47.4%) 22/100 (22%) NR 
Hb > 10.5 33/41 (80.5%) 0/15 (0%) NR 
      
Osterborg 2002 
  
  
All 114/170 (67%) 46/173 (27%) <0.001 
MM 44/58 (76%) 17/58 (29%) <0.001 
NHL 33/53 (62%) 12/49 (24%) <0.001 
 
 
Appendix Table C14.  KQ1 Outcome I.  Hematologic response subgroup analysis:  Darbepoetin versus control; no additional information 
 
 
Study Subgroups 
prospectively  
Darbepo n/N (%) Control n/N (%) p-value 
Hedenus 2003 stratified for     
lymphoma 64% (55/86) 13% (11/84) <0.001 
myeloma 56% (49/88) 22% (20/86) <0.001 
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Appendix Table C15.  KQ1 Outcome I.  Hematologic response subgroup analysis:  Darbepoetin versus epoetin 
 
Study Subgroups prospectively  
stratified for  
Darb n/N (%) Epo n/N (%) p-value 
Schwartzberg 2004 
  
  
  
  
  
Overall population  108/157 (69%) 112/155 (72%) NR 
Breast cancer 63/72 (88%) 56/69 (81%) NR 
Lung cancer 25/51 (49%) 30/51 (59%) NR 
Gynecological cancers 21/34 (62%) 26/35 (74%) NR 
Hb < 10.5 21/38 (55%) 18/38 (47%) NR 
Hb > 10.5 88/119 (74%) 94/117 (80%) NR 
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Appendix Table C16.  KQ1 Outcome II.  Transfusion:  Epoetin versus control  
 
Study ID Treatment n Treatment N Proportion (%) Control n Control N Proportion (%) First 4 wks 
included in 
analysis? 
Comments 
Baseline Hb below < 10g/dL        
Boogaerts 2003 43 133 32.33 67 129 51.94 included  
Case 1993 32 79 40.51 36 74 48.65 included data submitted for original 
Cochrane Review 
Dammacco 2001 19 69 27.54 36 76 47.37 excluded  
Fujisaka 2011 4 89 4.5 18 92 19.6 excluded  
Henry 1995 34 64 53.13 42 61 68.85 included  
Littlewood 2001 62 251 24.70 49 124 39.52 included  
Oberhoff 1998 32 114 28.07 44 104 42.31 included data submitted for original 
Cochrane Review 
Osterborg 2002 65 169 38.46 90 173 52.02 included data submitted for original 
Cochrane Review 
Porter 1996 9 10 90.00 10 10 100.00 unclear  
Razzouk 2006 72 111 64.86 86 111 77.48 included  
Rose 1994 
 
65 142 45.77 47 79 59.49 included data submitted for original 
Cochrane Review 
Witzig 2004 42 166 25.30 65 164 39.63 included  
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Appendix Table C16.  KQ1 Outcome II.  Transfusion:  Epoetin versus Control (continued)  
 
 
 
 
 
Study ID Treatment n Treatment N Proportion (%) Control n Control N Proportion (%) First 4 wks 
included in 
analysis? 
Comments 
Baseline Hb 10-12g/dL 
Aapro 2008 33 231 14.29 63 232 27.16 unclear  
Bamias 2003 11 72 15.28 24 72 33.33 included  
Blohmer 2011 14 127 10.7 38 129 29.6 unclear  
Chang 2005 15 175 8.57 40 175 22.86 unclear  
Christodoulou 2009 16 167 9.5758 36 170 21.18 unclear  
Gupta 2009 9 58 15.52 25 57 43.86 unclear  
Iconomou 2003 9 57 15.79 14 55 25.45 included  
Pronzato 2010 8 107 7.5 18 109 16.5 unclear  
Ray-Coquard 2009 39 108 36.11 61 105 58.10 unclear  
Savonije 2005 77 211 36.49 66 102 64.71 included  
Thomas 2002 7 62 11.29 31 65 47.69 unclear  
Tsuboi 2009 7 61 11.48 7 56 12.50 included  
Wilkinson 2006 9 114 7.89 18 59 30.51 excluded  
         
Baseline Hb 12g/dL 
Goss 2005 8 52 15.38 27 52 51.92 unclear  
Grote 2005 26 109 23.85 42 115 36.52 included  
Leyland-Jones 2005 47 469 10.02 66 470 14.04 unclear  
Milroy 2011 9 189 5 35 191 18 excluded  
Moebus 2007 41 320 12.81 86 305 28.20 unclear  
         
Baseline not reported 
EPO-INT-3 J%&J 2004 21 136 15.44 23 65 35.38 excluded  
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Appendix Table C17.  KQ1 Outcome II.  Transfusion:  Darbepoetin versus control  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study ID Dosage Treatment 
n 
Treatment 
N 
Proportion 
(%) 
Control 
n 
Control 
N 
Proportion 
(%) 
First 4 wks 
included in 
analysis? 
Comments 
Baseline Hb below < 10g/dL 
Hedenus 2003  2.25 
µg/kg/qw 
52 167 31.14% 79 165 47.88% excluded derived from K-M 
estimates, arm a: 
31%( 95% CI 24-38), 
N=167; 48% (95% CI 
41%-56%), N=165  
Kotasek 2003a 4.5 μg/kg 
Q3W  
8 30 26.67% 23 50 46% excluded arm a: 25% (9%-
41%), N=30; control 
46% (32%-61%), 
N=50 
Kotasek 2003b 6.75 μg/kg 
Q3W 
5 17 29.41%     arm b: 28% (7%-
51%), N=17 
Kotasek 2003c 9.0 μg/kg 
Q3W 
12 41 29.27%     arm c: 30% (16%-
44%), N=41 
Kotasek 2003d 12.0 μg/kg 
Q3W 
7 27 25.93%     arm d: 26% (7.5%-
41%), N=27 
Kotasek 2003e 13.5 μg/kg 
Q3W 
9 35 25.71%     arm e: 27% (11%-
40%), N=35 
Kotasek 2003f 15 μg/kg 
Q3W 
7 38 18.42%     arm f: 19% (6%-32%), 
N=38 
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Appendix Table C17.  KQ1 Outcome II.  Transfusion:  Darbepoetin versus Control, (continued) 
 
 
 
 
 
 
 
Study ID Dosage Treatment 
n 
Treatment 
N 
Proportion 
(%) 
Control 
n 
Control 
N 
Proportion 
(%) 
First 4 wks 
included in 
analysis? 
Comments 
Baseline Hb 10-12g/dL 
Hernandez 
2009 
300 µg 
Q3W 
58 193 30.05% 91 193 47.15% included  
Pirker 2008 300 µg 
Q4W, after 
4 wks 
changed to 
Q3W sc 
52 298 17.45% 116 298 38.93% unclear  
Untch 2011 NR 1 356 <1% 0 377 0.00% unclear  
Vansteen._FDA 
report 
2.25 µg/kg 
qw 
53 156 33.97% 89 158 56.33% included  
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Appendix Table C18.  KQ1 Outcome II.  Transfusion:  Darbepoetin versus epoetin  
 
Study ID Darbepoetin 
(n) 
Darbepoetin 
(N) 
Percentage 
(%) 
Epoetin 
(n) 
Epoetin 
(N) 
Percentage 
(%) 
Wks included Comments 
Baseline Hb below < 
10g/dL 
        
Glaspy 2002 Part A, c (1.5 
µg/kg/qw) 
9 35 25.71% 12 53 22.64% 5-13 K-M percentages 
reported, c: 26% 95% 
CI (9; 43), EPO 23% 
95% CI (10; 36) 
Glaspy 2002 Part A, d* 
(2.25 µg/kg/qw) 
8 59 13.56% see 
above 
see 
above 
see above see above d: 13% 95% CI (4; 23) 
Glaspy 2002 Part A, e (4.5 
µg/kg/qw) 
2 29 6.90% see above see above see above see above e: 6% 95% CI (2; 30) 
         
Baseline Hb below 10-12 
g/dL 
        
Schwartzberg 2004 a 
(breast cancer) 
4 72 5.56% 11 69 15.94% 1-16 percentages reported 
(a: 6% vs 16%, b: 27% 
vs 18%, c: 21% vs 17%) 
Schwartzberg 2004 b 
(lung cancer) 
14 51 27.45% 9 51 17.65%   
Schwartzberg 2004 c 
(gynecological) 
7 34 20.59% 6 35 17.14%   
Glaspy 2006  157 582 26.98% 126 571 22.07% 1- 17 K-M percentages 
reported, darb: 27%, 
EPO 22% 
Waltzman 2005 29 163 17.79% 20 155 12.90% 5 to end of 
treatment 
period (wk 17)  
p=0.2936 logistic 
regression, adjusted for 
CT 
Kotsori 2006 9 55 16.4% 3 55 5.5% NR assumed 1:1 
randomization 
*Glaspy 2002 A d is the arm used as main results for the meta-analysis. The arms c and e were applied for sensitivity analysis. 
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Appendix Table C19.  KQ1 Outcome II.  Transfusion studies omitted from meta-analysis:  Epoetin versus control  
Study ID Treatment 
n 
Treatment 
N 
Treatment 
Percentage 
Control 
n 
Control 
N 
Control 
Percentage 
First 4 wks 
included in 
analysis? 
Comment 
Thomas 2008 34 57 59.65% 29 52 55.77% unclear  
 
 
Appendix Table C20.  KQ1 Outcome II.  Transfusion studies omitted from meta-analysis:  Darbepoetin versus control  
 
Study ID Treatment 
n 
Treatment 
N 
Treatment 
Percentage 
Control 
n 
Control 
N 
Control 
Percentage 
First 4 wks 
included in 
analysis? 
Comment 
Vansteenkiste 
2002 
40 148 27.03% 77 149 51.68% excluding first 
4 wks, 
counting week 
5 to end of 
treatment 
Based on K-M 
estimates. Darb: 27% 
(20% to 35%), N=148, 
control: 52% (44% to 
66%), N=149, 
Difference of 25% 
(95% CI 14% to 36%) 
was statistically 
significant, p<0.001. 
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Appendix Table C21.  KQ1 Outcome II.  Transfusion subgroup analysis:  Epoetin versus control  
 
Study Subgroups prospectively  
stratified for  
Epo n/N (%) Control n/N (%) p-value Comments 
Razzouk 
2004 
All patients 72/111 (35%) 85/111 (23%) p=0.0536 p value refers to proportion NOT transfused 
ALL (n=75) 26/40 (65.0%) 22/35 (62.9%)   
Witzig 
2004Aapro 
2008 
All patients 42/166 
(25.3%)63/232 
(27.0%) 
65/164 
(39.6%)33/231 
(14.0%) 
p=0.005 
 
mild anemia (Baseline Hb 
> 9<11 g/dL)  
19%20/ 232 
(8.6%) 
29%39/231  
(16.9%) 
 
 
severe anemia (Basline Hb 
< 9>11 g/dL)  
40% 62%   
 
Chang 2005 All patients 15/175 (8.6%) 40/175 (22.9%) p<0.0001  
Adjuvant 10/175 (7.2%) 30/175 (22.1%) NR  
Metastatic 5/175 (14.7%) 10/175 (26.3%) NR  
Baseline Hb <11 g/dL 11/175 (20.4%) 20/175 (38.5%) NR  
Baseline HB≥11 g/dL 4/175 (3.4%) 20/175 (16.4%) NR  
Hernandez 
2009 
Study period 22/99 (22.2%) 48/116 (41.4%) p=0.008  
First 4 wks excluded 58/193 (30.1%) 91/193 (47.2%) p=0.003  
Per protocol analysis set, 
first 4 wks excluded 
44/181 (24.3%) 76/185 (41.1%) p<0.001 To account for protocol deviations, the primary 
endpoint was also examined using an alternate 
analysis set (per-protocol analysis set) 
Savonije 
2005 
Study period 77/211 (36%) 66 /102 (65%) p<0.001  
First 4 wks excluded 49/211 (23%) 53/102 (52%) p<0.001  
Tsuboi 2009 Study period 7/61 (11.5%) 7/56 (12.5%) p=0.856  
First 4 wks excluded 5/61 (8.2%) 7/56 (12.5%) p=0.443  
Witzig 2005 All patients 42/166 (25.3%) 65/164 (39.6%) p=0.005  
mild anemia (Hb > 9 g/dL)  32/166 (19.2%) 48/164 (29.3%) NR Numbers derived from percentages 19% and 
29% respectively 
severe anemia (Hb < 9 
g/dL)  
66/166 (39.8%) 102/164 (62.2%)  NR Numbers derived from percentages 40% and 
62% respectively 
Witzig 2005 All patients 39/154 (25.3%) 60/151 (39.7%) NR  
Baseline serum Epo level 
low (<44 U/ml) 
8/44 (18.2%) 18/57 (31.6%) NR 
 
Baseline serum Epo level 
mid (44-86 U/ml) 
14/56 (25.0%) 19/47 (40.4%) NR 
 
Baseline serum Epo level 
high (>86 U/ml) 
17/54 (31.5%`) 23/47 (48.9%) NR 
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Appendix Table C22.  KQ1 Outcome II.  Transfusion subgroup analysis:  Darbepoetin versus control  
 
 
Study Subgroups 
prospectively stratified 
for   
Epo % (n/N)  Control % 
(n/N) 
p-
value 
Comments 
Hedenus 2003      
excluding first 4 wks lymphoma 27% 49% 0.002  
 myeloma 35% 48% 0.042  
including first 4 wks lymphoma NR NR 0.011  
 myeloma NR NR 0.018  
Hernandez 2009 Study period 22/99 (22.2%) 48/116 (41.4%) p=0.008 Numbers were calculated using 
percentages given in a figure 
First 4 wks excluded 58/193 (30.1%) 91/193 (47.2%) p=0.003 Numbers were calculated using 
percentages given in a figure 
Per protocol analysis set, 
first 4 wks excluded  (To 
account for protocol 
deviations, the primary 
endpoint was also examined 
using an alternate analysis 
set) 
44/181 (24.3%) 76/185 (41.1%) p<0.001 Numbers were calculated using 
percentages given in a figure 
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Appendix Table C23.  KQ1 Outcome II.  Transfusion subgroup analysis:  Darbepoetin versus epoetin 
 
Study Subgroups 
prospectively 
Darbepoetin (n) Darbepoetin (N) Proportion 
(%) 
Epoetin (n) Epoetin 
(N) 
Proportion 
(%) 
Comments 
 stratified for         
Schwartzberg 
2004 
Overall 25 157 15.92% 26 155 16.77% wks 1 to 16, 
percentages 
reported 
Hb < 10 g/dL 8 38 21.05% 16 38 42.11%  
Hb > 10 g/dL 17 119 14.29% 10 117 8.54%  
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Appendix Table C24.  KQ1 Outcome VI.  Thromboembolic complications:  Epoetin versus control; definition for thromboembolic events as 
defined in journal publications 
Study Predefined definition TE recorded Other information reported 
Aapro 2008 No Yes Serious TE versus non serious 
Bamias 2003 Yes for all adverse events: “Death or any event requiring specific treatment, admission to hospital or a life-threatening event was reported as serious adverse event”.  Yes  
Blohmer 2011 No, but TEE included deep vein thrombois and pulmonary embolism in results Yes  
Case 1993 No Yes  
Chang 2005 No Yes TE attribution to epoetin  reported 
Engert 2009 No Yes  
Fujisaka 2011 No Yes  
Henke 2003 Vascular disorders were hypertension, hemorrhage, venous thrombosis and pulmonary embolism, and cerebrovascular disorders 
Yes, including 
hypertension Relation to study drug reported 
Henry 1995 No Yes  
Hoskin 2009 No Yes Clinically relevant TE reported 
Leyland-Jones 
2005 
TVEs were compiled by medical monitors at Johnson & Johnson Pharmaceutical 
Research Division, based on WHO Adverse Reaction Terms 97 Q4. Yes 
Fatal TE reported. Relation to study 
drug reported.  
Littlewood 2001 Thrombotic or possible thrombotic event Yes  
Machtay 2007 No Yes Relation to study drug reported 
Milroy 2011 No Yes  
Osterborg 2002 No Yes  
Pronzato 2010 Adverse events recorded regardless of their relationship to the drug and rated as mild, moderate or severe yes  
Ray-Coquard 
2009 
Thrombovascular events were compiled by medical monitor, on the basis of WHO 
Adverse Reaction Terms 97 Q4. No systematic specific exam was carried out to 
evaluate the risk; only reported events and/ or abnormal results of tests ordered by 
investigators were taken into account.  
Yes  
Razzouk 2006 
Thrombotic vascular events (intravenous thrombus, chest pain, edema, thrombosis, 
disseminated intravascular coagulation, cerebral infarction and pulmonary thrombosis) 
were summarized by seriousness and clinical relevance.  
Yes Seriousness, resolution and relation to study drug reported 
Savonije 2005 Adverse events recorded regardless of their relationship to the drug and rated as mild, moderate or severe Yes Relation of TE to study drug reported 
Thomas 2008 No Yes 
Associated grade, time of incidence, 
treatment attribution, patient’s baseline 
traits and hemoglobin levels at time of 
TE incident reported.  
TE: thromboembolic events, TVE: thrombovascular events 
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Appendix Table C24.  KQ1 Outcome VI.  Thromboembolic complications:  Epoetin versus Control, Definition for thromboembolic events as 
defined in journal publications (continued)  
Study Predefined definition TE recorded Other information reported 
Tsuboi 2009 Safety was assessed by National Cancer Institute- Common Toxicity Criteria, vers. 2 Yes Relation to treatment reported 
Wilkinson 2006 No Yes 
Information about whether TE led to 
death and whether patients recovered 
from TE 
Witzig 2005 No Yes 
Grade of TE and relation to drug 
reported. Relation to Hb change 
recorded. 
TE: thromboembolic events, TVE: thrombovascular events 
 
 
 
Appendix Table C25.  KQ1 Outcome VI.  Thromboembolic complications:  Darbepoetin versus control; definition for thromboembolic events as 
defined in journal publications 
 
Study Predefined definition TE recorded Other information reported 
Hernandez 2009 No Yes 
Adverse events were grouped by 
primary system organ class and 
preferred term within primary system 
organ class according to the Medical 
Dictionary for Regulatory Activities 
(MedDRA) dictionary (version 9.0). 
The frequency and percentage 
distributions of adverse events to 
study drug were summarized. 
Relation to study drug reported.  
Overgaard 2009 No No In abstract only cardiovascular adverse events are reported.  
Pirker 2008 No Yes Relation to treatment reported 
Vansteenkiste 
2002 No Yes  
Untch 2011 No Yes  
TE: thromboembolic events 
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Appendix Table C26.  KQ1 Outcome VI.  Thromboembolism data sources:  Epoetin versus control, updated 2009/2010 
 
Note: J&J 2007: definition for TVEs: clinically relevant if no otherwise specified, Amgen 2008: no definition given, FDA reports: no consistent definition used 
 
Study Full 
text/abstract 
 FDA report 2004 if not 
otherwise indicated 
J&J report  Other reports, 
as indicated 
 Investigator 
meta-analysis 
 
 EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
 
Aapro 2008 
BRAVE 
29/231 (13%) 13/231 (6%) 13% FDA 
2007 
6% FDA 2007 All 13%, 
serious 4%, 
J&J 2007 
All 6%, 
serious 3%, 
J&J 2007 
- - OR 2.41 (95% CI 1.22;4.76) 
Glaspy 2010, n not reported 
Bamias 2003 0/72 1/72 - - - - - - OR 0.33 (95% CI 0.01;8.20), 
Glaspy 2010, n not reported 
Blohmer 
2004 
AGO/NOGGO 
2/127 (2%) 3/129 (2%) - - 2/119 (2%) 
J&J 2004 
3/122 (2%) 
J&J 2004 
- - OR 0.34 ( 95% CI 0.03;3.30), 
Glaspy 2010, n not reported 
2% J&J 2007 2% J&J 2007, 
n=241 
Case  
Mixed non-
cisplatin 
4/81 4/76 - - 2/81 (2%) J&J 
2004 
3/76 (4%) J&J 
2004 
4% Amgen 
2008 
4% Amgen 
2008, n=157 
OR 0.94 (95% CI 0.23;3.88), 
Glaspy 2010, n not reported 
2% J&J 2007 4% J&J 2007, 
n=157 
Chang 2005 
EPO-CAN-17 
19/176a 14/178  TVE 20.5%, 
DVT 6.3%, 
FDA 2007 
TVE 16.9%, 
DVT 0.06%, 
n=354, FDA 
2007 
11% J&J 2007 8% J&J 2007, 
n=354 
- - OR 1.27 (95% CI 0.74;2.17), 
Glaspy 2010, n not reported 
 
                                                             
a Chang 2005: for the previous AHRQ 2006 report we used the following data for ESA and control: 19/175 and 14/175. Based on the publication Chang 2005 data were corrected as outlined in the table above.  
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Appendix Table C26.  KQ1 Outcome VI.  Thromboembolism data sources:  Epoetin versus Control (continued) 
 
Study Full text/abstract FDA report 2004 if not 
otherwise indicated 
J&J report Other reports, as indicated Investigator meta-analysis 
 EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
 
Dammacco 
2001 
EPO-INT-2 
- - - - 5/69 (7%) J&J 
2004 
 
1/76 (1%) J&J 
2004 
4% Amgen 
2008 
0% Amgen 
2008, n=145 
OR 5.86 (95% CI 0.67;51.46), 
Glaspy 2010, n not reported 
7% J&J 2007 1% J&J 2007, 
n=145 
Debus 2006 
EPO-GER-22 
- - TVE 17.7% , 
total TVE 26 
(23%), FDA 
2007 
TVE 8.5% , 
total TVE 11 
(9.4%), 230 of 
389 patients 
evaluated, 
FDA 2007 
20% J&J 2007 12% J&J 
2007, n=383 
- - OR 1.44 (95% CI 0.81;2.56), 
Glaspy 2010, n not reported 
Engert 2009 45/645   44/644  NC NC NC NC NC NC OR 1.48 (95% CI 0.74;2.96), 
Glaspy 2010, n not reported 
EPO-INT-1 - - - - 3/164 (2%) 
J&J 2004 
1/80 (1%) J&J 
2004 
2% Amgen 
2008 slides 
0% Amgen 
2008 slides, 
n=246 
OR 1.47 (95% CI 0.15;14.38), 
Glaspy 2010, n not reported 
2% J&J 2007 1% J&J 2007, 
n=244 
EPO-INT-3 - - - - 8/135 (6%) 
J&J 2004 
1/65 (2%) J&J 
2004 
6% Amgen 
2008 
0% Amgen 
2008, n=201 
OR 4.03 (95% CI 0.49;32.94), 
Glaspy 2010, n not reported 
6% J&J 2007 2% J&J 2007. 
n=200 
Fujisaka 
2011 
1/89 (1%) 0/92        
Goss 2005, 
EPO-CAN-15 
- - 18/53 FDA 
2004 
3/53 FDA 
2004 
16/52 (31%) 
J&J 2004 
2/52 (4%) J&J 
2004 
- - OR 9.40 (95% CI 2.58;34.34), 
Glaspy 2010, n not reported 
OR 7.73 FDA 2007 31% J&J 2007 4% J&J 2007, 
n=104 
Grote 2005, 
N93-004 
12/109 
(11.0%) 
11/115 
(9.6%),clinical
ly relevant 
All events 
24/109 FDA 
2004, 
calculated 
from reported 
22% 
All events 
26/115 FDA 
2004, 
calculated 
from reported 
23% 
12/109 (11%) 
J&J 2004 
11/115 (10%) 
J&J 2004 
- - OR 0.97 (95% CI 0.52;1.81), 
Glaspy 2010, n not reported 
11% J&J 2007 10% J&J 
2007, n=224 
Gupta 2009 0/57 grade 1-
4, 0/57 grade 
3-4 
0/59 grade 1-
4, 0/59 grade 
3-4 
- - - - - - NR 
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Appendix Table C26.  KQ1 Outcome VI.  Thromboembolism data sources:  Epoetin versus Control (continued) 
Study Full text/abstract FDA report 2004 if not 
otherwise indicated 
J&J report Other reports, as indicated Investigator meta-analysis 
 EPO 
event/sample 
size 
Control 
event/samp
le size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
 
Henke 
ENHANCE 
20/180 
(including 
hypertension), 
calculated 
from reported 
11% 
9/171 
(including 
hypertensio
n), 
calculated 
from 
reported 5% 
- - - - 10 (5.6%) 
assumed 180 
Roche 2004 
6 (3.5%), 
assumed 171 
Roche 2004 
OR 1.62 (95% CI 0.57;4.55), 
Glaspy 2010, n not reported 
Henry 
Mixed 
cisplatin 
6/67 2/65   6/67 (9%) J&J 
2004 
8/65 (12%) 
J&J 2004 
10% Amgen 
2008 
6% Amgen 
2008, n=132 
OR 0.70 (95% CI 0.23;2.14), 
Glaspy 2010, n not reported 
9% J&J 2007 12% J&J 
2007, n=132 
Hoskin 2009, 
GBR-07 
3/133 2/149 5 (3%), FDA 
2004 
1 (1%), FDA 
2004 
4/133 (3%) 
J&J 2004 
2/149 (1%) 
J&J 2004 
5 (3%) 2 (1%), 
Amgen 2007 
OR 1.70 (95% CI 0.28;10.31), 
Glaspy 2010, n not reported 
3% FDA 2007 1% FDA 2007 3% J&J 2007 1% J&J 2007, 
n=282 
Littlewood 
2001 EPO-
INT-10 
17/251 (7%) 8/124 (6%) -  14/251 (6%) 
J&J 2004 
5/124 (4%) 
J&J 2004 
4% Amgen 
2008 
4% Amgen 
2008, n=375 
OR 1.05 (95% CI 0.44;2.51), 
Glaspy 2010, n not reported 
6% J&J 2007 4% J&J 2007, 
n=375 
Leyland-
Jones 
EPO-INT-76 
16% / 469 
overall TVE, 
fatal TVE: 6, 
fatal TVE 
within 4 
months: 5 
14% / 470 
overall TVE, 
fatal TVE: 2, 
fatal TVE 
within 4 
months: 1 
2.3% FDA 
2004 
1.4% FDA 
2004 
36/448 (8%) 
J&J 2004 
25/456 J&J 
(5%) 2004 
- - OR 1.17 (95% CI 0.81;1.67), 
Glaspy 2010, n not reported 
8% J&J 2007 5% J&J 2007, 
n=904 
Machtay 
RTOG-99-03 
1/67, slides: 
2/71 (≥Grade 
3), publication 
6/72 (Grade 1-
5); 2/72 
(≥Grade 3) 
0/68, 
slides: 0/70 
(≥Grade 3), 
publication 
2/68 (Grade 
1-5); 0/68 
(≥Grade 3) 
- - 1/67 (1%) J&J 
2004 
0/68 (0%) J&J 
2004 
- - OR 6.72 (95% CI 0.34;132.38), 
Glaspy 2010, n not reported 
1% J&J 2007 0% J&J 2007, 
n=135 
Milroy 2011 18/214 (8.4%) 13/210 
(6.2%) 
       
Moebus 2007 
EPO-GER-7 
- - 3.0% FDA 
2007 
1.7% FDA 
2007, n=593 
3.0%, 9/305, 
J&J 2007 
1.7%, 5/288, 
J&J 2007 
  OR 1.86 (95% CI 1.12;3.11), 
Glaspy 2010, n not reported 
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Appendix Table C26.  KQ1 Outcome VI.  Thromboembolism data sources:  Epoetin versus Control (continued) 
 
Study Full text/abstract FDA report 2004 if not 
otherwise indicated 
J&J report Other reports, as indicated Investigator meta-analysis 
 EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sampl
e size 
EPO 
event/sampl
e size 
Control 
event/sample 
size 
EPO 
event/sampl
e size 
Control 
event/sample 
size 
 
Osterborg 
2002 
MF4467 
1/170 (P.E.) 0/173 (P.E.) - - - - - - OR 3.07 (95% CI 0.12;75.91), 
Glaspy 2010, n not reported 
Pronzato 
2010 
4/107 (4%) 1/109 (1%)        
Ray-Coquard 
2009 
4.5% 
(calculated 
5/110) 
3.7% 
(calculated 
4/107) 
- - - - - - NR 
Razzouk 2006 
PR-99-11-
034/044 
6/112 
clinically 
relevant, any 
TVE 25/112 
(calculated 
from reported 
22.3%) 
2/110 
clinically 
relevant, 
25/110 any 
TVE 
(calculated 
from reported 
22.7%) 
- - - - 7% Amgen 
2008 
2% Amgen 
2008, n=224 
OR 0.98 (95% CI 0.52;1.83), 
Glaspy 2010, n not reported 
Rose 1994 
J89-040 
- - - - 9/142 (6%) 
J&J 2004 
2/79 (3%) J&J 
2004 
3% Amgen 
2008 
1% Amgen 
2008, n=221 
NR 
6% J&J 2007 3% J&J 2007, 
n=221 
Savonije 
2004, 
Savonije 2005 
PRI/EPO-
NED-17 
9/211 (2004); 
7/211 (3.3%), 
2005) 
1/104 (2004); 
1/104 (1%, 
2005) 
- - - - 5% Amgen 
2008 
1% Amgen 
2008, n=315 
OR 3.53 (95% CI 0.43;29.11), 
Glaspy 2010, n not reported 
Thomas 2008; 
GOG-191 
11/57 4/52 9/58 FDA 
2004 
3/55 FDA 
2004 
10/58 (17%) 
J&J 2004 
5/55 (9%) J&J 
2004 
10/58, 17%, 
Amgen 2007 
5/55, 9%, 
Amgen 2007 
OR 2.87 (95% CI 0.85;9.66), 
Glaspy 2010, n not reported 
17% J&J 
2007 
9% J&J 2007, 
n=113 
19%, Amgen 
2008 
 9%, n=114 
Amgen 2008 
Tsuboi 2009, 
Watanabe 
2006 
1/62 0/58 - - - - - - NR 
Wilkinson 
2006 
INT-45 
10/121 (8.3%) 1/60 (1.7%) - - - - - - OR 5.32 (95% CI 0.66;42.54), 
Glaspy 2010, n not reported 
Witzig 2005 
PR98-27-008 
8/168 (5%), 
grade 3-4 
5/165 (3%), 
grade 3-4 
- - 9/168 (5%) 
J&J 2004 
6/165 (4%) 
J&J 2004 
5% Amgen 
2008 
4% Amgen 
2008, n=344 
OR 1.60 (95% CI 0.51;5.00), 
Glaspy 2010, n not reported 
5% J&J 2007 4% J&J 2007, 
n=233 
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Appendix Table C27.  KQ1 Outcome VI.  Thromboembolism data sources:  Darbepoetin versus control 
 
Study Full text/abstract FDA report 2004 if not 
otherwise indicated 
J&J report Other reports, as indicated Investigator meta-analysis 
 EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
EPO 
event/sample 
size 
Control 
event/sample 
size 
 
Hedenus 2003 
20000161 
- - 3.4% FDA 
2007, 
calculated 
6/175 
0.6% FDA 
2007, 
calculated 
1/169 
- - - - OR 2.00 (95% CI 
0.73;5.46), Glaspy 2010, n 
not reported 
Hernandez 
2009, Taylor 
2005 
20030232 
16/194 (8%) 11/192 (6%) 7.1% FDA 
2007 
3.6%, n=391 
FDA 2007 
- - - - OR 1.48 (95% CI 
0.67;3.28), Glaspy 2010, n 
not reported 
Kotasek 2003 
9802911 
- - - - - - - - OR 1.03 (95% CI 
0.40;2.68), Glaspy 2010, n 
not reported 
Overgaard 
2009 
DAHANCA-
10, SE-2002-
9001 
7/255 (3%), 
calculated 
from reported 
3% 
3/259 (1%), 
calculated 
from reported 
1% 
- - - - - - NR 
Pirker 2008 
20010145 
65/301 (22%) 43/296 (15%) - - - - - - OR 1.77 (95% CI 
0.92;3.42), Glaspy 2010, n 
not reported 
Untch 2011 
DE20010033 
 19/318 (6%)  12/396 (3%) NR NR NR NR NR NR OR 1.92 (95% CI 
0.91;4.05), Glaspy 2010, n 
not reported 
Vansteenkiste 
2002 
980297 
7/155 (5%) 5/159 (3%) 5/155 FDA 
2007 
5/159 FDA 
2007 
- - - - OR 1.46 (95% CI 
0.45;4.69), Glaspy 2010, n 
not reported 
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Appendix Table C28.  KQ1 Outcome VI.  Thromboembolic complications:  Epoetin versus control 
 
 
 
 
 
Study ID       
Hb </= 10 g/dL Treatment n Treatment N Percentage % Control n Control N Percentage % 
Case J&J 2004 2 81 2.47% 3 76 3.95% 
Dammacco 2001 J&J 2004 5 69 7.25% 1 76 1.32% 
Fujisaka 2011 1 89 1.1% 0 92 0.00% 
Henry 1995 J&J 2004 6 67 8.96% 8 65 12.31% 
Littlewood 2001 J&J 2004 14 251 5.58% 5 124 4.03% 
Osterborg 2002 1 170 0.59% 0 173 0.00% 
Razzouk 2006 6 112 5.36% 2 110 1.82% 
Rose 1994 J&J 2004 9 142 6.34% 2 79 2.53% 
Witzig 2005 J&J 2004 9 168 5.36% 6 165 3.64% 
        
Hb 10 to 12 g/dL Treatment n Treatment N Percentage % Control n Control N Percentage % 
Aapro 2008 29 231 12.55% 13 231 5.63% 
Bamias 2003 0 72 0.00% 1 72 1.39% 
Blohmer 2004 J&J 2004 2 127 1.5% 3 129 2.32% 
Chang 2005 19 176 10.80% 14 178 7.87% 
Gupta 2005 0 57 0.00% 0 59 0.00% 
Henke 2003 Roche 2004 10 180 5.56% 6 171 3.51% 
Pronzato 2010 4 107 3.73% 1 109 1% 
Ray-Coquard 2009 5 110 4.55% 4 107 3.74% 
Savonije 2005 7 211 3.32% 1 104 0.96% 
Thomas 2008 J&J 2004 10 58 17.24% 5 55 9.09% 
Tsuboi 2009 1 62 1.61% 0 58 0.00% 
Wilkinson 2006 10 121 8.26% 1 60 1.67% 
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Appendix Table C28.  KQ1 Outcome VI.  Thromboembolic complications:  Epoetin versus Control (continued) 
 
Study ID       
Hb > 12 g/dL Treatment n Treatment N Percentage % Control n Control N Percentage % 
Engert 2009 45 645 6.98% 44 644 6.83% 
Goss 2005 J&J 2004 16 52 30.77% 2 52 3.85% 
Grote 2005 J&J 2004 12 109 11.01% 11 115 9.57% 
Hoskin 2009 J%J 2004 4 133 3.01% 2 149 1.34% 
Leyland-Jones 2005 J&J 2004 36 448 8.04% 25 456 5.48% 
Machtay 2007 2 72 2.78% 0 68 0.00% 
Milroy 2011 18 214 8.4% 13 210 6.2% 
Moebus 2007 J%J 2007 9 305 2.95% 5 288 1.74% 
       
unclear Treatment n Treatment N Percentage % Control n Control N Percentage % 
Debus 2006 J&J 2007 38 192 19.79% 23 191 12.04% 
EPO-INT-1 J&J 2004 3 164 1.83% 1 80 1.25% 
EPO-INT-3 J&J 2004 8 135 5.93% 1 65 1.54% 
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Appendix Table C29.  KQ1 Outcome VI.  Thromboembolic complications:  Darbepoetin versus control 
 
 
Study ID       
Hb <10 g/dL Treatment n Treatment N Percentage % Control n Control N Percentage % 
Hedenus 2003 FDA 2007 6 175 3.43% 1 169 0.59% 
       
Hb 10-12 g/dL Treatment n Treatment N Percentage % Control n Control N Percentage % 
Hernandez 2009 16 194 8.25% 11 192 5.73% 
Pirker 2008 65 301 21.59% 43 296 14.53% 
Vansteenkiste 2002 7 155 4.52% 5 159 3.14% 
Untch 2011 19 318 6% 12 396 3% 
       
Hb > 12 g/dL Treatment n Treatment N Percentage % Control n Control N Percentage % 
Overgaard 2009 7 255 2.75% 3 259 1.16% 
        
 
 
 C-60 
Appendix Table C30.  KQ1 Outcome VII.  Other adverse events -- hypertension:  Epoetin versus control, evidence table and definition for 
hypertension 
 
Study ID Treatment 
n 
Treatment 
N 
Percentage Control 
n 
Control 
N 
Percentage Definition of Hypertension 
Bamias 2003 2 72 2.78% 0 72 0.00% not reported or available from detailed results 
Case 1993 4 81 4.94% 2 76 2.63% not reported or available from detailed results 
Dammacco 2001 3 69 4.35% 1 76 1.32% not reported or available from detailed results 
Fujisaka 2011 5 89 5.6% 3 92 3.3% not reported 
Henry 1995 2 67 2.99% 4 65 6.15% not reported or available from detailed results 
Hoskin 2009 5 133 3.76% 5 149 3.36% not reported or available from detailed results 
Iconomou 2003 0 61 0.00% 0 61 0.00% not reported or available from detailed results 
Littlewood 2001 9 251 3.59% 1 124 0.81% not reported or available from detailed results 
Milroy 2011 6 214 2.8% 3 210 1.43% not reported 
Österborg 2002 15 170 8.82% 9 173 5.20% not reported or available from detailed results 
Razzouk 2006 2 112 1.79% 1 110 0.91% not reported or available from detailed results 
Rose 1994 80 142 60.56% 47 79 63.29% systolic >140 mm Hg; from trial sponsor’s clinical study report 
Savonije 2005 7 211 3.32% 3 104 2.88% not reported or available from detailed results 
Tsuboi 2009 4 62 6.45% 2 58 3.45% not reported or available from detailed results 
Wilkinson 2006 3 121 2.48% 0 60 0.00% not reported or available from detailed results 
        
Alternative data        
Dammacco 2001 43 69 62.32% 36 76 47.37% systolic >150 mmHg or diastolic >100 mmHg; data from trial sponsor’s clinical study report 
Rose 1994 6 142 4.23% 3 79 3.80% diastolic >95 mmHg; data from trial sponsor’s clinical study report 
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Appendix Table C31.  KQ1 Outcome VII.  Other adverse events -- hypertension:  Darbepoetin versus control, evidence table and definition for 
hypertension 
 
Study ID Treatment 
n 
Treatment 
N 
Percentage Control 
n 
Control 
N 
Percentage Definition of Hypertension 
Hernandez 2009 6 194 3.09% 4 192 2.08% not reported or available from detailed results 
Pirker 2008 18 301 5.98% 15 296 5.07% not reported or available from detailed results 
Vansteenkiste 
2002 9 155 5.81% 6 159 3.77% not reported or available from detailed results 
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Appendix Table C32.  KQ1 Outcome VII.  Other adverse events -- thrombocytopenia:  Epoetin versus control 
Study ID Treatment n Treatment N Percentage (%) Control n Control N Percentage (%) 
Bamias 2003 2 72 2.78% 0 72 0.00% 
Boogaerts 2003 8 133 6.02% 13 129 10.08% 
Dammacco 2001 5 69 7.25% 5 76 6.58% 
Fujisaka 2011 61 89 68.5% 55 92 59.8% 
Goss 2005 1 52 1.92% 0 52 0.00% 
Gupta 2009 0 0 - 0 0 - 
Littlewood 2001 18 251 7.17% 9 124 7.26% 
Milroy 2011 15 214 7.0% 9 210 4.3% 
Savonije 2005 22 211 10.43% 6 104 5.77% 
Tsuboi 2009 31 62 50.00% 28 58 48.28% 
Witzig 2005 7 168 4.17% 10 165 6.06% 
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Appendix Table C33.  KQ1 Outcome VII.  Other adverse events -- thrombocytopenia:  Darbepoetin versus control 
Study ID Treatment  n Treatment N Percentage (%) Control n Control N Percentage (%) 
Pirker 2008 60 301 19.93% 38 296 12.84% 
Untch 2011 9 318 2.8% 11 396 2.7% 
 
 
Appendix Table C34.  KQ1 Outcome VII.  Other adverse events -- rash:  Epoetin versus control 
 
 
 
 
 
 
 
Appendix Table C35.  KQ1 Outcome VII.  Other adverse events -- seizures:  Epoetin versus control 
 
Study ID Treatment  n Treatment N Percentage (%) Control n Control N Percentage (%) 
Case 1993 2 81 2.47% 2 76 2.63% 
Henry 1995 3 67 4.48% 2 65 3.08% 
Savonije 2005 4 211 1.90% 0 104 0.00% 
 
Appendix Table C36.  KQ1 Outcome VII.  Other adverse events -- seizures:  Darbepoetin versus control 
 
Study ID Treatment n Treatment N Percentage (%) Control n Control N Percentage (%) 
Hernandez 2009 3 194 1.55% 1 192 0.52% 
Pirker 2008 4 301 1.33% 9 296 3.04% 
 
Study ID Treatment  n Treatment N Percentage (%) Control n Control N Percentage (%) 
Gupta 2009 0 58 0.00% 0 57 0.00% 
Henry 1995 7 67 10.45% 2 65 3.08% 
Osterborg 2002 2 170 1.18% 0 173 0.00% 
Tsuboi 2009 0 62 0.00% 2 58 3.45% 
Witzig 2005 12 168 7.14% 7 165 4.24% 
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Appendix Table C37.  KQ1 Outcome VI.  Antibodies:  Epoetin versus control 
 
Study ID Antibodies 
Reported 
Numbers Comments 
Aapro 2008 Not reported     
Antonadou 2001 Not reported     
Bamias 2003 Not reported     
Blohmer 2004 Not reported     
Boogaerts 2003 Not reported     
Case 1993 Yes   Serum samples for the determination of antibodies against rHuEPO were 
obtained at entry and after completion of the study's 12-week double 
blind phase or when a patient prematurely withdrew from the study. 
Chang 2005 Not reported     
Christodoulou 2009 Not reported     
Dammacco 2001 Not reported     
Debus 2006 Not reported     
Engert 2009 Not reported     
EPO INT-1 Not reported     
EPO INT-3 Not reported     
Fujisaka 2011 Not reported   
Goss 2005 Not reported     
Grote 2005 Not reported     
Gupta 2009 Not reported     
Henke 2003 Not reported      
Henry 1995 Yes Evaluated: 60 
(30/30). Negative: 
56 (28/28). Positive: 
4 (2/2) 
Assays for anti-r-HuEPO antibodies before and after therapy were done 
on 56 patients (28 in each group) and none had a positive titer to the r-
HuEPO. Four patients (2 r-HuEPO, 2 placebo) had a positive titer both 
before and during the study, suggesting a reaction to the albumin 
containing vehicle.  
Hoskin 2009 Not reported     
Iconomou 2003 Not reported     
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Appendix Table C37.  KQ1 Outcome VI.  Antibodies:  Epoetin versus control (continued) 
 
Study ID Antibodies 
Reported 
Numbers Comments 
Leyland-Jones 2005 Not reported     
Littlewood 2001 Not reported     
Machtay 2007 Not reported     
Moebus 2007 Not reported     
Milroy 2003 Not reported     
ML17620 Not reported     
Oberhoff 1998 Yes   Anti-EPO antibodies were measured at baseline and at the end of the 
controlled treatment phase. No anti-bodies against rhEPO developed 
during therapy in the study.  
Osterborg 2002 Yes   No antibodies to erythropoietin were detected in any patient.  
Porter 1996 Not reported     
Pronzato 2002 Not reported     
Ray-Coquard 2009 Not reported     
Razzouk 2006 Not reported     
Rose 1994 Not reported     
Savonije 2005 Not reported     
Thomas 2002 Not reported     
Thomas 2008 Not reported     
Tsuboi 2009 Yes   Anti-erythropoietin antibodies were masured by enzyme-linked 
immunosorbent assay and radioimmunoprecipitation assay and 
compared with the data of the last observation. Detection by either 
method was judged as positive. No anti-erythropoietin antibodies were 
reported  
Wagner 2004 Not repored     
Wilkinson 2006 Not repoted     
Witzig 2005 Not reported     
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Appendix Table C38.  KQ1 Outcome VI.  Antibodies:  Darbepoetin versus control 
 
Study ID Antibodies 
Reported 
Numbers Comments 
Hedenus 2003 Yes  Use of three validated assays to evaluate antibody formation. No 
evidence for neutralizing antibodies to darbepoetin alfa was detected for 
any patient.  
Hernandez 2009 Yes Evaluated pre and 
post treatment: 340 
(171/169) 
Screening for presence before study drug administration, at week 10 and 
at the end of treatment phase. No neutralizing ant-darbepoetin alfa 
antibodies were detected in this study population (185 and 191 patients 
tested at screening in the placebo and darbepoetin alfa groups 
respectively and 169 and 171 during the treatment period, respectively.  
Kotasek 2003 Yes  No neutralizing antibodies to darbepoetin alfa were detected 
Overgaard 2009 Not reported   
Pirker 2008 Yes Evaluated pre and 
post treatment: 516. 
No information for 
number of evaluated 
patients per arm. 
Assumed 258/258.  
Across both treatment groups 574 patients (96%) had a predose 
antibody result and 516 patients (86%) had one or more postdose 
results. No sample tested positive for neutrilizing antibodies to 
darbepoetin alfa.  
Untch 2008 Not reported   
Vansteekiste 2002 Yes Reporting just n of 
serum samples and 
not n of evaluated 
patients 
No anti-darbepoetin alfa antibodies were detected in 1054 serum 
samples (531 serum samples from patients in the darbepoetin alfa group 
and 523 serum samples from patients in the placebo group) tested 
during the study and no clinical sequelae indicative of antibody formation 
have been observed during the follow up period.  
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Appendix Table C39.  KQ2:  Study characteristics, Part I 
 
Study 
author 
Participants 
randomized 
Drug Inter-
vention 
(Early) 
Control Late Weight 
Based 
or 
Fixed 
Maxim
um 
duratio
n of 
ESA 
medica
tion 
(wks) 
Dose Adjustment Iron Transfusion 
Trigger 
(when 
transfusion 
assessed) 
Publication Primary and 
Secondary 
Outcomes of 
the Study 
Charu 
2007 
204 E: 102 L: 
102 
Darbepoetin 
alfa 
300 µg 
Q3W 
Observation 
until Hb≤ 10 
g/dl then start 
treatment 
300µg Q3W  
Fixed up to 
22   
Increase to 500µg /Dose- . for 
Early: if Hb <10g/dL;  for Late: 
if Hb <9 g/dL or if after 2 
consecutives doses of DA Hb 
<10 g/dL 
Withheld if Hb >13 g/dL 
NR NR Full text  
Abstract 
Charu 2004 
 
proportions 
with: Hb drop 
below 10 g/dl 
by week 12; 
Hb drop 
during 
therapy; RBC 
transfused 
during 
therapy; also, 
mean Hb 
over time; 
mean change 
in FACT-
Fatigue 
subscale 
score; 
proportion 
maintaining 
Hb 11.0 to 
13.0 (target) 
Straus 
2006 
269 E: 135 L: 
134 
Epoetin alfa 40,000 
IU QW 
Observation 
until Hb≤9 g/dl 
after 2nd 
chemotherapy 
cycle, then 
start 
treatment: 
40,000 IU QW 
[26 pt (19.4%)] 
Fixed 16 Increased to 60,000 in either 
group if after 4w of Epo 
treatment Hb I≤1g/dl 
Withheld if Hb >15 g/dl on 2 
consecutive evaluations. 
If Hb subsequently decreased 
to <13 g/dl treatment was 
resumed 
NR NR Full text  
Abstract 
Straus 2003 
Hb response; 
RBC 
transfusions, 
tumor 
response; 
QoL; Safety 
Health Care 
utilization 
Work / 
Productivity 
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Appendix Table C39.  KQ2:  Study Characteristics, Part I (continued) 
 
Study 
author 
Participants 
randomized 
Drug Inter-
vention 
(Early) 
Control Late weight 
based 
or fixed 
Maxim
um 
duratio
n of 
ESA 
medica
tion 
(wks) 
dose adjustment iron transfusion 
trigger 
(when 
transfusion 
assessed) 
publicati
on 
primary and 
secondary 
outcomes of the 
study 
Crawford 
2007 
216 E: 109 L: 
107 
Epoetin alfa 40,000 
IU QW 
Observation 
until Hb≤ 10 
g/dl, then start 
treatment at 
40,000 IU QW 
(46% of controls 
had Hb<10 g/dL 
and received 
late epoetin) 
Fixed 16 Increased to 60,000 IU QW if 
>2 g/dL Hb decrease; dose 
withheld if Hb >15 g/dL twice 
consecutively; re-start with 
dose decreased by 20,000 IU 
weekly when Hb <13 g/dL 
as needed 
(ferritin 
<100 
ng/mL or 
Tsat<20%) 
NR Full text 
Abstract 
(Crawford 
2003) 
Hb changes over 
time; proportion 
transfused; RBC 
units/patient; QoL 
changes with Fact-
An, Fact-G, Fact-L, 
LASA; tumor size; 
survival; adverse 
events 
Safety and efficacy 
Glaspy 
2009 
136 E: 68, L: 
68 
Epoetin alfa 120,000 
U Q3W 
Observation 
until Hb <11 g/dl 
then start 
treatment 
120,000 IU Q3W 
Fix 16 wks D if Hb >12.0 g/dl or I by >1.5 
g/dl in 3w: D from 120,000 to 
80,000U q3w, 80,000 to 60,000 
Uq3w, 60,000 to 40,000 Uq3w 
b: If Hb still >13.0 g/dl withheld 
of epo. 
I: a:if Hb dropped by ≥1 g/dl 
after dose reduction, the 
previous dose of epo was 
restarted. 
B: If Hb <10.0 g/dl after at least 
1 dose of epo q3w, patient 
treated with epo 40,000U qw. If 
Hb not risen by ≥ 1 g/dl after 4 
wks at this dose, epo dose 
increased to 60,000 U qw. If Hb 
still not increased by ≥ 1 g/dl 
from baseline after 4 wks at 
60,000qw, the patient was 
considered to have failed qw 
therapy 
325 mg 
orally 
Predefined 
for each site 
per local 
transfusion 
policy 
Full text Mean proportion of 
haemoglobin 
values within the 
target range (11.0-
13.0 g/dl) among 
randomized 
patients. 
Maintenance of all 
weekly Hb values 
during epoetin-α 
treatment between 
11.0-13.0 g/dl, 
beginning at week 
1 in the early 
intervention group 
and once Hb was ≥ 
11.0 g/dl in the 
standard 
intervention. 
Transfusion  
Adverse events 
QoL 
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Appendix Table C39.  KQ2:  Study Characteristics, Part I (continued) 
 
Study 
author 
Participa
nts 
randomiz
ed 
Drug Inter-
vention 
(Early) 
Control Late weight 
based 
or fixed 
Maxim
um 
duratio
n of 
EPO 
medica
tion 
(wks) 
dose adjustment iron transfusion 
trigger 
(when 
transfusion 
assessed) 
publication primary and 
secondary 
outcomes of 
the study 
Schouwink 
2008 
110 E: 54, 
L: 54 
Epoetin alfa 40,000 
UI 
weekly 
when Hb ≤10 
g/dl 
40,000 UI 
weekly 
fixed 24 When Hb >13 g/dl, epo 
withdrawn and resumed at 
40,000 IU QW when Hb < 12 
g/dl. 
If Hb did not increase > 1 g/dl 
within the 4 first wks of 
treatment, dose increase to 
80,000 IU QW 
All patients 
received 
oral iron 3 
times daily 
As needed 
with the 
recommenda
tion not to 
transfuse if 
Hb > 9.7 g/dl 
Full text Mean change in 
Hb after wks ¾, 
8/9, and 12, 
and at the end 
of treatment 
survival 
safety 
r-EPO 
antibodies 
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Appendix Table C39.  KQ2: Study characteristics, Part II 
 
Study 
author 
N randomized Cancer 
details 
Cancer 
category 
Therapy Hb eligibility 
criteria [g/dl] 
Hb baseline 
Early  
[mean g/dl 
(SD)] 
Hb 
baseline 
Late arm 
[mean g/dl 
(SD)] 
Hb cate-
gory 
 
Hb 
target 
Age Early 
arm 
[mean 
(SD)] if 
not stated 
otherwise 
Age Late 
arm [mean 
(SD)] if not 
stated 
otherwise 
age 
category 
(children 
adults 
elders (>65) 
Charu 
2007 
204 Breast; Lung; 
GiT; 
Genitourinary; 
hematologic; 
Gyne; Other  
Mixed chemotherapy ≥10.5 g/dl and 
≤12.0 g/dl 
11.1 (SD 
0.7) 
11.2 (SD 
0.6) 
>12 
 
>13 
63.2 (SD 
10.9) 
63.7 (SD 
12.2) 
Adults 
Straus 
2006 
269 NHL; MM ; 
Hodgkin; CL 
Hematologica
l 
chemotherapy 
with cycles 
week (1;2;3;4) 
Hb > 10 g/dl 
and Hb ≤12.0 
g/dl   
11.1(SE 0.7) 11.2 (SE 
0.7) 
>12 
 
15 
59.0 
(SD14.0)  
60,5 (SD14,9)   Adults 
Crawford 
2007 
216 Lung cancer 
(non-small 
cell) 
Solid chemotherapy 
with platinum, 
78-80% of each 
arm 
Hb >11 g/dL 
and <15 g/dL 
13.1 (SD 
1.0) 
13,0 (SD 
1,2) 
>12 
 
>15 
62,3 (SD 
11.0) 
62.7 (SD 
10.6) 
Adults 
Glaspy 
2009 
136 Breast; GiTl; 
Lung; 
Hematologic; 
Gyne; Other 
Mixed Chemotherapy Hb ≥11.0 g/dl - 
≤12.0 g/dl 
11.5 (0.3) 11.5 (0.4) 12 
 
12 
60.5 (12.8) 61.3 (15.4) Adults 
Schouwink 
2008 
110 NSCLC, 
SCLC, Ovary, 
Colon, breast, 
bladder, other 
Solid chemotherapy 
with and 
without 
platinum 
>10 g/dl and 
≤12 g/dl 
11.2 (0.8) 11.2 (0.7) >12 
 
>13 
60.0 (10.8) 61.7 (12.3) Adults 
 
Appendix Table C40.  KQ2:  Study quality 
 
Study author Random Allocation Blinding Placebo ITT or 10% Similar Characteristics At Baseline high or low 
quality 
Charu 2007 yes unclear no no placebo ITT yes low 
Straus 2006 yes NR no no placebo ITT  yes low 
Crawford 2007 unclear unclear no no placebo ITT  ECOG performance status 
0-1: 95.3% in early arm, 80% in delayed arm 
2: 5.7% in early arm, 20.0% in delayed arm 
Race: 
Caucasian 68.9% in early arm, 81.9% in delayed arm 
low 
Schouwink 2008 unclear unclear no no placebo ITT yes low 
Glaspy 2009 yes: Computer-generated 
randomization schedule 
The randomization was 
balanced using randomly 
permuted blocks. 
no no no placebo ITT yes low 
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Appendix Table C41.  KQ2:  Hematologic response 
 
Study Author Hb response definition Early 
(n) 
Early (N) Percentage 
(%) 
Late 
(n) 
Late 
(N) 
Percentage 
(%) 
Comments 
Charu 2007 Hb Increase > 2 g/dl 19 94 20,2 16 86 18,6 Data presented by Charu-2004 
 
Appendix Table C42.  KQ2:  Studies not included for hematologic response 
 
Study Author Hb response definition Early Late Comments 
Straus 2006 Hb increase > 2 g/dL OR Hb increase  
Hb ≥ 12 g/dl 
70,4% (95 Pt) 25,4% (34 Pt) P < 0,001 (ITT) 
Crawford 2007 Proportion maintaining Hb >10 g/dL  82% 
calculated 
56% 
calculated 
Reported is the proportion of patients with Hb 
decrease <10 g/dL. Therefore the following 
calculation was done: early arm 100%-
18%=82%, late arm 100%-44%=56% 
Glaspy 2009 Maintaining all Hb values between 
11.0 and 13.0 g/dL during treatment 
with epoetin- α q3w alone 
 49 (72%) 28 (68%)  
Schouwink 2008 NR NR NR  
 
Appendix Table C43.  KQ2:  Transfusion  
 
Study ID time of 
measurement 
Intervention (n) Intervention (N) Percentage (%) Control 
(n) 
Control(N) Percentage (%) Comments 
Charu 2007 12 wks 14 99 14% (CI 7;20) 22 102 22% (CI 13;30) P=0.18 calculated 
Charu 2007 22 wks 17 99 17,2% (CI 9-25) 27 102 26,5% (CI 16-35) P=0,12 calculated 
Straus 2006 16 wks 24 135 17,8% 35 134 26,1 P=0,11 reported 
Crawford 2007 16 wks 12 106 11,3% 19 105 18.1 P=0.17 calculated  
Glaspy 2009 16 wks 6 68 8.8% 4 51 7.8% P=0.23 calculated 
Schouwink 2008 24 wks 15 54 28% 15 54 28% P=1.00 calculated 
 
 
  
 C-72 
 
Appendix Table C44.  KQ2:  Thrombotic events 
 
Study ID Intervention 
Early n 
Intervention 
Early N 
Percentage (%) Control 
Late n 
Control 
Late N 
Percentage 
(%) 
Definition of TE Comments 
Charu 2007 16 99 16.2% 7 102 6.9% Cardiovascular and 
thromboembolic events 
 
Straus 2006 15 135 11.1% 4 134 3.0% Thrombovascular 
events 
 
Crawford 2007 13 108 12.0% 16 107 15.0% Any thrombovascular 
events 
safety population n=215 
correspond to the 
randomized population 
Glaspy 2009 6 68 8.8% 6 51 11.8% Thrombovascular 
events 
 
Schouwink 2008 10 54 18.5% 4 54 7.4%  pulmonary embolism, 
thrombosis and 
superficial venous 
phenomena pooled 
together 
 C-73 
Appendix Table C45. KQ2:  QoL data from Straus et al. 2006 
 
Straus 2006 Baseline 
Immediate 
Change  
Immediate 
Baseline 
Delayed 
Change 
Delayed 
p-value between 
groups 
comments 
FACT-G       
- FACT –G  
   Physical well being 
20.9 
(n=117) 
1.0 
(n=119) 
20.9 
(n=113) 
- 0.33 
(n=113) 
 0.007 Baseline from 
poster Straus 
2003 
- FACT –G  
  Functional well being 
17.6 
(n=118) 
0.43 
(n=119) 
18.3 
(n=114) 
- 1.03 
(n=113) 
 0. 024 Baseline from 
poster Straus 
2003 
- FACT -G 
  Emotional 
NR 0.64  
(n=119) 
NR 0.03  
(n=113) 
0.360  
- FACT -G 
  Social 
NR - 0.43 
(n=119) 
NR - 0.67  
(n=113) 
0.840  
FACT – anemia subscale       
- FACT – fatigue 
   subscale 
34.0 
(n=118) 
1.45 
(n=119) 
34.3 
(n=112) 
- 1.68 
(n=113) 
0.005 Baseline from 
poster Straus 
2003 
- FACT – F 
  Non-fatigue 
NR 0.54 
(n=119) 
NR - 0.03 
(n=113) 
0.078  
- Total of FACT anemia 
   subscale 
55.0 
(n=118) 
1.92 
(n=119) 
55.2 
(n=112) 
- 1.71 
(n=113) 
0.008 Baseline from 
poster Straus 
2003 
- Total of FACT anemia 
(FACT- General + anemia 
subscale; 47) 
NR 3.84 
(m=119) 
NR - 4.37 
(n=113) 
0.003  
 
Appendix Table C46. KQ2:  QoL data from Charu 2007 
Charu 2007 Baseline 
Immediate 
Change (week 
22)  
Immediate 
Baseline 
Delayed 
Change (week 
22) 
Delayed 
comments 
- FACT – fatigue 
subscale 
 n=94  n=86  
NR 0.7 ± 12.9 NR 0.6 ± 14.2 mean ± SD calculated 
from results reported in 
a figure 
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Appendix Table C47. KQ2:  QoL data from Glaspy 2009 
Glaspy 2009 Baseline 
Immediate 
Last visit 
(week)  
Immediate 
Baseline 
Delayed: 
Last visit 
(week ) 
Delayed 
comments 
- FACT – fatigue 
subscale 
33.5 ±  13.2 32.0 ± 13.2 27.8 ± 12.0 30.4 ± 11.7  
 
Schouwink 2008: no QoL reported. 
Crawford 2007: FACT-An mean change from baseline in the early intervention group was of -7.7. No data is reported for the late intervention group. BFI (Brief Fatigue 
Inventory) mean change from baseline in the early intervention group was of -3.2 and of -3.3 in the late intervention group. 
 
Appendix Table C48. KQ2:  On study mortality  
Study ID time of 
measurement 
Intervention 
Early (n) 
Intervention 
Early(N) 
Percentage (%) Control Late(n) Control Late (N) Percentage (%) Comments 
Crawford 2007 16 wks 6 106 5.7% 5 105 4.8%  
Schouwink 2008 16 wks 8 54 14.8% 5 54 9.3%  
Glaspy 2009 16 wks 2 68 2.9% 2 51 3.9%  
 
 
Appendix Table C49. KQ2:  Overall survival* 
Study ID time of 
measurement 
Intervention 
Early (n) 
Intervention 
Early(N) 
Percentage (%) Control Late(n) Control Late 
(N) 
Percentage (%) Comments 
Crawford 2007 b 40 months 11 108 10.2% 14 107 13.1% safety population n=215 
correspond to the 
randomized population 
Schouwink 2008 
b 
24 wks 39 54 72.2% 40 54 74.1%  
Straus 2006 20 wks 3 135 2.2% 4 134 3.0% on study + 30d 
none of the late Epo 
group’s death received 
Epo 
Charu 2007 up to 26 wks 6 99 6.1% 7 102 6.9% on study or within 30d of 
end of study 
 
*Overall survival is defined as on study mortality + follow up  
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Appendix D. Data Forms 
 
Study eligibility form    Date:  
first author, year: 
       Reviewer:  
  
TYPE OF STUDY 
 1. Is the study described as randomised?   NB: Answer ‘no’ if the study is in cross over or quasi randomised      design    
    Yes            Unclear       No                       Go to                Next question          Exclude 
PARTICIPANTS IN THE STUDY 
 2. Did the participants in the study have a previous treated or untreated    malignant disease?     
     Yes            Unclear        No                       Go to                Next question         Exclude 
   3. Were the participants anaemic or at risk for anaemia from    chemotherapy and/or radiotherapy or their malignant disease?  
                Yes           Unclear        No    
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                   Go to                Next question         Exclude 
INTERVENTIONS IN THE STUDY  4. Was one group given Epoetin alpha or Epoetin beta subcutaneously    or intravenously (not per os) in a dose of at least     300U /kg /week for at least four weeks?    
     Yes            Unclear       No                       Go to                Next question         Exclude 
  5. Did the control group receive the same care (eg chemotherapy and    supportive therapies) with or without placebo?     
     Yes            Unclear       No                       Go to                Next question         Exclude 
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OUTCOMES IN THE STUDY  6. Did the study document haematologic response? 
  Or   Did the study document number of patients or red blood cell units    transfused? 
  Or   Did the study document Quality of life?  
     Yes            Unclear       No                       Go to                Next question         Exclude 
Final Decision    1x ‘no’ ⇒ exlude  1x ‘unclear’ ⇒ unclear  
   Include   Unclear      Exclude  
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Study validity form      Date:  
First author, year:       Reviewer:            TREATMENT ALLOCATION        1. Was allocation truly random?     Yes: random numbers, coin toss, shuffle etc Yes No Unclear   No:  for patient number, date of birth, alternate     Unclear: if the method of randomisation was not                  stated or unclear        2. Was the treatment allocation concealed?     Yes: central allocation at trials office or pharmacy,           sequentially numbered or coded vials, other           methods where the trialist allocating treatment           could not be aware of the treatment  Yes  inadequate  Unclear  Inadequate: allocation was alternate (by patient, day                      of the week, admission on ward, etc) or                      based on information, such as date of                      birth, already known to the trialist)        Unclear: insufficient information given        SIMILARITY OF GROUPS      3.Were the patients characteristics at      baseline similar in all groups? Yes No   Unclear  IMPLEMENTATION OF MASKING     4. Was the treatment allocation masked       from the participants? Yes No Unclear   (either stated explicitly, or an identical placebo is      used)       5. Was the treatment allocation masked       from the clinicians? Yes No Unclear   COMPLETENESS OF THE TRIAL     6. Were the number of withdrawals, drop       outs and lost to follow up in each group       stated? Yes No  Unclear  NB: Yes, if there have not been any drop outs or lost          to follow up       7. Did the analysis include an intention-to-        treat analysis OR WERE LESS THAN 10% 
OF PATIENTS EXCLUDED? Yes No  Unclear  
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Data Extraction Main Review   Extractor initials:   Date: 
 
Section 1: Paper details  
Section 1. Paper details. Paper title:  Ref manager number and initials:  First Author:  Authors contact address (if available)  Publication year  Full text article or only published as an abstract  Number of trials included in this paper: (if more than one, complete separate extraction forms for each, and add letters A, B, C, etc to  the paper name) 
 
 
Papers of other trials with which this may link: (if other papers report further results of this trial,  incorporate them onto this form, and note what has been here) 
 
Trial design: Singlecentre or multicentre  Source of participants (inpatients or outpatients)  Method of recruitment:  Dates for recruitment:  Funding: pharmaceutical or not (give details);  In industry submission?  In IPD- Cochrane Review? If yes is it an included study, an excluded study or ongoing trial?  
 
Aim of study:  
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Details of comparisons evaluated in this trial: 
  X = yes comments Epoetin versus placebo   Epoetin versus no treatment   Epo versus standard care   Epo versus administration   Epo versus brand   Epo versus dose    x = yes comments Epoetin plus RBC Transfusions in all arms     Epoetin plus iron suppl. in all arms   Epoetin plus G-CSF in all arms    Epoetin plus other           
Eligibility criteria – describe in text box below:  
 
 
Exclusion criteria - describe in box below:   
How was epo deficiency derived?  ie tested for epo or diagnosed by elimination of other causes of anaemia? 
 
 
Staging evaluation: Histology/Cytology  Yes or no 
Describe Was compliance assessed?  
If so describe: 
 
Section 2: Outcomes sought 
Outcomes  
Primary  
Secondary  
QoL   
Describe statistics used:  
Any power calculations and if so for what?  
Time periods of surveillance – describe  
Maximum duration of surveillance:   Notes:  Dichotomous data:  N/n: number of events/total number of patients Continuous data: N/n/SD: treatment mean of outcome parameter/total number of patients in group/treatment standard deviation of outcome parameter.  
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Section 3. Intervention  
*Dosing regimen: Fixed (F): all patients were given continuously the same dose of Epoetin Decreasing (D):  patients with a defined response were given a reduced amount of Epoetin Increasing (I):  patients showing no response within a specified period of time were given an increased dose of Epoetin Notes: e.g. describe dosing regime: 
 
  Intervention Control    comments   Group 1[n=] (%) Group [n=](%)  
Intervention/control                                
Epo Dose IU/kg      
Epo dose frequency    
Epo dose per week IU/kg    
Duration of epo 
treatment (weeks) 
      
Dosing regimen 
 
      
Route (s.c or iv)       
RBC transfusion trigger? 
if so what ? 
    
iron supplementation? 
if so describe 
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1. Chemotherapy:   Chemotherapy regime describe: Cycles repeated (days): 
Times: Adjustments: Notes:  
(if stated add the number of pts on each chemo regime) {describe}  Intervention {} Control {} comments Please give numbers and  percentages  Group 1 [n=] (%) Group [n=] (%) Group 2 [n=] (%) Chemo agents (list) ↓ Dose/route/time schedule                                              
2. Radiotherapy: Radiotherapy regimen Radiation repeated every days Times: Adjustments: 
Notes: 
(if stated add the number of pts on each chemo regime) {describe}  Intervention {} Control {} comments Please give numbers and  percentages  Group 1 [n=] (%) Group [n=] (%)  Radiotherapy regime (list) 
↓ Dose/route/time schedule                                       
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Section 4. Results - Patient Characteristics 
 
Comment: number of patients evaluated usually varies 
in each outcome 
 
Number of patients recruited for this study:  
Number of patients randomized:  
Number of patients evaluated:  
Number of patients recruited for QoL:  
Number of patients evaluated in QoL    
  {} Intervention {} Control {} comments   Group 1 [n=] (%) Group [n=] (%)   Total Patients       randomised         Total Patients         evaluated        Total Patients not evaluated     Exclusions       Reasons:       Withdrawals        reasons:       Lost to follow up        reasons:       
Were the withdrawals and losses to follow up less than 10% of the study population?: 
 
 
Characteristics at baseline: Comment: this was designed to fit also studies with several treatment arms add extra 
columns if need be. {describe} Intervention {} Control {} comments Please give numbers and      percentages Group 1 [n=] (%) Group [n=] (%)  
 Age 
 (state if mean; median; range)       Gender M / F / / / 
 Disease category- 
Solid or haem 
     List diseases ↓                                   
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 Disease Stage       I      II      {describe} Intervention {} Control {} comments III      IV       
 Bone Marrow 
Involvement 
      
 Performance status        (Karnofsky, etc 0      1    2    3    4    
No. with previous epo 
therapy 
(describe if details given) 
      
No. with previous 
transfusion 
   
n = transfusion at 
baseline  
(give Hb value for pts 
with previous 
transfusion) 
   
Hb baseline (all patients)       
Hb baseline (no prior 
transfusion/n patients) 
   
Hematocrit baseline       
serum EPO, no. pts tested       
serum EPO baseline    
serum iron baseline       
serum ferritin baseline                      
Are these characteristics roughly balanced between the groups?:   
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Section 4. Results – Outcomes 
 
Maximum duration of surveillance: Describe surveillance:  
ie time on epo, time after trial stopped 
 dichotomous data: N/n  :  number of events/total number of patients in group continuous data: N/n/SD  :  treatment mean of outcome parameter/ total number of        patients in group/treatment standard deviation of outcome          parameter  
Haematologic response:   Definition 
 complete response   
 partial response    no response   
  {describe} Intervention {} Control  {} comments  Group 1 [n=] (%) Group [n=] (%)  
 overall response       
 complete response      
 partial response      
 no response       Data extracted from which    text,    table,    figure?  Expert statistical attention needed?  Notes: 
 
Haemoglobin: 
 {describe} Intervention {} Control  {} comments   Group 1 [n=] (%) Group [n=] (%)  Hb (g/dl) Baseline      Hb (g/dl) Finish of epo therapy(put time point in 
brackets)     Hb (g/dl) Endpoint (put time 
point in brackets)       Hb change (g/dl) if stated 
in the paper (put time point  
in brackets) {SD}    Other time points                      
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                Data extracted from which    text,    table,    figure?  Expert statistical attention needed? 
Notes: 
Haematocrit: 
 {describe} Intervention {} Control  {} comments   Group 1 [n=] (%) Group [n=] (%)  Hematocrit Baseline      Hematocrit Finish of  epo therapy(put time 
point in brackets)    Hematocrit Endpoint (put time 
point in brackets)       Hematocrit Change if stated in the  paper (put time 
point in brackets) {SD} 
   
       Other time points                                                 Data extracted from which    text,    table,    figure?  Expert statistical attention needed?  Notes:   
 
Transfusion:  {describe} Intervention {} Control {}  comments   Group 1 [n=] (%) Group [n=] (%)  Number of Patients transfused      Number of RBC-units transfused     Number of RBC-units  transfused per patient       
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Number of RBC-units transfused/patient/4weeks       Data extracted from which    text,    table,    figure? Expert statistical attention needed? Notes:  
Quality of Life / Performance status Quality of life outcomes? if so refer paper to Jayne and Susan   {describe} Intervention {} Control {} p-value comments  Group 1 [n=] (%) Group [n=] (%)   
QoL Baseline     FACT G – 27 items         Domain 1     Domain 2     Domain 3     Domain 4       FACT F – 13 items       
QOL Score - endpoint       FACT G – 27 items         Domain 1     Domain 2     Domain 3     Domain 4       FACT F – 13 items       
QOL Score - overall       FACT G – 27 items         Domain 1     Domain 2     Domain 3     Domain 4       FACT F – 13 items       
Performance       
Score       Endpoint         
Performance       
Score       Change         Data extracted from which    text,    table,    figure? Expert statistical attention needed? Notes:   
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Tumour response  
Reported?:    Definition 
CR 
complete response  
  
PR 
partial response 
  NR 
no response 
  When was tumour response assessed, ie at end of study, at n weeks? 
How was tumour response assessed? clinical exam, radiotherapy, computor tomagraphy, other? 
   {describe} Intervention {} Control {} Comments, p-value 
 Group 1 [n=] (%) Group [n=] (%)   CR        PR       NR    Data extracted from which    text,    table,    figure?  Expert statistical attention needed?  Notes:  
Mortality 
Reported?:  {describe} Intervention {} Control {} Comments, p-value 
Cause of death Group 1 [n=] (%) Group [n=] (%)            
 
  
      
 
 
   
 
 
   
 
 
   Data extracted from which    text,    table,    figure? Expert statistical attention needed? Notes: 
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Adverse events: document during which period the adverse events occurred: during study period, after completion of study  {describe} Intervention {} Control {} Comments, p-value  Group 1 [n=] (%) Group [n=] (%)   Hypertension (definition)      Rash/Irritation      Pruritis       Mortality       Thrombotic Event (Definition)      Seizure      Haemorrhage/Thrombopenia      Fatigue: Definition:      EPO Antibodies     
 
 
Other adverse events:  {describe} Intervention {} Control {} Comments, p-value  Group 1 [n=] (%) Group [n=] (%)                     Data extracted from which    text,    table,    figure?  Expert statistical attention needed? 
 
Notes:  
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Survival 
Reported?:  
Main results HR CI p Comments (inc 
details) Unadjusted (logrank or M-H)     
Stratified     Cox model          
Other data Group 1 Group 2 Total Comments (inc 
details) Number of events     Number analysed     Median survival     Follow-up (min/max/median)     Proportions alive at t     Kaplan Meier curves?     Other survival curves?          
Summary data estimates 
Method O-E V Favours... Comments (inc 
details)        *complete one sheet for each comparison between groups Comments   
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Data Extraction  Author, Date: _______________ Reviewer, Date: ____________________ Source: ______________ 
ADDITIONAL DATA: (x = yes/100% , nr = not reported, ‘number’%) 
Age of the Patients:  
(mean/median, SD, range: ESA: ……       …………control: ……..…………) 
 
 
 
 
 
 
 
 
 
 
Gender: male only  female only  both 
Type of Chemotherapy 
 
 
 
 
 
 
 
 
Hb- target (see ‘dosing regimen’), Hb-target defined as Hb level when ESA had to be stopped <10 g/dl 10 – 12 g/dl >12 g/dl 
Quality Assessment a. The study was a randomized controlled trial (‘Yes’ if stated to be randomized) b. The study was double-blind (‘Yes’ if a placebo is used) c. Less than 10% of subjects within each study arm were excluded from the analysis and the percentage of subjects excluded from analysis in each arm was less than 2:1; or less than 5% of subjects were excluded in each study arm. High Quality: A and B and C Low Quality: At least one not fulfilled 
Hypertension Is a Definition of Hypertension reported in the date extraction? If not, please note there.  
Transfusion Data Are the transfusion data reported in the data extraction including (a) and excluding (b) the first 4 weeks of ESA treatment? If not, please note there (data for (a) and/or (b) or “not reported” or “unclear”)  
 only children (<18 J)   > 68% children (<18 J)  adults (≥ 18 J), explain:   only elderly (≥ 65 J)  > 68% elderly  only non-elderly adults (≥ 18 J but ≤ 65 J)  > 68% non-elderly  other, explain: 
 platinum-based (100% of the study population received platinum-based ct)  platinum-based (> 70% of the study population received platinum-based ct)  both (less than 70% platinum-containing)  both (no numbers given)  without platinum (all patients)  other, explain:  
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TRIAL SELECTION FORM  Reviewer:         Date:  TO INCLUDE* KQ1 a,b,c KQ1 d KQ2 KQ3 QoL SURE      UNSURE      TO EXCLUDE**      CONFIRMED      Reason for exclusion** nrct allo ong none mbt ept surg nop msl ora eqol dup 
 REF ID  First author and year of publication  Connex to trial - No ongoing interim? => ex - Duplicate publication? => ex 
 
Source of evidence Full text Abstract FDA Personal Other (specify)   
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Appendix E.  Data Used in Meta-Analyses and Not 
Included in the Text 
 
Appendix Table E1. Hematologic response 
Study Treated Events 
Treated 
Total 
Controla 
Events 
Control 
Total Drug 
Aapro 2008 157 231 32 232 Epoetin 
Bamias 2003 15 72 2 72 Epoetin 
Boogaerts 2003 63 133 17 129 Epoetin 
Case 1993 46 79 10 74 Epoetin 
Chang 2005 115 175 11 175 Epoetin 
Dammacco 2001 38 66 6 66 Epoetin 
Henry 1995 31 64 4 61 Epoetin 
Iconomou 2003 25 57 7 55 Epoetin 
Littlewood 2001 172 244 22 115 Epoetin 
Milroy 2011 37 189 5 191 Epoetin 
ML17620 2006 29 61 14 60 Epoetin 
Oberhoff 1998 38 114 7 104 Epoetin 
Osterborg 2005 114 170 46 173 Epoetin 
Razzouk 2006 63 111 39 111 Epoetin 
Rose 1994 67 142 13 79 Epoetin 
Savonije 2005 143 208 31 100 Epoetin 
Witzig 2005 120 165 52 164 Epoetin 
Hedenus 2003 104 174 31 170 Darbepoetin 
Katakami 2008 57 103 21 104 Darbepoetin 
Kotasek 2003a 8 32 1 8 Darbepoetin 
Kotasek 2003b 8 17 1 8 Darbepoetin 
Kotasek 2003c 23 46 2 9 Darbepoetin 
Kotasek 2003d 17 28 1 8 Darbepoetin 
Kotasek 2003e 20 35 1 9 Darbepoetin 
Kotasek 2003f 20 40 1 9 Darbepoetin 
Glaspy 2002A 31 59 38 53 Darb vs Epo 
Waltzman 2005 74 177 101 175 Darb vs Epo 
a For darbepoetin versus epoetin control is epoetin, otherwise placebo 
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Appendix Table E2. Proportion transfused 
Study Treated Events 
Treated 
Total 
Control 
Events 
Control 
Total Drug 
Aapro 2008 33 231 63 232 Epoetin 
Bamias 2003 11 72 24 72 Epoetin 
Blohmer 2011 14 127 38 129 Epoetin 
Boogaerts 2003 43 133 67 129 Epoetin 
Case 1993 32 79 36 74 Epoetin 
Chang 2005 15 175 40 175 Epoetin 
Christodoulou 2009 16 167 36 170 Epoetin 
Dammacco 2001 19 69 36 76 Epoetin 
EPO-INT-3 21 136 23 65 Epoetin 
Fujisaka 2011 4 89 18 92 Epoetin 
Goss 2005 8 52 27 52 Epoetin 
Grote 2005 26 109 42 115 Epoetin 
Gupta 2009 9 58 25 57 Epoetin 
Henry 1995 34 64 42 61 Epoetin 
Iconomou 2003 9 57 14 55 Epoetin 
Leyland-Jones 2005 47 469 66 470 Epoetin 
Littlewood 2001 62 251 49 124 Epoetin 
Milroy 2011 16 189 43 191 Epoetin 
Moebus 2007 41 320 86 305 Epoetin 
Oberhoff 1998 32 114 44 104 Epoetin 
Osterborg 2005 65 169 90 173 Epoetin 
Porter 1996 9 10 10 10 Epoetin 
Pronzato 2010 8 107 18 109 Epoetin 
Ray-Coquard 2009 39 108 61 105 Epoetin 
Razzouk 2006 72 111 86 111 Epoetin 
Rose 1994 65 142 47 79 Epoetin 
Savonije 2005 77 211 66 102 Epoetin 
Thomas 2002 7 62 31 65 Epoetin 
Tsuboi 2009 7 61 7 56 Epoetin 
Wilkinson 2006 9 114 18 59 Epoetin 
Witzig 2005 42 166 65 164 Epoetin 
Hedenus 2003 52 167 79 165 Darbepoetin 
Hernandez 2009 58 193 91 193 Darbepoetin 
Katakami 2008 7 103 20 104 Darbepoetin 
Kotasek 2003a 8 30 4 8 Darbepoetin 
Kotasek 2003b 5 17 4 8 Darbepoetin 
Kotasek 2003c 12 41 4 9 Darbepoetin 
Kotasek 2003d 7 27 4 8 Darbepoetin 
Kotasek 2003e 9 35 3 8 Darbepoetin 
Kotasek 2003f 7 38 4 9 Darbepoetin 
Pirker 2008 52 298 116 298 Darbepoetin 
Untch 2011 1 356 0 377 Darbepoetin 
Vansteenkiste 2002 53 156 89 158 Darbepoetin 
Glaspy 2002A 8 59 12 53 Darb vs. Epo 
Glaspy 2006 157 582 126 571 Darb vs. Epo 
Kotsori 2006 9 55 3 55 Darb vs. Epo 
Schwartzberg 2004a 4 72 11 69 Darb vs. Epo 
Schwartzberg 2004b 14 51 9 51 Darb vs. Epo 
Schwartzberg 2004c 7 34 6 35 Darb vs. Epo 
Waltzman 2005 29 163 20 155 Darb vs. Epo 
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Appendix Table E3. Overall survival 
Study Treated Events 
Treated 
Total 
Control 
Events 
Control 
Total 
Observed- 
Expected Variance Drug 
Aapro 2008 169 231 169 232 5.77 85.29 Epoetin 
Antonadou 2001 10 190 30 195 -10.4 10 Epoetin 
Bamias 2003 7 72 4 72 1.5 2.56 Epoetin 
Blohmer 2004 25 127 29 129 -1.71 13.34 Epoetin 
Boogaerts 2003 16 132 12 127 2.85 6.71 Epoetin 
Case 1993 10 81 9 76 0.49 4.73 Epoetin 
Chang 2005 27 176 28 178 -0.84 13.64 Epoetin 
Christodoulou 2009 71 167 87 170 8.83 39.5 Epoetin 
Dammacco 2001 1 69 7 76 -3.03 2.06 Epoetin 
Debus 2006 146 195 159 190 -15.56 73.82 Epoetin 
Engert 2009 27 648 36 655 -7.15 20.05 Epoetin 
EPO-INT-1 11 165 3 81 2.02 3.19 Epoetin 
EPO-INT-3 9 135 3 65 1.19 2.71 Epoetin 
Fugisaka 2011 37 89 34 92 2.09 10.84 Epoetin 
Goss 2005 28 52 29 52 1.71 14 Epoetin 
Grote 2005 100 109 101 115 7.84 49.92 Epoetin 
Gupta 2009 17 58 14 57 -1.25 11.88 Epoetin 
Hedenus 2003 101 176 82 173 12.44 44.82 Darbepoetin 
Henke 2003 109 180 89 171 16.08 48.83 Epoetin 
Henry 1995 7 67 10 65 -1.61 4.18 Epoetin 
Hernandez 2009 17 196 20 195 -1.62 9.31 Darbepoetin 
Hoskin 2009 74 151 75 149 1.45 36.89 Epoetin 
Kotasek 2003 4 208 1 51 -0.01 0.8 Darbepoetin 
Leyland-Jones 2005 121 469 91 470 18.23 53.04 Epoetin 
Littlewood 2001 155 251 82 124 -11.23 50.33 Epoetin 
Machtay 2007 37 77 32 71 3.01 17.28 Epoetin 
Milroy 2003 136 214 126 210 7.74 63.36 Epoetin 
ML17620 2006 4 61 0 60 1.98 0.97 Epoetin 
Moebus 2007 59 324 56 319 0.28 28.43 Epoetin 
Oberhoff 1998 9 116 10 111 -2.08 4.36 Epoetin 
Osterborg 2002 110 173 109 176 2.14 54.57 Epoetin 
Overgaard 2009 144 255 119 259 15.02 64.98 Darbepoetin 
Pirker 2008 243 299 254 301 -7.26 117.39 Darbepoetin 
Pronzato 2002 23 110 20 113 0.52 10.72 Epoetin 
Ray-Coquard 2009 75 110 84 108 -9.37 39.76 Epoetin 
Razzouk 2004 2 112 2 110 -0.02 0.99 Epoetin 
Rose 1994 16 142 6 79 2.63 5.19 Epoetin 
Savonije 2005 132 211 61 104 5.7 43.51 Epoetin 
Thomas 2002 4 65 5 65 -0.52 2.21 Epoetin 
Thomas 2008 22 58 17 56 2.38 9.66 Epoetin 
Tsuboi 2009 21 61 19 56 -0.98 15.76 Epoetin 
Untch 2008 59 345 48 369 7.54 26.45 Darbepoetin 
Vansteenkiste 2002 101 159 118 161 -12.4 52.62 Darbepoetin 
Wilkinson 2006 3 121 0 61 0.99 0.66 Epoetin 
Witzig 2005 121 174 119 170 7.01 57.33 Epoetin 
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Appendix Table E4. On-study mortality 
Study Treated Events 
Treated 
Control 
Control 
Events 
Control 
Total 
Observed-
Expected Variance Drug 
Aapro 2008 47 231 35 232 6.57 20.4 Epoetin 
Bamias 2003 7 72 4 72 1.5 2.56 Epoetin 
Boogaerts 2003 10 132 10 127 0.1 4.94 Epoetin 
Case 1993 10 81 9 76 0.49 4.73 Epoetin 
Chang 2005 7 176 5 178 0.93 3.01 Epoetin 
Dammacco 2001 1 69 7 76 -3.03 2.06 Epoetin 
Debus 2006 26 195 18 190 3.51 10.91 Epoetin 
EPO-INT-1 6 165 2 81 0.74 1.79 Epoetin 
EPO-INT-3 9 135 3 65 1.19 2.71 Epoetin 
Fujisaka 2011 1 89 0 92 0.508 0.249 Epoetin 
Goss 2005 4 52 1 52 1.53 1.25 Epoetin 
Grote 2005 16 109 21 115 -2.13 9.04 Epoetin 
Henke 2003 9 180 7 171 0.8 4.01 Epoetin 
Henry 1995 7 67 10 65 -1.61 4.18 Epoetin 
Hoskin 2009 5 151 2 149 1.51 1.76 Epoetin 
Leyland-Jones 2005 121 469 91 470 18.23 53.04 Epoetin 
Littlewood 2001 40 251 22 124 -3.29 13.26 Epoetin 
Machtay 2007 5 77 3 71 0.9 1.99 Epoetin 
Milroy 2011 51 214 38 210 8.1 21.79 Epoetin 
ML17620 2006 4 61 0 60 1.98 0.97 Epoetin 
Moebus 2007 0 324 0 319 0 0 Epoetin 
Oberhoff 1998 9 116 10 111 -2.08 4.36 Epoetin 
Osterborg 2005 24 173 19 176 2.73 10.73 Epoetin 
Pronzato 2010 4 110 8 113 -1.98 3.02 Epoetin 
Ray-Coquard 2009 18 110 23 108 -3.09 10.26 Epoetin 
Razzouk 2006 2 112 2 110 -0.02 0.99 Epoetin 
Rose 1994 16 142 6 79 2.63 5.19 Epoetin 
Savonije 2005 24 211 13 104 -0.75 7.93 Epoetin 
Thomas 2002 4 65 4 65 -0.02 2.01 Epoetin 
Thomas 2008 1 58 1 56 -0.03 0.5 Epoetin 
Wilkinson 2006 2 121 0 61 0.69 0.45 Epoetin 
Witzig 2005 31 174 25 170 2.77 13.91 Epoetin 
Hedenus 2003 10 176 4 173 3.05 3.48 Darbepoetin 
Hernandez 2009 17 196 20 195 -1.62 9.31 Darbepoetin 
Kotasek 2003 4 208 1 51 -0.01 0.8 Darbepoetin 
Pirker 2008 53 299 51 301 0.52 26.45 Darbepoetin 
Untch 2011 0 353 0 376 0 0 Darbepoetin 
Vansteenkiste 2002 23 159 21 161 0.63 10.82 Darbepoetin 
Glaspy 2006 67 611 84 598 -9.31 33.06 Darb vs. Epo 
Waltzman 2005 34 180 25 178 4.34 12.35 Darb vs. Epo  
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Appendix Table E5. Thromboembolic events 
Study Treated Events 
Treated 
Total 
Control 
Events 
Control 
Total Drug 
Aapro 2008 29 231 13 231 Epoetin 
Bamias 2003 0 72 1 72 Epoetin 
Blohmer 2011 2 127 3 129 Epoetin 
Case 1993 2 81 3 76 Epoetin 
Chang 2005 19 176 14 178 Epoetin 
Dammacco 2001 5 69 1 76 Epoetin 
Debus 2006 38 192 23 191 Epoetin 
Engert 2010 45 645 44 644 Epoetin 
EPO-INT-1 3 164 1 80 Epoetin 
EPO-INT-3 8 135 1 65 Epoetin 
Fujisaka 2011 1 89 0 92 Epoetin 
Goss 2005 16 52 2 52 Epoetin 
Grote 2005 12 109 11 115 Epoetin 
Gupta 2009 0 57 0 59 Epoetin 
Henke 2003 10 180 6 171 Epoetin 
Henry 1995 6 67 8 65 Epoetin 
Hoskin 2009 4 133 2 149 Epoetin 
Leyland-Jones 2005 36 448 25 456 Epoetin 
Littlewood 2001 14 251 5 124 Epoetin 
Machtay 2011 2 72 0 68 Epoetin 
Milroy 2011 18 189 13 191 Epoetin 
Moebus 2007 9 305 5 288 Epoetin 
Osterborg 2005 1 170 0 173 Epoetin 
Pronzato 2010 4 109 1 111 Epoetin 
Ray-Coquard 2009 5 110 4 107 Epoetin 
Razzouk 2006 6 112 2 110 Epoetin 
Rose 1994 9 142 2 79 Epoetin 
Savonije 2005 7 211 1 104 Epoetin 
Thomas 2008 10 58 5 55 Epoetin 
Tsuboi 2009 1 62 0 58 Epoetin 
Wilkinson 2006 10 121 1 60 Epoetin 
Witzig 2005 9 168 6 165 Epoetin 
Hedenus 2003 6 175 1 169 Darbepoetin 
Hernandez 2009 16 194 11 192 Darbepoetin 
Overgaard 2009 7 255 3 259 Darbepoetin 
Pirker 2008 65 301 43 296 Darbepoetin 
Untch 2011 20 318 17 396 Darbepoetin 
Vansteenkiste 2002 7 155 5 159 Darbepoetin 
Glaspy 2006 37 611 42 598 Darb vs. Epo 
Schwartzberg 2004 2 157 2 155 Darb vs. Epo 
Waltzman 2005 17 177 20 175 Darb vs. Epo 
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Appendix F. Changes in Trials Included in Current 
and 2006 Reviews 
 
 
Appendix Table F1. Changes in trials included in current and 2006 reviews 
 
    Trials Hematologic Response Study 
Darbepoetin 
vs. Epoetin 
Excluded 2 Glaspy 2003, Alexopoulos 2004 
Included unchanged 2 Glaspy 2002, Waltzman 2005 
Data updated 0   
New data   
Total Studies Included 0   
Epoetin vs. 
Control 
Excluded 2 Cazzola 1995, Osterborg 1996  
Included unchanged 12 Bamias 2003, Boogaerts 2003, Case 1993, Chang 
2005, Dammacco 2001, Henry 1995, Iconomou 2003, 
Littlewood 2001, Oberhoff 1998, Osterborg 2002, 
Rose 1994, Witzig 2005  
Data updated 1   
New data 3 Razzouk 2006, Aapro 2008, ML17620 
Total Studies Included 16   
Darbepoetin 
vs. Control 
Excluded 1 Hedenus 2002 
Included unchanged 2 Hedenus 2003, Kotasek 2003 
Data updated 0   
New data 0   
Total Studies Included 2   
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Appendix Table F1. Changes in Trials Included in Current and 2006 Reviews (continued) 
   Trials Transfusion Rates Study 
Darbepoetin 
vs. Epoetin 
Excluded 1 Alexopoulos 2004 
Included unchanged 2 Glaspy 2002, Schwartzberg 2004 
Data updated 2 Glaspy 2005 → Glaspy 2006, Waltzman 2005 → 
Waltzman 2005 
New data 1 Kotsori 2006 
Total Studies Included 5   
Epoetin vs. 
Control 
Excluded 18 Aravantinos 2003 , Carabantes 1999, Cascinu 1994, 
Cazzola 1995, Del Mastro 1997, Dunphy 1999, Henze 
2002, Huddart 2002, Kunikane 2001, Kurz 1997, 
Osterborg 1996, Quirt 1996, Ten Bokkel Huinink 1998, 
Thatcher 1999, Throuvalas 2000, Vadhan-Raj 2004, 
Welch 1995, Wurnig 1996 
Included unchanged 13 Bamias 2003, Boogaerts 2003, Case 1993, Chang 
2005, Dammacco 2001, Henry 1995, Iconomou 2003, 
Littlewood 2001, Oberhoff 1998, Osterborg 2002, 
Thomas 2002, Rose 1994, Witzig 2005 
Data updated 3 Razzouk 2004 → Razzouk 2006, Janinis 2003→ 
Christodoulou 2009, Savonije 2004→Savonije 2005 
New data 15 Aapro 2008, Blohmer 2004, EPO-INT-3, Fujisaka 
2011, Goss 2005, Grote 2005, Gupta 2009, Leyland-
Jones 2005, Milroy 2011, Moebus 2007, Porter 1996, 
Pronzato 2010, Ray-Coquard 2009, Tsuboi 2009, 
Wilkinson 2006 
Total Studies Included 28   
Darbepoetin 
vs. Control 
Excluded 1 Hedenus 2002 
Included unchanged 3 Hedenus 2003, Kotasek 2003, Vansteenkiste 2002 
Data updated 0   
New data 4 Hernandez 2009, Katakami 2008, Pirker 2008, Untch 
2011 
Total Studies Included 7   
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Appendix Table F1. Changes in Trials Included in Current and 2006 Reviews (continued) 
  Trials Overall Survival Study 
Darbepoetin 
vs. Epoetin 
Excluded 1  Waltzman 2005 (abstract)→ Waltzman 2005 
(included in on-study mortality) 
Included unchanged 0   
Data updated 0  
New data 0   
Total Studies Included 2   
Epoetin vs. 
Control 
Excluded 13 Cascinu 1994, Cazzola 1995, Del Mastro 1997, 
Dunphy 1999, EPO-CAN-20, Kurz 1997, 
O’Shaughnessy 2005, Osterborg 1996, P-174, ten 
Bokkel 1998, Thatcher 1999, Throuvalas 2000, 
Vadhan-Raj 2004 
Included unchanged 1 Bamias 2003 
Data updated 21 Case 1993 → Case 1993 IPD, Chang 2005 → Chang 
2005 IPD, Coiffier 2001 → Boogaerts 2003 IPD, 
Dammacco 2001 → Dammacco 2001 IPD, Henke 
2003 → Henke 2003 IPD, Henry 1995 → Henry 1995 
IPD, Leyland-Jones 2003 → Leyland-Jones 2005 IPD, 
Littlewood 2001 → Littlewood 2001 IPD, Machtay 
2004 → Machtay 2007, Oberhoff 1998 → Oberhoff 
1998 IPD, Osterborg 2005 → Osterborg 2002 IPD, 
Rose 1994 → Rose 1994 IPD, Savonije 2004 → 
Savonije 2005 IPD, Witzig 2005 → Witzig 2005 IPD, 
EPO-CAN-15 → Goss 2005 IPD, EPO GBR-07 → 
Hoskin 2009 IPD, GOG-191 → Thomas 2008, N93004 
2004 → Grote 2005 IPD, INT-1 → EPO-INT-1IPD, 
INT-3 → EPO-INT-3 IPD 
New data 16 Aapro 2008 IPD, Fujisaka 2011, Pronzato 2002 IPD, 
Ray-Coquard 2009 IPD, Thomas 2002 IPD, Wilkinson 
2006 IPD, Milroy 2003 IPD, Moebus 2007 IPD, Debus 
2006 IPD, Antonadou 2001, Blohmer 2004, 
Christodoulou 2009, Gupta 2009, Tsuboi 2009, Engert 
2009, ML17620 
Total Studies Included 38   
Darbepoetin 
vs. Control 
Excluded 1 Hedenus 2002 
Included unchanged 4 Hedenus 2003, Kotasek 2003, Vansteenkiste 2002 
Data updated 0   
New data 4 Hernandez 2009, Pirker 2008, Overgaard 2009, Untch 
2011 
Total Studies Included 8   
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Appendix Table F1. Changes in Trials Included in Current and 2006 reviews (continued) 
  
Trials Thromboembolic Events Study 
Darbepoetin 
vs. Epoetin 
Excluded 0   
Included unchanged 1 Schwartzberg 2004 
Data updated 2 Glaspy 2005 → Glaspy 2006, Waltzman 2005 → 
Waltzman 2005 
New data 0   
Total Studies Included 3   
Epoetin vs. 
Control 
Excluded 10 Cascinu 1994, Osterborg 1996, P-174, Rosenzweig 
2004, Ten Bokkel 1998, Thatcher 1999, Throuvalas 
2000, Vadhan-Raj 2004, Welch 1995, EPO-CAN-20 
Included unchanged 13 Bamias 2003, Case J&J 2004, Chang 2005, 
Dammacco J&J 2004, EPO-INT-1 J&J 2004, EPO-
INT-3 J&J 2004, Henke Roche 2004, Henry J&J 2004, 
Leyland-Jones J&J 2004, Littlewood J&J 2004, 
Osterborg 2002, Rose J&J 2004, Witzig J&J 2004 
Data updated 7 EPO-CAN-15 → Goss 2005, N93004 2004 → Grote 
2005, EPO-GBR-07 → Hoskin 2009,    GOG 191 → 
Thomas 2008, Machtay 2004 → Machtay 2007, 
Savonije 2004→ Savonije 2005, Razzouk 2004 → 
Razzouk 2006 
New data 12 Aapro 2008, Blohmer 2011, J&J 2004, Debus 2006, 
J&J 2007, Engert 2009; Fujisaka 2011, Gupta 2009, 
Milroy 2011, Moebus 2007, Pronzato 2010, Ray-
Coquard 2009, Tsuboi 2009, Wilkinson 2006 
Total Studies Included 32   
Darbepoetin 
vs. Control 
Excluded     
Included unchanged 1 Vansteenkiste 2002 
Data updated     
New data 5 Hedenus 2003, Hernandez 2009, Pirker 2008, 
Overgaard 2009, Untch 2011 
Total Studies Included 6   
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Appendix Table F1. Changes in Trials Included in Current and 2006 reviews (continued) 
  
Trials QoL FACT-Fatigue (Complete Data) Study 
Darbepoetin 
vs. Epoetin 
Excluded 0   
Included unchanged 0   
Data updated 1 Glaspy 2005 → Glaspy 2006 
New data 0   
Total Studies Included 1   
Epoetin vs. 
Control 
Excluded 0   
Included unchanged 7 Boogaerts 2003, Chang 2005, Hedenus 2003, 
Iconomou 2003, Littlewood 2001, Osterborg 2002, 
Witzig 2005 
Data updated 0   
New data 4 Christodoulou 2009, Hoskin 2009, Savonije 2005, 
Tsuboi 2009 
Total Studies Included 11   
Darbepoetin 
vs. Control 
Excluded 0   
Included unchanged 1 Vansteenkiste 2002 
Data updated 0   
New data 2 Kotasek 2003, Pirker 2008 
Total Studies Included 3   
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Appendix Table F1. Changes in Trials Included in Current and 2006 reviews (continued) 
  Trials Tumor Response Study 
Darbepoetin 
vs. Epoetin 
Excluded 0   
Included unchanged 0   
Data updated 0   
New data 0   
Total Studies Included 0   
Epoetin vs. 
Control 
Excluded 3 Throuvalas 2000, N93004 2004, Vadhan-Raj 2004 
Included unchanged 1 Henke 2003 
Data updated 4 EPO-CAN-15 → Goss 2005, EPO-GBR-07 → Hoskin 
2009, GOG 191 → Thomas 2008, Machtay 2004 → 
Machtay 2007  
New data 8 Blohmer 2011, Debus 2006, Engert 2009, Gupta 
2009, Milroy 2011, Moebus 2007, Pronzato 2010, 
Wagner 2004 
Total Studies Included 13   
Darbepoetin 
vs. Control 
Excluded 0   
Included unchanged 0   
Data updated 0   
New data 2 Overgaard 2009, Untch 2011 
Total Studies Included 2   
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Appendix Table F1. Changes in Trials Included in Current and 2006 reviews (continued) 
  
Trials ADE (Hypertension) Study 
Darbepoetin 
vs. Epoetin 
Excluded 0   
Included unchanged 0   
Data updated 0   
New data 0   
Total Studies Included 0   
Epoetin vs. 
Control 
Excluded 9 Cascinu 1994, Kunikane 2001, Osterborg 1996, 
Rosenzweig 2004, Silvestris 1995, Ten Bokkel 
Huinink 1998, Thatcher 1999, Welch 1995 
Included unchanged 7 Bamias 2003,  Case 1993, Dammaccco 2001, Henry 
1995,  Iconomou 2003,a Littlewood 2001, Rose 1994 
Data updated 0   
New data 8 Fujisaka 2011, Hoskin 2009, Milroy 2011, Osterborg 
2002, Razzouk 2006, Savonije 2005, Wilkinson 2006, 
Tsuboi 2009 
Total Studies Included 15   
Darbepoetin 
vs. Control 
Excluded 0   
Included unchanged 1 Vansteenkiste 2002 
Data updated 0   
New data 2 Hernandez 2009, Pirker 2008 
Total Studies Included 3   
a No events 
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Appendix Table F1. Changes in Trials Included in Current and 2006 reviews (continued) 
  Trials ADE (Thrombocytopenia/Hemorrhage) Study 
Darbepoetin 
vs. Epoetin 
Excluded 0   
Included unchanged 0   
Data updated 0   
New data 1 Pirker 2008 
Total Studies Included 1   
Epoetin vs. 
Control 
Excluded 4 Cascinu 1994, Del Mastro 1997, Kunikane 2001, 
Thatcher 1999 
Included unchanged 3 Bamias 2003, Boogaerts 2003, Dammacco 2001 
Data updated 0   
New data 7a Fujisaka 2011, Goss 2005, Littlewood 2001, Milroy 
2010, Savonije 2005, Tsuboi 2009, Witzig 2005  
Total Studies Included 12   
Darbepoetin 
vs. Control 
Excluded 0   
Included unchanged 0   
Data updated 0   
New data 2 Pirker 2008, Untch 2011 
Total Studies Included 2   
a Gupta 2009 also reported thrombocytopenia but without consistent event frequency so not included in results. 
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Appendix Table F1. Changes in Trials Included in Current and 2006 reviews (continued) 
  Trials ADE (Rash) Study 
Darbepoetin 
vs. Epoetin 
Excluded 0   
Included unchanged 0   
Data updated 0   
New data 0   
Total Studies Included 0   
Epoetin vs. 
Control 
Excluded 5 Del Mastro 1997, Kurz 1997, Osterborg 1996, 
Thatcher 1999, Welch 1995 
Included unchanged 1 Henry 1995 
Data updated 0   
New data 5 Gupta 2009, Milroy 2011, Osterborg 2002, Tsuboi 
2009, Witzig 2005 
Total Studies Included 6   
Darbepoetin 
vs. Control 
Excluded 0   
Included unchanged 0   
Data updated 0   
New data 0   
Total Studies Included 0   
 F-10 
Appendix Table F1. Changes in Trials Included in Current and 2006 reviews (continued) 
  Trials ADE (Seizure) Study 
Darbepoetin 
vs. Epoetin 
Excluded 1 Glaspy 2003 
Included unchanged 0   
Data updated 0   
New data 0   
Total Studies Included 0   
Epoetin vs. 
Control 
Excluded 1 Cascinu 1994 
Included unchanged 2 Case 1993, Henry 1995 
Data updated 0   
New data 1 Savonije 2005 
Total Studies Included 3   
Darbepoetin 
vs. Control 
Excluded 0   
Included unchanged 0   
Data updated 0   
New data 2 Hernandez 2009, Pirker 2008 
Total Studies Included 2   
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Appendix Table F1. Changes in Trials Included in Current and 2006 reviews (continued) 
  Trials ADE (Antibodies) Study 
Darbepoetin 
vs. Epoetin 
Excluded 1 Glaspy 2003 
Included unchanged 2 Schwartzberg 2004, Glaspy 2002 
Data updated 1 Glaspy 2005 → Glaspy 2006  
New data 1 Waltzman 2005 
Total Studies Included 4   
Epoetin vs. 
Control 
Excluded 2 Thatcher 1999, Ten Bokkel 1998 
Included unchanged 4 Chang 2005, Henry 1995, Oberhoff 1998, Osterborg 
2002 
Data updated 0   
New data 1 Tsuboi 2009 
Total Studies Included 5   
Darbepoetin 
vs. Control 
Excluded 0   
Included unchanged 1 Vansteenkiste 2002 
Data updated 0   
New data 4 Hedenus 2003, Hernandez 2009, Kotasek 2003,  
Pirker 2008  
Total Studies Included 5        
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Appendix G. ESA Trials Included in Published 
Meta-Analyses Evaluated in This Review 
 
Appendix Table G1.  ESA trials included in published meta-analyses evaluated in this 
review 
 
Publi-
cation 
status 
ESA Glaspy 2010 
Bohlius 
2009 
Bennett 
2008 
Ludwig 
2009 
Number of included studies   60 53 51 7 
Sample size exclusions?   None Yesa None None 
Individual patient data meta-analysis?   No Yes No Yes 
Trials included in meta-analysis:       
Aapro 2008 full epo-b • •   
Abels 1993 full epo-a • • •  
Bamias 2003 full epo-a •  •  
Blohmer 2003/4 abs epo-a •  •  
Boogaerts 2003 (Coiffier 2001) full epo-b • • •  
Cascinu 1994 full epo-a •    
Case 1993 full epo-a • • •  
Cazzola 1995 full epo-b • • •  
Chang 2005 (EPO-CAN-17) full epo-a • • •  
Charu 2007 full darb • • •  
Dammacco 2001 full epo-a • • •  
Debus 2007 abs epo-a • • •  
Del Mastro 1997 full epo-? •  •  
Dunphy 1999 full epo-? •  •  
Engert 2007 unpub epo-a •    
EPO-CAN-203 unpub epo-a •    
EPO-CAN-303 unpub epo-a •    
EPO-GER-20 unpub epo-a  •   
OBE/EPO-INT-03 unpub epo-a  •   
Gordon 2006 abs darb • • •  
Goss 2005 (EPO-CAN-15) abs epo-a • • •  
Grote 2005 (N93-004) full epo-a • • •  
Hedenus 2002 full darb •   • 
Hedenus 2003 full darb • • • • 
Henke 2003 full epo-b • • •  
Henry 1995 full epo-a • • •  
Huddart 2002 abs epo-a  •   
Kotasek 2002 abs darb  •  • 
Kotasek 2003 full darb • • • • 
Kurz 1997 full epo-a •    
Leyland-Jones 2005 full epo-a • • •  
Littlewood 2001 full epo-a • • •  
Machtay 2007 full epo-a • • •  
Milroy 2003 abs epo-a • •   
Moebus 2007 abs epo-a • • •  
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Appendix Table G1.  ESA Trials Included in Published Meta-Analyses Evaluated in this 
Review (continued) 
 
Publi-
cation 
status 
ESA Glaspy 2010 
Bohlius 
2009 
Bennett 
2008 
Ludwig 
2009 
Mystakidou 2005 full epo-a •  •  
Oberhoff 1998 full epo-b • • •  
ODAC 2004, INT-1 unpub epo-a • • •  
ODAC 2004, INT-3 unpub epo-a • • •  
ODAC 2004, EPO-GBR-07 (Hoskin 2004) unpub epo-a • • •  
ODAC 2004, P-174 (Pangalis 1995) unpub epoa • • •  
O'Shaughnessy 2005 full epo-a • • •  
Osterborg 1996 full epo-b • • •  
Osterborg 2002/2005 full epo-b • • •  
Overgaard 2007 (ended early) abs darb •  •  
Pirker 2008 (Amgen DA 145) full darb • • • • 
Prozanto 2002 abs epo-a • •   
Quirt 1996 abs epo-a  •   
Ray-Coquard 2006 abs epo-a  •   
Razzouk 2004/2006 (all patients) abs/full epo-a •  •  
Razzouk 2006 (NHL/solid tumors only)  full epo-a  •   
Rose 1994 abs epo-a • • •  
Savonije 2005 full epo-a • • •  
Smith 2003 full darb •  •  
Smith 2008 (Glaspy 2007) full darb • • •  
Strauss 2008 full epo-b • • •  
Taylor 2005 abs darb • • • • 
Ten Bokkel Huinink 1998 full epo-b • • •  
Thatcher 1999 full epo-a • • •  
Thomas 2002 abs epo-a  •   
Thomas 2008 (GOG-191) full epo-a • • •  
Throuvalas 2000 abs epo-? •  •  
Untch 2008 (PREPARE) abs darb • • •  
Vadhan-Raj 2004 abs epo-a • • •  
Vansteenkiste 2002 full darb • • • • 
Wilkinson 2006 full epo-a • • •  
Witzig 2005 full epo-a • • •  
Wright 2007 (EPO-CAN-20) full epo-a • • •  
aExcluded RCTs with <100 patients or analyses based on <50 patients 
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Appendix H.  PFS and Other Outcomes 
 
Appendix Table H1.  Summary of trials reporting results related to tumor progression 
  ESA Progression-Free Survival Disease-Free survival Time to Progression Proportion of Patients with Progressive Disease 
Aapro 2008 epo Metastatic breast cancer; No 
definition of progression; 
HR=1.07; 95% CI, 0.89 to 1.30; 
P=0.448 at 18 mo. (treatment = 
24 wk) 
      
Antonadou 2001 epo   Pelvic malignancies receiving 
RT; 
No definition of DFS; 
4-yr DFS 85.3% (epo) vs. 
67.2%, p=0.0008 
    
Blohmer 2011 epo    At median follow-up of 50.3 mos, 
proportion with recurrence (18.1% 
epo vs 27.1%) 
Engert 2010 epo      Hodgkin’s Lymphoma;  
No definition of progression; 
Proportion with progression or 
relapse (8.3% epo vs. 7.8%), 
proportion with progressive disease 
(2.9% epo vs. 1.9%) 
EPO-INT-1 epo    Ovarian cancer; no definition 
of progression; 16% (epo) vs. 
15% 
  
Fujisaka 2011 epo    Tumor progression during treatment 
(27% epo vs 26.1%) 
Goss 2005, EPO-
CAN-15 
epo     Limited disease SCLC on 
chemoRx; no definition of 
progression; TTP, p=0.83 
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Appendix Table H1.  Summary of Trials Reporting Results Related to Tumor Progression (continued) 
  ESA Progression-Free Survival Disease-Free survival Time to Progression Proportion of Patients with Progressive Disease 
Grote 2005, N03-
004 
epo       SCLC on chemo; 
14.7% (epo) vs. 12.2% ; 
PD defined as (1) >25% increase in 
the size of at least one measurable 
malignant lesion or >25% increase 
in the estimated size of any 
assessable but nonmeasurable 
lesion; or (2) >25% increase in the 
estimated extent of assessable 
disease or >25% increase in the 
estimated extent of unmeasurable 
disease; or (3) development of a 
new malignant lesion. 
Henke 2003 epo Locoregional PFS; Tumour 
progression was assumed 
when tumour size increased by 
>25%;  RR=1·69 (1·16–2·47, 
p=0·007) 
      
Hoskin 2009, 
EPO-GBR-7 
epo   H&N Ca on radiotx; Local 
tumor recurrence was 
assessed clinically, and 
radiologically; HR=1.04; 95% 
CI, 0.77 to 1.41 
    
Leyland-Jones 
2005 
epo       Metastatic breast cancer on chemo; 
tumor response assessed by WHO 
criteria; 27% (epo) vs 22% 
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Appendix Table H1.  Summary of Trials Reporting Results Related to Tumor Progression (continued) 
  ESA Progression-Free Survival Disease-Free survival Time to Progression Proportion of Patients with Progressive Disease 
Machtay 2007 epo H&N Ca on radiotx + chemo; 
Local–regional failure was 
defined as the failure to obtain 
a complete response after 
definitive radiotherapy, or the 
reappearance of local and/or 
regional head-and-neck cancer 
after a complete response; 
biopsy confirmation was not 
required if convincing clinical/ 
radiographic evidence of 
locoregional 
persistence/recurrence 
in treating oncologist opinion 
Locoregional PFS, multi-
variate HR 1.26 (95% CI, 0.80–
1.99) 
      
Moebus 2007 epo   High risk breast cancer on 
chemo; no definition of DFS; 5-
year DFS 72% (epo) vs. 71% 
(p=0.86) 
    
Osterborg 2005 epo       B-CLL, NHL, MM; No definition of 
disease progression; 18% (epo) vs 
23% 
Ray-Coquard 
2009 
epo     solid or hematologic tumors 
on chemo; no definition of 
disease progression; median 
PFS (epo) 5.0 months (95% 
CI: 4.3–6.6) vs 4.4 months 
(95% CI: 3.8–5.2) 
  
Thomas 2008, 
GOG-0191 
epo  Cervical cancer on 
chemoradiotx; Progression was 
defined as > 50%  increase in 
the cross-product of the 
existing primary tumor relative 
to the smallest cross-product 
from all previous exams; 58% 
(epo) vs. 65% at 3 years 
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Appendix Table H1.  Summary of Trials Reporting Results Related to Tumor Progression (continued) 
  ESA Progression-Free Survival Disease-Free survival Time to Progression Proportion of Patients with Progressive Disease 
Wilkinson 2006 epo       ovarian cancer on chemo; no 
definition of disease progression; 
11% (epo) vs 2%, P=0.425) 
Witzig 2005 epo       incurable cancer on chemo; no 
definition of disease progression; 
33% (epo) vs 29% (p=0.86) 
Overgaard 2009 darb H&N on chemo; no definition of 
disease progression; RR: 1.47 
(1.14-1.94) 
RR: 1.32 (1.04-1.68)     
Pirker 2008 darb Extensive stage SCLC on 
chemo; disease 
progression defined by 
modified Response Evaluation 
Criteria in Solid Tumors; 
HR=1.02, (0.86 to 1.21) 
      
Untch 2011 darb   3-year DFS 74.3% (darb) vs 
80%; HR 1.31 (p=0.061) 
  breast cancer on chemo; no 
definition of disease progression; 
27% (darb) vs 21% 
Vansteenkiste 
2002 
darb     Lung cancer on chemo; no 
definition of disease 
progression; median duration 
22 weeks (95% CI 18 to 31 
weeks, darb) vs 20 weeks 
(95% CI 17 to 23) 
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Appendix Table I1. FACT-Fatigue subscale, trials comparing ESA to placebo or no treatment and reporting sufficient data for meta-
analysis 
Study 
(ESA) 
1°/2° 
out-
come 
N, 
ESA 
(% not 
eval-
uated) 
N, 
Ctl 
(% not 
eval-
uated) 
Blinding 
to treat-
ment/ 
Patient 
blinded 
to Hb 
ESA 
duration/
Trial 
follow-up 
for QoL 
(weeks) 
Base-
line Hb 
(g/dL) 
Hb 
Target 
(g/dL) 
ESA 
Baseline 
FACT-F 
Mean 
(SD) 
Ctl Base-
line 
FACT-F 
Mean 
(SD) 
Adjusted 
for 
baseline 
QoL/Hb in 
reported 
analysis 
ESA 
Mean 
Change 
(SD) 
Ctl 
Mean 
Change 
(SD) 
Mean Diff 
(95% CI) 
Boogaerts 
200384  
(Epo) 
1 133 (22) 
129 
(16) N/Y 12/12 <10 12-14 27 (12) 31 (11) N/N 
5.47 
(14.47) 
0.41 
(8.47) 
5.06 
(1.86 to 8.26) 
Chang 
200587  
(Epo) 
1 175 (4) 
175 
(3) N/Y 16/12 10-12 14 NR NR Y/N 
1.85 
(10.52) 
-3.55 
(11.14) 
5.1 
(2.79 to 7.41) 
Christodou-
lou 200988  
(Epo) 1 167 (54) 
170 
(55) N/NR NR/26 10-12 >12 
33 (12) 
non-plat;  
32  (11) 
plat 
32 (12) 
non-plat; 
27(13) 
plat 
Y/Y 
(>or 
<10.5) 
3.87 
(11.99) 
0.71 
(12.43) 
3.16 
(-0.72 to 7.04) 
Hedenus 
2003123  
(Darb) 
2 176 (14) 
173 
(13) Y/Y 12/12 <10 
13-14 
F NR NR 
Stratified 
analysis/
N 
2.68 
(8.88) 
0.8 
(9.71) 
1.88 
(-0.22 to 3.98) 
Hoskin 
20092 (Epo) 2 
151 
(0) 
149 
(0) N/NR 12/2 >12 >12 NR NR N/N 
-2.6 
(10.67) 
-2.6 
(12.45) 
0 
(-2.63 to 2.63) 
Iconomou 
2003103  
(Epo) 
1 61 (7) 
61 
(10) N/NR 12/12 10-12 NR 22 (12) 23 (11) N/N 
4.6 
(12.5) 
-1 
(12.8) 
5.6 
(0.91 to 10.29) 
Kotasek 
2003126 
(Darb) 
2 208 (5) 
51 
(0) Y/NR 12/10 <10 
13-14 
F 27 (12) 27 (12) N/N 
3.4 
(12.6) 
2.3 
(11.6) 
1.1 
(-2.58 to 4.78) 
Littlewood 
2001104 
(Epo) 
2 251 (23) 
124 
(29) Y/NR 
28/ 
4 to 24 <10 <15 NR NR N/N 
3 
(13.5) 
-2.2 
(12.5) 
5.2 
(2.01 to 8.39) 
Osterborg 
2002110  
(Epo) 
2 170 (38) 
173 
(40) Y/Y 16/16 <10 13-14 29 (11) 29 (11) Y/N 
5.2 
(12.2) 
3 
(12.1) 
2.2 
(-0.74 to 5.14) 
Pirker 
2008127  
(Darb) 
2 299 (18) 
301 
(21) Y/NR 19/19 10-12 13-14 31 (11) 31 (11) Y/N 
1.5 
(13.15) 
0.7 
(13.3) 
0.8 
(-1.56 to 3.16) 
 I-2 
 
Appendix Table I1. FACT-Fatigue subscale, trials comparing ESA to placebo or no treatment and reporting sufficient data for meta-
analysis (continued) 
Study 
(ESA) 
1°/2° 
out-
come 
N, 
ESA 
(% 
not 
eval-
uated) 
N, 
Ctl 
(% not 
eval-
uated) 
Blinding 
to treat-
ment/ 
Patient 
blinded 
to Hb 
ESA 
duration
/Trial 
follow-
up for 
QoL 
(weeks) 
Base-
line 
Hb 
(g/dL) 
Hb 
Target 
(g/dL) 
ESA 
Baseline 
FACT-F 
Mean 
(SD) 
Ctl 
Base-
line 
FACT-F 
Mean 
(SD) 
Adjusted 
for 
baseline 
QoL/Hb 
in 
reported 
analysis 
ESA Mean 
Change 
(SD) 
Ctl 
Mean Change 
(SD) 
Mean Diff 
(95% CI) 
Savonije 
2005116  
(Epo) 
2 211 (26) 
104 
(38) N/NR 1414 10-12 13-14 NR NR N/N 
3.48 
(12.67) 
-1.67 
(11.61) 
5.15 
(1.70 to 8.60) 
Tsuboi 
2009120 (Epo) 
2 63 (3) 
59 
(5) Y/NR 8/8 10-12 <14 36 (10) 34 (10) 
Stratified 
analysis/ 
Hb 
change 
influence
d QoL 
change 
-0.5 
(9.4) 
-3.6 
(9) 
3.1 
(-0.27 to 6.47) 
Vansteen-
kiste 200211 
(Darb) 
2 156 (19) 
158 
(19) Y/Y 12/52 10-12 
13-14 
F NR NR N/N 
0.8 
(10) 
-0.6 
(10.7) 
1.4 
(-0.89 to 3.69) 
Witzig 
2005122 (Epo) 1 
174 
(13) 
170 
(13) Y/Y 16/16 <=10 13-15 26 (11) 28 (12) N/N 
1.56 
(12.07) 
0.31 
(14.48) 
1.25 
(-1.77 to 4.27) 
Pooled           2.11 (3.90 to 8.07) 
-0.57 
(-6.47 to 5.28) 
2.74 
(1.69 to 3.74) 
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Appendix Table J1. Other tumor outcomes—epoetin or darbepoetin 
  
Author  Drug Outcome ESA 
Events/sample 
size  
Control 
Events/sample 
size  
Relative Risk  
Hazard Ratio  
(95% CI)  
Blohmer 20111 Epoetin relapse-free survival  23/127  35/129  0.66 (0.39-1.12), 
p=0.06 
Engert 20092 Epoetin freedom from treatment failure  n/644  n/641  0.9 (0.6-1.2)  
Goss 20053 Epoetin median time to progression  15.8m  16.5m  NR  
Goss 20053  Epoetin time to progression  NR  NR  NR  
Gupta 20094 Epoetin 2-year DFS  36/58  34/57  0.96 (0.72, 1.29)a 
Henke 20035 Stratum I  Epoetin locoregional tumor progression or death  47/102  41/94  0.95 (0.69, 1.29)a 
Henke 2003 Stratum II  Epoetin locoregional tumor progression or death  30/39  16/38  0.55 (0.36, 0.83)a 
Henke 2003 Stratum III  Epoetin locoregional tumor progression or death  39/39  35/39  0.90 (0.81, 1.00)a 
Henke 2003  Epoetin locoregional tumor progression  65/180  49/171 1.69 (1.16, 2.47)  
Henke 2003  Epoetin locoregional PFS  116/180  92/171  1.62 (1.22, 2.14)  
Hoskin 20096 Epoetin median duration local DFS 85/151, 31.5 mo 84/149, 35.4 mo  1.04 (0.77, 1.41)  
Hoskin 2009  Epoetin median DFS 87/151, 30.1 mo  85/149, 35.4 mo  1.06 (0.79, 1.43)  
Hoskin 2009  Epoetin time to local disease recurrence  NR  NR  0.94 (0.64, 1.38) 
Machtay 20077 Epoetin locoregional failure  31/72  27/69  0.91 (0.61, 1.35)a 
Machtay 2007  Epoetin 2-year locoregional failure  29/72  25/69  0.90 (0.59, 1.37)a 
Machtay 2007  Epoetin 3-year locoregional failure  32/72  25/69  1.20 (0.72, 2.02) 
Machtay 2007  Epoetin 2-year locoregional PFS  36/72  40/69  1.16 (0.85, 1.57)a 
Machtay 2007  Epoetin 3-year locoregional PFS  33/72  36/69  1.19 (0.76, 1.86) 
Moebus 20078 Epoetin 56m DFS  70.70% 72% NR  
Moebus 2007  Epoetin 62m DFS  240/333  231/325  0.99 (0.90, 1.09)a 
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a Calculated from events abstracted     
Author  Drug Outcome ESA 
Events/sample 
size  
Control 
Events/sample 
size  
Relative Risk  
Hazard Ratio  
(95% CI)  
Thomas 20089 Epoetin 3-year PFS  23/57  18/52  0.86 (0.53, 1.40)a 
Thomas 2008  Epoetin 3-year PFS  59% 62% 1.06 (0.58, 1.91) 
Thomas 2008  Epoetin recurrence (local+distant)  19/57  13/52  0.75 (0.41, 1.36) a 
Wagner 200410 Epoetin PFS  38.9%±11.5%  25.0%±8.8%  NR  
Overgaard 200911 Darbepoetin 5-year locoregional control  135/255  171/259  1.51 (1.05, 2.17)  
Overgaard 2009 Darbepoetin 5-year DFS  84/255  119/259  1.52 (1.07, 2.16)  
Overgaard 2009 Darbepoetin locoregional tumor control  143/255  179/260  0.81 (0.71, 0.93)  
Overgaard 2009 Darbepoetin locoregional PFS  130/255  174/260  0.52 (0.36, 0.74)  
Untch 201112 Darbepoetin 3-year DFS (med follow-up 43.5 mos) 106/345  90/369  1.31 (0.99, 1.74)  
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Author Comments  
Blohmer 200413 KM analysis p=0.0831, trend favoring ESA group. Info from Amgen ODAC 2008. total n for each group calculated based on reported 
17% and 25% in Amgen ODAC 2008, total n =250  
Blohmer 2004 abstract 2004  
Engert 20092 slide presentation  
Goss 20053 Amgen ODAC 2008  
Goss 2005 abstract, “no significant difference”  
Gupta 20094 numbers calculated from reported 62% and 60% respectively in full-text  
Henke 20035 Stratum I Kaplan Meier estimate, median locoregional progression-free survival in days: EPO: 1,049d, control 1,152d, p=0.9  
Henke 2003 Stratum II Kaplan Meier estimate, median locoregional progression-free survival in days: EPO 377d, control 1,791d p=0.001  
Henke 2003 Stratum III Kaplan Meier estimate, median locoregional progression-free survival in days: EPO 141d, control 207d, p=0.006  
Henke 2003 full text publication, ITT population, adjusted for stratum and American Joint Committee on Cancer stage. 115 and 122 patients were 
censored. Kaplan Meier estimate, median EPO 280 days vs. control not reached , p=0.09). Tumor progression was assumed when 
tumor size increased more than 25%.  
Henke 2003 full text and FDA 2007. ITT population, adjusted for stratum and American Joint Committee on Cancer Stage, 79 and 64 pts 
respectively were censored. Kaplan Meier estimate, median locoregional PFS in days, EPO 406d, control 745 d, p=0.04  
Hoskin 20096 full-text publication and Amgen ODAC 2008  
Hoskin 2009 full-text publication  
Hoskin 2009 full-text publication  
Machtay 20077 numbers reported in figure 1, full-text publication  
Machtay 2007 numbers calculated from reported 40% and 36% in full-text publication  
Machtay 2007 numbers calculated from reported 44% and 36% in full-text publication and Amgen ODAC 2008  
Machtay 2007 numbers calculated from reported 50% and 58% in full-text publication  
Machtay 2007 numbers calculated from reported 46.5% and 51.5% in full-text publication and Amgen ODAC 2008  
Moebus 20078 Amgen ODAC 2008. n per group not reported. Total n=643  
Moebus 2007 numbers calculated from reported 72% and 71% respectively in abstract publication  
Thomas 20089 full text publication, figure 1  
Thomas 2008 KM estimates from Amgen ODAC 2008. N per group not reported. Total n=114  
Thomas 2008 full-text publication  
Wagner 200410 probability of PFS at five years  
Overgaard 200911 numbers calculated from reported 53% and 66% in slide presentation ASCO 2009  
Overgaard 2009 numbers calculated from reported 33% and 46% in ASCO slide presentation  
Overgaard 2009 from Cochrane review 2009 (Lambin et al.)  
Overgaard 2009 from Cochrane review 2009  
Untch 200814 numbers calculated from reported 73% and 79% in Amgen ODAC 2008. Interim data   
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